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Midbrain dopamine neurons play a critical role in motor function, motivation, reward, 
and cognition by providing modulatory input to cortical and basal ganglia circuits. Given the 
importance of dopamine neurotransmission and its dysregulation in disease, mechanistic insight 
into the molecular underpinnings of dopaminergic neuronal function is needed. This thesis seeks 
to advance our understanding of dopamine neuronal cell biology by developing and applying 
cutting edge molecular profiling methods to study the subcellular translatome and proteome of 
dopamine neurons in mice. Chapter 1 provides an overview of the anatomy and cell biology of 
midbrain dopamine systems, with a particular emphasis on dopamine neurotransmission, 
neuronal heterogeneity, and selective vulnerability in Parkinson’s disease. Chapter 2 focuses on 
methods for studying local translation in neurons and describes newly discovered artifacts 
associated with two of these methods. Chapter 3 describes a global analysis of ribosome and 
mRNA localization in dopamine neurons; the results suggest that local translation in 
dopaminergic dendrites, but not axons, regulates dopamine release. Chapter 4 presents a method 
for subcellular proteomic profiling of dopamine neurons in the mouse brain, revealing the 
somatodendritic and axonal polarization of proteins encoded by Parkinson’s disease-linked 
genes. Emerging data are presented on Synaptotagmin 17, a novel axonal protein identified in 
midbrain dopamine neurons. Finally, I synthesize key findings regarding the molecular 
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Chapter 1: Cellular Biology of Midbrain Dopamine Neurons 
 
Midbrain dopamine neurons play a critical role in motor function, motivation, reward, 
and cognition by providing modulatory input to cortical and basal ganglia structures. Although 
they are a small population of ~20,000-30,000 in rodents and ~200,000-400,000 in humans [1], 
these neurons influence a wide range of neural circuits via dopamine release from expansive, 
long range forebrain projections [2]. On a behavioral level, dopamine signals convey information 
across time scales ranging from milliseconds to hours [3]. While the spatiotemporal interplay 
between dopamine signaling and neural systems is unfathomably complex, so too are the inner 
workings of a single dopamine neuron. Indeed, a single human cell exhibits many features of a 
prototypical complex system, such as barriers, external sensors, self-repair, transportation 
systems, data compression, and defense systems [4]. 
Alterations in cellular function can lead to dysregulation of dopamine neurotransmission, 
as observed in neuropsychiatric diseases such as schizophrenia and drug addiction, or to frank 
degeneration of dopamine neurons, as observed in Parkinson’s disease. In order to ameliorate 
dysfunction within a complex system like a dopamine neuron, we must first understand its inner 
workings in sufficient detail. Genome-wide profiling technologies such as RNA sequencing 
(RNA-seq) [5] and mass spectrometry-based proteomics [6] provide key information about the 
molecular composition of biological samples, but these methods typically average signals across 
a mixture of cell types and subcellular compartments. This thesis seeks to advance our 
understanding of dopamine neuronal cell biology by developing and applying cell type-specific 
methods to study the subcellular translatome and proteome of dopamine neurons in mice. 
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This introductory chapter will provide a framework of dopamine biology upon which the 
subsequent chapters of this thesis may build. First, I review the historical discovery of dopamine 
as a neurotransmitter and introduce the major dopamine pathways in the brain. Next, I review 
dopamine neuronal anatomy and cell biology, with a particular emphasis on axonal and 
somatodendritic dopamine release. Finally, I review literature regarding heterogeneity and 
selective vulnerability amongst midbrain dopamine neurons. 
 
1.1   A brief history of dopamine in the brain 
 
Carlsson’s rabbits lead to surprise 
The study of dopamine has a long and rich tradition in the history of neuroscience. 
Initially thought to be nothing more than an intermediate in the biosynthesis of norepinephrine 
(Figure 1.1), the discovery of dopamine as a neurotransmitter by Arvid Carlsson in 1957 forever 
changed the foundations of neuroscience, psychiatry, and neurology [7]. As revealed by classic 
experiments using the catecholamine-depleting agent reserpine [8], dopamine plays a critical role 
in motor control. Rabbits administered reserpine exhibited akinesia, rigidity, and occasionally 
tremor, symptoms that were strikingly similar to those described by James Parkinson in his 1817 
classic ‘An Essay on the Shaking Palsy’ [9]. Rigidity, bradykinesia, tremor, and postural 
instability are now known as the cardinal four motor symptoms of Parkinson’s disease (PD). The 
rabbits’ reserpine-induced symptoms were reversed upon administration of L-DOPA (L-3,4-
dihydroxyphenylalanine), an effect that was mediated by a monoamine rather than L-DOPA 
itself [8]. Of the monoamines, dopamine was considered to be largely irrelevant because it 
lacked significant activity on smooth muscle preparations [8]. At the time, Carlsson and 
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colleagues considered depletion of norepinephrine to be the most likely mediator of the reserpine 
syndrome, but they found no restoration of brain norepinephrine levels following L-DOPA 
treatment [8]. Left with no clear alternative, Carlsson and Waldeck had to develop the first 
fluorometric assay to measure dopamine [10]. Carlsson and colleagues demonstrated that 
dopamine was abundant in normal brains, depleted by reserpine, and restored by L-DOPA on a 
time scale that correlated with recovery of movement control [8]. Subsequent studies identified 
strikingly high concentrations of dopamine within the basal ganglia, structures critically involved 
in motor function [11]. Collectively, these findings led to the hypothesis that a lack of dopamine 
was central to PD pathophysiology [7,8]. 
 
Hornykiewicz helps turn the tide 
Carlsson’s data and theory were met with harsh skepticism when first presented at the 
1960 Ciba Foundation Symposium on Adrenergic Mechanisms [8], but the tide turned quickly 
thereafter. That same year, Oleh Hornykiewicz demonstrated dramatic depletion of dopamine in 
post-mortem striatal tissue from patients who had died of PD or postencephalitic parkinsonism 
[12,13]. In 1961, Hornykiewicz and neurologist Walther Birkmayer intravenously administered 
L-DOPA to PD patients and observed a temporary resolution of akinesia [14]. The first 
successful oral dosing regimens of L-DOPA were later developed by George Cotzias and 
colleagues, and L-DOPA remains the gold-standard in PD therapy today [15]. In addition to 
these pioneering efforts, Hornykiewicz was the first to propose that loss of pigmented neurons in 
the substantia nigra (SN) led to the depletion of striatal dopamine observed in PD [16]. Indeed, 
PD motor symptoms result from the loss of dopamine in the striatum and typically appear once 
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50-70% of dopamine neurons in the substantia nigra pars compacta (SNc) are lost [17]. 
Hornykiewicz will always be celebrated for his pioneering work, and over 230 scientists from 
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Swedish collaboration fuels discovery 
Research on dopamine and other monoamines accelerated rapidly in the early 1960’s. 
Carlsson, Bengt Falck, and Nils-Åke Hillarp made immense contributions during this time, 
leading a robust collaboration between the University of Göteburg, University of Lund, and the 
Karolinska Institute. In 1961, Carlsson, Falck, and Hillarp introduced the first method for 
converting catecholamines to fluorescent products for microscopic visualization, although this 
method did not work in brain tissue [19]. Falck and Hillarp then optimized the reaction of 
monoamines with formaldehyde vapor, known as the Falck-Hillarp method, which enabled 
detailed fluorescent visualization of monoamine-producing neurons in brain tissue [20]. By 
1966, these groups had established the localization of norepinephrine, serotonin, and dopamine-
producing neurons as well as their major projection pathways in the brain [21]. The major 
dopaminergic pathways supplied by midbrain dopamine neurons are illustrated in Figure 1.2. 
Figure 1.2: Major dopamine pathways 
Abbreviations: ventral tegmental area (VTA), substantia nigra (SN), medial forebrain 




Midbrain dopamine neurons reside primarily in the SNc and the ventral tegmental area (VTA), 
and their axonal projections course through the medial forebrain bundle (MFB) to reach 
forebrain targets. The dorsal striatum (DS) receives a dominant projection from the SN 
(Nigrostriatal Pathway). The nucleus accumbens (NAcc) and prefrontal cortex (PFC) receive 
dominant projections from the VTA (mesolimbic and mesocortical pathways, respectively). The 
biochemical and anatomical characterization of monoamine neurotransmission systems in the 
brain led to monumental advances in basic neuroscience and clinical medicine.  Along with Eric 
Kandel and Paul Greengard, Carlsson was awarded the 2000 Nobel Prize in Physiology or 
Medicine for his pioneering work on dopamine in the brain. 
 
Dopamine receptor signaling mechanisms 
In addition to anatomical and biochemical studies, Carlsson also led the first 
pharmacological study pointing towards dopamine receptors as the site of action for the 
antipsychotic drugs Chlorpromazine and Haloperidol [22]. In subsequent years, it became clear 
that dopamine receptor stimulation did not lead to rapid ionic currents like other the classical 
transmitters glutamate and GABA. Nobel Prize co-recipient Paul Greengard led foundational 
work on how slow-acting neurotransmitters like dopamine convey signals into postsynaptic 
cells. This work included the discovery and characterization of dopamine receptor signaling 
pathways, including adenylyl cyclases, cyclic AMP (cAMP)-dependent protein kinases, and 
downstream kinase substrates such as DARPP-32 (dopamine- and cAMP-regulated 
phosphoprotein of molecular weight 32,000) [23] (Figure 1.3). These mechanisms of 
dopamine signaling in the striatum were later shown to be central mediators of physiological 
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responses to dopamine, psychostimulant, and antipsychotic drugs [24]. The last half century 
has seen the discovery of new roles for dopamine signaling within diverse brain circuits 
underlying motivation, learning, reward processing, and cognition [25]. The goal of this thesis 
will be to delve deeply into the beating heart of these circuits: midbrain dopamine neurons, 
whose autonomous pacemaking provides the tonic dopamine required to sustain motor function 
and thus life itself. 
  
 
Figure 1.3: Dopamine receptor signaling in the striatum 
Schematic depicting the release of dopamine (DA) from striatal axons of midbrain 
dopamine neurons (green) and downstream signaling in striatal spiny projection neurons 
(SPNs, blue). Note that the dopamine D1 and D2 receptors (D1R and D2R) are shown on 
the same postsynaptic membrane only for illustrative purposes. Dopamine receptor 
expression in SPNs is predominantly segregated in distinct SPN populations: direct 
pathway SPNs express the D1 receptor, while indirect pathway SPNs express the D2 
receptor. The D1 and D2 receptors are coupled to G protein alpha subunits that stimulate 
or inhibit, respectively, adenylyl cyclase (AC) activity, cAMP production, cAMP-
dependent protein kinase A (PKA) activity, and downstream phosphorylation of 




1.2   Dopamine neurotransmission 
 
Dopamine synthesis 
The synthesis of dopamine occurs in a series of reactions within the dopamine neuronal 
cytoplasm (Figure 1.1). In the rate-limiting step, tyrosine hydroxylase (TH) catalyzes the 
addition of a hydroxyl group to the aromatic ring of tyrosine to form L-DOPA. TH requires a 
number of cofactors, including ferrous ion (Fe2+) and tetrahydropterin [26], and TH activity is 
tightly regulated by DA levels and post-translational modifications [27]. TH expression is also 
highly regulated at the level of transcription and translation [27]; in the brain, high levels of TH 
protein are found only within catecholaminergic neurons. As shown by others and in Chapter 3, 
a group of GABAergic interneurons within the cortex and striatum express TH mRNA, but 
nearly undetectable levels of TH protein [28]. Thus, TH protein is an excellent marker of 
midbrain dopamine neurons in the ventral midbrain (VM) as well as their axons in the MFB and 
striatum (Figure 1. 4) [29]. Axonal TH activity requires a constant supply of the cofactor 
tetrahydropterin, and thus dopamine axons contain high levels of tetrahydropterin synthesis 
enzymes GTP Cyclohydrolase 1 (GCH1), Sepiapterin Reductase (SR), and 6-pyruvoyl 
tetrahydrobiopterin synthase (PTPS) [30]. Genetic deficiencies in TH, GCH1, SR, or PTPS lead 
to defects in dopamine synthesis and a group of heterogeneous disorders known as dopa-
responsive dystonia (DRD) [31]. Dopamine neurons also express high levels of aromatic L-
amino acid decarboxylase (AADC, or dopa decarboxylase, DDC), which catalyzes the 
conversion of L-DOPA to dopamine. Since TH is rate-limiting, AADC typically operates below 
its saturation point. Thus, orally administered L-DOPA can cross the blood brain barrier and 







Spontaneous oxidation of dopamine can produce reactive oxygen species (ROS) that lead 
to oxidative stress and cellular damage, and the toxic potential of cytoplasmic dopamine likely 
contributes to the vulnerability of dopamine neurons in PD [32]. Excess cytosolic 
catecholamines also contribute to the formation of neuromelanin, a dark pigment that 
accumulates in autophagic lysosomes within human catecholamine neurons and for which the 
Figure 1.4: Tyrosine hydroxylase staining in the mouse brain 
Sagittal section of an adult mouse brain stained for Tyrosine Hydroxylase (TH). Scale bar, 
500 µm. Insets show a dopamine neuron in the midbrain and dopamine axons in the 
striatum. Scale bars, 10 µm. TH+ axonal fibers densely fill the striatal neuropil- the only areas 
completely devoid of TH staining are striatal cell bodies (dark ovals in center of inset) as 
well as cortical fibers that provide the striations for which the striatum is named. 
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substantia nigra is named (“black substance” in Latin) [33].  Efficient sequestration of 
cytoplasmic dopamine into the lumen of synaptic vesicles, which have an acidic pH that prevents 
dopamine oxidation, is critical to the long-term viability of dopamine neurons [34]. Cytoplasmic 
monoamines are transported into storage and release vesicles by vesicular monoamine 
transporters (VMAT), vesicle membrane proteins that leverage the proton electrochemical 
gradient established by the vesicular H+-ATPase (Figure 1.5) (reviewed in [35]). There are two 
VMAT genes in mammals, both of which were identified using cDNA screening strategies [36–
38]. VMAT1 (SLC18A1) is selectively expressed by neuroendocrine cells, while VMAT2 
(SLC18A2) is expressed in dopaminergic, noradrenergic, serotonergic, and histaminergic 
neurons of the central and peripheral nervous systems [39,40]. Early studies showed competitive 
inhibition of VMAT1 and VMAT2 by reserpine [37,41,42], linking the hypodopaminergic 
phenotype of Carlsson’s rabbits to a depletion of releasable dopamine in striatal dopamine axons. 
Both VMATs generate remarkable monoamine gradients of ~105, with vesicular 
monoamine levels approaching 0.5 – 0.7 molar concentrations [35]. In adrenal chromaffin 
granules, saturating concentrations cause monoamines to become insoluble and form electron-
dense aggregates known as dense cores [35]. Large dense core vesicles (DCVs) are typically 
100-250 nm in diameter, and in addition to catecholamines, they often contain secretory peptides 
such as chromogranins and secretogranins. While VMAT1 is preferentially localized to DCVs in 
chromaffin cells [43], ultrastructural studies demonstrated that VMAT2 within striatal dopamine 
axons is predominantly localized to ~40-50 nm small synaptic vesicles (SVs) [44]. Thus, SVs are 
the key organelles involved in axonal dopamine storage and exocytotic release. This is not the 
case in the soma and dendrites of dopamine neurons, where VMAT2 is predominantly found on 
tubulovesicular structures resembling smooth endoplasmic reticulum (SER) [45]. Dopamine 
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undergoes exocytotic release from both axonal and somatodendritic compartments of dopamine 
neurons (reviewed in [46]), and the distinct properties of VMAT2-bearing vesicles suggest 
distinct release mechanisms in these compartments (further discussion below). 
  
Axonal dopamine release and reuptake 
Axonal dopamine release is driven by the same basic mechanisms that drive SV 
exocytosis in all neurons, including 1) depolarization of the presynaptic membrane, 2) activation 
of voltage-gated calcium (Ca2+) channels (VGCC), 3) rapid influx of Ca2+, 4) conformational 
changes in Ca2+ sensing proteins, and 5) formation of SNARE complexes that promote vesicle 
fusion with the plasma membrane (Figure 1.5) (reviewed in [47,48]). After release, striatal 
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dopamine is cleared from the extracellular space primarily by reuptake into dopamine neurons 
via the dopamine transporter (DAT) [49,50]. DAT is the target of many psychostimulant drugs, 
and the increased extracellular dopamine concentration ([DA]o) caused by DAT inhibition leads 
to enhanced reward signaling [51]. In the striatum, diffusion also contributes to a rapid decrease 
in [DA]o near release sites [52]. Dopamine clearance is significantly slower in brain regions with 
sparse dopaminergic innervation [53]. In these regions, non-neuronal uptake and enzymatic 
degradation play more prominent roles compared to the striatum [54]. For example, catechol-o-
methyltransferase (COMT) degrades nearly 60% of dopamine in the prefrontal cortex [55]. 
Although many limbic structures receive sparse dopaminergic innervation, our 
understanding of dopamine release kinetics and dynamics mostly derive from studies within the 
densely innervated corpus striatum (dorsal striatum and nucleus accumbens). The striatal bias in 
the dopamine release literature primarily reflects technical limitations: measurement of 
catecholamine release using electrochemical detection methods such as amperometry [56] and 
fast-scan cyclic voltammetry (FSCV) with carbon-fiber electrodes [57] is difficult in brain 
regions with sparse innervation. Imaging of dopamine release in such regions is now possible 
thanks to the development of fluorescent probes and other chemical tools (reviewed in [58]). 
However, further review of dopamine release properties will focus solely on the striatum, as will 
all studies of dopamine axons in this thesis. 
After fusion with the plasma membrane, SVs are recycled locally by endocytic retrieval 
from the plasma membrane [47]. A detailed review of SV exocytosis and recycling mechanisms 
is beyond the scope of this thesis, but several unique features of axonal dopamine release are 
worth mentioning. Perhaps the most striking feature of dopamine axons in the striatum is their 
extraordinary density (Figure 1. 4), with an average distance of less than 5 µm between release 
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sites [59]. Along with the 2-5 Hz tonic firing pattern of dopamine neurons [60], the high density 
of striatal dopamine release sites contributes to a steady state [DA]o of 10-30 nM [61]. In 
addition to tonic firing, dopamine neurons also exhibit high-frequency burst firing of 2-6 action 
potentials (AP) at 10-15 Hz [62], which can lead to phasic changes in striatal dopamine that are 
critical for learning and reward processing (reviewed in [63]). 
 
Modulation of axonal dopamine release 
Axonal dopamine release is modulated by a variety of neurotransmitters, peptides, and 
other neuromodulators (reviewed in [48]). The major neurotransmitters that directly modulate 
dopamine release via axonal receptors are dopamine, acetylcholine, and GABA (Figure 1.5). 
Local autoregulation of striatal dopamine release is mediated by D2 autoreceptors present on 
dopaminergic axons [64], which provide direct feedback inhibition of further dopamine release. 
Somatodendritic D2 receptors decrease dopamine neuronal excitability through activation of 
GIRK channels [65], but current evidence suggests that axonal D2R autoregulation is mediated 
by voltage-gated potassium (K+) Kv1 channels [66]. Striatal dopamine release is heavily 
modulated by local cholinergic interneurons (ChIs). Acetylcholine release, especially from 
synchronously firing ChIs, enhances dopamine release via stimulation of nicotinic receptors 
(nAChRs) on dopaminergic axons [67,68]. Electrical stimulation of striatal slices in the presence 
or absence of nAchR antagonists revealed a major contribution of nAchR activation to evoked 
dopamine release [69]. GABA transmission also modulates axonal dopamine release, although 
evidence of GABA receptors on dopamine axons was not available until recently. An early study 
found that stimulation of metabotropic GABA-B receptors led to inhibition of dopamine release 
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[70], and more recent work identified a separate contribution of ionic GABA-A receptors [71]. 
While these studies used pharmacology and FSCV measurement of dopamine release to infer the 
localization of GABA receptors, a remarkable recent study was able to directly measure 
hyperpolarizing GABA-A receptor currents using patch clamp recordings of striatal dopamine 
axons [72]. In Chapter 4, I present proteomic data supporting the localization of GABA 
receptors in dopaminergic axons. 
 
Unresolved structure of striatal dopamine release sites 
Compared to glutamatergic and GABAergic synapses, the structural specialization of 
dopamine release sites remains a matter of debate. Early studies estimated that only ~30% of 
striatal dopamine release sites are synaptic [73], leading to theory of ‘volume transmission’, 
which argues that dopamine signals are conveyed across long distances through diffusion and 
flow in the extracellular fluid [74]. However, recent behavioral and pharmacological studies 
suggest that dopamine receptor signaling is rapid and requires high local concentrations of 
dopamine [75,76]. Of the dopamine release sites with synaptic contacts in the striatum, the 
majority are symmetric junctions onto dendritic branches [73]. Consistent with these 
ultrastructural findings, another study found that many striatal dopaminergic synapses share 
molecular features with inhibitory synapses [77]. However, another report found that midbrain 
dopamine axons in the NAcc formed asymmetric synapses, which are typically excitatory [78]. 
These findings are consistent with numerous studies demonstrating glutamate release from 
dopamine axons [79], which can elicit rapid excitatory postsynaptic currents in striatal neurons 
[80]. It is now well-established that subsets of dopamine neurons co-release glutamate and/or 
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GABA in addition to dopamine (reviewed in [81]), and these release sites may be segregated into 
distinct axonal domains [78]. Recent work has begun to identify synaptic adhesion molecules 
involved in dopamine axonal synaptic contacts [82–84], but the structural characteristics of 
dopamine, glutamate, and GABA release sites within dopamine axons are far from resolved. 
Given the ambiguous nature of dopaminergic synapses and the frequency of non-synaptic 
dopamine release sites, I will typically refer to axonal specializations as boutons or varicosities. 
 
Heterogeneity among dopaminergic varicosities 
The structural heterogeneity of dopamine release sites is matched by significant 
heterogeneity in the dopamine release properties of single axonal varicosities. Imaging of SV 
exocytosis in individual dopaminergic boutons was made possible by the development of 
fluorescent false neurotransmitters (FFNs), optical probes designed to mimic endogenous 
monoamines [85]. After uptake into dopamine axons and loading into SVs, exocytosis can be 
visualized as destaining of FFN fluorescence upon stimulation. Remarkably, only ~20% of FFN-
labeled varicosities in the striatum destained upon electrical stimulation, despite stimulation-
dependent Ca2+ influx at these sites [86]. At the time, it was hypothesized that these ‘silent 
synapses’ lacked an active zone [86], a specialized region of presynaptic boutons containing a 
dense network of scaffolding proteins that facilitate SV exocytosis. Active zone proteins such as 
RIM1, Munc13, ELKS, Liprin-α, RIM-BP, and Bassoon play key roles in SV docking, priming, 
and coupling to Ca2+ channels [87]. Consistent with the proportion of silent synapses measured 
by FFNs, a recent study found that only ~30% of dopaminergic varicosities contain the active 
zone proteins RIM1 and Bassoon [88]. Furthermore, axonal dopamine release is completely 
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abolished in the absence of RIM1 [88]. Emerging data suggest that Munc13 and Liprin-α are also 
required for axonal dopamine release [89], while ELKS and RIM-BP are not essential [88,89]. 
Thus, the active zone scaffolding machinery required for axonal dopamine release is relatively 
simple compared to conventional fast synapses. The mechanisms underlying trafficking and 
localization of active zone proteins in dopamine axons are unknown. In Chapter 3, I explore the 
hypothesis that local translation of these proteins plays a role in establishing and/or maintaining 
axonal dopamine release sites. However, my results suggest that local translation of active zone 
and SV release proteins regulates dopamine release from dendrites, but not axons.  
 
Somatodendritic dopamine release: anatomy and physiology 
Dopamine is released not only from striatal axons, but also from dopamine neuronal 
soma and dendrites in the midbrain [90,91]. Local axon collaterals from dopamine neurons are 
absent in the SNc and are very sparse in the VTA [92,93], while the somata and dendrites of 
dopamine neurons are intermixed within both regions (Figure 1.6). Most studies of midbrain 
dopamine release are conducted in the SNc or VTA and cannot distinguish somatic from 
dendritic dopamine release, hence the term ‘somatodendritic’ dopamine release. One exception is 
the substantia nigra pars reticulata (SNr), a region which contains ventrally-directed dendritic 
projections of SNc neurons and a few occasional dopamine neuronal soma (Figure 1.6). By 
dissecting the SNr away from the layer of soma in the SNc, Geffen et al. [90] were the first to 
demonstrate dendritic dopamine release. 
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Dopamine release in the ventral midbrain serves at least two major functions [46]: 1) 
autoregulation of dopamine neuronal firing activity [64], which is driven by stimulation of D2 
autoreceptors and subsequent hyperpolarizing GIRK currents [94], and 2) modulation of SNr 
neuronal activity, which is driven primarily by D1 receptors on axon terminals of striatal direct 
pathway SPNs that release GABA onto SNr neurons [95,96] (Figure 1.7), but also potentially 
through D1 receptors on SNr neurons [97]. The SNr is the output nucleus of the basal ganglia, 
and dopaminergic modulation of SNr activity is involved in motor control [98–100]. Although 
PD motor symptoms are thought to arise from loss of striatal dopamine, degeneration of SNc 
dopamine neurons would also be expected to compromise dendritic dopamine release in the SNr. 
Indeed, both nigral and striatal dopamine signaling contribute to L-DOPA-induced rotational 
behavior following toxin-induced degeneration of dopamine neurons in mice [101]. Unpublished 
Figure 1.6: Ventral midbrain anatomy 
Tyrosine Hydroxylase (TH) staining of midbrain dopamine neurons. Somata and dendrites 
are intermixed within the SNc and VTA, while the SNr contains ventral-directed dendrites 
of SNc dopamine neurons. Scale bar, 300 µm. 
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observations from the Surmeier Laboratory suggest that the loss of SNr dopamine may actually 
be the initial cause of motor symptom onset in a new mouse model of PD. 
 
Somatodendritic dopamine release: biochemistry and cell biology 
While midbrain dopamine signaling is clearly involved in motor behavior and in the 
regulation of dopamine neuronal activity, the mechanisms underlying somatodendritic dopamine 
release are not thoroughly characterized. Current evidence suggests that somatodendritic 
dopamine release is exocytotic and requires SNARE proteins [102–104]. Consistent with release 
from a vesicular organelle, multiple studies have shown that inhibition of VMAT2 blocks 
somatodendritic dopamine release [94,105,106]. As mentioned previously, the identity of 
releasable dopamine vesicles in the somata and dendrites of dopamine neurons is unknown. 
Clusters of SVs are virtually absent within dopaminergic dendrites in the SN and VTA; instead, 
VMAT2 is localized to organelles that resemble saccules of SER [45] (Figure 1.7). Molecular 
and functional characterization of these ‘tubulovesicles’ is lacking, and their involvement in 
somatodendritic release remains speculative. 
Another unresolved question is the molecular architecture and subcellular organization of 
somatodendritic dopamine release sites. Synaptic junctions for dendritic dopamine release are 
unlikely, since dendro-dendritic synapses are uncommon in the VTA and SNc [107], and they 
are nearly undetectable in the SNr [108]. Dopamine neuron-specific knockout of the active zone 
scaffolding protein RIM1 led to significant reduction in stimulation-evoked, but not spontaneous, 
somatodendritic dopamine release [109]. It remains to be determined whether other scaffolding 
proteins are involved in somatodendritic release, and whether RIM1 is localized to specialized 
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‘active zone-like’ sites in dopaminergic somata and dendrites. In Chapter 3, I present evidence 
of local translation for several active zone proteins, including RIM1, in dopaminergic dendrites. 
Despite substantial differences in axonal and somatodendritic dopamine vesicles, both 
compartments employ Ca2+-dependent exocytotic mechanisms. However, the extent to which 
somatodendritic release requires extracellular calcium ([Ca2+]o) is unresolved. Experimental 
results from different regions, species, and experimental methods are often contradictory 
(reviewed in [46]). The emerging consensus is that somatodendritic release requires at least a 
low [Ca2+]o in order to facilitate the release of intracellular Ca2+ stores from the endoplasmic 
reticulum (ER) [110,111]. Somatodendritic dopamine release can be evoked in low [Ca2+]o 
conditions that do not support axonal release [112], provided that Ca2+ influx is amplified by 
Ca2+-induced Ca2+ release [113]. Somatodendritic dopamine release can also be amplified by 
stimulation of metabotropic glutamate receptors (mGluRs) [113], which leads to intracellular 
Ca2+ release via stimulation of IP3 receptors on the ER (Figure 1.7). 
Although stimulation-evoked somatodendritic release requires voltage-gated Na+ 
channels [64,94], recent evidence suggests this is not the case for tonic somatodendritic release 
measured in the SNc [114]. Remarkably, the tonic [DA]o of ~40 nM in the SNc was decreased 
by less than 10%  after complete abolishment of neuronal firing by tetrodotoxin [114]. In 
contrast, experimental depletion of intracellular Ca2+ stores led to ~70% reduction of [DA]o 
[114]. Thus, sub-threshold membrane depolarizations are able to trigger intracellular Ca2+ release 
and elicit somatodendritic release in the absence of APs. Taken together with the role of RIM1 in 
stimulation-evoked, but not spontaneous dopamine release in the midbrain [109], it seems that 




The exocytotic proteins involved in vesicular dopamine release are not exhaustively 
defined, but current evidence indicates substantial differences between the somatodendritic and 
axonal release machinery. Dopamine neuronal somata and dendrites appear to lack common 
SNARE proteins such as Syntaxin 1a and Synaptobrevin 1 (Vamp1), but do contain others such 
Figure 1.7: Dopamine release in the substantia nigra 
Schematic representation of somatodendritic and distal dendritic release mechanisms in 
the SNc and SNr, respectively. Abbreviations: PLC, phospholipase C; IP3, inositol 1,4,5-
triphosphate. All other abbreviations and relevant references are in the main text. 
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as SNAP-25, Syntaxin 3b, and Synaptobrevin 2 (Vamp2) [115]. Although the Ca2+ sensor 
Synaptotagmin 1 (Syt-1) was recently shown to be essential for fast striatal dopamine release 
[116], Syt-1 immunoreactivity is undetectable within dopamine neuronal somata and dendrites 
[115,117]. Instead, the higher affinity Ca2+ sensors Synaptotagmin 4 and 7 (Syt-4 and Syt-7) 
predominate within the somatodendritic compartment of dopamine neurons [117] (Figure 1.7). 
However, unpublished data from the Trudeau Laboratory suggests that dopamine neuron-specific 
knockout of Syt-1 affects both axonal and somatodendritic dopamine release in vivo.  
 
Distal dendritic dopamine release in the SNr 
 Among many outstanding questions regarding the mechanisms of somatodendritic 
dopamine release, perhaps the most poorly understood is the difference between somatic release 
within the SNc/VTA and distal dendritic release in the SNr. As reported in 1975, reserpine-
sensitive stores of dopamine are present throughout dopaminergic dendrites in the SNr [118]. 
Shortly thereafter, Geffen et al. [90] provided the first evidence of depolarization-induced 
dendritic release by measuring radiolabeled dopamine efflux in the superfusate of dissected SNr 
slices [90]. Since then, few studies have focused on dopamine release in the SNr, in part due to 
the dense serotonergic innervation of this nucleus which precludes clean detection of dopamine 
using FSCV [119]. In addition to VMAT2 [45], the DAT is also present on SER-like 
tubulovesicles within dendrites of SN dopamine neurons [120]. Unlike VMAT2, DAT is also 
frequently observed on the plasma membrane of SNr dendrites [120] (Figure 1.7). 
Using amperometry and path-clamp recordings, one study found that dendritic dopamine 
release was driven by reversal of DAT [121]. In a follow-up study, the authors found that 
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metabotropic glutamate receptor stimulation and protein kinase C are essential for DAT-
mediated dopamine release [122]. If confirmed, these findings suggest a remarkable mechanism 
for locally increasing the cytosolic dopamine concentration ([DA]cyt) in dendrites, since the 
typical [DA]cyt is not high enough to reverse transport of the DAT [123]. DAT-driven dopamine 
release also seems unlikely in the SNc, where DAT inhibition leads to enhanced [DA]o following 
stimulation-evoked dopamine release [94,110].  
 Given the striking density of D1 receptors in the SNr [96,124], the role of midbrain 
dopamine signaling in motor behavior [98–100] and potentially in PD [101] is not surprising. A 
greater understanding of dendritic dopamine release mechanisms, regulation, and alteration in 
disease states may provide new insight into PD pathogenesis or lead to novel therapeutic 
strategies. In Chapter 3, I present local translation data on a number of vesicular release proteins 
that may be involved in dendritic exocytosis. Although I was unable to pursue mechanistic 
follow-up studies of these candidates, I am optimistic that new dopamine imaging technologies 
such as dLight [125] and GrabDA [126] will enable such studies in the near future. 
 
1.3   Dopamine neuronal heterogeneity and selective vulnerability 
 
Regional neurodegeneration and pathology in Parkinson’s disease 
 Progressive degeneration of SNc dopamine neurons is responsible for the cardinal motor 
symptoms of PD [127], but histopathological evaluation of postmortem brain tissue has made it 
clear that neuronal pathology is not limited to the SNc. The hallmark of PD neuropathology is 
the presence of intracellular protein aggregates containing alpha-synuclein (aSyn) within 
neuronal cell bodies (Lewy bodies, LB) and neurites (Lewy neurites, LN) [128]. Anatomical 
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mapping led by Heiko Braak has established that Lewy pathology (LP) is often found in a variety 
of neurons outside the ventral midbrain (reviewed in [129]). Such neuronal populations include 
enteric dopamine neurons in the myenteric plexus [130], various cholinergic and 
catecholaminergic neurons of the autonomic nervous system [131], cholinergic neurons in the 
dorsal motor nucleus of the vagus (DMV) [132], noradrenergic neurons in the locus coeruleus 
(LC) [133], serotonergic neurons in the raphe nuclei [134], several neuronal populations in the 
pedunculopontine nuclei (PPN) [135], cholinergic neurons in the nucleus basalis of Meynert 
(NBM) [136], and mitral cells in the olfactory bulb [137]. Although LP does not always correlate 
with degeneration of a given neuronal population [128], neurodegeneration in PD is not limited 
to dopaminergic neurons. Indeed, many non-motor PD symptoms such as constipation, dry-
mouth, excessive sweating, and low blood pressure can be attributed to enteric and autonomic 
dysfunction [130,131,138]. 
I would be remiss to omit a brief discussion of Braak’s hypothesis, although a thorough 
review is beyond the scope of the present work (see [139]). Braak famously introduced the 
hypothesis that an unknown pathogen could initiate sporadic PD within the gut [140], as well as 
a staging system for the spread of LP from the gut to the brain via the vagal nerve [135]. Braak’s 
hypothesis was subsequently modified to encompass the olfactory tract as a second site for 
seeding of aSyn pathology [141,142]. Braak’s hypothesis has been controversial, and it is clear 
that pathology in many PD patients does not progress according to Braak’s staging system [143]. 
Nonetheless, several recent studies have presented strong evidence for the trans-synaptic spread 
of aSyn pathology, including within the autonomic nervous system and from the gut to brain via 
the vagus nerve [144,145]. 
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Among midbrain dopamine neurons, those in the SNc are markedly more vulnerable in 
PD compared to those in the VTA and retrorubral field (RRF) [146,147]. SNc dopamine neurons 
appear to share a number of features with other vulnerable neurons, suggesting that a unique 
combination of these cellular phenotypes may contribute to degeneration in PD (reviewed in 
[148] and discussed below). A detailed understanding of the cellular and molecular features 
underlying selective neuronal vulnerability has enhanced our understanding of PD 
pathophysiology [148–150], including genetic PD [151] and PD linked to environmental toxins 
[152]. Furthermore, the identification of druggable targets linked to selective vulnerability led to 
clinical trials designed to prevent clinical progression of PD [153,154]. Given the emphasis of 
this thesis on dopamine neurons, I will focus primarily on dopamine neuronal heterogeneity and 
its relationship to selective vulnerability in PD. 
 
Massive axonal arbors come at a cost 
The most salient anatomical feature of vulnerable neurons in PD is the length and 
complexity of their highly branched axons [148]. The axon of SNc dopamine neurons in mice 
can reach over 500,000 µm in total length and contain hundreds of thousands of striatal release 
sites [155]. Thus, the striatal axons of SNc dopamine neurons likely comprise more than 90% of 
their total cellular volume and surface area [155]. Although there are more dopamine neurons in 
the VTA compared to SNc (∼8,000 in the SNc and ∼10,000 in the VTA of C57BL/6 mice) 
[156], SNc dopamine neurons achieve a similar density of striatal innervation in a ~5-fold 
greater tissue volume (dorsal vs. ventral striatum) [157]. It is thus estimated that mesolimbic 
axons of VTA dopamine neurons are substantially smaller and contain fewer release sites 
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compared to nigrostriatal axons [157,158]. The maintenance of membrane potential, propagation 
of action potentials, and recycling of SVs across such expansive axonal arbors is expected to 
place immense bioenergetic demands on tonically active SNc dopamine neurons [158,159]. 
Indeed, pharmacological manipulations that decrease the size of axonal arbors decrease 
mitochondrial oxidant stress in dopamine neurons [160]. Trafficking of proteins and organelles 
between midbrain somata and striatal axons represents another significant energetic burden for 
dopamine neurons, and deficits in axonal transport have been linked to neurodegeneration in PD 
[161,162]. Thus, while the massive axonal arbors of SNc dopamine neurons supply high levels 
of dopamine required for learning and motor control, they may render these neurons susceptible 
to a variety of genetic, environmental, and oxidative stressors. 
 
Autonomous pacemaking and L-type calcium channels 
A striking physiological phenotype shared among many vulnerable neurons in PD is their 
autonomous pacemaking activity [148,150]. Along with neurons in the LC, DMV, and PPN, 
dopamine neurons are spontaneously active and generate broad action potentials in the absence 
of synaptic input [60]. Pacemaking in VTA dopamine neurons is driven by HCN/Na+ channels 
[163,164], while SNc dopamine neurons primarily use L-type Ca2+ channels (LTCC) for 
pacemaking [165–167]. This distinction has significant implications for the selective 
vulnerability of SNc dopamine neurons [168]. The large cytosolic Ca2+ oscillations associated 
with pacemaking are specific to SNc dopamine neurons, are blocked by LTCC inhibitors, and 
lead to enhanced mitochondrial stress [169]. Mitochondrial stress is heavily implicated in PD 
pathogenesis (reviewed in [170]), and thus reduction of LTCC-mediated cytosolic Ca2+ could 
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restore mitochondrial function and prevent further neurodegeneration in PD. Indeed, the LTCC 
inhibitor Isradipine was found to be neuroprotective in a mouse model of PD [171] and several 
epidemiological studies found reduced incidence of PD in patients taking Ca2+ channel blockers 
for cardiac indications [172,173]. These data formed the basis for STEADY-PD (Safety, 
Tolerability, and Efficacy Assessment of Dynacirc® CR for PD), a series of clinical trials using 
Isradipine to treat early PD. Unfortunately, the phase III clinical trial (STEADY-PD III) found 
no significant benefit in the Isradipine group compared to placebo [154]. However, the 
pharmacokinetic profile of Isradipine was likely suboptimal and it is possible that target 
engagement was inadequate [168]. 
 
SNc-specific interactions: calcium, dopamine, and alpha-synuclein 
LTCC-mediated elevations in cytosolic Ca2+ can also lead to elevated cytoplasmic 
dopamine (DAcyt) [174], which is known to produce ROS and other toxic metabolites [32]. SNc 
dopamine neurons seem predisposed to higher DAcyt, with higher expression of DAT [175] and 
lower levels of VMAT2 compared to VTA dopamine neurons [176]. Consistent with these 
differences, VTA dopamine neurons produce substantially less neuromelanin [146,176], which is 
accumulated in autophagic lysosomes in the presence of elevated DAcyt and can be prevented by 
VMAT2 overexpression [33,177]. Intriguingly, toxicity of elevated cytosolic Ca2+ and dopamine 
in SNc dopamine neurons requires the presence of aSyn [174], and overexpression of aSyn can 
lead to elevated DAcyt [178]. A recent study found that SNc dopamine neurons exposed to the 
parkinsonian neurotoxin MPP+ exhibited cytosolic Ca2+ elevations mediated by LTCCs [179]. 
This phenotype, which was aSyn-dependent and not observed in VTA dopamine neurons, led to 
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elevated DAcyt, mitochondrial oxidative stress, and neuronal cell death [179]. Collectively, these 
findings suggest that differential handling of cytosolic Ca2+ and dopamine interact with aSyn to 
favor SNc over VTA dopamine neuronal degeneration in PD (reviewed in [180]) (Figure 1.8A). 
Distinct properties of dorsal and ventral tier SNc dopamine neurons 
Cytosolic Ca2+ oscillations are not a unique feature of vulnerable neurons in PD per se, 
since other neuronal populations exhibit autonomous pacemaking but are mostly spared in PD 
(e.g., striatal ChIs and cerebellar Purkinje neurons) [148]. A key feature that may contribute to 
the viability of these pacemakers in PD is the expression of Ca2+-binding proteins that buffer 
Figure 1.8: Dopamine neuronal heterogeneity and selective vulnerability 
Schematic representation of midbrain dopamine neurons and heterogeneity related to 
selective vulnerability. Key differences are summarized as follows: (A) at the population-
level (bulk) within the VTA vs. SNc, (B) in distinct subpopulations within the dorsal vs. 
ventral SNc, and (C) at the single-cell level throughout the ventral midbrain. All 
references and abbreviations are contained within the text. Schematic adapted from 
Poulin et al. (2020) 
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large cytosolic Ca2+ oscillations [168]. VTA dopamine neurons have a relatively high Ca2+-
buffering capacity that is mediated in part by robust expression of the Ca2+-binding protein 
Calbindin-D28 K (calbindin/Calb1) [181,182]. In contrast, most SNc dopamine neurons have a 
markedly low intrinsic Ca2+-buffering capacity [183] and express lower levels of calbindin [184].  
Consistent with a neuroprotective role in PD, calbindin is a marker of resilient dopamine neurons 
in both animal models of PD [185,186] and in the midbrain of PD patients [147,187]. 
Early gene expression profiling studies found that at the bulk population level, SNc 
dopamine neurons express ~2-3-fold lower levels of Calb1 mRNA compared to VTA dopamine 
neurons [188,189]. However, broadly classifying dopamine neurons as ‘SNc’ or ‘VTA’ 
overlooks significant heterogeneity at the single cell level. In fact, there are a significant number 
of Calb1+ dopamine neurons in the dorsal tier of the SNc, while the majority of ventral tier SNc 
dopamine neurons are Calb1- [184,186] (Figure 1.8B). Calbindin expression is only one among 
many significant differences between the dorsal and ventral tier SNc dopamine neuron 
populations. Ventral tier neurons express significantly higher levels of DAT and D2 receptor 
mRNA [184] and exhibit enhanced rebound firing following D2 autoreceptor-mediated 
hyperpolarization [190]. The larger T-type Ca2+ channel currents recruited at hyperpolarized 
potentials enable ventral tier Calb1- SNc neurons to recover firing more quickly than dorsal tier 
Calb1+ SNc dopamine neurons, suggesting that these populations may encode distinct dopamine 
signals [190]. Calb1- and Calb1+ SNc dopamine neurons have been shown to preferentially 
innervate the patch and matrix compartments of the striatum, respectively [191,192], providing 
anatomical support for this theory. 
Another distinguishing feature of Calb1- dopamine neurons in the ventral SNc is their 
expression of the aldehyde dehydrogenase ALDH1A1 [193]. Aldh1a1 is a key marker gene for 
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several dopamine neuronal subpopulations in single cell expression profiling studies [194–197], 
and a recent meta-analysis identified high Aldh1a1 and Sox6 mRNA expression as the defining 
features of rodent ventral tier SNc dopamine neurons [198]. Given the marked vulnerability of 
ventrolateral SNc dopamine neurons in PD [199,200], there is considerable interest in defining 
the unique features of ALDH1A1+/SOX6+ dopamine neurons (reviewed in [201]). ALDH1A1+ 
dopaminergic axons display unique patterns of striatal innervation and appear to be critical for 
motor skill learning [202,203]. ALDH1A1+ dopamine neurons are more susceptible to MPTP-
induced degeneration [194], although ALDH1A1 appears to protect ventral tier SNc dopamine 
neurons in a transgenic aSyn mouse model of PD [204]. However, the overwhelming consensus 
is that ALDH1A1+/ SOX6+ SNc dopamine neurons preferentially degenerate in PD. Indeed, a 
recent single cell atlas of the PD midbrain identified CALB1+ dopamine neurons in the dorsal 
SNc as the most resistant population, while ventral tier CALB1-/SOX6+ dopamine neurons were 
most susceptible [205] (Figure 1.8B). In Chapter 3, I present translatome profiling data for a 
small and relatively unstudied group of Aldh1a1+/Sox6+ dopamine neurons in the SNr. 
 
Dopamine neuronal heterogeneity at single-cell resolution 
Single cell RNA-sequencing (scRNA-seq) studies have revealed greater heterogeneity 
among midbrain dopamine neurons than was previously appreciated. A frequent goal of scRNA-
seq analysis is to identify discrete cellular populations, or clusters, based on their distinct gene 
expression profiles. For example, dopamine neurons are well-separated from glia and other 
neurons by high expression of canonical dopaminergic genes (e.g., TH, DAT, VMAT2, AADC) 
as well as other marker genes (see examples in Chapter 3). However, scRNA-seq enables the 
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interrogation of more subtle heterogeneity at the level of dopamine neuronal subpopulations, or 
subclusters. Despite significant variation in the species, age, methodology, and data analysis 
strategy employed, most scRNA-seq studies typically identify 6-10 transcriptomically distinct 
subpopulations of dopamine neurons [195–197,205–208] (Figure 1.8C). Based on supporting 
evidence from multiple studies, a recent meta-analysis proposed seven putative subpopulations 
of dopamine neurons [198]. The four clusters of VTA-enriched subpopulations are more 
ambiguously defined across studies, with key marker genes including neuropeptides such as 
cholecystokinin (Cck), gastrin-releasing peptide (Grp), and vasoactive intestinal peptide (Vip), 
the transcription factor Otx2, and the vesicular transporters VGLUT2 (Slc17a6) and VGAT 
(Slc32a1) [198]. There are three major SNc-enriched subpopulations, including the 
aforementioned ventral tier Aldh1a1+/Sox6+/Calb1-  neurons, dorsal tier Aldh1a1-/Sox6+/Calb1+ 
neurons, and a population of Aldh1a1-/VGLUT2+/Calb1+ neurons in the lateral SNc [198] 
(Figure 1.8C). Aldh1a1+/Sox6+ SNc dopamine neurons also express particularly high levels of a 
rodent-specific Aldh1a1 paralog (Aldh1a7), the Ca2+-dependent phospholipid-binding protein 
Annexin A1 (Anxa1), and neuron-derived neurotrophic factor (Ndnf) [198]; the role of these 
proteins within this vulnerable subpopulation warrants future investigation. 
The elucidation of molecularly distinct subpopulations is consistent with heterogeneity in 
neurotransmitter release [81], anatomical connectivity [209], and motivational signals encoded 
by dopamine neurons [210]. It was originally thought that the co-release of dopamine and 
glutamate was restricted to the NAcc [211,212], but more recent studies have demonstrated 
glutamatergic transmission from dopamine axons in the dorsolateral striatum [80,213–215]. 
These findings are consistent with an abundance of VGLUT2+ dopamine neurons in the VTA 
[211,216], along with a small population in the lateral SNc [198,214]. Lateral SNc neurons are 
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known to preferentially innervate the tail of the striatum [217], where their axonal activity plays 
a key role in reinforcement learning related to threatening stimuli [218]. Although these neurons 
likely overlap with the Aldh1a1-/VGLUT2+/Calb1+ population identified in scRNA-seq studies, 
the reinforcement of avoidance mediated by lateral SNc dopamine neurons does not require 
VGLUT2-mediated glutamate release [218]. Deletion of VGLUT2 in dopamine neurons renders 
them significantly more susceptible to neurotoxin-induced degeneration [219], although 
overexpression of VGLUT2 in SNc dopamine neurons leads to neurodegeneration [220]. 
In contrast to VGLUT2, expression of VGAT in dopamine neurons is controversial [81] 
and appears restricted to dopamine neurons in the VTA [198]. Previous studies have 
demonstrated GABA release evoked by optogenetic stimulation of dopamine axons in the 
habenula and striatum [221–224]. However, these studies proposed a variety of non-canonical 
mechanisms underlying GABA transmission by dopamine neurons, including synthesis via 
ALDH1A1 [222], uptake via plasma membrane GABA transporters [224], and vesicular loading 
via VMAT2 [223]. Although they appear rare (<5% of midbrain DA neurons), many of these 
cells express the GABA synthesis enzyme Gad2, the glutamate transporter VGLUT2, and lower 
levels of DAT and VMAT2 [208]. Thus, is it possible that some GABA transmission from VTA 
neurons is mediated by canonical mechanisms in dopamine neurons that can co-release 
dopamine, glutamate, and GABA [198]. 
 
Future directions 
With a suite of new techniques in hand, investigators may now pursue several promising 
directions to better understand dopamine neuronal heterogeneity and selective vulnerability in 
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PD. First, new intersectional genetic strategies (e.g., [209]) can be employed to elucidate the 
unique physiological and behavioral roles of distinct dopamine neuronal subpopulations. Second, 
the rapid mutagenesis and knock-out capabilities afforded by CRISPR-Cas9 technology [225] 
should facilitate functional studies of subpopulation-specific gene function and associated 
pathways in rodent models. Third, single nucleus RNA-seq (snRNA-seq) will enable detailed 
analysis of dopamine neuron subpopulations in postmortem brain tissue from PD patients and 
healthy control subjects. Recently, the first of such studies identified a primate-specific cluster of 
dopamine neurons [205]. Finally, dynamic studies involving genetic, environmental, and 
immunological rodent models of PD may reveal subpopulation-specific interactions with 
stressors and other brain cells. In the eyes of this optimistic author, these collective efforts will 
lead to actionable knowledge and innovative clinical strategies for PD therapy. 
 
1.4   Overview 
 
While many studies have focused on intercellular transcriptomic heterogeneity among 
dopamine neurons, the major focus of this thesis is on intracellular molecular heterogeneity 
within dopamine neurons (i.e., the non-random distribution of mRNA and protein within distinct 
subcellular compartments) (Figure 1.9). It has long been known that mRNAs contain regulatory 
sequence elements, some of which confer dynamic trafficking and translation at discrete 
locations within the cytoplasm. In Chapter 2, I provide an overview of subcellular mRNA 
localization and translation in neurons. Next, I describe newly discovered flaws in existing 
literature regarding puromycin immunostaining, a widely employed method for imaging of 
subcellular translation sites [226]. Finally, I describe advances in small particle flow cytometry 
33 
 
for the study of resealed presynaptic nerve terminals (synaptosomes) and artifacts that can 
confound these studies [227]. In collaboration with Etienne Herzog, I apply the latter 
methodology to study the putative mRNA content of dopaminergic synaptosomes in Chapter 3. 
Although a plethora of studies have investigated local translation within excitatory and 
inhibitory neurons, few, if any, have studied dopamine neurons. In Chapter 3, I present a 
comprehensive analysis of subcellular mRNA localization and translation in midbrain dopamine 
neurons [228] (Figure 1.9). First, I use RiboTag transgenic mice to study ribosome localization 
and identify translating mRNAs in dopamine neuronal dendrites and axons. Despite the length 
and massive arborization of dopaminergic projections, I find no evidence of ribosome-bound 
mRNA in these studies. Using an alternative approach, fluorescence-activated synaptosome 
sorting (FASS), I find a similar lack of evidence for mRNA localization in dopaminergic 
presynaptic boutons. Meanwhile, tagged ribosomes and mRNAs encoding dopamine 
transmission machinery were robustly localized within dopaminergic dendrites in the SNr. 
Surprisingly, I find dendritic localization of mRNAs encoding synaptic vesicular release 
proteins. Overall, these data suggest that local translation in dopamine neurons regulates 
dopamine release from dendritic projections, but not striatal axons. 
While local synthesis can serve to dynamically regulate the local abundance of some 
proteins, protein trafficking is the dominant mechanism underlying subcellular localization in 
neurons [229]. In Chapter 4, I implement a proximity labeling proteomics approach to study the 
subcellular proteome of dopamine neurons in the mouse brain [230] (Figure 1.9). Combining 
dopamine neuron-specific expression of APEX2 with proximity biotinylation in acute brain 
slices, I describe somatodendritic and axonal proteomic profiling of dopamine neurons in the 





Figure 1.9: Overview of Chapters 2-4 
Schematic depicting the major topic of each chapter in this thesis. The graphic 
representation of a dopamine neuron and corresponding insets indicate the subcellular 
compartment studied in each chapter. See main text for descriptions. Abbreviations: 
APEX2, ascorbate peroxidase 2; BP, biotin phenol; H2O2, hydrogen peroxide; LC-MS/MS, 
liquid chromatography tandem mass spectrometry; Syt-17, synaptotagmin 17 
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proteomics of dopaminergic striatal synaptosomes. I discuss novel features of the dopamine 
neuronal proteome, with a particular emphasis on the localization of proteins encoded by genes 
linked to PD. I conclude with emerging data from ongoing studies of a novel axonal protein that 
I identified in dopamine neurons, Synaptotagmin 17. 
Finally, I synthesize key findings across each chapter and summarize the molecular 
organization underlying dopamine neuronal cell biology. I conclude with future directions for 
subcellular molecular profiling and discuss how it will advance our understanding of basic 
neurobiology and neurodegenerative disease pathology.  
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Chapter 2: Methods and Artifacts in Studies of Local Translation 
 
“Progress in science depends on new techniques, new discoveries, and new ideas, probably in 
that order.” – Sydney Brenner, Nobel Laureate 
 
As mentioned in Chapter 1, differences in gene expression between subsets of midbrain 
dopamine neurons are now well appreciated. However, much less is known about the subcellular 
organization of mRNA translation within dopamine neurons. In part, this is due to the technical 
difficulty of studying local translation in the mammalian brain. A significant portion of my 
graduate work was dedicated towards the development of methods to study local translation in 
dopamine neurons. While attempting to build on previous methods, I encountered several major 
pitfalls that were not described in the literature. In this chapter, I provide a brief review of local 
translation in neurons and introduce methods commonly used in these studies. I then present two 
published studies in which I characterize technical artifacts associated with established methods. 
 
Contributions  
2.1 I wrote the literature review presented in section 2.1. 
2.2 Section 2.2 is an adaptation of a previously published manuscript. I conceived the 
eL22-HA/Puro PLA assay and designed subsequent experiments with input from Peter Sims.  
Linghao Kong and I conducted the IF and PLA imaging experiments. Linghao Kong and I 
executed the sucrose gradient fractionation experiments. I designed and executed the 
immunoprecipitation experiments. I designed and executed the SunTag imaging experiments 
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with assistance from Theresa Swayne and Laura Munteanu in the imaging core. Ruben Gonzalez 
and Erick Hartwick conducted structural modeling analysis with input from myself and Peter 
Sims.  I wrote the manuscript with Peter Sims and Ruben Gonzalez. All authors edited, read, and 
approved the final version published in eLife [226]. 
2.3 Section 2.3 is an adaptation of a previously published manuscript. I designed all 
research with minimal input from Peter Sims. I performed all mouse experiments, synaptosome 
fractionation, and sample preparation for flow cytometry. I acquired all flow cytometry with 
minor technical assistance from the flow cytometry core staff, which was limited to instrument 
setup and calibration. I became a trained operator and often used the cytometers outside of 
normal operation hours.  I conducted all data analysis and visualization. I wrote the manuscript 
together with Peter Sims. Along with Peter Sims, I was co-corresponding author on the 
publication in eNeuro [227]. 
 
2.1   Overview of mRNA localization and translation in neurons 
Ribosomes are the most abundant macromolecular machinery in eukaryotic cells: 
ribosomal RNA comprises 80-90% of total cellular RNA and ribosomal proteins represent ~30% 
of the cellular proteome [231–233]. At ~25 nm in diameter, eukaryotic ribosomes can be directly 
visualized by electron microscopy, particularly when in complexes known as polysomes, which 
consist of multiple ribosomes translating a single mRNA [234–236]. While polysomes are easily 
distinguished by their “beads on a string” morphology in in electron micrographs, single 
translating ribosomes (monosomes) or individual ribosomal subunits are difficult to distinguish 
from other cellular debris [237]. Thus, early ultrastructural studies of neurons focused primarily 
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on the cellular localization of polysomes [238]. From these studies, it became clear that the vast 
majority of neuronal polysomes are localized within the somata and proximal dendrites [238]. 
Meanwhile, polysomes were virtually undetectable within the axons and nerve terminals of 
mature neurons [239,240]. Around the same time, it was shown that newly synthesized proteins 
were transported from neuronal soma into axons in several distinct phases [241,242], forming the 
basis for the fast and slow rate classes of axonal transport [243,244]. Together, these studies 
established a prevailing view that all neuronal proteins were synthesized in the somata and 
subsequently transported into dendrites and axons. This dogma remained unchallenged for 
several decades, but is no longer a consensus view in modern neuroscience. As discussed below, 
there is overwhelming evidence for local translation in dendrites and its role in synaptic plasticity 
(reviewed in [245]). Similarly, local translation within peripheral axons and axonal growth cones 
of developing neurons is now well-established (reviewed in [246,247]). Although it remains 
controversial, several recent studies have provided evidence of axonal translation within mature 
CNS neurons [248–251]. 
 
Methods to study local translation in neurons 
Visualization and quantification of local translation within neuronal processes is 
technically challenging, particularly within the crowded environment of the brain. Low levels of 
ribosomes and newly synthesized proteins in dendrites and axons can be difficult to distinguish 
from neighboring neuronal and glial somata. The last two decades have seen an explosion of 
research in local translation, aided by a variety of technical advances. In this section, I will 
review key methods employed in studies of local translation (see Table 2.1.1). 
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Polysomes, but not monosomes, can be readily 






Immunostaining of ribosomal proteins and/or newly 
synthesized proteins within axons, nerve terminals, 







Puromycin incorporation into nascent polypeptides 







amino acid labeling 
Methionine analog incorporation into nascent 
polypeptides provides a Click-chemistry compatible 






Signal produced only when two antibodies are within 
< 20 nm, often used with anti-puromycin to detect 







Targeted hybridization or probes, +/- signal 
amplification, enables single mRNA detection 
[262,
263] 
Live Imaging MS2-MCP 
MS2 repeats and GFP-MCP enable live tracking of 
single mRNAs in cultured cells 
[264,
265] 
Live Imaging SunTag 
GFP binding to a tandem array of repeats in a 
reporter mRNA enables live tracking of single 
polysomes in cultured cells 
[266–
269] 
Electrophysiology Field potential 
Field potential recordings in the hippocampus report 
on post-synaptic potentiation, including after severing 







Whole-cell patch clamp recordings enable 
measurement of post-synaptic plasticity, including 
with PS inhibitors in the internal solution 
[249,
272] 
Biochemical TRAP / RiboTag 
Cell type-specific tagged ribosomal subunits can be 
used to IP translating ribosomes, including from 
axons, dendrites, or synaptosomes; captured mRNAs 







Purification of resealed presynaptic nerve terminals 
and adherent post-synaptic densities enables isolation 
of synapse-localized mRNAs; further specificity 





Table 2.1.1: Methods used to study local translation in neurons 
Abbreviations: IP, immunoprecipitation; GFP, green fluorescent protein; MCP, MS2 Coat Protein; 
PS, protein synthesis; TRAP, translating ribosome affinity purification. 
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Electron microscopy provided the first clues that translation in neurons was not entirely 
restricted to the soma. Ultrastructural studies of hippocampal synaptosome preparations revealed 
accumulations of polyribosomes within resealed dendritic spines [281], and under the base of 
dendritic spines in the dentate gyrus [252]. Electron microscopy, particularly in combination 
with immunogold labeling, remains one of the most powerful methods for visualizing 
exceedingly low levels of ribosomes or newly synthesized proteins in axonal nerve terminals 
[248,250,251]. As mentioned above, it was previously thought the virtually all translation occurs 
on polyribosomes. However, recent biochemical evidence suggests that a majority of local 
translation in dendrites and axons may be mediated by monosomes [282]. Thus, electron 
microscopy may underestimate the extent of local translation in these compartments. 
Radioactive amino acid labeling provides sensitive measurement of newly synthesized 
proteins in biochemical studies, but the optical resolution afforded by autoradiography is often 
insufficient to study fine neuronal processes. The development of metabolic and antibiotic 
labeling methods for fluorescent detection of newly synthesized proteins greatly accelerated 
studies of local translation. Non-canonical amino acid labeling, such as with modified 
methionine analogs containing a biorthogonal alkyne group, allows full-length proteins to be 
synthesized and subsequently tagged with biotin or fluorophores using Click-chemistry 
[258,259]. Proteins synthesized within a discrete time period can then be captured for 
biochemical analysis or visualized within specific subcellular compartments. However, this 
strategy requires methionine depletion and is therefore typically limited to slice preparations or 
cultured cells. A more general approach involves treatment with puromycin, an antibiotic that 
covalently binds nascent polypeptides and ejects them from translating ribosomes [283]. Anti-
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puromycin antibodies can be used to directly visualize the labeled peptides [284], which are 
truncated at their C-terminus.  
Metabolic labeling of newly synthesized proteins has also been used in conjunction with 
a proximity ligation assay (PLA) that generates fluorescent signal by rolling circle amplification, 
which requires two oligonucleotide-conjugated antibodies to be within ~20 nm [261]. The most 
common form of the assay, ‘Puro-PLA’, employs an N-terminal antibody against a protein of 
interest along with an anti-puromycin antibody [260]. It is claimed that Puro-PLA primarily 
detects binding of the protein-specific and anti-puromycin antibodies to the N- and C-terminus of 
the same nascent peptide, respectively [260]. However, there is substantial evidence that PLA 
can detect proximity between two antibodies based on random overlapping localization rather 
than specific interaction [285]. As shown below in section 2.2 [226], this caveat significantly 
hampered my attempts to use PLA for cell type-specific detection of translating ribosomes. 
Another serious caveat with these metabolic labeling methods is that the newly 
synthesized peptides/proteins are released from their translation sites and can freely diffuse or be 
trafficked away from the original site of synthesis. Indeed, as I show below in section 2.2 [226], 
puromycin-labeled peptides are rapidly released from ribosomes even in the presence of 
elongation inhibitors. Most studies typically employ labeling times of 5-15 minutes and assume 
that diffusion and/or trafficking do not contribute significantly to the fluorescent signal in 
dendrites or axons [250,260,282,286]. To the best of my knowledge, this assumption was 
asserted by the Schuman Lab without any supporting evidence and has never been 
experimentally tested. While the labeling times may be short, the extra time taken to remove 
media, wash cells, and add fixative solutions may substantially lengthen the transit time prior to 
complete fixation. The contribution of somatically synthesized products is likely minimal in 
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certain cases, such as axonal nerve terminals after 5 minutes of labeling in cultured neurons 
[250]. Other situations are not so clear-cut. For example, one study injected puromycin into the 
lateral ventricles, waited 10 minutes, then initiated isoflurane anesthesia and perfusion fixation 
[282]. In our hands, it would typically take at least 10 minutes between anesthesia induction and 
observable fixation of mouse tissues. The additional time required to complete these procedures 
was not mentioned in the study; instead, it was simply claimed that puromycin staining of 
proximal dendrites in the hippocampus was derived from local translation because of the “very 
short window of metabolic labeling” [282]. 
While it remains unknown exactly how many and which mRNAs are locally translated in 
neurons, microdissection and biochemical have identified over 2,000 mRNAs present in the 
hippocampal synaptic neuropil [282,287]. Although this layer is typically devoid of neuronal 
soma, strong claims of local translation for a specific mRNA must be supported by direct 
visualization of the mRNA in the relevant compartment. Fluorescence in situ hybridization 
(FISH) is the gold standard for visualizing the endogenous localization pattern of specific 
mRNAs. Single molecule FISH (smFISH) employs fluorophore-labeled ~17-22 bp probes to 
produce diffraction-limited puncta without signal amplification [262]. Although smFISH is well-
established and permits true quantification of single mRNA molecules, the dim signals require 
low background noise and can be difficult to resolve within tissue. Another widely employed 
FISH technique is the commercial assay RNAscope [263], which employs many pairs of ~18-25 
bp probes that contain 14 bp oligonucleotide tails. The two 14 bp tails of a probe pair are then 
bound by 28 bp secondary oligonucleotides, facilitating downstream signal amplification with a 
high signal-noise ratio [263]. Although the RNAscope puncta are not diffraction limited and may 
contain multiple mRNAs in some cases, the assay is certainly capable of detecting single mRNA 
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molecules [263]. RNAscope has proven to be the most robust FISH assay for my studies of 
dopamine neurons in the mouse brain, particularly when combined with anti-TH 
immunofluorescence. As shown later in Chapter 3, this assay enables simultaneous detection of 
two mRNAs within dopaminergic somata and neuronal processes. 
FISH represents an invaluable assay for determining the precise subcellular localization 
of mRNAs, but the data are limited to static ‘snapshots’ of fixed cells or tissues. Significant 
advances in molecular imaging now enable real-time tracking of single mRNAs in living cells. 
The classic MS2 tagging system employs repeated stem-loop elements within a reporter mRNA, 
which are bound by MS2 Coat Protein (MCP) fused to GFP [265]. More recently, a similar 
strategy known as ‘SunTag’ has been developed to target GFP fused to antibody fragments to 
repeated peptide motifs encoded by a reporter mRNA [266–269]. Once the repeated motifs 
within nascent polypeptides begin to emerge from translating ribosomes, they are immediately 
bound by GFP-antibody fusion proteins. When the reporter is engaged in polysome translation, 
discrete bright spots can be distinguished from the diffuse background fluorescence of the free 
GFP fusion proteins (see Figure 2.2.3 below). The SunTag system has been employed with 
alongside MS2 tagging of the same RNA, enabling live tracking of single mRNAs engaged in 
polysome translation within neuronal dendrites [269]. Although I did not use the SunTag system 
for translational imaging in dopamine neurons, it was an invaluable tool for real-time monitoring 
of puromycin-labeled peptide release in section 2.2. 
Electrophysiological recordings are critical for monitoring changes in synaptic strength, 
and have long been obtained in the presence of protein synthesis inhibitors to demonstrate the 
involvement of de novo protein synthesis in various forms of post-synaptic plasticity. However, 
the loss of a synaptic change upon bath application of protein synthesis inhibitors does not 
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demonstrate the requirement for de novo protein synthesis within a specific cellular 
compartment. In a classic study, Kang and Schuman demonstrated that neurotrophin-induced 
synaptic potentiation in the hippocampal neuropil required de novo protein synthesis even when 
dendrites had been severed from their cell bodies [270]. In paradigms of pre-synaptic plasticity, 
several studies have shown that protein synthesis inhibitors within the internal solution of patch 
clamp pipettes do not reproduce the effect of bath application on evoked post-synaptic responses 
[249,272]. In this case, de novo protein synthesis is required for plasticity, but not within the 
post-synaptic neuron, suggesting that the presynaptic nerve terminal is the relevant site of action 
for bath application of protein synthesis inhibitors [249,272]. 
As mentioned above, the low levels of ribosomes found within the dendrites and axons 
are difficult to distinguish from surrounding neuronal and glial somata in imaging and 
biochemical studies. Biochemical studies of translation within specific CNS cell types became 
possible with the introduction of translating ribosome affinity purification (TRAP) [276] and 
RiboTag mice [278]. These mice express tagged ribosomal proteins under the control of cell 
type-specific promoters (or Cre recombinase expression); translating ribosomes derived from a 
specific population can then be immunoprecipitated from bulk tissue lysates and profiled by 
RNA-seq. While most TRAP/RiboTag studies focus on whole-cell profiling, recent studies have 
combined cell type-specific ribosome capture with regional dissection or subcellular 
fractionation to study the translatome of axonal or dendritic compartments 
[248,251,273,275,288]. For example, CA1 pyramidal neuron-specific expression of tagged 
ribosomes enabled isolation of dendritic mRNAs from microdissections of hippocampal synaptic 
neuropil [288]. The separation of cell bodies and axons has also been leveraged to study the 
translatome of specific axonal projections, such as retinal ganglion cell axons within the superior 
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colliculus [248] or cortical axons within the amygdala [251]. A major goal of my thesis was to 
study translation within specific compartments of midbrain dopamine neurons using DATIRES-
Cre:RiboTag mice [278,289], which express HA-tagged ribosomes under control of the 
endogenous DAT locus (see Figure 3.1). 
For neurons whose processes are intermingled with their somata, cell type-specific 
ribosome capture has been combined with synaptosome fractionation (‘SynapTRAP’) [273,274]. 
Although synaptosomes are canonically described as resealed nerve terminals that often retain an 
adherent post-synaptic density [279], synaptosome fractions also contain a mixture of non-
neuronal elements, including peri-synaptic membranes derived from astrocytes [281]. Indeed, 
ribosomes derived from peripheral astrocyte processes have been isolated from hippocampal 
synaptosomes (‘PAP-TRAP’) [275]. Thus, the mixture of pre-synaptic, post-synaptic, and glial 
elements present in synaptosomal fractions limits the utility of bulk synaptosomal RNA 
profiling. Fluorescence-activated synaptosome sorting (FASS) enables enrichment of a specific 
synaptosomal population based on genetically encoded fluorophores localized within the nerve 
terminals of target neurons [290]. For example, VGLUT1+ synaptosomes can be sorted and 
directly analyzed by RNA-seq for enrichment of specific mRNAs [250]. In collaboration with 
Etienne Herzog, who developed FASS, I implemented a similar strategy to study mRNAs 
enriched by sorting dopaminergic synaptosomes (see Chapter 3). However, I also independently 




Dendritic translation in synaptic plasticity 
Local protein synthesis in dendrites is involved in synaptic plasticity within a variety of 
brain regions and neuronal populations. Behavioral studies in the 1960’s found that performance 
on several learning tasks could be dramatically reduced by concomitant administration of protein 
synthesis inhibitors [291,292], thus demonstrating a requirement for de novo protein synthesis in 
these forms of learning (reviewed in [293]). It was later discovered that the molecular basis for 
these forms of learning was persistent, activity-dependent increases in synaptic strength within 
the hippocampus, known is long-term potentiation (LTP) [294]. Various forms of LTP have 
distinct mechanisms and requirements for de novo transcription and translation (reviewed in 
[293]). As noted above, the earliest evidence that de novo protein synthesis within dendrites was 
involved in plasticity came from the hippocampus, where the layers of neuronal cell bodies can 
be surgically severed from their dendrites. Using this technique, dendritic translation was shown 
to be necessary for neurotrophin-induced synaptic potentiation [270] as well as late long-term 
potentiation [295,296]. It is generally assumed that activity-dependent synthesis of proteins 
within dendrites can modify synaptic strength, providing neurons with rapid, tunable control of 
the local proteome. 
One of the most well-studied forms of protein synthesis-dependent plasticity is long-term 
depression (LTD) mediated by Group 1 metabotropic glutamate receptors (mGluRs) [271,297]. 
mGluR-LTD occurs in most brain regions, although the underlying mechanisms are not universal 
(reviewed in [297]). Hippocampal mGluR-LTD requires de novo protein synthesis in dendrites 
[271] and is aberrantly augmented in Fmr1-KO mice lacking fragile X mental retardation protein 
(FMRP) [298]. It is thought that in the absence of FMRP, post-synaptic neurons excessively 
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translate ‘LTD proteins’ that are normally upregulated by mGluR-induced protein synthesis to 
facilitate LTD [299]. The newly synthesized proteins and their role in the post-synaptic 
expression of LTD remain unknown. 
In contrast to hippocampal neurons, studies of protein synthesis and synaptic plasticity in 
dopamine neurons are scarce. However, one study demonstrated that mGluR-LTD in VTA 
dopamine neurons employs a protein synthesis-dependent post-synaptic mechanism [300]. It had 
previously been established that a single dose of cocaine induces LTP in VTA dopamine neurons 
by increasing surface expression of AMPA receptors [301]. Mameli et al. [300] found that 
mGluR-LTD in VTA dopamine neurons was sufficient to reverse cocaine-induced LTP by 
increasing the proportion of GluR2-containing AMPA receptors. The LTD was abolished by 
protein synthesis inhibitors and by targeted degradation of GluR2 mRNA within VTA dopamine 
neurons, suggesting that mGluR stimulation triggers de novo synthesis and surface expression of 
GluR2 [300]. Given that none of these manipulations were dendrite-specific, it is not clear 
whether the newly synthesized GluR2 subunits are derived from somatic or dendritic translation. 
Alterations in VTA dopamine neuronal plasticity are heavily implicated in drug addiction 
(reviewed in [302]), but it remains unknown whether or not LTP and LTD in these neurons 
require local translation. To the best of my knowledge, no studies have investigated dendritic 
translation in SNc dopamine neurons. 
 
Axonal translation in the peripheral and central nervous systems 
It is broadly accepted that PNS axons are endowed with a greater capacity for protein 
synthesis than CNS axons [303], which may correlate with the enhanced regenerative capability 
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of peripheral nerves [304]. Why might this be the case? One answer may be differences between 
myelinating glial cells of the PNS and CNS. While ribosomes are difficult to find in electron 
micrographs of CNS axons, they are readily identified in peripheral nerves as periodic clusters 
known as peri-axoplasmic ribosomal plaques (PARP) [305]. The periodic nature of these clusters 
and their proximity to the myelinating membranes suggested that these axonal ribosomes might 
be transferred from Schwann cells [306]. Indeed, subsequent studies have generated considerable 
evidence of Schwann cell-derived ribosomal transfer into axons [306–308]. In fact, an increase 
in Schwann cell-derived axonal ribosomes within the sciatic nerve was observed in a mouse 
model of amyotrophic lateral sclerosis [309]. The relative contributions of axonal transport and 
glial transfer of ribosomes are currently unknown, and there is no evidence that oligodendrocytes 
are similarly capable of transferring ribosomes into CNS axons. 
The regulation of axonal translation is tightly linked to the developmental age and growth 
status of the axon (reviewed in [310,311]). It is well-established that response to guidance cues 
during axonal pathfinding requires local translation in growth cones (reviewed in [246,312]), but 
axonal ribosomes are significantly less abundant in mature axons [313–315]. Recent evidence 
suggests that a massive reduction of axonal ribosomes is induced by presynaptic differentiation 
and is mediated by proteasomal degradation [316]. Accordingly, the repertoire of axonal mRNAs 
exhibits dramatic changes from embryonic development into adulthood [248,317]. 
The role of local translation in axonal pathfinding has been extensively studied in the 
growth cones of retinal ganglion cells [318]. Gradients of the guidance cue Netrin-1 induce 
growth cone turning by a remarkable mechanism that involves asymmetric local translation of β-
actin [318]. Intriguingly, the Netrin-1 receptor DCC has emerged as a critical regulator of 
cortical dopamine axon targeting during adolescence [319]. It was recently demonstrated that 
49 
 
DCC-signaling in dopamine axons mediates ongoing migration from the NAcc into the PFC 
[320]. The canonical role of local translation in Netrin-1/DCC guidance [318,321] suggests that 
axonal translation may be involved in the adolescent migration of NAcc dopamine axons. 
Although Netrin-1/DCC are critical to mesocortical DA axon development [322], the role of 
local protein synthesis in developing DA axons has not been investigated. 
More recently, multiple studies have demonstrated local translation within the axons of 
multiple CNS populations, including retinal ganglion cells [248], GABAergic neurons in the 
hippocampus [249], globular busy cells in the ventral cochlear nucleus [257], and cortical 
projection neurons [251]. Several of these studies demonstrated regulation of presynaptic 
neurotransmission by axonal translation, including release probability at the Calyx of Held 
synapse [257] and endocannabinoid-induced presynaptic LTD in hippocampal inhibitory 
terminals [249]. Striatal LTD is also mediated by retrograde endocannabinoid signaling and a 
presynaptic mechanism that appears to require axonal protein synthesis [272]. Other studies have 
demonstrated alterations in axonal translation in response to pharmacological or behavioral 
stimuli, such as neurotrophin signaling in hippocampal axons [250] or fear-related learning in 
cortical-amygdalar axons [251]. The signaling mechanisms which engage axonal translation are 
not completely understood, and may involve coupling of axonal ribosomes to cell surface 
receptors, such as the Netrin-1 receptor DCC [321,323]. The mammalian target of rapamycin 
(mTOR) has been shown to play a dominant role in translational regulation within peripheral 
axons, where feed-forward mTOR signaling can increase local translation of mTOR itself [324]. 
mTOR signaling also appears to play a major role in the axonal growth cones of developing 
cortical projection neurons [325], although no clear role has yet emerged in mature CNS axons. 
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While many studies have focused on local protein synthesis in glutamatergic and 
GABAergic neurons, virtually none have investigated local translation in catecholaminergic 
neurons within the central nervous system. However, there are several intriguing studies of 
axonal translation in cultured sympathetic neurons [326,327]. Sympathetic axons display a 
marked localization of tyrosine hydroxylase (TH) mRNA, suggesting that local translation may 
regulate axonal catecholamine synthesis [326]. It was later shown that ablation of an axonal 
localization motif in the 3’ untranslated region (UTR) of Th mRNA decreases axonal TH protein 
levels as well as release of norepinephrine [327]. Local translation of mitochondrial proteins is 
also prominent within sympathetic axons [328] and plays a critical role in maintaining axonal 
viability [329]. Given the extensive catecholamine synthesis machinery and mitochondrial mass 
present in dopaminergic striatal axons, similar mechanisms of axonal mRNA localization could 
be employed by midbrain dopamine neurons. 
Collectively, these findings led to the formation of my qualifying examination proposal, 
which focused primarily on studying local protein synthesis within dopaminergic axons. In many 
ways, dopamine axons seemed like the perfect candidates for local translation: far from their cell 
bodies, massively arborized, heavily dependent on mitochondrial metabolism, and highly 
heterogenous in their dopamine release properties. Nonetheless, I knew that these studies would 
be technically challenging. I planned to study local translation in dopamine neurons using many 
of the methods described above, including RiboTag RNA-seq, FISH, synaptosome sorting, 
puromycin labeling, and proximity ligation assay. Most of these studies are described in 
Chapter 3. However, I found that several of these methods were plagued by technical artifacts 
that limited their utility in studies of dopamine neurons. The following two sections summarize 
51 
 
my efforts to characterize these technical artifacts and prevent further misuse of these methods 
by others in the field. 
 
2.2   Puromycin labeling of nascent polypeptides and putative local 
translation sites 
 In my early studies using puromycin to detect nascent polypeptides, I conducted several 
experiments with Ori Lieberman where we labeled, fixed, and stained striatal slices. My hope 
was that we could detect puromycin immunoreactivity within dopaminergic axons. However, 
this strategy immediately failed: the puromycin signal derived from striatal somata was an order 
of magnitude brighter than the surrounding neuropil, and the dim neuropil signal could not be 
confidently assigned to dopamine axons, dendrites of striatal SPNs, or glial processes. A more 
efficient strategy would be to generate a puromycin-derived fluorescent signal that was specific 
to dopamine neurons. Since I was working with DATIRES-Cre:RiboTag mice, I envisioned a PLA 
that would combine anti-puromycin and anti-HA staining, resulting in fluorescent labeling of 
nascent polypeptides bound to dopamine neuron-specific ribosomes (see schematic in Figure 
2.2.1B below). Such a strategy required that the puromycin-labeled peptides would remain stably 
bound to the translating ribosomes, which one study claimed could be accomplished by treating 
cells with elongation inhibitors prior to puromycin [286]. 
I recruited Linghao Kong, a bright young undergraduate student, to assist me with this 
project. The plan was to establish the assay conditions in culture, and then use it to detect 
translating ribosomes in dopaminergic dendrites and axons in the mouse brain. We began to test 
the anti-ribosome/anti-puromycin PLA in a RiboTag glioma cell line, which was a generous gift 
from the laboratory of Peter Canoll. As it turned out, we never found any conditions that enabled 
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puromycin-labeled peptides to remain stably bound to ribosomes and accessible to antibody 
labeling. As we began to pull on the threads of the published literature, the claims of the 
previously published study began to unravel. Not content to simply bury these results away in a 
drawer of failed experiments, I decided to go the extra mile and complete a full set of 
experiments to conclusively document the artifacts associated with the previously published 
method [286]. Unbeknownst to us, Rachel Green’s lab had recently made similar findings and 
was preparing to submit their manuscript. We were very lucky to post our findings to bioRxiv 
around the same time, which allowed us to coordinate co-submission and back-to-back 
publication in eLife [226,330]. The following section contains our manuscript, which describes 
these experiments in chronological order. 
 
The following is adapted from: 
Hobson BD, Kong L, Hartwick EW, Gonzalez RL, Sims PA (2020) Elongation Inhibitors do 
not Prevent the Release of Puromycylated Nascent Polypeptide Chains from Ribosomes. 
eLife. 2020;9:e60048. doi: 10.7554/eLife.60048. 
 
Supplementary figures are in Appendix A. 
Figure 2.2.3 - video 1 is available at: https://elifesciences.org/articles/60048/figures#fig3video1 
 
2.2.1 Abstract 
Puromycin is an amino-acyl transfer RNA analog widely employed in studies of protein 
synthesis. Since puromycin is covalently incorporated into nascent polypeptide chains, anti-
puromycin immunofluorescence enables visualization of nascent protein synthesis. A common 
assumption in studies of local messenger RNA translation is that the anti-puromycin staining of 
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puromycylated nascent polypeptides in fixed cells accurately reports on their original site of 
translation, particularly when ribosomes are stalled with elongation inhibitors prior to puromycin 
treatment. However, when we attempted to implement a proximity ligation assay to detect 
ribosome-puromycin complexes, we found no evidence to support this assumption. We further 
demonstrated, using biochemical assays and live cell imaging of nascent polypeptides in 
mammalian cells, that puromycylated nascent polypeptides rapidly dissociate from ribosomes 
even in the presence of elongation inhibitors. Our results suggest that attempts to define precise 
subcellular translation sites using anti-puromycin immunostaining may be confounded by release 
of puromycylated nascent polypeptide chains prior to fixation. 
 
2.2.2 Background 
Subcellular localization of messenger RNA (mRNA) translation enables dynamic, rapid 
regulation of protein synthesis in a wide range of biological systems [247,331,332].  The number 
of localized mRNAs is much greater than originally appreciated [333], and the study of 
subcellular translation sites is now an area of active research across multiple organisms and cell 
types. A powerful, widely used technique to study protein synthesis involves the incorporation of 
puromycin into nascent polypeptide chains (NPC) of translating ribosomes. As an amino-acyl 
transfer RNA (tRNA) analog, puromycin enters the ribosomal aminoacyl-tRNA binding site (A 
site) and is covalently coupled to the carboxyl-activated NPC at the ribosomal peptidyl-tRNA 
binding site (P site) that is adjacent to the A site within the ribosomal peptidyl transferase center 
(PTC), terminating protein synthesis and ejecting a C-terminal puromycylated NPC [283]. This 
reaction was first exploited to label nascent polypeptides with fluorescent puromycin analogues 
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[255,256,334], and became widely used both in vitro and in vivo following the development of 
anti-puromycin antibodies [284] and ‘click’-chemistry-compatible puromycin analogues [254]. 
Despite technical advances, using puromycin labeling to visualize the subcellular 
distribution of nascent protein synthesis in specific cell types within complex tissues remains 
challenging. This is particularly true for polarized cells such as neurons, where levels of protein 
synthesis in dendrites and axons are relatively low compared to neighboring neuronal and glial 
cell bodies. Although large nerve terminals may be readily visualized [257] and expansion 
microscopy can provide higher resolution [250], diffusion or trafficking of puromycylated NPCs 
prior to chemical fixation may confound attempts to determine the original translation site. To 
combat this problem,  David et al. [286] introduced the ribopuromycylation (RPM) assay and 
used it to argue in favor of active protein synthesis within the nucleus. The premise of the RPM 
assay is that pretreatment of cells with elongation inhibitors, such as emetine or cycloheximide, 
prevents release of puromycylated nascent chains from translating ribosomes [286,335]. These 
studies assert that anti-puromycin immunostaining of labeled nascent chains in fixed cells occurs 
in situ on elongation-stalled ribosomes bound to mRNA. 
We sought to develop a puromycin labeling assay based on RPM that would 
simultaneously provide cell type-specificity and preserve the ribosomal localization of the anti-
puromycin signal. In the course of our studies, we found that elongation inhibitors do not prevent 
the release of puromycylated NPCs from ribosomes. Furthermore, structural modeling revealed 
that antibodies are unlikely to be able to directly contact and recognize puromycin within the 
PTC of intact ribosomes due to steric hindrance. Together, these results suggest that anti-
puromycin immunostaining occurs only on puromycylated nascent chains released from 
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Implementation of a Cell Type-Specific Ribopuromycylation Proximity Ligation Assay 
 
 
To develop a cell type-specific assay for visualization of local translation sites, we 
envisioned combining the ‘RiboTag’ system [278] of Cre-dependent HA-tagged Rpl22 
(eukaryotic ribosomal protein L22, hereafter referred to as eL22-HA) with the RPM assay [286] 
(Figure 2.2.1A). Based on the premise that elongation inhibitors prevent puromycylated NPC 
release from ribosomes, we reasoned puromycin would be in specific proximity to the eL22-HA 
antigen present on ribosomes in RiboTag-expressing cells (Figure 2.2.1B). Such complexes 
could be visualized by the proximity ligation assay (PLA), which requires two targets to be 
within <40nm [261]. Because the HA tag on eL22-HA is on the C-terminus, intramolecular 
eL22-HA/Puro PLA from nascent eL22 peptides is unlikely to contribute significant signal 
[260]. 
We utilized murine RiboTag glioma cells [336] to test the feasibility of eL22-HA/Puro 
PLA in vitro. After pretreatment with emetine and brief puromycin labeling, we fixed cells and 
analyzed anti-puromycin immunofluorescence (IF) and eL22-HA/Puro PLA in parallel (Figure 
2.2.1C, see Table A.1 for summary statistics and testing). Similar to anti-puromycin IF, the 
eL22-HA/Puro PLA produced a robust fluorescent signal in RiboTag glioma cells treated with 
puromycin, which was blocked by pretreatment with anisomycin, an antibiotic that binds to the 
A-site ‘cleft’ and competitively inhibits puromycin incorporation [337,338]. We verified that the 
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eL22-HA/Puro PLA signal was specific to the presence of both antibodies by omitting either the 
anti-puromycin or the anti-HA antibody (Figure 2.2.1C, see Table A.1 for statistics) We further 
tested the cell-type specificity of the eL22-HA/Puro PLA using human U87 glioma cells, which 
do not express eL22-HA (Figure A.1A). As expected, these cells exhibit minimal eL22-HA/Puro 
PLA signal despite robust anti-puro IF labeling (Figure 2.2.1C). We also utilized high-resolution 
confocal imaging to visualize eL22-HA/Puro PLA puncta (Figure 2.2.1D and Figure A.1C). 
Quantification of eL22-HA/Puro PLA puncta per cell revealed ~200 puncta per cell, while 
omission of either puromycin or HA antibodies reduced this to <8 puncta per cell (Figure A.1B). 
Thus, the eL22-HA/Puro PLA accurately reports on the presence of puromycin in labeling 
controls (omission of puromycin/anisomycin pretreatment) and meets the standard specificity 
criteria of PLA (lack of signal with omission of either primary antibody or antigen). 
 Previous imaging studies have demonstrated that in the absence of elongation inhibitors, 
puromycylated NPCs dissociate from ribosomes in minutes [266–269]. Therefore, we expected 
that cells receiving no pretreatment would produce significantly less eL22-HA/Puro PLA signal 
compared to cells pretreated with emetine, which should prevent release of puromycylated 
nascent chains according to David et al. [286]. However, emetine pretreatment produced a 
minor, but statistically significant, decrease in the eL22-HA/Puro PLA signal relative to the 
corresponding anti-puromycin IF (Figure 2.2.1C) and relative to eL22-HA/Puro PLA signal 
from cells receiving no pretreatment (Figure 2.2.1C). This effect of emetine was specific to 
eL22-HA/Puro PLA, as emetine pretreatment did not significantly alter anti-puromycin IF 
(Figure 2.2.1C). Surprised by these results, we conducted the eL22-HA/Puro PLA following 
puromycin washout (Figure A.2A). We reasoned that after a short pulse of puromycin and an 







After up to 45 minutes of washout, the eL22-HA/Puro PLA still produced intense signal 
comparable to anti-puromycin IF (Figure A.2C). We conducted a similar experiment using 
harringtonine runoff (Figure A.2B). Since the small-molecule drug harringtonine stalls newly 
initiating ribosomes [339], extended incubation in harringtonine eliminates the presence of NPCs 
once elongating ribosomes are runoff. We first confirmed that harringtonine runoff removed 
NPCs available for puromycylation by conducting the harringtonine runoff before puromycin 
treatment (Figure A.2C). However, conducting harringtonine runoff after puromycin treatment 
and washout still produced robust eL22-HA/Puro PLA signal that was only slightly reduced 
relative the corresponding anti-puromycin IF (Figure A.2C). Therefore, we conclude that while 
the eL22-HA/Puro PLA is specific for the presence of antigen and antibody, it reports primarily 
on the cytoplasmic abundance of puromycylated NPCs, regardless of whether they are currently 
bound to ribosomes. 
 
 
Figure 2.2.1: PLA targeting eL22-HA and puromycylated nascent chains produces 
translation- and antigen-dependent signal, but does not distinguish between emetine-
stalled and untreated ribosomes 
(A) Schematic depicting the ribopuromycylation assay as described by David et al. 
(2012). Experimental procedures used in these studies are shown below. (B) Schematic 
depicting our intended model of combining ribopuromycylation with proximity ligation 
assay to enable cell type-specific visualization of translation, based on David et al. 
(2012). (C) Violin plots of normalized fluorescence intensity for puromycin IF or eL22-
HA/Puro PLA signal in RiboTag glioma cells treated as indicated. Exceptions are noted 
below the plots for omission of primary antibodies or use of U87 glioma cells (lacking 
eL22-HA expression). Data are derived from 3-4 experiments and 112-288 cells per 
condition, and statistical comparisons indicated were conducted using Mann-Whitney U 
test. See Table A.1 for details. * indicates p < 0.05, **** indicates p < 1e-4. Representative 
images (10x) are shown below; DAPI in blue, puromycin IF or eL22-HA/Puro PLA in 
magenta. Scale bar, 50 µm. (D) Representative confocal images (60x; Z-stack maximum 
projection) of eL22-HA/Puro PLA fluorescence for RiboTag glioma cells treated as 




Instability of Puromycylated NPC-Ribosome Complexes 
 
 
The results of our eL22-HA/Puro PLA were somewhat surprising, since PLA is generally 
assumed to produce signals based only on specific proximity (i.e., antigen-antigen interaction) 
given the distance requirement of <40nm. However, recent evidence suggests that PLA signals 
can be generated by a variety of non-interacting antigen pairs, provided they have overlapping 
spatial distributions and are present at high concentrations [285]. Such a model of ‘non-specific 
proximity’ seemed to fit our PLA data, but was inconsistent with the claims of David et al. [286] 
that puromycylated NPCs remain tethered to ribosomes pretreated with elongation inhibitors. 
Cycloheximide binds to the ribosomal large, 60S, subunit in the tRNA ‘exit’ site (E site), stalling 
elongation by preventing exit of the deacylated E-site tRNA [340]. Emetine acts similarly to 
pactamycin, binding the ribosomal small, 40S, subunit in the E site and preventing translocation 
of the tRNA-mRNA complex [341]. However, we are unaware of any evidence that translocation 
is required for puromycin to exit the ribosome after covalently reacting with the NPC. In fact, 
previous imaging studies demonstrated that puromycylated NPCs are released from ribosomes in 
the presence of cycloheximide  [268].  
To resolve the discrepancy between these findings and the claims of David et al. [286], 
we sought biochemical evidence that elongation-inhibited ribosomes and puromycylated NPCs 
are stable biochemical complexes. We conducted sucrose gradient fractionation of polysomes 
from RiboTag glioma cells pretreated with emetine (Figure 2.2.2A) or cycloheximide (Figure 
2.2.2B) prior to puromycin treatment. We found that puromycin immunoreactivity was 
undetectable in polysome fractions, and that puromycylated NPCs were abundant primarily in 
the top two fractions corresponding to free material (Figure 2.2.2A-B). The absence of 
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puromycylated NPCs in polysome fractions of cells treated with puromycin, even after 
pretreatment with elongation inhibitors, is consistent with previous work [342,343]. However, 
these results seem to contradict those of David et al. [286], who first bound untreated polysomes 
to polyvinylidene fluoride (PVDF) membranes before puromycin treatment, fixation, and 
immuno-ELISA. 
Since puromycylated NPCs are released from polysomes either prior to or during sucrose 
gradient centrifugation (Figure 2.2.2A-B), we suspected that puromycylated NPCs would also 
be released from polysomes bound to PVDF [286]. However, puromycylated NPCs could 
directly bind to the PVDF matrix, creating the appearance that they are still tethered to 
ribosomes. We therefore conducted immunoprecipitation (IP) experiments using either anti-
puromycin or anti-HA antibodies bound to magnetic beads (Figure 2.2.2C). RiboTag glioma 
cells were pretreated with emetine followed by puromycin, or pretreated with emetine, lysed, and 
treated with puromycin in solution. Regardless of emetine pretreatment, western blotting of 
captured proteins showed no evidence of co-IP: puromycin immunoreactivity was observed only 
in anti-puromycin IP samples, while eL22-HA and Rps6 immunoreactivity were observed only 
in anti-HA IP samples (Figure 2.2.2D). Although emetine pretreatment did not prevent release 
of puromycylated NPCs from ribosomes (Figure 2.2.2A-D), the RNA captured by eL22-HA IP 
confirmed that emetine inhibits polysome breakdown (Figure A.3A). RNA captured by anti-HA 
IP from emetine pretreated cells had a significantly higher total yield and a lower ratio of 60S 
subunit 28S ribosomal RNA (rRNA) to 40S subunit 18S rRNA (28S/18S ratio), reflecting 
enhanced capture of intact polysomes in the presence of emetine (and enhanced capture of HA- 
tagged free 60S subunits in the absence of emetine). In contrast to the anti-HA IP, no detectable 
rRNA was captured by anti-puromycin IP, even with emetine pretreatment (Figure A.3B). These 
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results are consistent with the work of Grollman [343] and suggest that although emetine 







Direct imaging of puromycin-induced nascent chain release from ribosomes 
 
 
Our biochemical studies demonstrated that puromycylated NPCs are not stably bound to 
ribosomes in polysome lysates, but did not reveal the kinetics of the release process or whether it 
occurs within puromycin-treated cells in situ. We utilized the SunTag translation reporter system 
[266–269] in HEK-293FT cells in order to directly visualize puromycylated NPC release (Figure 
2.2.3A). We employed the version of this system described by Wu et al. [269], which comprises 
(i) an mRNA encoding the SunTag array of 24 GCN4 repeats followed by oxBFP and an auxin-
induced degron (AID), (ii) super folder green fluorescent protein (sfGFP)-bound single-chain 
variable fragment (scFv) of GCN4 antibody (scFv-GCN4-sfGFP), and (iii) Oryza Sativa 
transport inhibitor response 1 (OsTIR1) to remove completed proteins containing the AID 
(Figure 2.2.3A). Because the soluble scFV-GCN4-sfGFP binds rapidly to the SunTag array 
[344] present in NPCs as they emerge from the ribosome, polysomes translating the reporter are 
 
 
Figure 2.2.2: Regardless of pretreatment with elongation inhibitors, ribosomes and 
puromycylated nascent chains are not stable biochemical complexes 
(A) Sucrose gradient fractionation of polysomes from cells pretreated with emetine prior 
to puromycin. Top: Absorbance spectra from 15-50% linear sucrose gradient. Dashed lines 
indicate fractions collected, which correspond to western blots below. Bottom: Western 
blots for puromycin, Rps6, and eL22-HA. Note that Rb α S6 and Ms α HA were probed 
first, and some residual Ms anti-HA remained on the membrane during subsequent 
probing with Ms α Puromycin (see identical staining pattern below). (B) Same as (A), but 
with cycloheximide pretreatment. (C) Schematic depicting experimental workflow for 
eL22-HA and puromycin co-immunoprecipitation experiment. Numbers in parentheses 
indicate the number of samples along each branch of the workflow. All indicated splits of 
lysates and beads were equal, such that each RNA or protein sample represents an equal 
input of cell lysate. (D) Western blots of puromycin, eL22-HA, and Rps6 from input and 
IP samples as indicated. In blots using Ms α Puromycin or Ms α HA, strong bands 
corresponding to Ms IgG are present in the Ms α Puro lanes. Note that the Ms IgG light 




visualized as bright spots (hereafter SunTag puncta) on top of the cytoplasmic background 
fluorescence (Figure 2.2.3B). Consistent with previous work [266–269], we found that the 
SunTag puncta disappear in minutes upon treatment with puromycin (Figure 2.2.3B). Thus, the 
fading of SunTag puncta into the cytoplasmic background is caused by GFP-bound 
puromycylated NPCs diffusing away from polysome complexes (Figure 2.2.3A). 
To study the kinetics of puromycylated NPC release, we conducted time lapse imaging in 
live cells, continuously cycling between 7-12 cells per dish. We pretreated cells with emetine or 
cycloheximide prior to the onset of imaging, and then added puromycin 60 seconds into each 8-
minute imaging trial. We observed complete loss of SunTag puncta in all puromycin-treated cells 
within this timeframe (Figure 2.2.3C), with minimal loss of SunTag puncta in untreated control 
cells (Figure 2.2.3C) and negligible photobleaching in all conditions (Figure A.4B). 
Representative single-cell trajectories are shown in Figure A.5. Replicate imaging trials for all 
drug treatment conditions were highly reproducible (Figure A.4C), enabling kinetic analysis of 
puromycylated NPC release. Consistent with previous work [268], we found that cycloheximide 
pretreatment slowed, but did not prevent, the disappearance of SunTag puncta (Figure 2.2.3C). 
We note that our assay cannot distinguish between the rate of puromycin binding to nascent 
chains and the rate of their release from ribosomes. A previous report on cycloheximide-
pretreated polysome lysates found that 50% of nascent peptides were released in a 30-second 
exposure to puromycin, while complete release was observed with a 5-minute exposure [342]. 
The same 30-second puromycin exposure caused complete release of nascent chains from 
untreated polysomes [342], suggesting that cycloheximide slows the rate of puromycin binding 
to ribosomes and/or to nascent chains. These observations are consistent with our results (Figure 
2.2.3C) and with recent work by Wang et al. [268], who proposed that the conformation of the 
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ribosomal pre-translocation complex that is stabilized by cycloheximide causes crowding of the 
A site and slows the ability of puromycin to covalently react with the NPC. Although we cannot 
exclude that cycloheximide also slows the release kinetics of NPCs once they have been 
transferred to puromycin, we found no evidence that elongation is required for the release 
process (Figure 2.2.3C). 
In contrast to cycloheximide, emetine pretreatment enhanced the initial puromycin-
induced release kinetics compared to puromycin alone (Figure 2.2.3C). Although emetine 
pretreatment eliminated the apparent lag phase seen in cells treated with puromycin or 






alone. Emetine pretreated cells lost one-third of SunTag puncta significantly faster than those 
treated with puromycin alone (Figure 2.2.3D, Welch’s t-test for time at 66.6% remaining: t(5) = 
3.932, p = 0.0271), but the effect was smaller for half-life (Welch’s t-test for time at 50% 
remaining: t(5) = 3.183, p = 0.0294) and was no longer significant when two-thirds of puncta 
were lost (Welch’s t-test for time at 33.3% remaining: t(5)= 0.967, p = 0.3996). 
Although the mechanisms underlying these kinetic differences remain unknown, it is 
possible that emetine-bound ribosomes have either a higher affinity for puromycin and/or an 
enhanced reaction efficiency upon binding. Such a model is consistent with previous work 
describing enhanced puromycin incorporation in the presence of emetine [286], particularly at 
 
 
Figure 2.2.3: SunTag translation imaging shows that elongation inhibitor pretreatment 
does not prevent puromycylated nascent chain release from polysomes  
(A) Schematic depicting the SunTag translation reporter system used in this study, as 
described by Wu et al. (2016). Note that although the SunTag reporter construct harbors 
MS Coat Protein Binding Sites (MBSV5) in the 3’ UTR, we did not employ RFP-labeled MS 
Coat Protein for mRNA tracking. (B) Representative spinning disk confocal images (100x) 
of a live HEK-293FT cell before and 2 minutes after addition of 220 µM puromycin. 
Regions depicted in white dashed lines are displayed in the inset. Scale bars: 10 µm for 
large field, 2 µm for inset. (C) Live imaging time course of SunTag puncta in cells with 
pretreatments as indicated (355 µM cycloheximide or 54 µM emetine), followed by 
treatment as indicated (220 µM puromycin). Puromycin was added at 60 seconds into the 
8-minute imaging trial (dashed black line). SunTag puncta for each cell were normalized to 
the average SunTag puncta in that cell during the initial 60 seconds. Data are comprised of 
3-4 replicate imaging trials per treatment condition, with each replicate containing 7-12 
cells (Veh-Veh: n=27 cells from 3 replicates, Veh-Puro: n=30 cells from 3 replicates, Chx-
Puro: n=27 cells from 3 replicates, Emt-Puro: n=41 cells from 4 replicates). Plotted are the 
mean ± standard deviation of all cells, computed in five second time intervals (see 2.2.5
 Methods). (D) The mean normalized SunTag puncta in each replicate imaging trial 
was used to determine the time after puromycin addition at which two thirds, half, and 
one third of SunTag puncta remain in each condition. Welch’s t-test was used to assess 
differences between Veh-Puro and Emt-Puro (for 66.6%: t(5) = 3.932, p = 0.0271, for 50%: 




low temperatures [345]. Regardless, these data clearly show that puromycylated NPCs are 
rapidly released from ribosomes even when cells are pretreated with emetine. 
 
Anti-puromycin IgG molecules are unlikely to be able to directly contact and recognize 
puromycin within the PTC of intact 80S ribosomal complexes 
 
David et al. [286] did not propose a model for where the puromycin is physically located 
during fixation and immunostaining in the RPM procedure. For puromycylated NPCs to truly 
remain ‘tethered’ to ribosomes, the puromycin would have to be localized in either the PTC or in 
the proximity of the nascent polypeptide exit tunnel. Despite the rapid kinetics of puromycylated 
NPC release, it is conceivable that a few puromycin-terminated NPCs might become chemically 
fixed inside ribosomes. We therefore conducted structural modeling to assess whether it is 
feasible that an anti-puromycin IgG molecule could directly contact and recognize puromycin 
within an intact 80S ribosomal complex. It is inconceivable that the antigen binding fragment 
(Fab) of an immunoglobulin G (IgG) molecule could access puromycin within the narrow, 
constricted geometry of the exit tunnel, so we focused our structural modeling on the PTC 
(Figure 2.2.4A). We used a 2.8 Å cryogenic electron microscopy (cryo-EM) structure of a 
stalled mammalian 80S ribosomal complex containing a P-site tRNA [346] and a 2.8 Å X-ray 
crystallographic structure of an intact mouse IgG2a monoclonal antibody [347], the exact isotype 
of the anti-puromycin clone 12D10 used in our study and in many others [284]. 
After we positioned puromycin within the PTC of the 80S ribosomal complex (see 
Methods), we docked the IgG2a Fab within the A site such that the antigen binding site of the 
variable fragment was within ~6 Å or closer of puromycin. Such a model immediately presented 
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with obvious steric clashes between the Fab and multiple sites encompassing the 60S subunit 
ribosomal proteins, 28S rRNA, and P-site tRNA (Figure 2.2.4C-D). We analyzed the steric 






MolProbity to analyze ribosomal and tRNA residues located within a 12 Å radius of the Fab 
[348,349]. The MolProbity Clashscores, the number of serious steric overlaps (> 0.4 Å) per 1000 
atoms, ranged from 85.79-246.3 (Figure 2.2.4B). 
All of these MolProbity Clashscores were in the 0th percentile of all structures solved by 
cryo-EM to any resolution in the Protein Data Bank, i.e., there were no cryo-EM structures 
solved to any resolution with worse Clashscores (Figure 2.2.4B, Table A.2). In contrast, the 
individual structures of the 80S ribosomal complex and IgG2a each have MolProbity 
Clashscores < 21 (Figure 2.2.4B) and are in the 87th percentile of all cryo-EM structures solved 
to any resolution or of all X-ray crystallographic structures solved to similar resolutions, 
respectively (Table A.2). Next, we attempted to model the Fab fragment so it was positioned as 
close as possible to puromycin within the A site of the 80S ribosomal complex but in such a 
manner so as to minimize steric clashes. This model generated a MolProbity score of 22.89, 
 
 
Figure 2.2.4: Structural analysis does not support a model of IgG antibodies directly 
contacting and recognizing puromycin within intact 80S ribosomal complexes 
(A) Schematic depicting structural modeling workflow: puromycin was positioned within 
the PTC of a stalled mammalian 80S ribosomal complex and the Fab fragment of a mouse 
IgG2a antibody was docked into the A site such that the antigen recognition loop could 
directly contact puromycin (see 2.2.5 Methods). Twelve such positions were analyzed by 
MolProbity. (B) MolProbity clashscores, the number of serious steric overlaps (> 0.4 Å) per 
1000 atoms, for the A Site Fab positions in which the Fab could contact puromycin (within 
~6 Å), the IgG2a alone, the 80S alone, or the ‘best fit’ model of the Fab in the A site in 
which the Fab cannot contact puromycin (29.1 Å away). Mean ± standard deviation are 
plotted for the 12 models with puromycin contact. MolProbity clashscore percentiles (the 
percent of structures of comparable resolution in PDB with worse clashscores) are listed 
below. See Table A.2 for detailed summary. (C) Representative positioning of IgG2a 
antibody manually docked in the A site of the 80S ribosomal complex. (D) One of the 
twelve representative models of the IgG2a Fab within the A site of the 80S ribosomal 
complex highlighting the numerous steric clashes with the 60S ribosomal proteins, 28S 




representing the 25th percentile of all cryo-EM structures solved to any resolution (Figure 
2.2.4B, Table A.2). Most strikingly, for this “best” fit scenario, the Fab is positioned 29.1 Å 
away from puromycin, well outside the distance that would be required for the antigen binding 
site of the Fab to directly contact puromycin via non-covalent interactions. Thus, the numerous 
steric clashes between the Fab and the A site of the ribosome would preclude positioning of the 
antigen recognition site close enough to recognize puromycin within the PTC of intact ribosomal 
complexes. 
It is worth noting that our modeling was conducted using a stalled 80S ribosomal 
complex in which the ribosomal subunits are in their ‘non-rotated’ conformational state and the 
P-site tRNA is in its ‘classical’ configuration [346]. Although the non-rotated/classical 
conformation is likely favored in ribosomal complexes stalled by cycloheximide [350] and 
emetine [351], it is conceivable that a minor sub-population of ribosomal complexes becomes 
chemically fixed in the so-called ‘rotated’ conformational state in which the tRNAs occupy their 
‘hybrid’ configurations. In this case, the relative rotation of the subunits dramatically narrows the 
aperture of the A site, making it even less likely that the IgG Fab could access the PTC. Overall, 
these results suggest that anti-puromycin antibodies are unlikely to access the interior of intact 
ribosomes during immunostaining. 
 
2.2.4 Discussion 
Although we successfully visualized puromycin labeling in RiboTag glioma cells, the 
most appealing applications of the eL22-HA/Puro PLA were based on the premise that each 
translating ribosome could be visualized with its NPC in situ. Unfortunately, we found no 
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evidence to support the RPM model proposed by David et al. [286]. Our results have important 
implications for the study of subcellular translation sites using puromycin labeling, since the 
RPM model is often cited as evidence that puromycylated NPCs cannot move away from 
translation sites in the presence of elongation inhibitors [352]). The first major problem with the 
RPM model is the kinetics of puromycylated NPC release. We found that the half-life of 
puromycylated NPC-ribosome complexes is less than 40 seconds when cells are pretreated with 
emetine, and extended by only ~2 minutes with cycloheximide (Figure 2.2.3D). Although the 
precise mechanisms underlying these kinetic differences are unknown, our results strongly 
suggest that once the carboxyl-activated NPC is coupled with puromycin, no further 
translocation or dissociation of the 80S complex is required for puromycylated NPC release 
(Figure 2.2.2, Figure A.3).  
We suspect that puromycin is small enough to simply bypass the P site tRNA and 
proceed directly from the PTC through the exit tunnel. Critically, all SunTag puncta were 
undetectable at ~5 minutes after puromycin in all conditions (Figure 2.2.3C). Even with short 
incubations at lower puromycin concentrations, labeled NPCs would continue to be released 
during washing and fixation. Furthermore, complete cytoplasmic fixation can take longer than 15 
minutes at room temperature when using conventional 4% paraformaldehyde to fix monolayer 
cultures [353]. Thus, it is likely that the vast majority of puromycylated NPCs are not 
crosslinked to their ribosomal origin during chemical fixation. The second major problem with 
the RPM model is that antibodies are unlikely to directly contact and recognize puromycin 
within the PTC of fixed, intact ribosomes (Figure 2.2.4). Thus, even if a small sub-population of 
puromycin molecules are retained in the PTC after chemical fixation, our structural modeling 




Based on the kinetics of puromycylated NPC dissociation (Figure 2.2.3) and 
inaccessibility of intra-ribosomal puromycin to antibody binding (Figure 2.2.4), there should be 
no general expectation that anti-puromycin immunostaining accurately reports on the original 
ribosomal translation site. However, our results do not preclude the possibility that released 
puromycylated NPCs are bound by neighboring proteins, organelles, and/or ribonucleoprotein 
complexes immediately adjacent to their translation site. Such nascent polypeptide binding 
complexes would include canonical targeting motifs such as the signal recognition particle, 
cytoplasmic chaperones [354]), and neuron-specific RNA granules [355]). Indeed, puromycin-
resistant SunTag puncta have been observed in dendrites, and these puncta are thought to contain 
stalled polyribosomes and NPCs [356]. Given that emetine does not impede puromycylated NPC 
release (Figure 2.2.3), it is not surprising that the labeling of these complexes by anti-puromycin 
IF did not require emetine [356]. Instead, the persistence of puromycin at these sites must require 
context-specific binding of NPCs within these ribonucleoprotein complexes. Since anti-
puromycin IF is unlikely to occur within the ribosome (Figure 2.2.4), it is likely that these 
nascent polypeptide interactions occur outside of the ribosome. 
Given the implausibility of a true ‘RPM-PLA’ as we had envisioned (Figure 2.2.1), the 
results of our eL22-HA/Puro PLA also contribute to growing concerns that PLA can produce 
false positive signals when both antigens are highly abundant and have overlapping subcellular 
distributions [285]. This issue of ‘non-specific proximity’ may broadly affect puromycin-based 
PLAs (e.g., [260]), as was the case in our study. Ribosomes are the most abundant 
macromolecular machine in the cell, with typical cultured cells estimated to harbor at least 1 
million ribosomes [357]. Accordingly, even a brief treatment with puromycin will produce an 
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immense number of puromycylated NPCs per cell. Viewed through this lens, it is not surprising 
that our eL22-HA/Puro PLA could produce ~200 puncta per cell based solely on non-specific 
proximity (Figure A.1B). However, it should be noted that our assay is an outlier in this regard, 
as both antigens are extremely abundant and broadly distributed throughout the cytoplasm. The 
use of direct-conjugated primary antibody PLA probes would be expected to reduce the 
frequency of false positives. We remain optimistic that development of new technologies for 
imaging subcellular translation sites in specific cell-types will accelerate studies of local 




The murine RiboTag glioma line expressing eL22-HA was a gift from the laboratory of 
Peter Canoll and has been previously described [336]. Briefly, gliomas were generated by 
injection of PDGFA-IRES-Cre expressing retrovirus into subcortical white matter of mice 
harboring floxed p53, RiboTag, and stop-flox mCherry-luciferase alleles. Glioma cells isolated 
from the retrovirus-induced tumor of a male mouse were expanded in culture to establish the 
murine RiboTag glioma line. HEK-293FT cells were obtained from ThermoFisher (Cat# 5700-
07, RRID:CVCL_6911). U-87MG (U87) human glioma cells (ATCC cat# HTB-14 , 
RRID:CVCL_0022) were a gift from the laboratory of Ramon Parsons.  U87 cells, murine 
RiboTag glioma cells, and HEK-293FT cells were cultured in Dulbecco’s modified eagle 
medium (DMEM, Life Technologies, catalog #11965118) supplemented with 10% fetal bovine 
serum (FBS, Life Technologies, catalog #16000044). 
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Plasmids and Drugs 
pUbC-FLAG-24xSuntagV4-oxEBFP-AID-baUTR1-24xMS2V5-Wpre was a gift from 
Robert Singer (Addgene plasmid # 84561; RRID: Addgene_84561). pUbC-OsTIR1-myc-IRES-
scFv-sfGFP was a gift from Robert Singer (Addgene plasmid # 84563; RRID: Addgene_84563). 
The following drugs were obtained from Sigma: Anisomycin (catalog #A9789), Cycloheximide 
(catalog #C7698), Emetine dihydrochloride (catalog number #E2375), and Puromycin (catalog 
#P7255). Harringtonine was obtained from Santa Cruz Biotechnology (catalog #sc-204771). 
 
Cell Treatment with Translation Inhibitors 
Cells were seeded 24-48 hours prior to treatment and were approximately 70-80% 
confluent at the time of experiments. Pretreatments were conducted for 5 minutes as described in 
the most recent RPM methods paper [335]. Cycloheximide was used at 355 µM, and anisomycin 
at 37 µM. Emetine was used at 45 µM, as suggested by Bastide et al. [335], which is ~4.6 times 
lower than the 208 µM used in David et al. [286]. Note that maximal inhibition of translation is 
achieved at 1 µM emetine [343], and 45 µM emetine is thus a saturating concentration for 
inhibiting elongation. Pretreatment inhibitors were maintained at the same concentration 
throughout puromycin treatment and washing.  
After pretreatment, cells were then treated with 10 µM puromycin for 5 minutes. Both 
pretreatment and treatment occurred at 37°C. Following the pretreatment and treatment, cells 
were immediately and quickly washed twice in ice-cold 1X phosphate buffered saline (PBS) 
with 5 mM MgCl2, then fixed in 1X PBS with 5 mM MgCl2, 4% sucrose, and 4% 
paraformaldehyde (PFA) for 15 minutes at room temperature. The samples were then washed 
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three times with 1X tris-buffered saline (TBS). After washing, cells were used for 
immunofluorescence staining or proximity ligation assay as described below. 
For the puromycin washout experiments, cells were treated with 10 µM puromycin for 5 
minutes, then washed twice with fresh media, then incubated in fresh media for 15 or 45 
minutes. For the harringtonine runoff experiments, cells were treated with 10 µM puromycin for 
5 minutes, then washed twice with fresh media, then incubated in fresh media with 100 µM 
harringtonine for 20 minutes. Cells that did not receive puromycin prior to harringtonine were 
treated with 10 µM puromycin for 5 minutes after 20 minutes of harringtonine treatment. 
Treatment with puromycin and harringtonine occurred at 37°C. Cells were then washed and 
fixed as described above. 
 
Immunofluorescence 
After fixation samples were incubated in blocking/permeabilization buffer consisting of 
1X TBS with 10% normal goat serum (NGS) and 0.1% Tween 20. Following blocking, samples 
were incubated with primary antibodies in 1x TBS with 2% NGS and 0.1% Tween 20. Primary 
antibodies were used as follows: monoclonal mouse anti-puromycin (clone 12D10, 
MilliporeSigma, catalog #MABE343, RRID:AB_2566826) at 1:500, human anti-ribosomal P 
(Immunovision, catalog #HPO-0100) at 1:3000, and rabbit anti-HA (Abcam, catalog #ab9110, 
RRID:AB_307019) at 1:500 – for 60 minutes at room temperature. Samples were then washed 
three times with 1X TBS. Next, samples were incubated with secondary antibodies in 1X TBS 
with 2% NGS and 0.1% Tween 20 for 30 minutes at room temperature. Secondary antibodies 
were used as follows: goat anti-mouse Alexa647 (Invitrogen, catalog #A-21236, 
RRID:AB_141725) at 1:1000, goat anti-rabbit A488 (Invitrogen, catalog #A-11034, 
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RRID:AB_2576217) at 1:1000, and donkey anti-human Cy3 (Jackson ImmunoResearch, catalog 
#709-165-149, RRID:AB_2340535) at 1:500. Following secondary antibody incubation, cells 
were washed three times with 1X TBS at room temperature, then stored in DAPI Fluoromount G 
(Southern Biotech, catalog #0100-20) for <24 hr at 4°C prior to imaging. 
 
Proximity Ligation Assay 
PLA (Duolink, MilliporeSigma) was performed in accordance with the manufacturer’s 
instructions with slight modifications to accommodate simultaneous immunofluorescence. 
Blocking and permeabilization were first conducted as described for immunofluorescence above. 
Further blocking was conducted using Duolink blocking buffer at 37°C for 30 minutes. Primary 
antibodies and concentrations were used as in immunofluorescence above (Rabbit anti-HA, 
Mouse anti-Puromycin, Human anti-Ribosomal P), but diluted in Duolink Antibody Diluent. 
PLA probe incubation, ligation, amplification, and final washes were conducted as per 
manufacturer’s instructions. Anti-Rabbit MINUS and Anti-Mouse PLUS probes 
(MilliporeSigma, catalog #DUO92004 and #DUO92001, respectively) were used in conjunction 
with Duolink In Situ Detection Reagents Far Red (MilliporeSigma, catalog #DUO92013). 
Following the final washes in Duolink Wash Buffer B, samples were incubated in 1X TBS with 
2% NGS and 0.1% Tween 20 plus donkey anti-human Cy3 at 1:500 for 20 minutes at room 
temperature. Finally, the cells were washed three times with 1X TBS and stored in Duolink 






Immunofluorescence/PLA Image Acquisition and Quantification 
Widefield imaging of anti-puromycin IF or eL22-HA/Puro PLA was conducted on a 
Nikon Ti2 Eclipse equipped with a SpectraX light engine (Lumencor) and a DS-Qi2 camera 
(Nikon), using a 10x/0.25 NA or 20x/0.75 NA air objectives (Nikon) as indicated in the figure 
legends. Confocal imaging was conducted on a Leica SP8 laser scanning system using a 
60x/1.45 NA objective (Leica). 
Each treatment condition had 3-5 replicates, and at least 32 individual cells per replicate 
were selected randomly across a minimum of three fields. Cells were manually segmented using 
the anti-Ribo P IF profile, and the average puromycin signal intensity (from either anti-
puromycin IF or eL22-HA/Puro PLA) was acquired from each cell. For each experiment, the 
highest average anti-puromycin IF (or eL22-HA/Puro PLA) intensity across all conditions was 
used to normalize each individual cell’s anti-puromycin IF (or eL22-HA/Puro PLA) intensity. 
Note that this normalization was conducted separately for anti-puromycin IF and eL22-HA/Puro 
PLA signal intensities. The highest average anti-Puromycin (or eL22-HA/Puro PLA) intensity 
was always from cells treated with puromycin alone or from cells treated with emetine + 
puromycin. The normalized signal intensities from 3-5 separate experiments are reported. See 
Table A.1 for complete summary of replicates, cell numbers, and statistical information. 
 
Cell Treatment and Lysis for Biochemical Studies 
Cells were pretreated with cycloheximide or emetine as described above for 
immunofluorescence/PLA. Cells were then treated with 100 µM puromycin for five minutes, at 
which point media was removed and cells were lysed in ice cold polysome buffer (150 mM KCl, 
10 mM MgCl2, 5 mM HEPES pH 7.4, 1% Igepal CA-630) supplemented with EDTA-free 
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protease inhibitor cocktail (Roche, catalog #5056489001) and SUPERaseIN (Invitrogen, catalog 
#AM2696). For cells receiving elongation inhibitor pretreatments, cycloheximide and emetine 
concentration was maintained (355 µM and 45 µM, respectively) in polysome lysis 
buffers/sucrose gradients throughout the entire procedure. After rotating polysome lysates for 15 
minutes at 4°C, lysates were clarified by centrifugation at 16,000xg for 15 minutes at 4°C. For 
the polysome immunoprecipitation experiment, the clarified polysome lysates from cells not 
receiving puromycin were split in half. Half the lysate was incubated with 100 µM puromycin 
for five minutes at room temperature and then returned to ice. Clarified polysome lysates were 
then subjected to polysome immunoprecipitation or sucrose gradient fractionation as described 
below. 
 
Sucrose Gradient Fractionation 
Clarified polysome lysates were loaded onto 15%–50% sucrose gradient and centrifuged 
at 37,000 RPM in a SW41 rotor for 3.5 hr at 4°C. Polysome gradients were fractionated and the  
optical density at 254 nm was continuously recorded using Isco-UA5 fluorescence/absorbance 
monitoring system. Ten fractions were collected from top to bottom of the gradient with 
approximately 1 mL volume each. Samples were concentrated to approximately 0.3 mL using a 
speed-vac, mixed with 0.1 mL of 4x Laemmli Sample Buffer, boiled for 5 minutes at 95°C, and 
stored at -80°C until western blotting. 
 
Polysome and Puromycin Immunoprecipitation 
Dynabeads Protein G (Invitrogen, catalog #10004D) were washed two times in polysome 
buffer. Protein G beads were then incubated with an excess of primary antibodies (Rabbit anti-
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HA or Mouse anti-Puromycin) in polysome buffer for 20 minutes at room temperature. Unbound 
antibodies were removed by washing the beads three times in polysome buffer, and antibody-
bound beads were then added to clarified polysome lysates (equivalent amounts of 
beads/antibodies were used for each IP). Antigen capture was conducted for one hour at 4°C, 
after which the supernatant was discarded. Beads were further washed four times at 4°C in 
polysome buffer supplemented with protease and RNAse inhibitors (as above for cell lysis). 
After the final wash, beads were split into equal aliquots for RNA and protein analysis. 
For RNA analysis, RNA was eluted from the beads with RLT buffer and purified using RNEasy 
MinElute columns (Qiagen, catalog #74204). RNA was eluted into 10 µL of nuclease free water 
and analyzed on Agilent 2100 Bioanalyzer using the RNA 6000 Pico kit (Agilent, catalog #5067-
1513). For protein analysis, protein was eluted from the beads by boiling for 5 minutes at 95°C 




Equal volumes of polysome fractions or bead eluates were separated on 4-15% 
polyacrylamide gradient gels (BioRad, catalog #4561086) and transferred to PVDF membranes 
(Immobilon-P, MilliporeSigma, catalog #IPVH00010). Membranes were initially washed for 15 
minutes in TBST (1X TBS + 0.1% Tween 20), blocked for an hour in 5% BSA/TBST, and 
incubated overnight at 4°C with primary antibodies in 5% bovine serum albumin/TBST 
overnight. Primary antibodies were used as follows: Mouse anti-HA (Cell Signaling, catalog 
#2367S) at 1:1000, Mouse anti-Puromycin (clone 12D10, MilliporeSigma, catalog #MABE343, 
RRID:AB_2566826) at 1:1000, and Rabbit anti-S6 Ribosomal Protein (clone 5G10, Cell 
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Signaling, catalog #2217, RRID:AB_331355) at 1:1000. After primary incubation, membranes 
were washed three times in TBST prior to incubation with horseradish peroxidase (HRP)-
conjugated secondary antibodies in 5% non-fat dried milk/TBST for one hour at room 
temperature. Secondary antibodies were used as follows: Goat Anti-Mouse HRP (Jackson 
ImmunoResearch, catalog #115-035-003, RRID:AB_10015289) at 1:5000, and Goat Anti-Rabbit 
HRP (Jackson ImmunoResearch, catalog #111-005-003, RRID:AB_2337913) at 1:5000. After 
secondary incubation, membranes were washed three times in TBST. Signal was developed 
using Immobilon enhanced chemiluminescent substrate (Millipore, catalog #WBKLS0500) and 
imaged on an Azure Biosystems C600 system. Where membranes were re-probed with different 
primary antibodies, 0.05% sodium azide with primary antibodies overnight to quench residual 
HRP bound to membranes. 
 
SunTag Cell Transfection, Drug Treatment, and Image Acquisition 
HEK-293FT cells were transfected approximately 48 hours before imaging using 
CalFectin (SignaGen Laboratories, catalog number #SL100478). A plasmid ratio of 3:1 for the 
SunTag:scFv-sfGFP/OsTIR1 plasmids was used, while maintaining the total DNA concentration 
and reagent ratios recommended by the manufacturer. Transfection media was replaced with 
fresh media after 14 hours. Cells were split 12 hours after the media change and 0.6 x106 cells 
were seeded into 35mm glass dishes for imaging (MatTek, catalog #P35G-1.5-10-C). Indole-3-
acetic acid (IAA; Sigma, catalog #I5148) was added to the medium at 500 µM overnight. 
The following morning immediately prior to imaging, cells were briefly washed once 
with pre-warmed Leibowitz’s L15 media (ThermoFisher, catalog #11415064). Cells were then 
placed in warm L15 media supplemented with 500 µM IAA and transferred to a pre-warmed, 
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humidified stage-top incubator maintained at 37°C (Tokai Hit). Imaging was conducted using a 
100X/1.45 NA oil-immersion objective on a Nikon TiE Eclipse equipped with a spinning disk 
confocal unit (Yokogawa CSU-X1) and an EM-CCD camera (Photometrics Evolve 512). 
Between six and twelve fields per dish were selected for continuous imaging, which 
resulted in an image of each field on average every 5.4 ± 1.9 seconds (mean ± standard 
deviation, range 2.5 – 9.8 seconds). Pretreatment with cycloheximide (355 µM) or emetine (54 
µM) was initiated 4 minutes prior to the onset of image acquisition. Puromycin treatment (220 
µM) was initiated 1 minute after the onset of image acquisition (drug pretreatment was therefore 
5 minutes). The total length of image acquisition was approximately 8 minutes. 
 
SunTag Image Processing and Quantification 
Time lapse image stacks were quantified for the presence of cytoplasmic SunTag puncta 
using the freely available ImageJ plugin TrackMate v4.0.1 [358]. We used the Laplacian of 
Gaussian spot detector with estimated blob diameter of 0.5 µm and initial quality threshold of 
300. Additional filtering was implemented using a combination of quality, contrast, and total 
intensity as necessary to suppress nuclear spot detection. Figure A.4A shows representative 
SunTag puncta detection. The average cytoplasmic GFP intensity was quantified across the time 
lapse images. Cells showing greater than 10% decrease in cytoplasmic GFP intensity, either due 
to photobleaching or loss of focal plane, were discarded from subsequent analysis (9 such cells 
were discarded out of 140 total cells imaged). Representative single cell traces and images are 
shown in Figure A.5. 
Exported spot statistics and cytoplasmic GFP intensity for each frame were aligned to the 
appropriate timestamps from the image metadata. SunTag puncta counts for all frames from each 
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cell were normalized to the average of SunTag puncta counts of that cell during the first 60 
seconds (pre-puromycin addition). Cytoplasmic GFP intensity was normalized to the average of 
the first 10 frames. The normalized SunTag puncta counts from each experimental replicate 
(consisting of 7-12 cells) were smoothed using a boxcar filter (rolling window mean) with a 
window width of k=10 observations. Specific decay times (t2/3, t1/2, t1/3) were calculated for each 
replicate by averaging the time stamps of all frames within ± 0.01 of the relevant smoothed 
normalized SunTag puncta values (i.e. for t1/2, 0.49-0.51). Comparisons between decay times of 
drug treatments were made using an independent samples Welch’s t-test. For plotting, five-
second interval bins were used to compute the mean and standard deviation across drug 
treatment replicates. 
To create a single movie featuring multiple fields with distinct, non-uniform frame rates 
(Figure 2.2.3 - video 1), the frames from each time lapse image stack were duplicated to the 
lowest common denominator so that all stacks had the same frame number. The time of each 
frame acquisition in each image stack was stamped on the images, along with the time of 
puromycin addition, before merging the image stacks and down-sampling to 102 frames. The 
resulting stack was converted to an AVI file with JPEG compression at 8 frames per second, 




Modeling of the mouse IgG2a puromycin antibody [347] (PDB ID: 1igt) bound to a 
mammalian 80S ribosomal complex containing a peptidyl-transfer RNA (tRNA) in the ribosomal 
peptidyl-tRNA (P) site [346] (PDB ID: 6sgc) and carrying puromycin in the ribosomal 
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aminoacyl-tRNA (A) site [359] (PDB ID: 1q82) was performed using PyMOL [360,361]. 
Briefly, PDB 1q82 was aligned to PDB 6sgc using the large ribosomal subunit RNA (rRNA) to 
position puromycin within the A-site side of the ribosomal peptidyl transferase center (PTC). We 
then defined a smaller region of the IgG2a antibody, referred to as the Fab [362], that consisted 
of two variable domains from the light and heavy chains (VH and VL respectively) and two 
constant domains (CH1 and CL, respectively) corresponding to residues 1-214 and 1-230 from 
chains A and B, respectively. 12 models of the Fab-, puromycin-, and P-site tRNA-bound 
ribosomal complex were then manually generated such that the position of the Fab within the A 
site was varied in each model while maintaining the Fab complementarity determining regions 
(CDRs) within ~6 Å or closer to the puromycin moiety. These conservative constraints would 
enable a direct interaction, but prevent strong van der Waals clashes, between the CDRs and 
puromycin. A 12 Å radius centered on the Fab was then analyzed using MolProbity [349], an all-
atom structure validation tool, in order to assess all-atom clashes by calculating the MolProbity 
clashscore and percent of structures of comparable resolution with worse MolProbity 
clashscores. The calculated clashscores, percent of structures of comparable resolution with 
worse MolProbity clashscores, and clash sites were used for the data reported in Table A.2 and 
the structural models and bar graph reported in Figure 2.2.4. 
 
Statistical Analysis 
Comparisons of immunofluorescence and PLA intensity distributions in were conducted 
using the Mann-Whitney U-test. Comparison of rRNA yields and 28s/18s ratios was conducted 
using Welch’s independent samples t-test. Comparison of SunTag puncta decay times was 
conducted using Welch’s independent samples t-test. Details regarding replicates, cell numbers, 
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and test statistics are provided in the figure captions (except see Table A.1 for summary of 
testing presented in Figure 2.2.1C and Figure A.2C). Statistical significance was considered at 
p < 0.05. 
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2.2.8 Conclusions 
 Unfortunately, the above results made it clear to us that the eL22-HA/Puro PLA would 
not be suitable for detection of translating ribosomes in DATIRES-Cre:RiboTag mice. It was 
discouraging to spend so many months questioning our own results and methods, only to find 
that the literature had led us astray. We were encouraged to learn that Rachel Green’s lab had 
reached similar conclusions regarding the claims of David et al. [286]. I have received several e-
mails complimenting the study and expressing their concerns about the misuse of 
puromycylation to study local translation in the field. Nonetheless, a recent paper used the RPM 
assay to study ‘nuclear translation’ following cellular stress [363]. 
 Our study suggests that precise mapping of translation sites is not possible using anti-
puromycin labeling. Nonetheless, puromycin is widely employed in studies of local translation. 
Another serious concern raised by our results is the specificity of PLA, especially when one of 
the antibodies is against a highly abundant protein. In the case of Puro-PLA [260], it seems likely 
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that a great majority of puncta may derive from pre-existing, non-puromycylated proteins that 
happen to be within 20 nm of a puromycylated nascent polypeptide. Thankfully, another group 
has voiced serious concerns about the “limited significance of the in situ proximity ligation 
assay” [285]. In this study, the authors demonstrate PLA signals arising from a variety of antigen 
pairs that do not specifically interact, such as cytoplasmic GFP and inner plasma membrane 
proteins, or epitopes on opposing faces of the plasma membrane [285]. Perhaps unsurprisingly, 
the field seems reluctant to accept these results. I am particularly thankful to the reviewers who 
recognized and appreciated the relevance of our manuscript. 
 
2.3   Particle detection artifacts in synaptosome flow cytometry 
Due to the technical difficulty of studying axonal translation in the mammalian brain, I 
sought to develop multiple, independent approaches to study axonal mRNA and ribosomes in 
dopamine neurons. As mentioned above, cell type-specific ribosome capture and synaptosome 
sorting have both been employed to study presynaptic mRNA localization (Table 2.1.1) 
[248,250]. As an alternative approach to purification of tagged ribosomes from DATIRES-
Cre:RiboTag mice [278], I became interested in the use of fluorescence-activated synaptosome 
sorting (FASS) for direct purification of dopaminergic synaptosomes. Such a procedure had 
already been implemented for glutamatergic synaptosomes using VGLUT1VENUS mice [290]. As 
I began to delve into the microparticle flow cytometry literature, I uncovered serious flaws in the 
application of these methods to synaptosomes. This section, which was published in eNeuro 
[227],  describes a series of studies exploring particle aggregation and detection artifacts 
encountered in synaptosome flow cytometry experiments. 
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The following is adapted from: 
Hobson BD, Sims PA (2019) Critical Analysis of Particle Detection Artifacts in 
Synaptosome Flow Cytometry. eNeuro. doi: 10.1523/ENEURO.0009-19.2019 
 
Supplementary figures are in Appendix B. 
 
2.3.1 Abstract 
Flow cytometry and fluorescence-activated sorting are powerful techniques that hold 
great promise for studying heterogeneous populations of submicron particles such as 
synaptosomes, but many technical challenges arise in these experiments. To date, most flow 
cytometry studies of synaptosomes have relied on particle detection using forward scatter (FSC) 
measurements and size estimation with polystyrene (PS) bead standards. However, these 
practices have serious limitations, and special care must be taken to overcome the poor 
sensitivity of conventional flow cytometers in the analysis of submicron particles. Technical 
artifacts can confound these experiments, especially the detection of multiple particles as a single 
event. Here, we compared analysis of P2 crude synaptosomal preparations from murine forebrain 
on multiple flow cytometers using both FSC- and fluorescence-triggered detection. We 
implemented multicolor fluorescent dye-based assays to quantify coincident particle detection 
and aggregation, and we assessed the false colocalization of antigens in immunostaining 
analyses. Our results demonstrate that fluorescence-triggering and proper dilution can control for 
coincident particle detection, but not particle aggregation. We confirmed previous studies 
showing that FSC-based size estimation with PS beads underestimates biological particle size, 
and we identified pervasive aggregation in the FSC range analyzed in most synaptosome flow 
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cytometry studies. We found that analyzing P2 samples in sucrose/tris/EDTA (SET) buffer 
reduces aggregation compared to phosphate-buffered saline (PBS), but does not completely 
eliminate the presence of aggregates, especially in immunostaining experiments. Our study 
highlights challenges and pitfalls in synaptosome flow cytometry and provides a methodological 
framework for future studies. 
 
2.3.2 Significance Statement 
 
Synaptosomes are an invaluable model for synaptic biology, but these synaptic particles 
are traditionally analyzed in bulk preparations rather than at the level of single particles. 
Although flow cytometry is a powerful technique for high throughput particle analysis, 
submicron particles present unique challenges. Here, the authors investigate key elements of 
synaptosome flow cytometry experiments, especially those related to artifacts that confound the 
analysis of single synaptosomes. They identify aggregation as especially problematic and 
implement methods to minimize its impact on flow cytometry analysis. 
 
2.3.3 Background 
Synaptosomes are synaptic particles consisting of resealed presynaptic nerve terminals 
that often remain bound to postsynaptic elements [279]. These structures were originally isolated 
by homogenization of brain tissue in isotonic sucrose [364], and have been further purified using 
a variety of filtration and density gradient centrifugation procedures [365,366]. Synaptosomes 
retain functional properties such as membrane potential and depolarization-induced 
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neurotransmitter release, making them key model systems for fundamental synaptic biology 
[279]. However, studies of synaptosomes in bulk are limited by the purity of the preparations, 
which contain a mixture of synapse types (e.g., glutamatergic, GABAergic, etc.) as well as 
contaminating neuronal and glial membranes. In principle, high throughput purification and 
analysis of single synaptosomes is a powerful tool for addressing the incredible heterogeneity of 
the billions of synapses in mammalian brains. 
Flow cytometry employs a pressurized fluidic system to pass suspensions of cells or 
particles through an optical flow cell, where scattered light and fluorescence measurements are 
collected for each particle. Analysis of submicron particles on conventional flow cytometers 
faces a variety of limitations and pitfalls due to the limited sensitivity of these instruments [367]. 
Event detection in flow cytometers, known as triggering, occurs when a particle passing through 
the flow cell causes the trigger parameter to rise above a manually set threshold. The trigger 
parameter, usually FSC, must have a minimum threshold set as to avoid electronic and buffer 
noise, but this limits detection of submicron particles. It is generally accepted that conventional 
flow cytometers have a lower limit of FSC-triggered detection around 300-500nm PS beads 
[368], but this does not correspond to the size of biological particles that can be detected 
[367,369]. FSC intensity for submicron particles depends on many factors besides particle size, 
especially refractive index, which is generally 1.59-1.61 for PS beads, 1.40-1.46 for silica beads, 
and ranges from 1.33-1.40 for cell-derived particles [367]. Biological particles therefore scatter 
light approximately 10-fold less efficiently than PS beads [370], and direct comparison of PS 




In addition to difficulties with size estimation using light scatter, numerous reports have 
identified particle detection artifacts in submicron flow cytometry. Particles below the trigger 
threshold can be detected when analyzed at high concentrations, a phenomenon known as 
coincidence or ‘swarm detection’ [372,373]. While coincidence is caused by the simultaneous 
presence of multiple, single particles in the path of the laser, others have reported detection of 
single events comprised of multiple, aggregated submicron particles [374]. Although these 
artifacts have been recognized in the cell-derived microparticle community [367,369], most flow 
cytometry studies of synaptosomes have not addressed triggering or detection artifacts [375–
378]. Despite claims that single synaptosomes can be detected by FSC-triggering and identified 
apart from contaminating particles based solely on FSC signal [379,380], this has been a point of 
recent controversy (see comments on [378]). In contrast to these studies, Biesemann and Herzog 
found that sorting of FSC-triggered events bearing genetically encoded vesicular glutamate 
transporter 1 (VGLUT1) fluorescence yielded samples contaminated with GABAergic 
synaptosomes and myelin [381]. Instead, fluorescence-triggering and sorting events below the 
FSC trigger threshold yielded a VGLUT1 synaptosomal sample of unprecedented purity [290]. 
The flow cytometry protocols published by these groups are clearly at odds in terms of the best 
practices to ensure detection, analysis, and sorting of single synaptosomes [380,382].  
Here, we present a critical flow cytometry analysis of P2 crude synaptosome preparations 
on two cytometers, the BD Influx and BD LSRFortessa. We investigated several experimental 
aspects of synaptosome flow cytometry, including: 1) FSC- and fluorescence-triggered particle 
detection, 2) FSC-based size estimation with PS and silica bead standards, 3) range of particle 
concentration, 4) coincidence and aggregation as causes of false double-positive events, 5) 
sucrose and PBS buffers for sample preparation and acquisition, and 6) false colocalization of 
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antigens in immunostained samples. Our study highlights technical challenges and identifies 
methods to minimize their impact on experimental results. 
 
2.3.4 Results 
FSC- and FM4-64-triggering of Synaptosomes and Comparison to Bead Standards 
 
Conventional flow cytometers generally use forward scatter (FSC) measurements for 
detection of cells, but the sensitivity of each instrument in FSC-triggered detection of submicron 
particles varies widely depending on the refractive index of the particles, the angle of collection 
for scattered light, detector sensitivity, and other factors [368]. We used PS and silica beads to 
determine the relative sensitivity of two cytometers: a BD LSR Fortessa analyzer and a BD 
Influx sorter. We optimized FSC-threshold parameters on each instrument in order to maintain a 
mixture of PS and silica bead standards ranging 585 -1300nm in the dynamic range of detection, 
while simultaneously avoiding electronic and buffer noise.  
As shown in Figure 2.3.1A, the lowest FSC signal resolvable above the background 
noise on the Influx was the 585nm silica bead. Cross-referencing the FSC signal with the green 
fluorescence signal allowed us to clearly identify PS beads apart from the non-fluorescent silica 
beads (Figure 2.3.1A, right). As expected due to their higher refractive index, the FSC signals 
for PS beads were substantially higher than for similarly sized silica beads. We also identified 
events that appeared to be simultaneous detection of two 500nm PS beads, which we confirmed 
by comparing their FSC and green fluorescence to the ‘singlet’ gate as previously described 







PS doublet population (1.7-fold higher FSC, 1.8-fold higher green fluorescence), the FSC signal 
for these events still fell below the 880nm silica beads.  
In contrast to the Influx, the Fortessa displayed poor FSC resolution when running the 
silica/PS bead mixture (Figure 2.3.1B), which required separately running the individual PS 
beads (500nm and 800nm PS labeled with (B) in Influx plots). The lowest FSC signal resolvable 
above the noise background on the Fortessa included 880nm silica as well as 500nm PS ‘singlet’ 
and ‘doublet’ bead populations, which could only be separated by SSC or green fluorescence 
intensity (Figure 2.3.1B). A complete summary of FSC and SSC measurements for gated bead 
populations can be found in Table B.1. 
Having established FSC-triggering limits and relative bead positions on the instruments, 
we next sought to compare FSC- and fluorescence-triggering of P2 crude synaptosome (hereafter 
‘P2’) samples. Despite contamination by a heterogeneous mixture of free mitochondria, myelin, 
and membranous debris, P2 samples are enriched with synaptosomes and have been widely 
employed in flow cytometry studies [375–378]. As previously described by Biesemann et al. 
 
 
Figure 2.3.1: Determining Detection Sensitivity Using Bead Standards and FSC- vs. 
FM-Triggering of P2 Fraction 
(A) Mixture of non-fluorescent silica/fluorescent PS beads (Apogee; A) and fluorescent PS 
beads (Bangs Labs; B) detected in FSC-trigger mode on the Influx. Left: forward and side 
scatter, right: forward scatter and green fluorescence detector (FITC) allows fluorescent 
PS beads and bead doublets to be clearly distinguished from non-fluorescent silica beads. 
(B) Mixture of non-fluorescent silica/fluorescent PS beads (Apogee; A) detected in FSC-
trigger mode on the Fortessa. Note that the Bangs Labs 500nm and 800nm fluorescent PS 
beads could not be run simultaneously with the Apogee mixture on the Fortessa due to 
poor FSC resolution. (C) FM4-64 stained P2 sample on the Influx. Left: FSC-trigger mode, 
right: FM-trigger mode. ‘FSC Noise’ gate was set by running clean PBS. (D) FM4-64 
stained P2 sample on the Fortessa. Left: FSC-trigger mode, right: FM-trigger mode. ‘FSC 
Noise’ gate was set by running clean PBS. See Table B.1 for median FSC and SSC values 
from gated bead populations. 
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[290], FM4-64 is a styryl dye with favorable properties for fluorescence-triggered detection of 
synaptosomes. FM4-64 is minimally fluorescent in aqueous media but becomes intensely 
fluorescent upon partitioning into membranes [384], and its far-red emission is efficiently 
excited by a 488nm laser, which is required for triggering on our cytometers. As shown in 
Figure 2.3.1C-D, FM-triggering enabled highly sensitive detection of P2 samples compared to 
FSC-triggering, with more than half of particles in the P2 sample below the FSC noise threshold 
on both cytometers. These results are consistent with the work of Biesemann [381], who found 
~70% of particles in sucrose gradient synaptosome preparations were undetectable by FSC-
triggering on the BD FACS Aria. 
Since previous studies have analyzed putative synaptosomal particles with FSC signals as 
high as 4.5µm PS beads [376], we sought to assess the size of biological particles in such an FSC 
range. In the absence of a refractive index mismatch between PS beads and biological particles, 
one would expect neuronal nuclei, which sediment in the P1 fraction, to exhibit significantly 
higher FSC than 2µm PS beads due to their size. Although we had to lower the FSC voltage to 
place 0.5, 0.8, and 2µm PS beads within the same dynamic range, 2.0 µm PS beads were clearly 
resolved from 0.5 and 0.8 µm PS beads by FSC on both the Influx and Fortessa (Figure B.1A). 
We identified neuronal nuclei based on Hoechst 33342 intensity and NeuN immunofluorescence 
(Figure B.1B) and found that they were adjacent to and partially overlapping with the FSC range 
defined by 2µm PS beads on the Influx (Figure B.1C). These results confirm that FSC-based 
sizing relative to PS beads underestimates the size of biological particles with lower refractive 





Serial dilutions define a range of linear detection for FM4-64-triggering 
 
It has previously been demonstrated that high concentrations of particles below the 
trigger threshold can be detected when they simultaneously occupy the focal point of 
illumination [372,373]. This phenomenon of coincident detection (also known as ‘coincidence’ 
or ‘swarm detection’) is thought to be particularly problematic for FSC-triggered detection of 
submicron particles [373]. In order to define a linear range of particle detection and further 
compare FSC- vs. FM-triggering, we conducted dilution series on both Influx and Fortessa. 
Compared to FM-triggering, FSC-triggered P2 samples did not maintain a constant FSC vs. 
FM4-64 profile on either the Influx or Fortessa (Figure 2.3.2A-B and Figure B.2). Specifically, 
the abundance of events near the FSC threshold with low FM4-64 fluorescence decreased with 
dilution, and the appearance of ‘noise’ events (although <10 events/sec) became more apparent 
with dilution on the Fortessa. On the Influx, quantification of the event rate across the dilution 
series revealed a sub-linear profile for both FSC- and FM-triggering, which was fit with high 
accuracy using a quadratic model (Figure 2.3.2C, left panel, R2 = 0.99 for both series). FM-
triggering was similar on the Fortessa, but FSC-triggering was better fit with a linear model 
(Figure 2.3.2D, left panel, R2 = 0.93 for FSC and R2 = 0.99 for FM series). These results confirm 
that event rate saturates at high particle concentrations [385] and that FSC-triggering 
underestimates the true event rate across the entire dilution series. 
Given that much of the P2 remains undetected by FSC-triggering, we also wondered 
whether particle concentration might alter the FSC and FM fluorescence measurements. On the 
Influx, the median FSC remained relatively constant for both FSC- and FM-triggering (Figure 
2.3.2C, middle panel), while the median FM4-64 fluorescence varied dramatically for FSC-
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triggering but not for FM-triggering (Figure 2.3.2C, right panel). On the Fortessa, both median 




triggering, but not FM-triggering (Figure 2.3.2D, middle and right panels). The increase in 
median FM4-64 fluorescence with dilution seen in FSC-triggered samples seems related to the 
‘FM4-64 Low’ events described above. Given the heterogeneous population of particles 
contained in P2 samples, we cannot make strong conclusions about the mechanisms underlying 
these effects. Nonetheless, it is clear that FM-triggering is superior to FSC-triggering in terms of 
the stability and accuracy of event rate, FM4-64 fluorescence, and FSC of P2 particles across the 
dilution series on both instruments. We conducted all further studies using only FM-triggering 
and maintaining reasonably dilute samples so as to stay in the most linear range of the event rate 
dilution curves (Figure 2.3.2C-D, left panels, fewer than 10,000 events/sec on the Influx and 
fewer than ~3,000 events/sec on the Fortessa). Since sample flow rates and event rates may vary 
across cytometers, we also measured the absolute particle concentration across a typical dilution 
series on the Influx using volumetric count beads (Figure B.2C). We found that the most linear 
range of the event rate curve was for samples below ~1000 particles/µL. A previous study on the 
Influx [385] showed that the trigger pulse baseline becomes continuously elevated at high event 
rates where coincidence is prominent, so we used a digital oscilloscope on the Influx to confirm 
that the trigger pulse remained at baseline under these conditions (data not shown).  
 
 
Figure 2.3.2: Dilution Series Define a Range of Linear Particle Detection 
(A) Representative density plots of a P2 dilution series detected on the Influx in FSC-
trigger mode. FM4-64 Low gate was set arbitrarily to quantify disappearance of events in 
this region with dilution. (B) Representative density plots of same P2 dilution series as in 
A, but detected on the Influx in FM-trigger mode. (C) Measurements from full P2 dilution 
series on the Influx. Left: Event rate data fit with a quadratic model. Middle: Median FSC of 
all detected events. Right: Median FM4-64 fluorescence of all detected events. (D) 
Measurements from full P2 dilution series on the Fortessa. Left: FM-trigger series fit with a 
quadratic model and FSC-trigger series fit with a linear model. Middle: Median FSC of all 




Development of a multicolor fluorescence assay for false colocalization 
 
Although FM-triggering and dilution should help to reduce coincident particle detection, 
another reported source of ‘false double-positive’ events in submicron flow cytometry is the 
physical aggregation of multiple particles [374]. Multiple microscopy studies have noted the 
presence of aggregated synaptosomes [364,386,387], but conventional flow cytometry does not 
provide a means to verify whether events truly represent single particles. We sought to design a 
fluorescence-based flow cytometry assay to estimate ‘false double-positive’ events in our P2 
samples (Figure 2.3.3). 
The assay workflow is similar to previously described “cell barcoding” flow cytometry 
methods [388,389]. A P2 sample is first split and single-labeled with spectrally separated, non-
transferable fluorescent dyes. After washing, single-labeled samples are mixed prior to flow 
cytometry (Figure 2.3.3A). Single particle events should therefore bear only one fluorescent 
label, while coincidences and aggregates derived from separate single-labeled samples will be 
positive for multiple fluorescent labels (Figure 2.3.3B). Although the samples are washed twice 
to remove any residual dye, it is critical to use dyes that cannot be transferred between particles. 
Synaptosomes are well-labeled with Calcein AM dyes [376,378,387], lipophilic dyes that rapidly 
cross cell membranes and become trapped following hydrolysis of the AM ester. In addition to 
calcein AM and Calcein Red-Orange AM (hereafter ‘calcein red’), we also used violet amine-
reactive dye (covalent reaction with proteins) and MitoTracker Deep Red FM (thiol-conjugation 
and retention in mitochondria) to expand the number of dyes in some experiments. As shown in 




A representative set of density plots for a P2 sample single-labeled with calcein AM or 
calcein red, as well as a mixture of the two, on the Influx is shown in Figure 2.3.3C. Note that 
because even the background fluorescence is linearly related to FSC on the log-log plots, 





To avoid this problem, we used polygon gating of each fluorophore individually vs. FSC (Figure 
2.3.3C). Boolean logic is used to determine the number of double-positive events, which can be 
visualized by displaying only the positive-gated population of one fluorophore on a plot of FSC 
vs. the other fluorophore (Figure 2.3.3C, right). 
Having verified the presence of calcein double-positive events in P2 mixtures (Figure 
2.3.3C), we sought experimental confirmation that the dyes did not transfer between particles. 
Because only the cleaved, polar dye molecules are retained, we reasoned that even if some 
membrane disruption and dye leak occurred during mixing and centrifugation, the polar 
molecules would be unable to label surrounding intact particles bearing the other calcein dye. 
We confirmed this by sonicating a P2 sample truly double-labeled with both calcein dyes and 
adding an unlabeled P2 sample to the sonicated solution using the exact same experimental 
 
 
Figure 2.3.3: Experimental Assay for Measuring Coincidence and Aggregation 
(A) Schematic representation of the P2 sample labeling workflow. A single sample is 
split into equal portions for single-color labeling, followed by two washes to remove 
residual dye. The samples are then mixed and washed a third time before flow 
cytometry. (B) Schematic representation of particle detection and artifacts in 
microparticle flow cytometry. Particles flow in the sample fluid, which is surrounded by 
sheath fluid. Note that the width of the sample stream is enlarged for illustrative 
purposes; we run our cytometers at the minimum sample pressure (and thus sample 
stream width) in order to ensure optimal hydrodynamic focusing. When the trigger 
parameter detector crosses a user-defined threshold, the time duration of this pulse is 
then integrated on all detectors to generate an event. “Single” events that are detection 
artifacts occur when multiple particles simultaneously occupy the focal point of laser 
illumination (coincidence) or are physically bound (aggregates). (C) Representative 
density plots of a P2 sample from the double-calcein assay on the Influx. Left: Calcein 
AM-labeled P2 sample shows no cross-emission in the calcein red detector. Mid-left: 
Calcein Red-labeled P2 sample shows no cross-emission in the calcein AM detector. Mid-
right: Mixture of single-labeled P2 samples is gated for calcein AM+ and calcein red+ 
particles, which are then cross-checked for the other fluorophore (diagonal arrows). 
Right: Calcein AM+ or calcein red+ gated particles are analyzed to quantify double 




workflow. As shown in Figure B.3B, no calcein AM- or calcein red-positive events were 
detected. This demonstrates that even after complete membrane disruption to liberate the entire 
dye content of one sample, we do not observe measurable transfer to an unlabeled sample after 
washing and mixing.  
 
Aggregation, but not coincidence, causes false double-positive events in P2 samples 
 
With our multicolor fluorescence assay in hand, we turned towards distinguishing 
between coincidence and aggregation. Similar to previous studies [390], we used mixtures of 
green- and red-fluorescent 500nm PS beads to model coincidence. We repeated the dilution 
series experiments with mixtures of beads or mixtures of single calcein-labeled P2 samples on 
both Influx (Figure 2.3.4A-B) and Fortessa (Figure B.4A-B). For bead mixtures, we observed a 
clear population of double-positive events (red- and green-bead coincidences) on both 
instruments. At high concentrations, the Fortessa performed particularly poorly with regard to 
coincidence, with a wide smear of red-fluorescent bead multiplets and double-positive events 
(Figure B.4A). On both instruments, we observed a linear reduction in the number of double-
positive bead events with dilution, with virtually none detected at event rates <500 events/sec 
(Figure 2.3.4C-D). In contrast, the percentage of double-positive events from P2 samples 
remained relatively constant across the entire dilution series. P2 double-positive events persisted 
even at event rates <100 events/sec, which strongly suggests that coincidence is not the source of 






We speculated that the double-positive events might come from the physical association 
of two separate fluorescent particles in the P2 samples. To further probe the nature of these 
events, we sorted double-positive events from bead or P2 mixtures on the Influx and reanalyzed 
the sorted material (Figure 2.3.5A-B). Sorting of bead double-positive events failed to increase 
the frequency of these events in the sorted sample, with reanalysis showing a ~4-fold decrease 
(Figure 2.3.5C). Consistent with the dilution experiments, this result suggests that the majority 
of green- and red-fluorescent beads are not physically associated with each other during 
detection of double-positive events. In contrast, sorting of P2 double-positive events increased 
the frequency of these events ~3-fold in the sorted sample reanalysis (Figure 2.3.5C). We note 
that a 3-fold increase in fluorescent particles during sort reanalysis is similar to that achieved for  
fluorescent VGLUT1+ synaptosomes [290], suggesting that P2 double-positive events behave as 
stable, ‘single particles’ in this experiment. It is also possible that the high pressures encountered 
during sorting physically disrupt some aggregates, as suggested by Biesemann [381], which 
would further decrease the frequency of double-positive events in reanalysis. 
 
 
Figure 2.3.4: Dilution Series Reduces False Double-Positive Bead Events but Not 
Double-Calcein Positive P2 Events 
(A) Representative density plots of a dilution series for a mixture of fluorescent 0.5 µm 
PS beads detected using FSC-triggering on the Influx. Individual PS beads and double-
positive events are distinguished by their green (FITC detector) or red (PE detector) 
fluorescence. (B) Representative density plots of a dilution series for a mixture of single 
calcein-labeled P2 samples detected using FM-triggering on the Influx. Only events gated 
positive for calcein red are displayed. (C) Measurements from full dilution series of bead 
mixture or single calcein-labeled P2 mixtures (n=3) on the Influx. P2 data are displayed 
as mean +/- SEM. Left: Event rate. Right: Double-positive events expressed as a 
percentage of all fluorescent events. (D) Measurements from full dilution series of bead 
or single calcein-labeled P2 mixtures on the Fortessa. Left: Event Rate. Right: Double-




The divergent behavior of bead and P2 samples in dilution and sorting experiments 
strongly suggests that the majority of P2 double-positive events are aggregates. Since we 
routinely vortex samples at high speed for 5 seconds prior to flow cytometry, this suggests that 
the double-positive aggregates are relatively stable. We hypothesized that these aggregates form 
during centrifugation and are not fully disrupted during resuspension and filtration. To test this 
hypothesis, we conducted the multicolor dye-labeling assay with and without centrifuging the 
sample mixture and monitored the samples over time on the Influx. As shown in Figure 2.3.5D, 
centrifugation-resuspension significantly increased the frequency of double-positive events 
compared to mixing without centrifugation. Intriguingly, the frequency of double-positive events 
increased over time for nearly every sample (Figure 2.3.5D, left panel).  
Taken together with the dilution and sorting experiments, these results suggest that 
particle aggregation in P2 samples is an ongoing process that is accelerated by centrifugation. 
We emphasize that our assay actually underestimates the frequency of true aggregates; green-
green or red-red aggregates are not detected as double-positive events, but such aggregates are 
surely formed during centrifugation and washing of single-labeled samples. The mixing of 
single-labeled samples without centrifugation shown in Figure 2.3.5D (‘Mix’ samples) actually 
underestimates the true proportion of aggregates, and we therefore conducted all other 
experiments in this study with centrifugation of the mixtures. 
Aggregation of cells can also affect conventional flow cytometry experiments, and we 
wondered whether commonly employed ‘singlet gating’ procedures could discriminate 
aggregates in our P2 samples. We plotted the trigger pulse width (in this case, FM4-64) vs. FSC 
on the Influx, or FSC-H vs. FSC-A on the Fortessa, for events gated as single or double calcein-
positive (Figure B.5). Cell doublets generally deviate from linearity on such plots, forming a 
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‘cloud’ that can be gated apart from the linear singlet profile [391]. We found no such deviation 






Although they bear only one fluorophore, single-positive events are expected to contain at least 
as many or even more aggregates than double-positive gated events (i.e., green-green, red-red, 
red-nonfluorescent, green-nonfluorescent, etc.). The lack of deviation from linearity for any 
events in these pulse profiles suggests that a ‘doublet profile’ does not exist for our P2 samples. 
Indeed, a recent flow cytometry study using this gating procedure in analysis of FSC-triggered 
P2 samples found that all their events obeyed this ‘linear singlet profile’ [378]. The lack of a 
distinguishing ‘doublet profile’ becomes especially apparent when looking only at double-
positive events, which are predominantly aggregates and display a similar linear pulse profile to 
single-positive events (Figure B.5). Thus, we found no evidence that pulse profile is an effective 
 
 
Figure 2.3.5: Effects of Fluorescence-Activated Sorting, Centrifugation-Resuspension, 
and Time Lapse on Double-Positive P2 Events. 
These experiments were conducted using FM-triggering on the Influx. (A) Representative 
density plots of pre-sorted samples. Left: Mixture of fluorescent 0.5 µm PS beads on the 
Influx. The ‘Bead Double+’ gate was used for sorting. Mid left and right: Mixture of single 
calcein-labeled P2 samples. Right: Calcein AM+ gated events from single calcein-labeled 
P2 samples were gated for calcein red+. This ‘Double Cal+’ gate was used for sorting. (B) 
Representative density plots of sorted samples re-analyzed on the Influx. Left: Sample 
sorted for ‘Bead Double+’ gate above. Mid left and right: Sample sorted for ‘Double Cal+’ 
gate above. Right: Calcein AM+ gated events from ‘Double Cal+’ sorted sample. (C) 
Summary of pre-sort vs. reanalysis of sorted double-positive bead and P2 (n=3) samples. 
P2 data are plotted as mean +/- SEM. (D) Comparison of time lapse data for 
centrifugation-resuspension (‘Spin’) vs. mixing without centrifugation (‘Mix’) of single-
labeled P2 samples. Left: Time lapse of double-positive events plotted expressed as a 
percentage of all fluorescent events. Samples include the following mixtures of single-
labeled P2 samples: violet amine-reactive dye/MitoTracker Deep Red FM (n=2), calcein 
AM/calcein red (n=3), violet amine-reactive dye/calcein AM (n=1), violet amine-reactive 
dye/calcein AM/calcein red (n=2), all four dyes (n=2). Right: Comparison of averages for 
the individual trajectories shown on the left, plotted as mean +/- SEM. A Student’s t-test 
was performed comparing ‘Mix’ vs. ‘Spin’ at each time point. * indicates p < 0.05, ** 
indicates p < 0.01. 
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means of removing false double-positive aggregates from downstream analysis of submicron 
particles. 
 
Double-positive event frequency increases with FSC and is reduced in nonionic buffer 
 
Although bead standards do not provide accurate size estimation of biological particles, 
we wondered whether the relative size information afforded by FSC intensity would correlate 
with the presumably larger size of aggregates. We analyzed five discrete regions ranging from 
low to high FSC on the Influx, based on beads and the FSC noise threshold (Figure 2.3.6A-B). 
A representative overlay of the FSC gates onto gated double-positive P2 events is shown in 
Figure 2.3.6C. Strikingly, the top two FSC gates contain ~50% of all double-positive events 
(percentages in red) but only ~19% of all calcein-positive events (percentages in black), while 
the bottom two FSC gates contain only ~25% of all double-positive events amongst ~65% of all 
calcein-positive events. Accordingly, the percentage of fluorescent events within each FSC gate 
that were double-positive steadily increased with FSC (Figure 2.3.6C, percentages in blue). For 
all fluorescent events within each FSC gate, we quantified the percentage of single-, double-, and 
triple-positive events on the Influx (Figure 2.3.6D-F). 
Although the overall frequency of single-positives was ~90%, this steadily decreased 
from ~97% in the FSC Noise region to ~70% in the region above or equal to 1300nm silica 
beads (Figure 2.3.6D). The overall frequency of double-positives was ~10%, but steadily 
increased from ~2% in the FSC Noise region to ~27% in the region above or equal to 1300nm 
silica beads (Figure 2.3.6E). Similarly, the overall frequency of triple-positives was ~2%, but 







silica beads (Figure 2.3.6F). These results suggest that although aggregates are present in all 
FSC regions, their presence is strongly correlated with increasing FSC. Again, we emphasize that 
our fluorescence assay underestimates aggregation, even in samples where the measured double-
positive frequency exceeds 40% in the highest FSC regions (e.g., Figure 2.3.6C). 
 
 
Figure 2.3.6: Distribution of Double-Positive P2 Events Across FSC Ranges and in 
Different Sample Buffers 
These experiments were conducted using FM-triggering on the Influx. (A) Representative 
density plot of non-fluorescent silica and fluorescent PS beads (Apogee) showing the five 
FSC gated regions based on noise threshold and bead positions. (B) Same sample and 
FSC gates as in A but plotted to display green fluorescence of PS beads (FITC detector). 
(C) Representative density plot showing the five FSC gated regions on a mixture of single 
calcein-labeled P2 samples. Only gated double-positive events are displayed. The 
percentage of all fluorescent (i.e. calcein-labeled) events that falls into each FSC gate is 
displayed in black (all five FSC gates sum to 100%). The percentage of all calcein double-
positive events that falls into each FSC gate is displayed in red (all five FSC gates sum to 
100%). The number of double-positive events within each FSC gate, expressed as a 
percentage of all fluorescent events in that FSC gate, is displayed in blue. (D-F) Box and 
whiskers plots of single-positive, double-positive, or triple-positive events, expressed as a 
percentage of all fluorescent events within the respective FSC gate. Central bar represents 
the median. Lower and upper edges correspond to 25th and 75th percentiles. Lower and 
upper whiskers extend to the smallest or largest value no greater than 1.5 times the 
interquartile range away from the corresponding edge. Data for single- and double-
positive events are derived from two-color mixtures of P2 samples single-labeled with 
calcein AM/calcein red (n=4), violet amine-reactive dye/MitoTracker Deep Red FM (n=1) 
or calcein AM (n=1) or calcein red (n=1), as well as three-color mixtures single-labeled 
with violet amine-reactive/calcein AM/calcein red (n=3). Triple-positive event data are 
derived only from the three-color mixtures. A Student’s t-test was performed comparing 
each FSC gate to that directly above or below it. * indicates p < 0.05, ** indicates p < 0.01. 
(G) Diagram of buffer scheme during sample preparation. ‘PBS’ and ‘SET’ samples are 
labeled, washed, and run on the flow cytometer in their respective buffers. ‘PBS-SET’ 
samples undergo calcein labeling and the first two washes in PBS prior to mixing, a third 
wash, and flow cytometry in SET buffer. (H) Box and whiskers plot of double-positive 
events, expressed as a percentage of all fluorescent events within the respective FSC gate. 
Data are derived from two-color mixtures of P2 samples single-labeled with calcein 
AM/calcein red using the indicated buffer scheme: ‘PBS’ (n=10), ‘PBS-SET’ (n=8), or ‘SET’ 
(n=10). Two-way ANOVA was performed, revealing significant main effects of FSC Gate 
(Df = 5, F = 20.06, p=2.7e-15) and Buffer (Df = 2, F = 20.14, p=1.8e-8), as well as a significant 
interaction (Df = 10, F = 2.78, p=0.004). 
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Several groups familiar with microscopic analysis of synaptosomal preparations have 
noted that ionic buffers (e.g., PBS) cause synaptosomes to aggregate, while nonionic media (e.g., 
sucrose buffer) favors an even distribution of single particles [386,387]. We repeated our double 
calcein assay on the Influx using the sucrose/EDTA/Tris (hereafter ‘SET’) buffer recommended 
by Daniel et al. [387]. Because many assays are not possible in nonionic media, we tested 
labeling in PBS and then switching to SET for flow cytometry (designated ‘PBS-SET’) in 
addition to conducting the entire procedure in SET (Figure 2.3.6G). Compared to PBS, both 
PBS-SET and SET samples displayed similar FSC vs. FM4-64 profiles (Figure B.6A), 
indicating that SET did not impair FM-triggered particle detection or FSC measurement. FSC 
and green-fluorescence measurements of PS beads in PBS and SET were also indistinguishable 
(Figure B.6B). However, we noticed that the total number of calcein-positive events was 
reduced to ~20% in when calcein-labeling was conducted in SET, compared to ~40% for PBS or 
PBS-SET (Figure B.6C). We suspect that the nonionic media and divalent cation sequestration 
by EDTA somewhat reduce the esterase activity of synaptosomes; nonetheless, the labeling 
efficiency was sufficient to analyze a large number of labeled particles present in these mixtures.  
As shown in Figure 2.3.6H, the percentage of fluorescent events within each FSC gate 
that were double-positive was reduced in SET compared to PBS. A stepwise pattern was 
observed, wherein the double-positive frequency was highest for PBS, lower for PBS-SET, and 
lowest for SET. Two-way ANOVA revealed highly significant main effects of both FSC gate 
(Df = 5, F = 20.06, p=2.7e-15) and buffer (Df = 2, F = 20.14, p=1.8e-8) as well as a significant 
interaction (Df = 10, F = 2.78, p=0.004). The significant interaction makes sense given that 
buffer has little effect in the lower FSC regions, while the reduction of double-positive events is 
greater in the higher FSC regions (Figure 2.3.6H). These results provide further evidence that 
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double-positive events are aggregates, and that such aggregates are less abundant in nonionic 
SET buffer. 
 
False colocalization of antigens in immunostained P2 samples 
 
Given reports claiming high purity of synaptosomes in FSC ranges between 500 – 
1500nm PS beads [377–379], we suspected that many of the aggregates in our P2 samples 
contain synaptosomes. Although the violet amine reactive and calcein dyes efficiently label 
many particles in P2 samples, they do not provide information about the identity of these 
particles. We conducted three-color immunostaining of P2 samples on the Influx, targeting 
presynaptic markers expressed by excitatory, inhibitory, and monoaminergic neurons, 
respectively: VGLUT1, vesicular GABA transporter (VGAT), and vesicular monoamine 
transporter 2 (VMAT2). Although we did not attempt immunostaining in SET buffer, we did 
mimic the PBS-SET condition described above by resuspending stained and washed samples in 
SET for flow cytometry. 
As shown in Figure 2.3.7A, immunopositive events for all three transporters were 
observed across the entire FSC range and reflect their abundance in the brain (VGLUT1 > 
VGAT > VMAT2). Looking at all immunopositive events across FSC gates (Figure B.7A), 
VGAT+ and VMAT2+ events displayed an asymmetric distribution centered below 500nm PS 
beads, while VGLUT1+ events were distributed fairly uniformly just below 880nm silica beads. 
Although the distribution of all immunopositive events across FSC gates was not affected by 
buffer (Figure B.7B), the percentage of immunopositive events within each FSC gate was 






main effect of buffer for VGAT (Df = 1, F = 4.70, p=0.034) and VMAT2 (Df = 1, F = 5.21, 
p=0.026) but not VGLUT1 (Df = 1, F = 0.36, p=0.55). A highly significant main effect of FSC 
gate was observed for all three markers (Df = 5, F = 21.51, p=2.9e-12 for VGAT; Df = 5, F = 
68.9, p<2e-16 for VGLUT1; Df = 5, F = 12.54, p=2.4e-8 for VMAT2), where the percentage of 
immunopositive events within each FSC gate increased with FSC (Figure 2.3.7B). All buffer x 
 
 
Figure 2.3.7: Fractional Abundance of Immunostained P2 Events in Different FSC 
Ranges and in Different Sample Buffers 
These experiments were conducted using FM-triggering on the Influx. (A) Representative 
density plots of P2 samples immunostained for VGAT, VGLUT1, and VMAT2 and run in 
PBS. Top: Secondary-only controls in which primary antibodies were omitted. Bottom: 
immunostained with indicated primary antibodies. (B) Box and whiskers plot of 
immunostained events as indicated, expressed as a percentage of all events within the 
respective FSC gate. Central bar represents the median. Lower and upper edges 
correspond to 25th and 75th percentiles. Lower and upper whiskers extend to the smallest 
or largest value no greater than 1.5 times the interquartile range away from the 
corresponding edge. Data are derived from P2 samples triple-stained and washed in PBS, 
and subsequently run in either PBS (n=6) or SET (n=6) as sample buffer. Two-way 
ANOVA was performed for each dataset. Left: For VGAT+ events, FSC Gate (Df = 5, F = 
21.51, p=2.9e-12) and Buffer (Df = 1, F = 4.70, p=0.034) were both significant, with no 
significant interaction (Df = 5, F = 0.40, p=0.85). Middle: For VGLUT1+ events, only FSC 
Gate (Df = 5, F = 68.9, p<2e-16) was significant, while Buffer (Df = 1, F = 0.36, p=0.55) and 
the interaction (Df = 5, F = 0.19, p=0.97) were not. Right: For VMAT2+ events, FSC Gate (Df 
= 5, F = 12.54, p=2.4e-8) and Buffer (Df = 1, F = 5.21, p=0.026) were both significant, with no 
significant interaction (Df = 5, F = 0.27, p=0.93). (C) Box and whiskers plots of single-, 
double-, and triple-positive events expressed as a percentage of all fluorescent events 
within the respective FSC gate. Data are derived from the same immunostained P2 
samples as in B. Two-way ANOVA was performed for each dataset. Left: For single-
positive events, FSC Gate (Df = 5, F = 19.83, p=1.3e-11) and Buffer (Df = 1, F = 6.74, p=0.012) 
were both significant, with no significant interaction (Df = 5, F = 0.15, p=0.98). Middle: For 
double-positive events, FSC Gate (Df = 5, F = 23.25, p=6.6e-13) and Buffer (Df = 1, F = 8.00, 
p=0.006) were both significant, with no significant interaction (Df = 5, F = 0.40, p=0.85). 
Right: For triple-positive events, only FSC Gate (Df = 5, F = 8.37, p=4.7e-6) was significant, 
while Buffer (Df = 1, F = 1.91, p=0.17) and the interaction (Df = 5, F = 0.19, p=0.97) were not. 
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FSC gate interactions were non-significant. Consistent with recent studies [378], the percentage 
of VGLUT1+ events in the highest FSC gate approaches ~60%. 
Although specific cases of neurotransmitter co-transmission and co-release have been 
observed (reviewed in [392,393]), the expression of VGLUT1, VGAT, and VMAT2 should be 
mutually exclusive for the majority of presynaptic terminals. For all immunopositive events 
within each FSC gate, we quantified the percentage of single-, double-, and triple-positive events 
(Figure 2.3.7C). Similar to double calcein-positive events, we observed a steady decrease in 
single-positive and a steady increase in double- and triple-positive events with increasing FSC. 
Two-way ANOVA revealed a significant main effect of FSC gate for each event type (Df = 5, F 
= 19.83, p=1.3e-11 for single-positive; Df = 5, F = 23.25, p=6.6e-13 for double-positive; Df = 5, 
F = 8.37, p=4.7e-6 for triple-positive). PBS-SET samples had higher single-positive event 
frequencies and lower double-positive event frequencies compared to PBS (Figure 2.3.7C). The 
main effect of buffer was significant for single-positive (Df = 1, F = 6.74, p=0.012) and double-
positive (Df = 1, F = 8.00, p=0.006), but not for triple-positive events (Df = 1, F = 1.91, p=0.17). 
None of the buffer x FSC gate interactions were significant. Thus, although PBS-SET samples 
did display reduced aggregation, the effect was modest, especially for triple-positive events. 
Similar to the percentage of immunopositive events within each FSC gate, the frequency of false 
co-localization increases with FSC. To further illustrate this point, we calculated the percentage 
of immunopositive events for each antigen that were single-, double-, or triple-positive within 
each FSC gate (Table B.2). In the FSC noise region we found that ~80% of VGAT+, ~75% of 
VGLUT1+, and ~63% of VMAT2+ events were single-positive. Strikingly, in the highest FSC 
gate, the single-positive percentage was only ~12% for VGAT+, ~51% for VGLUT1+, and ~9% 
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for VMAT2. These results suggest that many of the putative ‘synaptosomal’ events in the upper 
FSC regions are aggregates containing multiple synaptosomes. 
The quantification of double-positive events described above represents the sum of the 
three possible subtypes (i.e., VGAT+/VGLUT1+, VGLUT1+/VMAT2+, and 
VMAT2+/VGAT+). We wondered whether the frequency of these double-positive subtypes was 
related to the overall abundance of their respective antigens (Figure B.7C). We used the 
percentage of all events immunopositive for each antigen to construct a simple probability 
model. In this model, a double-positive event represents the random sampling of two events with 
replacement. The probability of a particular double-positive subtype is therefore obtained by 
multiplying the frequencies of its’ respective event types (Figure B.7D). Consistent with the 
expected frequencies of double-positive subtypes, we found that VGLUT1+/VGAT+ events 
were by far the most abundant (~75%), followed by VGLUT1+/VMAT2+ (~20%), and finally 
VMAT2+/VGAT+ (~5%, Figure B.7D). These results are consistent with a simple ‘collision’ 
model of aggregation in the P2 crude synaptosome preparation. Furthermore, they strongly 
suggest that many double-positive events observed in these immunostaining experiments are 
aggregated particles rather than single synaptosomes co-expressing multiple vesicular 
transporters. 
Although scatter measurements of submicron particles may vary dramatically across 
cytometers, fluorescence measurements can be readily calibrated. We determined the 
fluorescence intensity of VGAT/anti-mouse AlexaFluor488 immunostaining in molecules of 
equivalent soluble fluorophore (MESF) using calibrated bead standards (Figure B.7E). Because 
particle fluorescence is directly related to FSC intensity regardless of the immunostaining 
procedure, many immunopositive events at a given FSC intensity would exhibit fluorescence 
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intensity less than or equal to immunonegative events at a higher FSC intensity nearby. We 
therefore analyzed the median fluorescence intensity of gated immunopositive and 
immunonegative events within each FSC gate (Figure B.7F). Numerical MESF data are also 
included in Table B.3, which should facilitate comparison across laboratories. 
 
Particle Recovery Following Repeated Centrifugation 
 
Given the increased frequency of aggregates after centrifugation (Figure 2.3.5D), in 
higher FSC regions (Figure 2.3.6D-F), and in PBS (Figure 2.3.6H), we wondered whether 
buffer and centrifugation might interact to bias sample composition towards aggregates 
following repeated centrifugations. Indeed, Gray and Whittaker (1962) previously reported 
increased recovery of acetylcholine in the low-speed P1 pellet when using saline instead of 
sucrose buffer, which was interpreted as aggregation in saline increasing the effective size of 
synaptosomes (and thus sedimentation at lower speed). To assess whether multiple centrifugation 
steps might bias particle recovery in PBS vs. SET, we conducted two sequential 5-minute 
centrifugations of P2 samples in PBS or SET buffer at varying speeds and used flow cytometry 
with absolute counting beads to determine the particle concentration of the pellets and 
supernatants (Figure 2.3.8A). We found that under carefully controlled conditions with the 
absolute counting beads, PBS reduced particle abundance by ~3-fold prior to any centrifugation 
(Figure 2.3.8B). It is possible that certain particles in the P2 sample are susceptible to 
destruction in PBS, but several features of the data suggest that aggregation contributes to the 
reduction in particle counts. First, the median fluorescence intensity of membrane staining by 







brighter, larger events with higher FSC (Figure 2.3.8C-D). In line with the findings of Gray and 
Whittaker (1962), we found that these ‘FSC High’ particles were more efficiently pelleted in 
PBS at lower relative centrifugal force (2500-5000xg) compared to SET buffer (Figure 2.3.8D). 
The relative abundance of these particles was dramatically increased in the two pellets, P2-1 and 
P2-2, compared to the input sample and two supernatants (Figure 2.3.8E). The relative 
abundance of the large particles in PBS samples was highest in 2500xg pellets and lowest in 
10000xg pellets, while no clear relationship between relative abundance and centrifugation speed 
was observed in SET buffer (Figure 2.3.8F). A slight increase in these ‘FSC High’ particles was 
observed when comparing spin 1 vs. spin 2 for both buffers, but this effect was modest compared 
to the increase in PBS vs. SET (Figure 2.3.8F). As expected, the overall efficiency of particle 
recovery in the pellet of each spin increased with centrifugation speed, with the exception of the 
 
 
Figure 2.3.8: Effects of Repeated Centrifugation in Different Sample Buffer on Particle 
Abundance and Composition of P2 Samples 
These experiments were conducted using FM-triggering on the Influx. (A) Diagram of 
buffer/centrifugation scheme. A P2 sample resuspended in PBS or SET was aliquoted to 
measure input (P2-0), followed by two centrifugations for 5 min at the indicated relative 
centrifugal force (xg). An aliquot of the first pellet (P2-1) is reserved prior to the second spin. 
All samples are then analyzed by flow cytometry using absolute counting beads to measure 
particle number in each fraction. (B) Input samples (P2-0) in PBS or SET buffer (n=4 each). 
Left: Total particle counts. Right: Median fluorescence intensity of FM4-64 for all events. (C) 
Representative histogram of FM4-64 fluorescence of all events for two replicate input 
samples (P2-0) in PBS and SET buffer. (D) FSC vs. FM4-64 density plots for P2-1 (top) or S2-1 
(bottom) samples in PBS or SET buffer centrifuged at 2500xg (left) or 5000xg (right). ‘FSC 
High’ gate corresponds to the top 2 FSC gates from Fig. 6 and 7. (E) Gated ‘FSC High’ events, 
expressed as % of all events, plotted for PBS (left) or SET (right) in each of five fractions 
moving through the centrifugation protocol at indicated relative centrifugal force (xg). Left to 
Right in each panel: Input (P2-0), first pellet (P2-1) and supernatant (S2-1), second pellet (P2-
2) and supernatant (S2-2). (F) Gated ‘FSC High’ events, expressed as % of all events, for P2-1 




first spin in PBS (Figure B.8A-C). Similar to the input samples, it appears that a combination of 
aggregation and/or destruction contribute to the loss of particle counts in the first PBS spin, 
although the recovery in the second spin was higher than in SET buffer. Critically, the first 5-
minute spin at 2500-5000xg in either buffer leaves over half the P2 particles in the supernatant 
(Figure B.8D). Collectively, these data suggest that P2 samples do undergo a certain degree of 
further fractionation during repeated centrifugation-based wash steps. Although some 
centrifugation bias is inevitable regardless of buffer and centrifugation speed, our data suggest 
that lower centrifugation speeds and ionic buffers will bias the overall sample composition 
towards larger particles that are more likely to be aggregates. 
 
2.3.5 Discussion 
The goal of most flow cytometry experiments is to accurately detect and quantify the 
fluorescence intensity of single particles or cells in suspension. Towards that goal, we employed 
a variety of experimental assays that can be used to optimize synaptosome flow cytometry 
experiments. We have summarized our approach in Table 2.3.1 and will mirror the workflow in 
our discussion. We note that this workflow could be employed for any type of small particle, but 
our discussion will focus on aspects specific to synaptosomes. 
 
FSC triggering and bead-based size estimation 
 
It is now widely accepted that FSC-based size estimation using PS beads underestimates 
biological particle size [367,369]. This consequence of the refractive index mismatch has been 
experimentally validated in numerous flow cytometry studies [370–372]. The extent of 
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underestimation depends on a variety of factors including the scattering parameters used, 
refractive indices of the sample and beads, and optical configuration of the cytometer. Estimates 
of the lipid vesicle size range defined by PS beads have been conducted on various cytometers 
and are shown in Table 2.3.2. 
 












FSC vs. fluorescence 
triggering with lipid 
dye (e.g., FM4-64 or 
other) 
 
PS and Silica bead 
standards 
A number of dyes are suitable for 
fluorescence-triggering 
[383,385,394,395]. Multiple studies, 
including ours, have demonstrated 
the increased sensitivity, accuracy, 
and reliability of fluorescence-
triggering [373,394]. 
FSC signal from bead standards 
(especially PS) does NOT accurately 
reflect the size of biological particles 
detected. Refractive index 
differences lead to size 
underestimation, the extent of which 
is highly cytometer-dependent 
(Table 2.3.2). 
Determine linear 






Conducting a dilution series is 
critical to identify the range of linear 







Multicolor dye labeling 
A number of dyes are suitable for 
multicolor dye labeling assays, as 













1) Dilution series with 
multicolor dye labeling 
2) Sorting double-
positive events from 
beads vs. samples 
3) ‘Spin’ vs. ‘Mix’ 
multicolor dye labeling 
 
We found that mixtures of different 
color PS beads are a suitable model 
of coincidence. Double-positive 
sample events that do not decrease 
with dilution, and those that can be 
enriched by sorting, strongly suggest 
aggregates vs. coincidence. This can 
be further supported by testing 
whether the frequency of double-










Use of nonionic 
buffers 
As reported in previous microscopy 
studies [386,387], we found that 
nonionic sample buffers tend to 
reduce aggregation of synaptosomes. 
This is not a complete solution to 
eliminating false double- and triple-
positive events. 
Identify suitable 








multicolor dye labeling 
FSC of beads provides relative 
references for avoiding regions with 










Highly abundant antigens that 
should be mostly exclusive are best 
for these experiments. 
 
Synaptosomes are heterogeneous in size, but a generally accepted size range is 0.5 – 1.0 
µm [280,364–366,396,397]. Although certain preparations contain larger synaptosomes, such as 
Dunkley’s percoll fraction 4 from striatum [398], most studies of cortical synaptosomes 
consistently obtain mean diameters of ~500-600 nm (Table 2.3.3). Based on the synaptosome 
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size ranges in Table 2.3.3 and vesicle size ranges defined by PS beads in Table 2.3.2, a majority 
of single synaptosomes would be expected to produce lower FSC signals than 500nm PS beads 
and therefore would be undetectable by FSC-triggering on many cytometers. Indeed, we could 
detect neither 585nm silica beads nor more than half of P2 samples by FSC-triggering on the 
Fortessa (Figure 2.3.1C-D). 
 
Table 2.3.2: Comparisons of PS Bead vs. Lipid Vesicle Scattering Measurements 
Ref Cytometer Model Parameter PS Bead Range Vesicle Range 




FSC 0.5 - 0.9 µm 1.00 – 1.75 µm 








SSC 110 nm 400 nm 
 
Although the greater sensitivity afforded by the Influx enabled detection of 585nm silica 
beads above the FSC noise threshold, more than half of the P2 sample was still undetectable by 
FSC-triggering (Figure 2.3.1C-D). Our results are consistent with those of Biesemann et al. 
[290], who sorted fluorescent VGLUT1 synaptosomes from below the FSC noise threshold using 
FM-triggering on a BD FACS Aria. These electron microscopy, immunostaining, and proteomic 
studies convincingly demonstrated that single synaptosomes can be purified by sorting events 




Table 2.3.3: Previous Size Range Measurements of Mammalian Synaptosomes 
Ref Method Species/Region 
Synaptosome 
Fraction 
Mean Diameter  
(± SEM) 
[365] Electron microscopy Rat Cortex P2 Percoll Fraction 3 515 ± 17 nm 
[365] Electron microscopy Rat Cortex P2 Percoll Fraction 4 568 ± 14 nm 
[365] Electron microscopy Rat Cortex P2 Percoll Fraction 5 539 ± 12 nm 
[396] Electron microscopy Rat Cortex S1 Percoll Fraction 1 320 ± 130 nm 
[396] Electron microscopy Rat Cortex S1 Percoll Fraction 2 460 ± 150 nm 
[396] Electron microscopy Rat Cortex S1 Percoll Fraction 3 550 ± 130 nm 
[396] Electron microscopy Rat Cortex S1 Percoll Fraction 4 640 ± 120 nm 
[396] Electron microscopy Rat Cortex S1 Percoll Fraction 5 630 ± 190 nm 
[398] Electron microscopy Rat Striatum S1 Percoll Fraction 3 591 ± 9 nm 
[398] Electron microscopy Rat Striatum S1 Percoll Fraction 4 905 ± 12 nm 





560 ± 15 nm 




















In contrast, another widely adopted protocol [380] implements FSC-triggering and 
specifically analyzes only events in the FSC range defined by 0.5 – 1.5 µm PS beads. Based on 
the high percentage of events that carry immunofluorescent signal for synaptic markers, these 
events are assumed to represent single synaptosomes and material below 500nm PS beads is 
regarded as debris [379]. One study analyzed ‘large synaptosomes’, events in an FSC range 
defined by 1.5 - 4.5 µm PS beads [376]. We found that the FSC range above 2 µm PS beads 
includes particles as large as neuronal nuclei (Figure B.1C). To our knowledge, the only single 
synaptosomes approaching this size are derived from mossy fiber terminals of the hippocampus 
and cerebellum, and accordingly these synaptosomes sediment along with nuclei in the P1 
fraction [399,400]. In our hands, the FSC region above 1.3µm silica beads (which would fall 
below both 1.5 and 4.5µm PS beads) represents <5% of all events in the P2 sample (Figure 
2.3.6C) and contains the highest frequency of false double-positive events (Figure 2.3.6E-
H and Figure 2.3.7C). Our results strongly suggest that a large fraction of events in these 
regions are synaptosome-containing aggregates, while single synaptosomes are often found 
below 500nm PS beads and the FSC noise threshold. 
 
Fluorescence-triggering and dilution to control for coincidence 
 
Maintaining an appropriately low sample concentration is critical to prevent coincident 
particle detection in submicron flow cytometry experiments. It has been suggested that 
coincidence is especially prominent when operating in FSC-trigger mode [373], which might 
explain the variations in FSC and FM4-64 fluorescence we observed with dilution in FSC-trigger 
mode on both cytometers (Figure 2.3.2C-D). Importantly, we found that FSC-trigger mode 
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substantially underestimates the true event rate in P2 samples on both cytometers. In such a 
situation, undetected particles in the sample volume associated with a detectable particle can 
contribute to the fluorescence measurements and/or be sorted in the same drop [390]. Thus, with 
FSC-triggering at high event rates, one cannot determine whether sorted material accurately 
reflects the detection and sorting of single particles. Although we found that aggregation was the 
major source of double-positive events in our samples, we did not conduct these assays using 
FSC-trigger mode or at high event rates. Serial dilutions and fluorescence-triggering should be 
conducted in all submicron flow cytometry experiments in order to avoid coincidence.  
 
Detection of coincidence and aggregation 
 
To our knowledge, our study is the first to systematically address coincidence and 
aggregation in flow cytometric analysis of synaptosomes (Figure 2.3.3). We chose a strategy 
analogous to a ‘mixed-species’ experiment commonly employed to validate single cell RNA-
sequencing systems, where a mixture of mouse and human cells is analyzed in order to quantify 
cell-doublet rates [401,402]. Our dye labeling strategy is also employed in high throughput flow 
cytometry studies, where cells from different conditions are given non-transferable fluorescent 
barcodes prior to mixing, staining, and acquisition in a single batch [388]. Although the cellular 
fluorescent barcodes are decoded with high accuracy in these protocols, even when multiple 
barcodes are encoded by discrete concentrations of a single dye [389], our results demonstrate 
that synaptosome preparations do not behave similarly to cells in these experiments. Determining 
the extent of single-particle detection in submicron flow cytometry experiments is a challenging 
task. Image cytometry, which combines confocal microscopy with the fluidics of a cytometer, is 
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powerful in this regard since images of each event can be manually examined after acquisition. 
However, these instruments require extensive optimization and are not widely available to all 
labs. The fluorescent labeling and mixing assay we describe here can be implemented on most 
conventional flow cytometers and should be broadly useful to the microparticle flow cytometry 
community. 
 
Distinguishing between coincidence and aggregation 
 
As we were unable to reduce the frequency of ‘false double-positive’ events with 
extensive dilution and FM-triggering of our P2 mixtures (Figure 2.3.4C-D), we began to suspect 
aggregation as the source of these events. Aggregated particles would behave as ‘single’ particles 
in terms of dilution and coincidence, but nonetheless present serious problems for both cellular 
and submicron flow cytometry analysis. The large scatter signals produced by cells result in 
abnormal width/height vs. area pulse profiles, which can be used to remove cell-doublet events 
in conventional flow cytometry experiments. To date, we are unaware of any study 
demonstrating that this gating strategy works on submicron particles, and our results strongly 
suggest it does not (Figure B.3C). We further demonstrated that double-positive events in our P2 
mixtures can be enriched by sorting (Figure 2.3.5A-C), while fluorescent PS bead double-
positive events are depleted by sorting. These results are highly consistent with our dilution 
series and provide further evidence that the dominant source of double-positive events in P2 
mixtures is aggregation. Combined with our fluorescent labeling and mixing assay, comparison 
to fluorescent PS bead mixtures in dilution series and sorting experiments provides a general 





Single events comprised of aggregated cell-derived microparticles have been definitively 
identified using image cytometry [374]. It is unclear how often and under what conditions cell-
derived microparticles aggregate, but one can speculate that their endogenous function within 
physiological bodily fluids would make them somewhat resistant to aggregation. In contrast to 
cell-derived microparticles, presynaptic nerve terminals do not exist as soluble particles in vivo, 
and the aggregation of synaptosomes in ionic media (saline-based solutions such as PBS) is a 
well-described phenomenon. Gray and Whittaker (1962) analyzed the minimum concentration of 
various electrolytes required to induce aggregation of particles in the P2 and sucrose-
gradient synaptosome fractions. They describe how the particles behave as though negatively 
charged, since divalent and trivalent cations are particularly effective in causing aggregation. 
However, the minimum concentration for sodium chloride was 20 mM [364], far below the 137 
mM present in PBS. Others encountered such aggregates using a filtration procedure to purify 
‘synaptoneurosomes’ from brains homogenized in saline [366].  
Most synaptosome flow cytometry studies have employed ionic media for incubation, 
washing, and sample analysis, whilst assuming that each event generated by the flow cytometer 
represents a single synaptosome [375–379]. Studies of cell-derived microparticles have clearly 
demonstrated situations where this assumption breaks down [374,390], and this issue was 
recently brought forth in synaptosome flow cytometry (see comments on [378]). The 
centrifugation and time-lapse variations of our fluorescent mixture experiments provide further 
insight into particle aggregation in P2 samples (Figure 2.3.5D). Most strikingly, we found that 
centrifugation and resuspension of the single-labeled mixture dramatically increases the 
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frequency of double-positive events. This finding strongly suggests that resuspension of the P2 
pellet does not completely eliminate particles that aggregate during centrifugation. We also 
observed a steady increase in the frequency of double-positive events over time with or without 
centrifugation (Figure 2.3.5D), suggesting that aggregation is an ongoing process in P2 sample 
mixtures. These results also further argue against coincidence as a cause of these double-positive 
events, as coincidence would not be expected to increase over time. Although washing steps are 
critical to these experiments, our data suggest that repeated centrifugation will bias the sample 
composition. The enhanced relative abundance of larger, brighter particles following 
centrifugation in PBS (Figure 2.3.8D-F), especially at low speeds, is consistent with previous 
work [364] and provides further evidence that many of these high FSC events are aggregated 
particles. Future studies should carefully consider the effects of duration, speed, and number of 
centrifugations on downstream experimental results. 
 
Reducing synaptosome aggregation 
 
Analogous to the microscopy results of other groups [386,387], we found that SET buffer 
significantly reduced the frequency of double-positive events in our P2 mixtures, especially in 
the higher FSC gates (Figure 2.3.6H). However, calcein-labeling efficiency was also lower in 
SET buffer (Figure B.6C) and SET would not be compatible with many physiological assays 
[386]. We found that conducting the labeling procedure in PBS and switching to SET buffer for 
flow cytometry also reduced the double-positive event frequency, although the effect was 
smaller than for SET alone (Figure 2.3.6H). Our flow cytometry assay provides a quantitative 
measure (albeit an underestimate) of synaptosomal aggregation in each buffer condition and 
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should be useful to monitor the impact of future protocol improvements. Even without the 
fluorescent mixture assay, we observed that SET buffer reduces the relative abundance of 
particles in the highest FSC regions most likely to contain aggregates (Figure 2.3.8D-F). 
Anecdotally, we noticed that the P2 pellet disperses relatively easily in SET buffer compared to 
PBS. Based on the findings of Gray and Whittaker (1962), we suspect that removing cations 
reduces aggregation by allowing the negatively charged neuronal membranes to repel each other. 
 
Pitfalls in Immunophenotyping of Synaptosomes 
 
The heterogeneity of presynaptic nerve terminals, including specific cases of 
neurotransmitter co-release [392,393], makes high-throughput immunophenotyping of 
synaptosomes by neurotransmitter content an appealing direction for synaptosome flow 
cytometry. Indeed, Gajera et al. [403] have recently demonstrated high-dimensional analysis of 
human synaptosomal preparations using mass cytometry. Our results suggest that the presence of 
synaptosomal aggregates is a serious problem for such experiments, especially in the top two 
FSC ranges in our study (higher than 880nm silica beads, Figure 2.3.7C). We found implausibly 
high co-labeling of VGAT, VGLUT1, and VMAT2 in our P2 samples (Table B.2), and the 
increasing frequency of double- and triple-positive events observed across FSC gates 
corroborates the analogous finding in our fluorescent mixture assay (Figure 2.3.6D-F, Figure 
2.3.7C). These findings further support our conclusion that a high percentage of events in this 
FSC range are synaptosome-containing aggregates. As expected based on synapse abundance, 
VGAT+/VGLUT1+ double-positive events were observed most frequently (Figure B.7C-D). 
Similarly, Biesemann previously demonstrated co-enrichment of VGAT and VGLUT1 by 
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sorting VGLUT1 fluorescent events between 0.75-1.5 µm beads [381]. Western blotting of the 
sorted material revealed enrichment of VGAT and myelin proteolipid protein (PLP), proteins 
that should be depleted in a sort of pure VGLUT1+ synaptosomes. After implementing FM-
triggering and sorting only VGLUT1 fluorescent events below the FSC noise threshold, the 
authors demonstrated unprecedented purity of sorted VGLUT1 synaptosomes with the expected 
depletion of VGAT and other glial markers [290]. Overall, our results are highly consistent with 
their conclusion that the previously sorted events were aggregates containing at least one 
glutamatergic synaptosome [381].  
As others have pointed out [374], immunophenotyping of submicron particles can result 
in detection, but not necessarily accurate quantification. Unfortunately, we found that SET buffer 
was less effective in reducing false double- and triple-positive immunostained events (Figure 
2.3.7C) compared to those observed in the fluorescent mixture assay (Figure 2.3.6H). Since 
resuspension of the P2 pellet is unlikely to completely eliminate aggregates, we suspect that 
some aggregated particles are cross-linked during formaldehyde fixation prior to 
immunostaining. Accordingly, we found that single-positive event frequency was generally 
~90% below the FSC noise threshold in immunostained samples (Figure 2.3.7C), while the 
single-positive frequency in this region was generally ~97% in the calcein mixtures (Figure 
2.3.6D). Although this suggests that some of the double-positive events in the immunostained 
samples are single synaptosomes with true colocalization (e.g., VGAT+/VGLUT1+ nerve 
terminals in cortical layer V [404]), distinguishing such events from aggregates would require 
extensive experimental validation. Flow cytometry studies claiming to study single 
synaptosomes often report a high-degree of co-labeling for markers that are expected to 
colocalize, such as VGLUT1, PSD95, synaptophysin, SNAP25, etc. [378,379]. Such data does 
130 
 
not provide evidence that the detected particles are single synaptosomes, since synaptosome-
containing aggregates would be expected to yield similar, if not even higher co-labeling for these 
markers. Instead, we propose that such studies should explicitly report the co-labeling of 
neurotransmitter-specific markers (i.e., VGLUT1, VGAT, etc.) that should be mutually exclusive 
for most single synaptosomes. As suggested previously [373], claims of co-localization should 
be supported by direct evidence that coincidence and aggregation are not contributing to the 
measurement. 
 
Challenges and Future Directions 
 
Here we highlighted a number of technical challenges that hinder the detection and 
analysis of single particles in synaptosome flow cytometry. In the absence of new purification 
methods, synaptosome preparations will inevitably be contaminated with membranes, myelin, 
and mitochondria. Currently, it seems that transgenic mice harboring fluorescent protein 
reporters are required for sorting, since tractable surface markers are limited and most 
downstream assays are not compatible with fixation and immunostaining of cytoplasmic 
proteins. A sorting protocol for VGLUT1VENUS synaptosomes has described by Herzog and 
colleagues [290,382] (also see [325] for growth cone sorting) and should be readily adaptable for 
other fluorescent proteins and synapse types. However, if immunostained synaptosome events 
are the analytical endpoint for an experiment, the methods described in our study will minimize 
the effects of coincidence and aggregation on the analysis of single synaptosomes. Such 
procedures will need to be routinely performed on each cytometer, and confirmation of accuracy 
by microscopy seems prudent. We remain optimistic that future advances in instrumentation, 
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reagents, and sample preparation will obviate the need for such extensive quality control. Despite 
current limitations, we expect synaptosome flow cytometry studies to continue enhancing our 




Male C57BL/6J mice (6-10 weeks old) were used in all experiments. Mice were housed 
on a 12-hour light/dark cycle with food and water available ad libitum. All animal procedures 
were performed in accordance with the [Author University] Institutional Animal Care and Use 
Committee and followed NIH guidelines. 
 
P1 Crude Nuclei and P2 Crude Synaptosome Preparations 
Preparation of the P2 crude synaptosome fraction was performed using standard 
procedures [364]. Mice were sacrificed by cervical dislocation, after which forebrains were 
rapidly dissected and placed in 10 volumes of ice-cold buffer consisting of 0.32 M sucrose, 4 
mM HEPES pH 7.4, and protease inhibitors (cOmpleteTM EDTA-free protease inhibitor, Roche). 
Tissue was homogenized on ice in a glass-glass dounce homogenizer with 10 gentle strokes of 
loose and tight clearance pestles. All subsequent purification steps were performed on ice or at 
4oC unless otherwise specified. The homogenate was centrifuged at 1,000 xg (Eppendorf 5424R) 
for 10 min to remove nuclei and cellular debris, yielding a P1 pellet and an S1 supernatant. 
A crude nuclei preparation was prepared for flow cytometry according to established 
procedures  [405]. The P1 pellet was resuspended in ice cold buffer containing 250 mM sucrose, 
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25 mM KCl, 5 mM MgCl2, 10 mM Tris pH 7.4, 1 µM DTT, 0.1% Triton X-100, and 1 µM 
Hoechst 33342 and homogenized again with 10 strokes of the tight pestle to facilitate release of 
nuclei. The homogenate was rotated for 15 min at 4oC, filtered through a 40µm cell strainer cap, 
and centrifuged at 500 xg (Eppendorf 5424R) for 5 min to yield a crude nuclear pellet. 
The S1 supernatant was further centrifuged at 10,000 xg (Eppendorf 5424R) for 20 min 
to obtain the crude synaptosome pellet (P2). P2 pellets were cryopreserved by resuspension in 4 
mM HEPES/0.32 M sucrose buffer + 5% DMSO and slowly frozen to -80o C using an 
isopropanol freezing container. Frozen synaptosomes were used within 2 months. This protocol, 
when combined with rapid thawing at 37oC on the day of the experiment, has been shown to 
preserve synaptosome function and morphology [387,406]. After thawing, all experiments were 
conducted with either PBS (137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, and 2 mM KH2PO4) 
or SET buffer (320 mM sucrose, 5 mM Tris, 1 mM EDTA). 
 
Flow Cytometry Instrumentation and Setup 
All flow cytometry data acquisition was carried out using the instrument software 
FACSDiva (BD Biosciences). All flow cytometry data analysis including gating, quantification, 
and generation of density plots/histograms was performed using FCS Express 6 (De Novo 
Software). Number of events, % of all events, and channel statistics (median, geometric mean, 
standard deviation, etc.) for all gates were exported using ‘Batch Export’ for further statistical 
analysis. 
All data acquisition on LSRFortessa (hereafter 'Fortessa', BD Biosciences) was conducted 
using the lowest possible sample pressure settings. Optical configuration employed and 
fluorophores detected in these channels are summarized in Table 2.3.4. 
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The powers of the lasers in the Fortessa are 405nm 100 mW, 488nm 50 mW, 561nm 
100mW, 640 100mW. Detector voltages underwent minor fluctuations over the course of these 
studies in order to maintain comparable sample fluorescence and FSC/SSC values for the 
fluorescent microspheres, which were run at the beginning of each experiment. Approximate 
detector voltages were as follows: FSC (300), SSC (265), Pacific Blue (407), FITC (588), 
PerCP-Cy5.5 (500), PE (511), and APC (537). 
 
Table 2.3.4: Optical configuration of the LSRFortessa 
Laser Band Pass 
Filter 
Dichroic Filter Detector name Fluorophores used in this 
study 
405nm 450/50 Blank Pacific Blue Violet amine-reactive dye 
488nm 488/10 Blank SSC  
488nm 530/30 505LP FITC Alexa488, Calcein AM 
488nm 710/50 685LP PerCP-Cy5.5 FM4-64 
561nm 582/12 Blank PE Alexa555, Calcein red 
633nm 670/30 Blank APC 
Alexa647, MitoTracker Deep 
Red FM 
 
The BD Influx (hereafter ‘Influx’, BD Biosciences) was operating using a 100 μm nozzle 
at 11.1 psi. The sample pressure differential was kept as low as possible.  The frequency was set 
at 25.8 kHz, piezo amplitude between 5 and 10. Optical configuration employed and 
fluorophores detected in these channels are summarized in Table 2.3.5. 
The power of the lasers in the Influx are 405nm 100mW, 488nm 200mW, 561nm 
120mW, 640 120mW.  Detector voltages underwent minor fluctuations over the course of these 
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studies in order to maintain comparable sample fluorescence and FSC/SSC values for the bead 
standards. Approximate detector voltages were as follows: FSC (22.70), SSC (25.77), BV421 
(52.55), FITC (44.51), PerCP-Cy5.5 (41.68), PE (63.65), APC (54.78). 
 
Table 2.3.5: Optical configuration of the Influx 
Laser Band Pass Filter Detector name Fluorophores used in this study 
405nm 460/50 BV421 Hoechst 33342, Violet amine-reactive dye 
488nm 488/10 SSC  
488nm 530/40 FITC Alexa488, Calcein AM 
488nm 692/40 PerCP-Cy5.5 FM4-64 
561nm 589/29 PE Alexa555, Calcein red 
638nm 670/30 APC Alexa647, MitoTracker Deep Red FM 
 
In the annual preventive and maintenance conducted by the BD engineer, a quality 
control (QC) is run with the 6 peak rainbow beads. In the daily setup, the QC setting is retrieved 
and the daily alignment is compared with the QC setting. The complete overlay of the 6 peaks 
with the QC setting indicates the proper alignment of the laser. Drop delay is done with the drop 
delay beads and the accudrop camera, a step which calculates the distance between the laser 
interrogation point and the charging point.   
Daily setup also includes running a mixture of fluorescent PS bead standards (Bangs 
Labs, Inc.) and a mixture of non-fluorescent silica and fluorescent PS bead standards (Apogee 
Flow Systems). To ensure reproducibility in FSC-positioning of samples across experiments, the 
positions of bead populations on FSC vs. SSC and FSC vs. FITC (green fluorescence detector for 
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PS beads) plots are maintained within tight gates stored in the QC workspace. Only occasionally 
did this require minor adjustments to detector voltages. 
 
Flow Cytometry Gating 
 
Gating of bead populations was performed using density plots of FSC vs. SSC and FSC 
vs. FITC (green fluorescence detector for PS beads). Gating of all fluorescent channels was 
performed using a polygon gate on a bivariate density plot of FSC vs. fluorophore. Boolean logic 
gating was used to assess all intersections of positive vs. negative for each fluorophore (e.g., 
double-negative, calcein AM+/calcein red-, calcein AM-/calcein red+, double-positive). Where 
applicable, hierarchical gating was used to assess all intersections of positive vs. negative for 
each fluorophore within each FSC gate. 
 
FSC- and FM4-64-triggered detection 
 
On both the Influx and Fortessa, the FSC voltages were set in order to place 500nm PS 
beads just left of center on the FSC axis, near 102 on the Influx and near 103 on the Fortessa. 
This enabled the beads to be detected just above the FSC noise threshold while also allowing 
800nm PS and 1300nm Sil beads to be collected on scale. Critically, this also allowed for a 
significant amount of floor space on the FSC axis below the FSC noise threshold, which became 
accessible upon fluorescence-triggering with FM4-64. 
For FSC-triggering on the Influx and Fortessa, the FSC trigger threshold was first 
lowered to the minimum value on the instrument while running clean PBS to define the range of 
electronic, optical, buffer, and all other sources of FSC noise. After collecting ~10,000 events, 
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the FSC voltage was raised to the minimum level just above the FSC noise threshold such that 
event rates were <10 events/sec while running clean PBS. Using the configurations described 
above, the FSC-trigger threshold was generally 250-300 on the Fortessa and generally 0.9-1.10 
on the Influx. 
FM4-64 fluorescent triggering was implemented on the Influx and Fortessa using a 
procedure similar to FSC-triggering. FM4-64 was obtained from ThermoFisher, reconstituted at 
100 µg/µL, and diluted into PBS or sucrose buffer at 1.5 µg/mL. This concentration was 
previously shown to be effective for fluorescence-triggering of synaptosomes [290,382]. We 
found optimal detection of FM4-64 fluorescence in the PerCP-Cy5.5 channel and used this 
channel for triggering on the Influx and Fortessa. As with FSC triggering, the fluorescence 
trigger threshold was first lowered to a minimum while running clean buffer + FM4-64 to define 
the noise range. The fluorescent trigger threshold was raised to the minimum level above the 
noise range such that event rates were <10 events/sec while running buffer + FM4-64. Using the 
configurations described above, the FM-trigger threshold was generally 120-150 on the Fortessa 




For sorting on the Influx, populations of interest were gated using the FACSDiva 
software. For bead double-positive and double calcein-positive sorting, the event rate was <5,000 
events/sec. The sort was conducted using ‘1.0 Drop Pure’ mode. At least 20,000 events were 
sorted directly into FACS tubes, which were then used to reanalyze the sorted samples. 
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Reanalysis was conducted <15 minutes after sorting using the exact same cytometer settings, and 
at least 1,500 events were re-analyzed. 
 
Multicolor Labeling and Mixing Assays 
 
Cryopreserved P2 samples were rapidly thawed at 37oC, washed in PBS, and centrifuged 
at 10,000 xg (Eppendorf 5424R) for 5 min at 4oC. Pellets were resuspended in PBS and equally 
divided into separate tubes for single dye labeling. Synaptosomes were incubated at room 
temperature in PBS supplemented with one of the following dyes: calcein AM for 15-30 minutes 
at a final concentration of 1 µM, calcein red-orange AM (hereafter ‘calcein red’) for 15-30 
minutes at a final concentration of 1.9 µM, violet amine-reactive dye for 30 minutes (1:1000 
from 50µL stock, as per manufacturer’s guidelines), or MitoTracker Deep Red FM for 30 
minutes at a final concentration of 500 nM. Synaptosomes were returned to ice and subsequently 
washed and re-centrifuged twice with ice-cold PBS to remove residual dye. All samples were 
maintained on ice and protected from light after labeling. After the second wash, pellets were 
resuspended in equal volumes of PBS + 1.5 µg/mL FM4-64 and mixed in equal volumes to 
generate mixtures of single color-labeled synaptosomes.  
In most experiments, these mixtures were re-centrifuged and resuspended prior to passing 
the suspension through a 40µm cell strainer cap prior to flow cytometry. 
 In time lapse experiments, individual samples were passed through a 40µm cell strainer 
cap and mixed immediately prior to flow cytometry.  
For experiments employing different buffer combinations, the above protocol was 
identical, with SET used in place of PBS as indicated in Figure 2.3.6G: ‘PBS’ represents the 
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standard assay, ‘PBS-SET’ represents the standard assay but with the mixing, 3rd wash, and flow 
cytometry conducted in SET instead of PBS, and ‘SET’ employs SET instead of PBS for all 
steps.  
For fluorescence mixture assays, we observed some variability in the calcein labeling 
efficiency across samples. Since only fluorescent particles are eligible to report on coincidence 
or aggregation, we normalize each fluorescent event type (i.e. single-positive/double-positive) to 




Crude nuclear pellets were resuspended in blocking buffer (PBS, pH 7.4 with 5% BSA) 
supplemented with 1 µM Hoechst 33342 and blocked on ice for 15 min. Primary antibody 
staining was conducted in blocking buffer at 4oC on a rotator for 30 min. Samples were washed 
with blocking buffer, centrifuged at 500 xg (Eppendorf 5424R) for 5 min and resuspended in 
blocking buffer with goat anti-mouse Alexa Fluor 488. Secondary staining was 4oC on a rotator 
for 20 min. Samples were again washed with blocking buffer plus 1 µM Hoechst 33342 and 
centrifuged at 500 xg (Eppendorf 5424R) for 5 min, following resuspension in PBS for flow 
cytometry. 
P2 crude synaptosomes were briefly fixed in 4% paraformaldehyde (PFA) in PBS, pH 7.4 
for 15 minutes at room temperature. After washing in blocking buffer to quench residual PFA, 
synaptosomes were centrifuged at 10,000 xg (Eppendorf 5424R) for 5 min at 4oC. The P2 pellet 
was resuspended in blocking buffer + 0.1% Tween-20 at room temperature for 30 minutes prior 
to addition of primary antibodies. Primary antibody staining was conducted at room temperature 
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for 30 minutes, followed by two washes in PBS with centrifugation and resuspension. Pellets 
were resuspended in blocking buffer + 0.1% Tween-20 with secondary antibodies and stained for 
20 minutes at room temperature. Samples were washed twice with PBS, and final samples were 
resuspended in PBS + 1.5 µg/mL FM4-64 for flow cytometry. For the ‘PBS-SET’ condition, the 
final wash and flow cytometry were conducted in SET buffer. 
 
Absolute Particle Count Measurements 
 
P2 samples from dilution series (Figure B.2C) or from repeated centrifugation 
experiments (Figure 2.3.8 and Figure B.8) were diluted to a precise final volume (200-500µL) 
in PBS+FM or SET+FM. A precise volume of resuspended CountBrightTM absolute counting 
beads was added to each sample. Counting beads were run alone to confirm that they could be 
gated apart from FM4-64-triggered P2 events, and were gated based on SSC and blue 
fluorescence (BV421 channel). Particle concentration was calculated for each sample as per the 
manufacturer’s guidelines using the number of FM4-64-triggered P2 events, count bead events, 
bead count of the lot (beads/µL), and bead/sample volumes. For repeated centrifugation 
experiments (all using indicated relative centrifugal force (xg) on Eppendorf 5424R), absolute 
particle counts were calculated based on the total sample volume, and total particle counts in 
each fraction were determined by back-calculation using the aliquot and sample volumes. 
 
AlexaFluor488 MESF Calibration 
 
QuantumTM AlexaFluor488 MESF calibration beads were run on the Influx at the same 
time and under identical conditions (sample pressure, detector voltages, etc.) as the 
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immunostained samples. MESF calibration beads (7µm) could be identified based on SSC with 
only a slight reduction (~10%) in the SSC voltage for this experiment. The five calibration beads 
(blank and MESF beads 1-4) were run individually to confirm separation by the green 
fluorescence detector (FITC channel). Beads were first gated based on SSC and then based on 
green fluorescence histograms (see Figure B.7E) using full width at half-maximum gating as 
recommended by the manufacturer. The median fluorescence intensity of the calibration beads 
was used to fit the MESF calibration curve (see Figure B.7-E) using the QuickCal V.2.3 
template from the manufacturer (Bangs Laboratories, Inc.). The calibration curve was used to 
calculate the median fluorescence intensity of indirect immunofluorescence (Ms anti VGAT + 
anti-mouse AlexaFluor488) in MESF for subsets of gated events (see Figure B.7F). Numerical 
data are available in Table B.3. 
 
Beads, Chemicals, and Antibodies 
 
Polystyrene bead standards (200, 500, and 800 nm diameter) with refractive index ɳ=1.59 
and Yellow-Green fluorescent label were obtained from Polysciences Inc. (Submicron Bead 
Calibration Kit, Catalog no. BLI832, Bangs Laboratories Inc.). A bead standard mixture of 
Yellow-Green fluorescent polystyrene beads with refractive index ɳ=1.59 (110 and 500 nm 
diameter) and non-fluorescent silica beads with refractive index ɳ=1.43 (180, 240, 300, 585, 880, 
and 1300 nm diameter) was obtained from Apogee Flow Systems (Product #1493). Unlabeled 
polystyrene beads (2.0 µm diameter) were obtained from Spherotech Inc. (Catalog no. PP-20-
10). CountBrightTM absolute counting beads were obtained from Invitrogen (Catalog no. 
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C36950). QuantumTM AlexaFluor488 MESF calibration bead kit was obtained from Bangs 
Laboratories, Inc. (Catalog no. 488). 
The following dyes were obtained from Molecular Probes/Invitrogen: Hoechst 33342 
(Catalog no. H3570), FM4-64 (Catalog no. T13320), calcein AM (Catalog no. C34852), calcein 
red-orange AM (Catalog no. C34851), LIVE/DEADTM Fixable Violet amine-reactive dye 
(Catalog no. L34955), and MitoTracker Deep Red FM (Catalog no. M22426). Antibodies used in 
these studies and their concentrations are summarized in Table 2.3.6. 
 
Table 2.3.6: List of antibodies 
Primary Antibody List 
Origin Antigen Conc. Manufacturer Product 
No. 
RRID 
Mouse NeuN 1:5,000 Millipore MAB377 AB_2298772 
Mouse VGAT 1:400 Synaptic 
Systems 
131 011 AB_887872 
Guinea 
Pig 
VGLUT1 1:500 Synaptic 
Systems 
135 304 AB_887878 
Rabbit VMAT2 1:500 Immunostar 20042 AB_10013884 
Secondary Antibody List 


























Gated data exported from FCS Express 6 were further processed in Excel and in R. 
Where indicated, the robust standard deviation (rSD) was calculated using FCS Express 6 
software. All graphs were generated using the ggplot2 package in R, except those in Figure 2.3.8 
and Figure B.2C, Figure B.7C-F, and Figure B.8A-F which were generated in Excel. All 
statistical testing was conducted in R. Where indicated, a Welch’s t-test was performed with the 
indicated contrasts (Figure 2.3.5D, Figure 2.3.6D-F, Figure B.6C). Where indicated, a two-way 
ANOVA was performed using FSC Gate and Buffer as factors (Figure 2.3.6H and Figure 
2.3.7B-C); degrees of freedom, F statistic, and p values for main effects as well as interaction are 
listed in the figure captions. A summary of all statistical tests is provided in Table B.4. 
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The use of flow cytometry to study synaptosomes is perhaps a deceptively simple idea: 
each synaptic particle behaves as a ‘mini-cell’ and each flow cytometry event corresponds to one 
such particle. Furthermore, one might imagine that simply using bead standards and scattered 
light to estimate the size of these particles would enable clean detection of single synaptosomes. 
I found that all of these assumptions, and possibly much of the published literature that relies on 
them, are seriously flawed. Perhaps this is not so surprising, considering that flow cytometers 
were designed to analyze cells that are several orders of magnitude larger than synaptosomes. 
Technical issues such refractive index mismatching, scatter-based size estimation, 
coincidence, swarm detection, and aggregation are well known within the microparticle flow 
cytometry field [372,374,385]. The use of microparticle flow cytometry has exploded in recent 
years, largely due to widespread interest in extracellular vesicles (e.g., exosomes and other cell-
derived vesicles). Unfortunately, the significant advances made in the microparticle flow 
cytometry field are largely unappreciated within the neuroscience community. Hopefully the 
analysis I have presented will raise awareness about these issues, which are not obvious even to 
those well-versed in traditional flow cytometry analysis of cells (most neuroscience labs are not). 
While some of the aforementioned issues have straightforward solutions, others appear 
relatively intractable. These issues loomed large over my subsequent efforts to purify 
dopaminergic synaptosomes using fluorescence-activated synaptosome sorting (FASS). For 
example, I found that eliminating coincident particle detection and sorting requires running 
samples at dilute concentrations and low event rates (typically <5,000 events/sec). However, the 
population of fluorescent dopaminergic synaptosomes eligible for sorting in our experiments is 
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often as low as 2-5% of all events [83]. This leads to slow sort rates for the target population and 
places practical limits on the amount of material collected for analysis. As I show in Chapter 3, 
millions of synaptosomes are required to approach the levels of mRNA found in a single cell 
[228]. Thus, typical event rates for sorting that I conducted with Etienne Herzog were 15,000-
22,000 events/sec. These speeds are required to sort enough material for downstream analysis 
within a typical work day (often up to 10-12 hours of sorting, not including synaptosome 
preparation). However, sorting at such high event rates invariably leads to decreased purity of the 
sorted material. Combined with the uncontrolled effects of synaptosomal particle aggregation, 
we were never able to achieve a purity of >70% for sorted dopaminergic synaptosomes (for 
comparison, typical cell sorting can achieve purity of >95-98%). Nonetheless, even a sorted 
purity of ~60% represents a massive enrichment of a rare population (typically ~20-fold in our 
studies). Thus, in collaboration with Etienne Herzog, I pursued dopaminergic synaptosome 





Chapter 3: Subcellular mRNA Translation in Dopamine Neurons 
  
“All great work is the fruit of patience and perseverance, combined with tenacious concentration 
on a subject over a period of months or years.” – Santiago Ramón y Cajal, Nobel Laureate 
 
 Although I didn’t end up with the full arsenal of tools I had hoped for, my studies of local 
translation in dopamine neurons continued unabated. From conception to submission, this project 
is the longest standing effort of my graduate studies. I was initially focused on ribosome 
immunoprecipitation (IP) from striatal axons, which ultimately proved to be too difficult. Despite 
employing an RNA-seq protocol with single cell sensitivity, making dramatic improvements in 
the IP conditions, and years of experiments with different ages of mice, I ended up with no 
evidence of axonal translation. As detailed below, synaptosome sorting did little to alleviate 
these frustrations. However, an unexpected observation on the confocal microscope one evening 
took the project in a new and interesting direction. 
I was conducting FISH on mouse brain sections, hoping to identify dopaminergic 
mRNAs (e.g., Th, Slc6a3/DAT) in the medial forebrain bundle and striatum. After failure to 
detect any signal in these regions, I checked several midbrain sections to ensure the Th and 
Slc6a3/DAT probes had labeled dopamine neuronal somata. Indeed, they had; each soma in the 
VTA and SNc lit up like a blazing comet. But to my great surprise, I found myself staring below 
the SNc at a starry sky of individual puncta within the SNr, which is mostly devoid of dopamine 
neuronal somata. Where was this mRNA signal coming from? Non-specific labeling seemed 
unlikely, since the cell bodies were clearly stained and the puncta were largely absent outside the 
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ventral midbrain. Did SNr neurons express low levels of TH and DAT? At the time, I knew 
relatively little about the SNr, but I surmised that these mRNA puncta might be localized within 
the ventrolaterally projecting dendrites of SNc dopamine neurons. 
I spent the next several months optimizing the FISH procedure to accommodate anti-TH 
immunofluorescence, which enabled unambiguous co-localization of dopaminergic mRNA 
puncta within TH+ dendrites. With renewed vigor, I delved into the fascinating literature 
surrounding dendritic dopamine release and conducted additional studies focused on the 
dopaminergic dendrites in the SNr. To the best of my knowledge, the following chapter presents 
the first major treatise on local translation in midbrain dopamine neurons. 
 
Contributions  
3 Chapter 3 is an adaptation of a bioRxiv preprint [228] that is currently under 
review at Cell Reports. I conceived the overall project with input from Peter Sims and David 
Sulzer. I executed all dissection, immunoprecipitation, western blotting, qRT-PCR, and RNA-
Seq experiments. Maria Angelo Flor and I performed FASS experiments with input and 
supervision from Etienne Herzog. I performed histology and immunofluorescence experiments 
with assistance from Ori Lieberman and Eugene Mosharov. I performed FISH experiments with 
assistance from Linghao Kong. I conducted all image analysis. I conducted RNA-Seq analysis 
with input from Peter Sims. Peter Sims, David Sulzer, and Etienne Herzog supervised the 
research. I wrote the manuscript with input from Peter Sims, David Sulzer, and Etienne Herzog. 
 
The following is adapted from: 
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Hobson BD, Kong L, Angelo MF, Lieberman OJ, Mosharov EV, Herzog E, Sulzer D, Sims 
PA (2021) Subcellular and regional localization of mRNA translation in midbrain dopamine 
neurons. bioRxiv. doi: 10.1101/2021.07.30.454065 
 
Supplementary figures are in Appendix C. 




Local translation within excitatory and inhibitory neurons is involved in neuronal 
development and synaptic plasticity. Despite the extensive dendritic and axonal arborizations of 
central monoaminergic neurons, the subcellular localization of protein synthesis is not well-
characterized in these populations. Here, we investigated mRNA localization and translation in 
midbrain dopaminergic (mDA) neurons, cells with enormous axonal and dendritic projections, 
both of which exhibit stimulation-evoked dopamine (DA) release. Using highly-sensitive 
ribosome-bound RNA-sequencing and imaging approaches in mDA axons, we found no 
evidence for axonal mRNA localization or translation. In contrast, mDA neuronal dendritic 
projections into the substantia nigra reticulata (SNr) contain ribosomes and mRNAs encoding the 
major components of DA synthesis, release, and reuptake machinery. Surprisingly, we also 
observed dendritic localization of mRNAs encoding synaptic vesicle-related proteins, including 
those involved in vesicular exocytic fusion. Our results are consistent with a role for local 
translation in the regulation of DA release from dendrites, but not from axons. Our translatome 
data further defined a molecular signature of the sparse mDA neurons resident in the SNr, 




3.2 Background  
 
Midbrain dopaminergic (mDA) neurons play critical roles in reward processing, 
movement control, and cognitive function. The wide range of neural systems modulated by 
dopamine (DA) signaling is matched by an elaborate mDA neuronal cytoarchitecture that 
includes unmyelinated axons that course through the medial forebrain bundle (MFB) to reach 
multiple basal ganglia and cortical targets [2]. Remarkably, single mDA neurons of the murine 
substantia nigra pars compacta (SNc) can innervate nearly the entire volume of the dorsal 
striatum, with axonal arborizations reaching up to 500 mm in total length that possess 104-105 
presynaptic varicosities [155]. mDA neurons of the ventral tegmental area (VTA) send axons to 
the nucleus accumbens (NAcc) and prefrontal cortex (PFC), a relatively late maturational step in 
development that continues into adolescence [319,322].  
As originally reported in back to back papers from the Westerink and Iversen laboratories 
[90,91], mDA neurons also release DA within the midbrain (reviewed in [46,407]), including 
from large, ventrally-directed dendrites of SNc neurons that can project over 500 μm into the 
substantia nigra pars reticulata (SNr) [90,93]. Although recent work has begun to identify 
molecular mechanisms that enable and control DA release in the midbrain [109,110,115,117] 
and striatum [88,116], it is unclear how mDA neurons localize and maintain DA 
neurotransmission machinery in both dendritic and axonal compartments. The energetic demands 
placed on SNc neurons due to their extensive cytoarchitecture may contribute to 
neurodegeneration in Parkinson’s disease [150,158,159], underscoring the importance of proper 
protein production and distribution in these neurons. 
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The subcellular proteome of neurons is regulated in part by local translation. Dendritic 
protein synthesis plays a critical role in various forms of postsynaptic plasticity, including 
synaptic potentiation [270], late long-term potentiation [295,296], and long-term depression 
(LTD) mediated by Group 1 metabotropic glutamate receptors (mGluRs) [271,297]. Axonal 
mRNA localization and protein synthesis are well-established in peripheral neurons and in 
developing axonal growth cones (reviewed in [310,311]). More recent evidence suggests that 
local translation occurs in mature central nervous system (CNS) axons [248], with evidence for 
presynaptic protein synthesis in hippocampal cannabinoid-induced presynaptic LTD [249], 
neurotransmitter release at the Calyx of Held synapse [257], responses to neurotrophins [250], 
and fear-related learning in cortical-amygdalar axons [251]. While accumulating evidence 
supports a role for dendritic and axonal protein synthesis in excitatory and inhibitory neurons, 
less is known about axons engaged in modulatory neurotransmission, particularly those that 
release monoamine neurotransmitters. Intriguingly, the mRNA encoding tyrosine hydroxylase 
(TH), the rate-limiting enzyme in catecholamine biosynthesis, is localized to axons of 
sympathetic neurons in vitro [326]. Ablation of an axonal localization motif in the 3’ 
untranslated region (UTR) of Th mRNA decreases axonal TH protein levels as well as release of 
norepinephrine [327]. These results suggest that local protein synthesis might regulate DA 
neurotransmission in the central nervous system. 
Here, we present a systematic investigation of mRNA localization and translation within 
mDA neurons in the mouse brain. Using cell-type specific ribosomal capture (RiboTag) and 
imaging, we find a striking localization of ribosomes and mRNAs encoding DA transmission 
machinery within dopaminergic dendrites. In contrast, RiboTag studies provided no evidence of 
translating mRNAs in mDA striatal axons. Fluorescence-activated synaptosome sorting (FASS) 
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of dopaminergic synaptosomes of provided very limited evidence of mRNA localization in 
dopaminergic axonal varicosities. Surprisingly, we show that mRNAs encoding canonical 
presynaptic proteins involved in synaptic vesicle neurotransmission are localized within 
dopaminergic dendrites. Our results reveal the subcellular organization of protein synthesis in 





Visualization and capture of mDA neuronal ribosomes  
To study the subcellular landscape of translation in mDA neurons, we crossed DATIRES-
Cre mice [289] with RiboTag mice [278] in order to express HA-tagged eukaryotic ribosomal 
protein L22 (eL22-HA) specifically in mDA neurons (Figure 3.1A). We confirmed high 
efficiency and specificity of eL22-HA expression in TH+ mDA neurons in the SNc and VTA 
(Figure C.1A). Anti-HA immunoprecipitation (IP) of ventral midbrain polysome extracts from 
Cre-positive RiboTag mice (DATIRES-Cre/wt;RiboTag+/-) yielded >64-fold enrichment of mDA 
neuron-specific mRNAs Th and Slc6a3 (DAT), while glial and mRNAs Gfap, Mbp, and the 
soluble polyadenylated spike-in standard ERCC-0096 were depleted based on qRT-PCR (Figure 
3.1B). mDA neuron-specific mRNAs were not enriched in control IPs from Cre-negative 
littermates (DATwt/wt;RiboTag+/-). 
Consistent with previous studies of recombination in DAT-Cre lines [289,408–410], no 







(Figure 3.1C). DAT-driven expression of tagged ribosomal protein L10a has been previously 
observed in A12 [411], but this hypothalamic nucleus was readily dissected from the ventral 
midbrain. Recent work showed that another DAT-Cre line [412] drove off-target expression in 
multiple regions outside the midbrain, including the bed nucleus of stria terminalis (BNST) and 
the lateral septum (LS) [413]. We found no evidence of eL22-HA expression in the BNST or LS 
in DATIRES-Cre/wt;RiboTag+/- mice (Figure C.1B). Similar results were obtained when crossing 
DATIRES-Cre/wt mice with Ai9 tdTomato reporter mice [414], with the exception that scattered TH-
/tdTom+ cells were present in the LS (Figure C.1B). Although these cells were eL22-HA- in 
DATIRES-Cre/wt;RiboTag+/- mice, nonetheless, we removed all tissue medial to the lateral 
 
 
Figure 3.1: Subcellular distribution of eL22-HA tagged ribosomes in DATIRES-Cre:RiboTag 
mice 
Data in Figure 3.1 are from mature adult mice (10-14 mo.) (A) DATIRES-Cre:RiboTag mice 
genetics Upper left: and immunostaining for tyrosine hydroxylase (TH; green) and eL22-HA 
(magenta). Upper right: mDA neurons in the SNc, DAPI in blue, scale bar: 20 µm. Middle: 
Coronal midbrain section, scale bar: 100 µm. Lower: Sagittal section, scale bar: 500 µm. (B) 
qRT-PCR of RiboTag IP and input samples from ventral midbrain of DATIRES-Cre:RiboTag 
mice (Cre+, n=7) or Cre negative littermates (Cre-, n=5). Cq values were normalized to β-
Actin within each input or IP sample. Mean delta-delta Cq (log2 fold changes) +/- SEM are 
plotted. (C) Coronal midbrain section of ventrolateral SNc and SNr stained for TH and 
eL22-HA (location shown in upper left). Dashed white lines indicate insets labeled x and y 
or dendrites d1-d4 which are displayed below in panel E. Main image scale bar: 100 µm, ‘x’ 
inset scale bar: 5 µm, ‘y’ inset scale bar: 5 µm. cpd: cerebral peduncle. (D) Representative 
immunofluorescence of TH and eL22-HA staining in the medial forebrain bundle, striatum, 
and SNr of Cre-/Cre+ RiboTag mice. Scale bar: 10 µm. (E) Straightened dendritic segments 
d1-d4 shown in panel (C). For each straightened dendrite, eL22-HA fluorescence intensity 
was normalized to local background and plotted below the images. Arrows indicate 
‘hotspots’ of eL22-HA fluorescence along the dendrites. (F) Quantification of enhanced 
eL22-HA immunofluorescence within TH+ neurites in the medial forebrain bundle (axons), 
striatum (axons), and SNr (dendrites) of Cre- and Cre+ mice. Box and whiskers plots depict 
the background-normalized eL22-HA mean fluorescence intensity of TH+ pixels within a 





ventricles, including the LS, BNST, and NAcc shell in striatal dissections (see Methods). Thus, 
in midbrain and striatal dissections of DATIRES-Cre/wt;RiboTag+/- mice, eL22-HA was exclusively 
derived from mDA neurons. 
We leveraged the mDA neuron-specific eL22-HA expression to study the subcellular 
distribution of ribosomes via immunohistochemistry. Using fluorophore-conjugated secondary 
antibodies, the majority of eL22-HA labeling was present in soma and proximal dendrites 
(Figure 3.1A, Figure C.1C), with no apparent labeling of axons in the MFB or striatum (Figure 
3.1A). We used tyramide signal amplification [415,416] to enhance the anti-HA signal, which 
produced more intense labeling of dendrites and provided ~8-fold brighter fluorescence in the 
soma (Figure C.1D-E). SNc mDA neurons typically possess three to six long, mostly 
unbranched dendrites; one or two of these are directed ventrolaterally into the SNr and exhibit 
the largest diameters and overall length [93,191,417]. With signal amplification, eL22-HA 
labeling was apparent within such dendrites in the SNr (Figure 3.1C & 1E), even at the distal 
edge near the cerebral peduncles (cpd; Figure C.1F, lower). Co-localization with TH staining 
confirmed that eL22-HA clusters were scattered throughout the ventral-directed dendrites of SNc 
mDA neurons (Figure 3.1C & 1E), which could be distinguished from a few mDA neuronal 
soma present in the SNr (Figure C.1F, upper). We confirmed the specificity of immunolabeling 
by quantifying eL22-HA fluorescence in TH+ processes in the SNr of Cre-positive and Cre-
negative RiboTag mice (Figure 3.1D & 1F). A previous study found an absence of eGFP-tagged 
ribosomal protein L10a in dopaminergic axons using conventional immunostaining and low 
magnification [411]. In agreement with that report, even with strong signal amplification and 
high-resolution confocal imaging, we observed no specific eL22-HA labeling in the MFB or 
striatum (Figure 3.1D & 1F). We conclude that the majority of mDA neuronal ribosomes are 
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located in the soma and proximal dendrites, with lower abundance in distal dendrites and 
exceedingly low levels in axons. 
 
Quantitative capture of dopaminergic ribosomes from regional dissections 
To identify translating mRNAs in distinct subcellular compartments of mDA neurons, we 
conducted RiboTag IP on dissections of four regions (Figure 3.2A): 1) the entire striatal 
complex, including dorsal and ventral striatum, containing mDA axons, 2) the VTA, which 
contains mDA neuronal soma and dendrites, 3) the SNc, which contains mDA neuronal soma 
and horizontally oriented dendrites [93], and 4) the SNr, which contains a few mDA neuronal 
soma amidst a high density of ventral-projecting dendrites of SNc mDA neurons (Figure C.1G). 
As described previously, the exceedingly low yields associated with axonal RiboTag IP 
necessitate the use of Cre-negative (DATwt/wt;RiboTag+/-) mice to control for non-specific 
binding [248]. Compared to previous protocols using Protein G Dynabeads, we found that 
biotinylated anti-HA IgG and streptavidin T1 Dynabeads enabled rapid binding with higher 
specificity (Figure C.1H). The total RNA yield from Cre-negative IPs was typically tens to 
hundreds of picograms and could be accurately estimated using qRT-PCR for beta-actin (Actb) 
(Figure C.1I). 
Since we were unable to visualize eL22-HA immunofluorescence in the MFB or 
striatum, we employed western blotting of eL22-HA IPs to estimate eL22-HA abundance in each 
dissected region. Although prior studies have employed axonal ribosome IP [248,251], these did 
not include a diluted soma spike-in control to assess the relative abundance of captured 
ribosomes. To estimate the sensitivity of our IP in the striatum, we included control samples 
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consisting of Cre-negative striatal lysates spiked with 1% of ventral midbrain (VM) lysates from 
Cre-positive mice. Western blotting of captured eL22-HA revealed prominent bands in VTA and 
SNc IPs, while faint bands were only visible at high contrast in IPs from the striatum and 1% 
VM spike-in control (Figure 3.2B-C). Quantification revealed that of all eL22-HA captured, 
approximately 37.4% was from the SNc, 54.5% from the VTA, 4.13% from the SNr, 2.23% from 
the striatum, and 1.75% from our 1% VM spike-in control (Figure 3.2D). The striatal eL22-HA 





eL22-HA abundance measured by western blot correlates remarkably well with our spike-in 
control (1% of VM lysate vs. estimated 1.75% eL22-HA) as well as the reported distribution of 
mDA neurons in C57BL/6J mice [156]: ~8,000 in the SNc (38% of mDA neurons vs. 37.4% of 
eL22-HA) and ~10,000 in the VTA (47.6% of mDA neurons vs. estimated 54.5% of eL22-HA). 
The eL22-HA western blot (Figure 3.2B-D) and histology (Figure 3.1) data correlate well with 
typical ribosome distribution in neurons and are consistent with very low levels or absence of 
ribosomes in striatal mDA axons. However, these assays do not establish if the eL22-HA in a 
given subcellular compartment is derived from translating ribosomes, and so we next analyzed 
dopaminergic mRNA capture in the same eL22-HA IPs. 
 
 
Figure 3.2: Regional distribution of eL22-HA protein and dopaminergic mRNAs 
captured by RiboTag IP  
Data in Figure 3.2 are from mature adult mice (10-14 mo.) (A) Subcellular translatome 
profiling workflow schematic. DATIRES-Cre:RiboTag mice (and Cre negative controls) are 
quickly sliced using an ice-cold brain matrix and razor blades, followed by rapid 
dissection of the striatum, VTA, SNc, and SNr. Tissues are lysed and subjected to RiboTag 
IP for capture of mDA neuronal ribosome-bound mRNA. (B) Western blot of captured 
eL22-HA from RiboTag IPs. eL22-HA (23 kDa) is detected just below IgG light chain (LC, 
~25 kDa). Bands in striatal samples and 1% VM spike-in are seen only at high contrast 
(lower). Blot is representative of n=3-4 samples for each condition. (C) Quantification of 
western blot eL22-HA signal intensity, normalized to IgG light chain intensity. Mean +/- 
SEM are plotted for the indicated regions and genotypes: (SNc Cre+) n=3, (VTA Cre+) n=4, 
(SNr Cre+) n=3, (Str Cre+) n=3, (Str Cre- / 1% VM Cre+ spike-in), n=3. (D) Fractional 
abundance of eL22-HA captured in each region, calculated using normalized eL22-HA 
intensity from panel C. (E-F) qRT-PCR of Th and Slc6a3 (DAT) mRNA in RiboTag IPs from 
the indicated regions and genotypes (n=3-4 each for region/genotype). * p < 0.05, ** p < 
0.01, *** p < 0.001, Welch’s unequal variances t-test. (E) mRNA abundance in arbitrary 
units (240 – Cq). Mean a.u. +/- SEM are plotted. (F) RiboTag IP enrichment relative to Input. 
Cq values were normalized to β-Actin within each input or IP sample. Mean delta-delta Cq 




qRT-PCR of RiboTag IPs revealed significant Cre-dependent increases in both yield and 
enrichment of Th and Slc6a3 (DAT) mRNA in IPs from the SNc and VTA (Figure 3.2E-F). We 
also found a significant Cre-dependent yield increase for Th and Slc6a3 (DAT) mRNAs in SNr 
IPs (Figure 3.2E), and an enrichment of Th and Slc6a3 (DAT) from the SNr that was higher than 
in the SNc and VTA (Figure 3.2F). When comparing striatal IPs from Cre-positive and Cre- 
negative mice, we found no significant differences in Th mRNA yield or enrichment, and Slc6a3 
(DAT) was undetectable in all samples (Figure 3.2E-F). Similar to the results in the SNr, we 
found >64-fold Cre-dependent enrichment of both Th and Slc6a3 (DAT) in our 1% VM spike-in 
control despite a low yield (Figure 3.2E-F). The yield and enrichment of Th mRNA were both 
significantly higher in our 1% VM spike-in controls compared to striatal IPs from Cre-negative 
and Cre-positive mice (Figure 3.2E-F). These results suggest that Th and Slc6a3 (DAT) mRNAs 
are translated in dopaminergic dendrites in the SNr, but not in striatal mDA axons. A complete 
statistical summary and yield distribution of eL22-HA, Th mRNA, and Slc6a3 (DAT) mRNA 
captured by RiboTag IP across all regions are shown in Table 3.1. These data demonstrate 
sensitive, quantitative RiboTag IP of small quantities (~1%) of mDA neuronal ribosomes from 
distinct subcellular compartments. 
 
Lack of Evidence for Axonal Translation in Striatal RiboTag IPs 
To identify any mRNAs bound to putative axonal ribosomes, we analyzed the content of 
striatal RiboTag IPs using RNA-Sequencing (RNA-Seq). Since axonal RiboTag IP yields are 
exceedingly low, analysis of IPs derived from Cre-negative and Cre-positive samples is critical 
to control for non-specific binding [248]. To accommodate picogram samples, we used an low 
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input, pooled library construction strategy that is normally used for single-cell RNA-Seq 
(scRNA-Seq) in 96-well plates [418] to conduct RNA-Seq of striatal input and IP samples from 
Cre-negative and Cre-positive mice. This 3’ end RNA-Seq workflow incorporates unique 
  
 
Table 3.1: Yield and statistical summary of RiboTag IP capture for eL22-HA, Th 
mRNA, and Slc6a3/DAT mRNA 
Upper: Mean percentage of total yield ± standard error for each region across all Cre-
positive RiboTag IPs for the indicated protein or RNA. Data are derived from Figure 
3.2B-D (eL22-HA protein, n=3 for each region) and Figure 3.2E-F (Th and Slc6a3 mRNA, 
n=3-4 for each genotype/region). 
Lower: Mean log2 differences in yield (left) or enrichment (right) ± standard error between 
Cre-positive and Cre-negative RiboTag IPs for each region/mRNA. Data are derived 
from Figure 3.2E-F (Th and Slc6a3 mRNA, n=3-4 for each genotype/region) along with 
corresponding Welch’s t-test t-statistic and p values. 
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molecular identifier (UMI) barcodes during reverse transcription to mitigate PCR bias. UMI 
counts provide an estimate of the number of captured mRNA transcripts associated with a 
specific gene. It is generally appreciated that developing axons have a higher translational 
capacity than mature axons, which may reflect downregulation of axonal ribosomes following 
synaptogenesis [316]. Thus, in addition to middle-aged adult mice (10-14 months, Figure 3.2), 
we also conducted RiboTag IPs from the striatum of Cre-positive and Cre-negative mice at 
postnatal ages P0, P7, P14, P21, P31, and P90 (69 mice total, n=2-7 each for Cre-negative and 
Cre-positive mice at each age). We employed a generalized linear model (GLM) within DESeq2 
[419] to test whether any mRNAs were significantly enriched in IP vs. Input samples only in 
Cre-positive mice. Specifically, we used the likelihood ratio test (LRT) to identify genes whose 
deviance was significantly affected by removal of each term from the full model: ~age + 
genotype + fraction + genotype:fraction (see Methods). In this case, omission of the 
genotype:fraction interaction term (reduced model: ~age + genotype + fraction) tests for a 
differential effect of fraction (IP vs. Input) samples across genotype (i.e., ‘Cre-dependent’ 
enrichment and depletion) (Figure C.2A). 
When analyzing the entire dataset, we found no significant effect of genotype for any 
genes (Figure 3.3A-B), indicating that the single DATIRES-Cre allele does not alter the striatal 
transcriptome consistently across age and fraction. However, there was a statistically significant 
effect of fraction for over 5000 genes (Figure 3.3A-B), demonstrating that IP vs. Input sample 
differences in these genes are conserved across genotype and age. This result reflects age- and 
genotype-independent bias in the non-specific binding of striatal polysome lysates during 
RiboTag IP. We also found a statistically significant effect of age for over 7000 genes (Figure 







Figure 3.3: Striatal RiboTag IP and dopaminergic synaptosome sorting provide no 
evidence of translation in dopamine axons 
Data in Figure 3.3A-B are from mice spanning postnatal day P0 to mature adult (10-14 mo.) 
as specified below. All other data pertaining to synaptosome sorting are from adult mice (3-4 
mo.). (A) RNA-Seq analysis of striatal RiboTag IP and Input samples at the following ages: 
(P0, Cre-) n= 6, (P0, Cre+) n=6, (P7, Cre-) n=6, (P7, Cre+) n=6, (P14, Cre-) n=6, (P14, Cre+) n=6, 
(P21, Cre-) n=6, (P21, Cre+) n=7, (P31, Cre-) n=2, (P31, Cre+), n=2, (P90, Cre-) n=2, (P90, Cre+), 
n=3, (10-14 mo., Cre-) n=6, (10-14 mo., Cre+) n=4, where each n indicates an IP and 
corresponding Input sample. Volcano plots are derived from the DESeq2 LRT, with the 
indicated terms removed from the following three-factor GLM: ~Age + Genotype + Fraction + 
Genotype:Fraction. Note that a volcano plot from the Age LRT (i.e., reduced model omitting 
the Age term: ~Genotype + Fraction + Genotype:Fraction) is not shown since there are many 
possible Age contrasts (i.e., P7 vs. P0, P21 vs. P14, etc.). Left: Genotype effect across levels of 
Fraction (IP and Input). Middle: Fraction effect across levels of Genotype (Cre-positive and Cre-
negative). Right: Genotype:Fraction effect, which tests for an interaction between Fraction and 
Genotype. Log2(GenoCrePos.FractionIP) represents the difference in the Fraction effect 
between genotypes: { Cre-positive log2FC(IP/Input) – Cre-negative log2FC(IP/Input) }. See 
Figure C.2A for schematic representation. (B) Number of differentially expressed genes 
(DEGs, BH FDR < 0.05) from the DESeq2 LRT test for the indicated factors, related to panel A. 
See Supplementary File 5 for complete summary of DESeq2 testing. (C) Fluorescence-
activated synaptosome sorting (FASS) schematic. Fluorescent synaptosomes are sorted from 
cortex and/or striatum dissected from mice expressing VGLUT1VENUS or DAT-Cre driven 
EGFP. (D) Representative density plot of EGFP-sorted striatal synaptosomes from DAT-Cre 
mice expressing EGFP in mDA neurons. Sorted samples are 43-58% EGFP+ on re-analysis, 
which represents a ~22-fold enrichment from unsorted samples (see panel E). (E) 
Comparison of fluorescent synaptosomes in unsorted and sorted (re-analysis) material for 
the indicated target sorts. Mean +/- SEM for the %EGFP+/VENUS+ out of all particles are 
plotted for the indicated samples: DAT:EGFP Striatum (n=6), VGLUT1VENUS striatum (n=3), 
and VGLUT1VENUS cortex (n=3). Each sample (n) comprises dissected tissue from 1-3 mice, 
and both unsorted and sorted (re-analysis) synaptosomes were measured from each sample. 
** indicates p < 0.01, **** indicates p < 0.0001, paired t-test. (F) Number of differentially 
expressed genes (DEGs, BH FDR < 0.05) from the DESeq2 LRT test corresponding to panel E, 
with the indicated terms removed from the following three-factor generalized linear model: 
~FASS + Region + Genotype + Region:FASS + Genotype:FASS. See Supplementary File 6 for 
complete summary of DESeq2 testing. (G) Volcano plot for FASS LRT, comparing sorted 
samples to all small particles (enriched/depleted genes, BH FDR < 0.05). (H) Gene Ontology 
analysis (Enrichr) of FASS-Enriched and FASS-Depleted DEGs, corresponding to panel G. 
Enriched ontologies were predominantly related to ribosomal subunits and mitochondrial 
proteins. See Supplementary File 7 for complete summary. 




conserved across fraction and genotype. Critically, we found no significant effect of the 
genotype:fraction interaction for any genes (Figure 3.3A-B), and thus found no statistical 
evidence for age-conserved, Cre-dependent axonal RiboTag IP enrichment of any genes. 
We also conducted the same analyses at each individual age, again finding no significant 
effect of genotype or genotype:fraction interaction, but a significant effect of fraction for >1,000 
genes at most ages (Figure C.2B). These findings are consistent with undetectable Cre-
dependent mRNA capture in all striatal RiboTag IPs, regardless of age. In further support of 
these findings, we found no significant Cre-dependent differences in Th or Actb yield (Figure 
C.2C) or in total mRNA yield as determined by total UMIs per sample (Figure C.2D). Thus, 
despite our improved RiboTag IP conditions and RNA-Seq protocol with single-cell sensitivity, 
we found no evidence of ribosome-bound mRNAs derived from DA axons in the striatum. The 
yield from Cre-negative striatal IPs in our conditions was on the order of 1-50 cells (10-500 pg 
total RNA estimated via qRT-PCR and 20,000-200,000 UMIs via RNA-Seq), and thus the yield 
of any axonally-derived ribosomes likely falls well below these background levels. We conclude 
that translating ribosomes in striatal DA axons are extremely sparse and not amenable to 
detection using striatal RiboTag IP. 
 
 
(continued from previous page)  
(I) Abundance vs. rank plots for all small particles (left) and FASS-sorted (right) samples. 
FASS-enriched and -depleted mRNAs are shown in red and blue, respectively. Labeled 
mRNAs encoding proteins with presynaptic function (pink boxes) were not enriched 
and were substantially lower in abundance compared to glial-derived mRNAs (light 
blue boxes). (J) Estimated mRNAs per sorted particle as a function of FASS RNA-Seq 
efficiency, which includes RNA extraction and reverse transcription. Corresponding 
estimates for whole forebrain VGLUT1VENUS sorted particles from Hafner et al. (2019) are 
shown in blue, based on 1-5% of total RNA mass corresponding to mRNA. See 3.5
 Methods for details. 
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Lack of dopaminergic mRNA signature in sorted striatal synaptosomes 
Another approach to study the presynaptic transcriptome involves fluorescence-activated 
synaptosome sorting (FASS), which enables enrichment of resealed nerve terminals containing a 
genetically encoded fluorescent reporter [250,290,382]. Notably, a previous study found that 
VGLUT1VENUS FASS from whole forebrain enriched mRNAs encoding active zone proteins 
RIM1 and Bassoon [250]. Since these active zone proteins are critically involved in striatal DA 
release [88], we sought to directly interrogate the transcriptome of dopaminergic synaptosomes. 
We employed our recently developed DA FASS protocol [83], where mDA neurons are labeled 
by injection of AAV expressing Cre-dependent eGFP into DAT-Cre mice (Figure 3.3C). After 
gating on small particles to avoid synaptosomal aggregates [227,290], we used synaptosomes 
from WT control mice to establish a background fluorescence threshold for sorting of 
DAT:EGFP+ particles (Figure C.2E). Reanalysis of DAT:EGFP-sorted synaptosome samples 
revealed 43-58% EGFP+ particles in the sorted material (Figure 3.3D). Compared to 2-6% 
EGFP+ particles in unsorted striatal synaptosomes, sorting thus achieved >20-fold enrichment of 
DAT:EGFP+ synaptosomes (Figure 3.3E, Figure C.2E). However, as we previously reported, 
resealed axonal varicosities of mDA neurons can remain stably bound to VGLUT1+ presynaptic 
boutons and other synaptic elements in striatal synaptosome preparations [83]. To control for 
mRNA derived from co-enrichment of these other synaptic elements, we also sorted VGLUT1+ 
synaptosomes from the striatum and cortex of VGLUT1VENUS mice (Figure 3.3C). Amongst all 
striatal synaptosomes, VGLUT1VENUS+ particles are more abundant than DAT:EGFP+ particles, 
resulting in a slightly higher sorted purity (50-60%), but substantially lower enrichment (~5-fold) 
of VGLUT1VENUS+ synaptosomes compared to DAT-EGFP+ synaptosomes (Figure 3.3E, 
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Figure C.2E). In addition to DAT:EGFP+/VGLUT1VENUS+ sorted FASS samples, we also sorted 
all small particles from each sample to control for bias due to the small particle gating and 
sorting procedure. 
We used the same RNA-Seq protocol as above to characterize the transcriptome of FASS 
and small particle sorted samples. For each sample of 1.5 - 7.5 million particles, we obtained 
between 10,000-110,000 UMIs (Figure C.2F). For striatal samples, DAT:EGFP and 
VGLUT1VENUS FASS samples yielded significantly fewer UMIs per sorted particle compared to 
all small particles (Figure C.2G), although the yield from both sample types was very low (1 
UMI per 50-200 sorted particles). Principal components analysis (PCA) revealed that PC1 
captured 44% of the variance and clearly separated FASS from small particle sorted samples, but 
striatal DAT:EGFP FASS samples were not separated from striatal or cortical VGLUT1VENUS 
FASS samples (Figure C.2H-I). As above, we used the DESeq2 LRT to identify genes for which 
the statistical deviance was significantly affected by omission of terms from the following GLM: 
~Region + FASS + Genotype + Region:FASS + Genotype:FASS. We found a significant effect 
of FASS (DAT:EGFP/VGLUT1VENUS sorted vs. all small particles) for >2,000 genes, but no 
significant effect of Region:FASS or Genotype:FASS interactions for any genes (Figure 3.3F). 
These data demonstrate that the FASS transcriptome is distinct from all small particles, but that 
the VGLUT1VENUS and DAT:EGFP sorted samples are largely indistinguishable, regardless of 
region. Given the paucity of DA axons in the cortex compared to the striatum, this result argues 
against any detectable contribution of DA synaptosome-specific mRNAs to the striatal FASS 
transcriptome. Consistent with this interpretation, most of the 240 genes enriched in FASS 
samples were enriched by <2-fold (Figure 3.3G), substantially lower than the >20-fold 
enrichment of DAT-EGFP+ particles in FASS sorted samples. No canonical dopaminergic 
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mRNAs (Th, Slc6a3/DAT, Ddc, and Slc18a2/VMAT2) or other DA neuron-specific mRNAs were 
detected in any FASS samples. Gene ontology (GO) analysis revealed that mRNAs encoding 
ribosomal proteins and nuclear-encoded mitochondrial proteins are overrepresented amongst 
FASS-enriched mRNAs (Figure 3.3H), while mRNAs encoding axonal, dendritic, and 
cytoskeletal proteins were overrepresented amongst FASS-depleted mRNAs. 
Nerve terminals are often bound to other particles in synaptosome preparations, which 
can represent non-specific aggregation [227] or native adherence of synaptosomes to 
postsynaptic densities or other nerve terminals [83]. Astrocytic processes containing mRNA and 
ribosomes are also present in synaptosome preparations [275,281,420] and are a likely source of 
mRNA in our FASS samples. We found that despite being depleted relative to all small particles, 
astrocyte-enriched mRNAs such as Gfap, Glul, and Fads1-2 were abundant in our striatal FASS 
samples (Figure 3.3I). Similarly, we found many oligodendrocyte-enriched mRNAs are still 
highly abundant in FASS samples, and the microglia- and astrocyte-enriched mRNAs Cst3 and 
Apoe are enriched in FASS samples (Figure 3.3I). We found no evidence for local translation of 
active zone proteins in dopaminergic synaptosomes: Rims1 and Bsn mRNAs were very low 
abundance in small particle sorted samples and were further depleted from FASS samples 
(Figure 3.3I). The most abundant RNA species in all samples were derived from mitochondrial-
encoded genes such as Mt-Rnr1, Mt-Rnr2, and Mt-Nd1 (Figure 3.3I). Although mRNAs 
encoding ribosomal proteins and nuclear-encoded mitochondrial proteins have been observed in 
axons [248,317,328,421–423], these mRNAs are also present in dendrites [424,425], the synaptic 
neuropil [282,287], and perisynaptic astrocyte processes [420]. Given the ambiguous cellular and 
subcellular contribution to the mRNA content of our FASS samples, it is unclear whether any 
FASS-enriched mRNAs are derived from DA synaptosomes. Since we had to sort millions of 
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synaptosomal particles in order to obtain UMI counts similar to a single cell (Figure C.2F), we 
estimated the mRNA content of sorted synaptosomal particles as a function of RNA extraction 
and reverse transcription efficiency (see Methods). Based on reasonable estimates ranging from 
1-10% efficiency, we estimate that there are between 0.2 – 2 mRNAs per sorted synaptosomal 
particle (Figure 3.3J). Similarly, based on mRNA comprising 1-5% of the total RNA yield from 
whole forebrain VGLUT1VENUS FASS samples [250], we estimate 0.1 – 2.2 mRNAs per sorted 
synaptosomal particle (Figure 3.3J). Thus, in addition to the lack of a DAT:EGFP-specific 
signature and the major contribution of glial and mitochondrial-derived RNAs to the striatal 
FASS transcriptome, it is possible that many striatal synaptosomes contain no mRNA. 
Collectively, these data provide no evidence for mRNA localization in dopaminergic 
synaptosomes. 
In a final effort to enrich DA neuron-specific axonal mRNAs, we conducted RiboTag IP 
and RNA-Seq on striatal synaptosome lysates from Cre-negative and Cre-positive DATIRES-
Cre:RiboTag mice. We reasoned that RiboTag IP on striatal synaptosome lysates would provide a 
lower background than  bulk striatal lysates, and could capture some of the FASS-enriched 
mRNAs bound to putative axonal ribosomes. Similar to whole striatal IPs, we observed no 
significant effect for Genotype or for Genotype:Fraction interaction, while hundreds of genes 
were significantly affected by Fraction (Figure C.2J). We found no significant difference in the 
estimated total mRNA yield via UMIs (Figure C.2K), and there was no Cre-dependent RiboTag 
IP bias for either FASS-enriched or FASS-depleted genes (Figure C.2L-M). Collectively, these 
data strongly suggest that mRNAs enriched in DAT:EGFP FASS samples are not derived from 




mRNAs encoding DA transmission machinery are localized to dendrites, but 
not axons 
The eL22-HA staining in SNr dendrites (Figure 3.1) and the striking enrichment of Th 
and Slc6a3 (DAT) mRNAs in SNr RiboTag IPs (Figure 3.2) suggest local translation of these 
mRNAs in dopaminergic dendrites. Given the presence of occasional mDA neurons in the SNr, 
we sought to confirm the dendritic localization of Th and Slc6a3 (DAT) mRNAs using FISH 
(RNAscope). In addition to dense staining of mDA neuronal soma in the SNc, we observed 
dispersed Th and Slc6a3/DAT mRNA puncta throughout the SNr (Figure C.3A). This staining 
pattern was not observed for Ppib mRNA, a positive control which encodes a ubiquitously 
expressed endoplasmic reticulum protein and labels all cell bodies (Figure C.3B). No puncta 
were observed in sections stained for the bacterial mRNA DapB, a negative control (Figure 
C.3B).  
We optimized the FISH procedure to enable simultaneous immunostaining for TH, which 
revealed a striking density of Th and Slc6a3 (DAT) mRNA puncta co-localized with TH+ 
dopaminergic dendrites in the SNr (Figure 3.4A). We found that Slc18a2 (vesicular monoamine 
transporter 2; VMAT2) and Ddc (aromatic l-amino acid decarboxylase) mRNAs were similarly 
localized in dopaminergic SNr dendrites (Figure 3.4B). Among these four dopaminergic 
mRNAs, Ddc is the least specific to mDA neurons and is expressed by a variety of cells in the 
midbrain (Figure C.3C). Nonetheless, Z-stack confocal imaging enabled us to clearly 
distinguish Ddc puncta within TH+ SNr dendrites from those within neighboring soma (Figure 
C.3D-E). All four mRNAs were observed within dopaminergic dendrites deep in the SNr, 






In contrast to cultured sympathetic neurons [326,327] and to dopaminergic SNr dendrites, 
we found no Th mRNA puncta in MFB mDA axons (Figure 3.4C). Based on the absence of 
catecholamine-synthesizing neurons in the striatum, previous work proposed mDA axons as the 
source of striatal Th mRNA in vivo [426]. In the striatum, we found dense clusters of Th mRNA 
puncta in soma-sized areas devoid of TH-immunopositive axons (Figure 3.4C). Given that Th 
mRNA is expressed within a subset of striatal neurons [196], these clusters likely represent Th 
 
 
Figure 3.4: Fluorescence in situ hybridization reveals dendritic, but not axonal, 
localization of dopaminergic mRNAs in the mouse brain 
Data in Figure 3.4 are from mature adult mice (10-14 mo.) (A) Immunostaining for TH and 
FISH (RNAscope) for Th and Slc6a3 (DAT) mRNA in the substantia nigra, cpd: cerebral 
peduncle. Main image scale bar: 100 µm, inset scale bar: 10 µm. (B) Immunostaining for TH 
and FISH (RNAscope) for Ddc and Slc18a2 (VMAT2) mRNA in the murine substantia nigra 
pars reticulata. Upper image scale bar: 5 µm, lower images scale bar: 15 µm. (C) 
Representative immunostaining for TH and FISH (RNAscope) for Th and Slc6a3 (DAT) 
mRNA in the indicated regions. Scale bar: 15 µm. (D) Quantification of RNA puncta within 
TH+ neurites in SNr (dendrites), MFB (axons), and striatum (axons) of mice, related to panel 
C. Box and whiskers plots represent the specified metric for RNA puncta within a given 
field in each region: (SNr, Th) n=19 fields from 6 sections from 6 mice, (SNr, Slc6a3) n=19 
fields from 6 sections from 6 mice, (SNr, Ddc) n=21 fields from 5 sections from 5 mice, (SNr, 
Slc18a2) n=21 fields from 5 sections from 5 mice, (MFB, Th) n=8 fields from 6 sections from 6 
mice, (MFB, Slc6a3) n=8 fields from 6 sections from 6 mice, (Str, Th) n=8 fields from 6 
sections from 6 mice, (Str, Slc6a3) n=8 fields from 6 sections from 6 mice. Upper: % of puncta 
within TH+ neurite. Lower: puncta per 10 µm3 of TH+ neurite. (E) Representative segments of 
TH+ dendrite and indicated RNAs at various distances into the SNr. Scale bars: 10 µm. (F) 
Quantification of RNA puncta within TH+ dendrites at various distances into the SNr, 
related to panel E. Box and whiskers plots represent puncta per µm for each segmented 
dendrite in each region: (50-200µm, Th) n=32 dendrites from 6 sections from 6 mice, 
(>200µm, Th) n=32 dendrites from 6 sections from 6 mice, (50-200µm, Slc6a3) n=32 dendrites 
from 6 sections from 6 mice, (>200µm, Slc6a3) n=32 dendrites from 6 sections from 6 mice, 
(50-200µm, Ddc) n=31 dendrites from 5 sections from 5 mice, (>200µm, Ddc)  n=38 dendrites 
from 5 sections from 5 mice, (50-200µm, Slc18a2) n=31 dendrites from 5 sections from 5 
mice, (>200µm, Slc18a2) n=38 dendrites from 5 sections from 5 mice.  * indicates p < 0.05, ** 




mRNA+ interneurons that release GABA, not DA [28] (Figure C.4A). Indeed, these Th mRNA+ 
neurons occasionally expressed detectable TH immunolabel, although in our hands this was 
uncommon (Figure C.4B). To further establish that striatal interneurons are the source of striatal 
Th mRNA, we measured dopaminergic mRNA levels by qRT-PCR in wild-type and Pitx3-KO 
mice, which display virtually no dopaminergic innervation of the dorsal striatum due to 
developmental cell death of SNc mDA neurons [427,428]. Despite a >4-fold decrease in Th, 
Slc6a3/DAT, and Slc18a2/VMAT2 mRNA in the ventral midbrain, where VTA mDA neurons are 
still intact, we found no significant difference in any of these dopaminergic mRNAs in dorsal 
striatum tissue (Figure C.4C). Collectively, these data show that Th mRNA+ striatal 
interneurons, and not dopaminergic axons, are responsible for the changes in total striatal Th 
mRNA observed following ablation of mDA striatal axons [426]. 
Using stringent criteria to quantify mRNA puncta within TH+ neurites (see Methods), we 
found that >70% of all Th, Slc6a3/DAT, and Slc18a2/VMAT2 mRNA puncta in the SNr were 
clearly localized in dopaminergic dendrites (Figure 3.4D). Since Ddc is expressed in other 
midbrain cells, only about a third of Ddc mRNA puncta met the co-localization criteria. 
Meanwhile, <5% of Th and Slc6a3/DAT mRNA puncta were co-localized within dopaminergic 
axons in the MFB and striatum (Figure 3.4D). Despite being the least mDA neuron-specific, 
Ddc mRNA was most abundant in dopaminergic SNr dendrites, followed closely by Th and 
Slc6a3/DAT (Figure 3.4D). Slc18a2/VMAT2 mRNA puncta were least abundant in dopaminergic 
SNr dendrites (Figure 3.4D). In addition to three-dimensional quantification per dendritic 
volume, we also quantified dopaminergic mRNA abundance along segmented dendrites. We 
analyzed single dendritic segments in the proximal SNr (50-200 µm from the SNc) or distal SNr 
(>200 µm from the SNc), since the mRNA abundance within the first 50 µm was often too high 
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for proper puncta quantification (Figure 3.4E). Similar to 3D quantification, the abundance of 
Th and Slc6a3/DAT mRNA in proximal dendritic segments was notably higher than 
Slc18a2/VMAT2 mRNA (Figure 3.4F). However, Th and Slc6a3/DAT mRNA abundance 
significantly declined in distal dendritic segments, while Ddc and Slc18a2/VMAT2 mRNA did 
not, such that the abundance of all four mRNAs was comparable within distal dendritic segments 
(Figure 3.4F). We thus conclude that mRNAs encoding dopamine synthesis, release, and 
reuptake machinery are present throughout mDA dendritic projections into the SNr. 
 
Aldh1a1+/Sox6+ molecular profile of SNr mDA neurons 
Although we identified dendritic ribosomes and mRNAs within the SNr, a few mDA 
neuronal soma are present in this region. To characterize the mDA neuronal translatome in our 
SNr dissections (Figure 3.2), we conducted full-length total RNA-Seq (see Methods for details) 
of Input and RiboTag IP samples from the SNc, VTA, and SNr. Principal component analysis 
(PCA) clearly separated IP vs. Input samples along PC1 and Regions along PC2 (Figure C.5A). 
Differential expression of IP vs. Input samples from Cre-positive mice using DESeq2 revealed a 
core enrichment signature of dopaminergic gene expression in all three regions (Figure 3.5A), 
including Th, Ddc, Slc18a2/VMAT2, and Slc6a3/DAT, as well as other canonical mDA marker 
genes such as Pitx3, En1, Ret, Gch1, and Dlk1 (Figure 3.5A & 5C). Thousands of genes were 
enriched or depleted from IP samples from each region (Figure 3.5B), including canonical glial 
and GABAergic genes (Figure 3.5C). The enrichment of virtually all dopaminergic genes was 
strikingly higher in SNr IPs than in VTA and SNc IPs (Figure 3.5C). Together with the 
substantially lower yield from SNr samples (Figure 3.2), these results suggested the possibility 
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that eL22-HA tagged ribosomes derived from a very small number of SNr mDA neurons 
dominated the RNA content of our SNr RiboTag IPs. 
To further analyze the anatomical specificity of our dissections and explore this 
hypothesis, we leveraged recent datasets analyzing RNA expression at the single mDA neuron 
level. We mapped our data onto the classification scheme recently introduced by Poulin et al. 
[198] (Figure C.5B), which synthesizes single-cell expression data from six studies [194–
197,207,208]. Using only 20 marker genes spanning the mDA neuronal clusters proposed by 
Poulin et al. [198], we were able to accurately cluster SNc, VTA, and SNr RiboTag IP samples 
(Figure C.5C). VTA-enriched marker genes included Lpl, Tacr3, Calb1, Calb2, Cck, Neurod6, 
and Grp, which mostly correspond to the Otx2+/Aldh1a1+ population. Meanwhile, SNr-enriched 
marker genes included Aldh1a1, Sox6, Aldh1a7, and Anxa1, which correspond to the defining 
markers of the Aldh1a1+/Sox6+ ventral-tier SNc mDA neuronal population. Given the enhanced 
vulnerability of this population in models of Parkinson’s disease [194,201,204], we investigated 
the translatome of our SNr RiboTag IP in greater detail. 
The yield of RiboTag IPs from Cre-positive VTA, SNc, and SNr samples was 
significantly higher than Cre-negative samples (Figure C.5D), and the yield of Cre-negative 
midbrain IPs was generally below the 500 pg required for full length RNA-Seq (Figure C.5E). 
Using the ultra-low input, UMI-based RNA-Seq protocol, we identified mRNAs significantly 
enriched in Cre-negative IP samples relative to Cre-positive IP samples and removed these non-
specific binders from subsequent analyses (Supplementary File 9). We used DESeq2 to identify 
mRNAs differentially expressed between SNr and SNc IPs (Figure 3.5D), with further filtering 







We identified 249 genes with higher abundance in SNr compared to SNc IPs, including the 
ventral-tier SNc mDA neuronal markers noted above (Aldh1a1, Sox6, Aldh1a7, Anxa1) (Figure 
3.5D) (see Supplementary File 9 for complete summary).Other SNr-enriched mRNAs encoded 
 
 
Figure 3.5: SNr RiboTag translatome reveals Aldh1a1+ molecular signature and Atp2a3 
(SERCA3) expression in SNr mDA neurons 
Data in Figure 3.5 are from mature adult mice (10-14 mo.) (A) Volcano plots for RiboTag 
IP vs. Input comparisons (DESeq2) in VTA, SNc, and SNr samples (n=4 each). Points 
colored red or blue correspond to the genes shown in panel C, which are specific to mDA 
neurons or specific to glia and other neurons, respectively. (B) Number of RiboTag IP 
enriched or depleted genes (FDR < 0.05) from DESeq2 comparison of IP vs. Input samples 
in the indicated regions, related to panel A. See Supplementary File 9 for complete 
summary of DESeq2 testing. (C) Heatmap of average RiboTag IP enrichment for VTA, 
SNc, and SNr RiboTag IP samples (n=4 each). Genes specific to mDA neurons (left) or glia 
other neurons (right) correspond to red and blue labeled points in the above volcano plots 
from panel A. (D) Average DESeq2 rlog normalized counts for SNr and SNc RiboTag IP 
samples (n=4 each). Red and blue genes indicate differential expression between SNr and 
SNc IP samples, with select genes and cellular function labeled. Genes indicated in red 
text are canonical markers of Aldh1a1+/Sox6+ ventral-tier SNc mDA neurons. (E) Summary 
of pre-ranked Gene Set Enrichment Analysis using the top 50 marker genes of each mDA 
neuronal cluster from Saunders et al. (2018) as gene sets and the rank lists from SNr vs. 
SNc or SNr vs. VTA RiboTag IPs as indicated. * indicates FDR < 0.05 for the given rank 
list/gene set combination. (F) Left: Immunostaining for TH and ALD1A1 reveals distal SNr 
mDA neurons are ALDH1A1+. Scale bar: 100 µm. Inset scale bars: 20 µm. Right: FISH for 
Atp2a3 (SERCA3) and Homer2 in the SNr reveals the presence of these mRNAs in distal 
SNr mDA neurons, not in dopaminergic SNr dendrites. Scale bar: 100 µm. Inset scale bar: 
20 µm. (G) Quantification of Atp2a3 mRNA expression in mDA neurons using RNA scope 
and TH immunofluorescence. Upper left: Anatomical representation of TH+/Atp2a3+ 
neurons in a single hemi-section (15 µm thickness) containing the indicated ventral 
midbrain regions (approximately -3.2 mm posterior to Bregma). Each dot represents 1, 5, 
or 10 mDA neurons as indicated, approximating the average of 5 hemi-sections from 4 
mice: (RLi/IF) 9.8, (VTA) 31.6, (SNc) 62.8, (SNL) 28.8, and (SNr) 2.8. Right: Pie charts 
indicating the percentage of mDA neurons positive or negative for Atp2a3 mRNA 
(TH+/Atp2a3- or TH+/Atp2a3+) and SEM as indicated, corresponding to the anatomical 
representation in Upper left. Total cell counts for each region (TH+ neurons / TH+Atp2a3+ 
neurons): RLi/IF (49/338), VTA (158/503), SNc (314/555), SNL (144/187), SNr (28/29). Lower 
left: Box plot of Atp2a3 mRNA puncta per TH+ neuron in the indicated regions. Data in 
each region are derived from 5 sections from 4 mice: (SNr) 22 cells, (SNL) 47 cells, (SNc) 64 




proteins involved in lipid/calcium signaling, metabolism, and postsynaptic function (Figure 
3.5D). Many of these genes were also higher in SNr compared to VTA IPs (Figure C.5F-H), 
suggesting a relative enrichment of Aldh1a1+/Sox6+ mDA neurons in our SNr dissection. To 
further test this interpretation, we conducted pre-ranked gene set enrichment analysis (GSEA) 
[429] on the SNr vs. SNc IP and SNr vs. VTA IP differential expression rank lists using the top 
50 marker genes of each cluster reported in Saunders et al. [196]. The top 50 markers for 
Aldh1a1+ cluster #4-8 were significantly enriched in both SNr vs. SNc and SNr vs. VTA 
comparisons (Figure 3.5E). Using immunostaining, we found ALDH1A1 expression in all of the 
few TH+ mDA neurons within the proximal SNr (Figure C.6A) and distal SNr (Figure 3.5F). 
Finally, we used FISH to study the distribution of several SNr-enriched mRNAs that were not 
previously described as markers of Aldh1a1+/Sox6+ mDA neurons (Atp2a3, Homer2, Dgkz, and 
Prkca). Although we could readily identify FISH puncta within mDA neuronal soma in the 
proximal and distal SNr (Figure 3.5F and Figure C.6B-D), we found no evidence of dendritic 
localization for these mRNAs. Thus, our RiboTag IP predominantly reflects the translatome of 
mDA neurons within the SNr, demonstrating a molecular signature that significantly overlaps 
with Aldh1a1+/Sox6+ mDA neurons in the ventral-tier SNc [196,198]. 
Given the importance of autonomous pacemaking activity and cytosolic Ca2+ oscillations 
to mDA neuronal physiology [168], the SNr enrichment of Atp2a3 mRNA, which encodes the 
sarco/endoplasmic reticulum Ca2+-ATPase isoform 3 (SERCA3), is of particular interest. 
SERCA3 is predominantly expressed in hematopoietic and endothelial cells [430–432], with 
cerebellar Purkinje neurons being the only neuronal population previously demonstrated to 
express SERCA3 [433]. Our RiboTag data indicate translation of Atp2a3/SERCA3 in the SNr, 
SNc, and VTA, although relative abundance was highest in the SNr (Figure 3.5E). We used TH 
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immunostaining and FISH to further define the anatomical distribution of Atp2a3/SERCA3-
expressing mDA neurons. In addition to the SNr (Figure 3.5F), we found Atp2a3/SERCA3+ 
mDA neurons in the substantia nigra pars lateralis (SNL), SNc, VTA, and midline nuclei (rostral 
linear nucleus and interfascicular nucleus, RLi/IF) (Figure C.6E-H), although Atp2a3/SERCA3 
expression was substantially lower in the VTA and midline nuclei. The anatomical distribution 
of Atp2a3/SERCA3+ mDA neurons in a typical midbrain hemi-section is shown in Figure 3.5G, 
along with quantification of mRNA puncta per neuron and the percentage of TH+ cells 
expressing Atp2a3/SERCA3 within each region. While few in number, SNr mDA neurons were 
virtually all Atp2a3/SERCA3+ and expressed the highest levels of mRNA per neuron (Figure 
3.5G). mDA neurons in the SNL also express high levels of Atp2a3/SERCA3 and are nearly 80% 
Atp2a3/SERCA3+, while Atp2a3/SERCA3 expression is extremely sparse in the midline nuclei 
(Figure 3.5G). Future studies will be required to investigate the physiological function of 
SERCA3 in mDA neurons and explore the consequences of its heterogeneous expression profile. 
 
Dendritic localization of mRNAs encoding vesicular release proteins 
In addition to regional dissection, another approach to identify translating mRNAs in 
dendrites is to combine cell type-specific ribosome IP with subcellular fractionation [273,274]. 
SNc mDA neurons possess dendritic spines, although at lower densities than classical spiny 
neurons [434,435]. Critically, resealed dendritic elements within midbrain synaptosome 
preparations exhibit capacity to uptake and release DA [436–438]. As an orthogonal approach to 
SNr dissection, we conducted RiboTag IP on synaptosomes prepared from ventral midbrain 






mRNA in Cre-positive IPs compared to Cre-negative controls (Figure 3.6B). Similarly, Th and 
Slc6a3/DAT mRNA were enriched roughly nearly 16-fold greater in IP vs. Input comparisons for 
 
 
Figure 3.6: Dendritic localization of mRNAs encoding exocytosis and vesicular release 
proteins in dopamine neurons 
Data in Figure 3.6A-H are from mature adult mice (10-14 mo.), while Figure 3.6I-K are from 
postnatal mDA neuronal cultures. (A) Schematic depicting midbrain synaptosome 
fractionation and RiboTag IP. (B) qRT-PCR measurement of Th, Slc6a3/DAT, and Actb from 
RiboTag IP of VM synaptosomes from Cre-negative (n=5) and Cre-positive mice (n=6). Log2 
mRNA abundance is in arbitrary units (40 – Cq). *** p < 0.001, Welch’s unequal variances t-
test. (C) qRT-PCR measurement of Th and Slc6a3/DAT enrichment in RiboTag IP from Cre-
negative (n=5) and Cre-positive mice (n=6). Cq values were normalized to β-Actin within 
each input or IP sample. Mean delta-delta Cq (log2 fold changes) +/- SEM are plotted. * p < 
0.05, Welch’s unequal variances t-test. (D) UMIs per sample for VM synaptosome RiboTag 
IPs from Cre-negative (n=6) and Cre-positive mice (n=8). *** p < 0.001, Welch’s unequal 
variances t-test. (E) Volcano plots are derived from the DESeq2 LRT, with the indicated 
terms removed from the following two-factor GLM: ~Genotype + Fraction + Genotype:Fraction. 
Left: Genotype effect across levels of Fraction (IP and Input). Middle: Fraction effect across 
levels of Genotype (Cre-positive and Cre-negative). Right: Genotype:Fraction effect, which 
tests for an interaction between Fraction and Genotype. Log2(GenoCrePos.FractionIP) 
represents the difference in the Fraction effect between genotypes: { Cre-positive 
log2FC(IP/Input) – Cre-negative log2FC(IP/Input) }. (F) Number of differentially expressed 
genes (DEGs, FDR < 0.05) from the DESeq2 LRT test for the indicated factors, related to 
panel E. See Supplementary File 10  for complete summary of DESeq2 testing. (G) Upper: 
Gene Ontology analysis (Enrichr) of Cre-positive IP enriched genes, corresponding to panel 
E. Lower: Gene Ontology analysis (SynGO) of Cre-positive IP enriched genes, corresponding 
to panel E. See Supplementary File 11 for complete summary of Enrichr and SynGO 
analysis. (H) Average DESeq2 rlog normalized UMI counts for Cre-positive (n=8) and Cre-
negative (n=6) VM synaptosome IPs. Red and blue genes indicate Cre-positive IP enriched 
and depleted genes (FDR < 0.05), respectively. Select genes related to dopaminergic (green), 
glial (blue), and presynaptic function (pink) are labeled. (I) Representative immunostaining 
for TH and FISH (RNAscope) for Snca and Rims1 mRNA in cultured mDA neurons. Dashed 
white lines indicate the inset shown on the right. Scale bar: 20 µm. (J) Representative 
immunostaining for TH and FISH (RNAscope) for Cplx1 and Rims1 mRNA (left) or for 
Cadps2 and Sv2c mRNA (right) in dendrites of cultured mDA neurons. Dashed white lines 
indicate the inset shown on the right. Scale bars: 10 µm. (K) Quantification of RNA puncta 
within dendrites of cultured mDA neurons, related to panels I-J. Box and whiskers plots 
represent RNA puncta per 10µm of dendrite. Data are derived from 2-3 independent 
cultures, with n dendrites quantified for each mRNA: Cplx1 (n=16), Snca (n=19), Sv2c (n=25), 
Cadps2 (n=25), Rims1 (n=35). 
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Cre-positive mice compared to Cre-negative controls (Figure 3.6C). Given the absence of local 
axon collaterals from mDA neurons [92,93], these data demonstrate mDA neuron-specific 
ribosome capture from postsynaptic elements. 
We next analyzed the mDA neuronal translatome of these midbrain synaptosome samples 
using 3’ UMI-based RNA-Seq. Consistent with the Cre-dependent increase in mRNA yield 
measured by qRT-PCR, Cre-positive IP samples had significantly more UMIs compared to Cre-
negative controls (Figure 3.6D). As above, we used the DESeq2 LRT to identify genes whose 
statistical deviance was significantly affected by omission of terms from the following GLM: 
~genotype + fraction + genotype:fraction. Consistent with a major influence of non-specific 
binding in all ultra-low input ribosome IP experiments, we found a significant effect of fraction 
for >1,000 genes (Figure 3.6E-F). However, in contrast to bulk striatal and striatal synaptosome 
RiboTag IP experiments (Figure 3.3), we observed a significant effect of genotype:fraction 
interaction for 154 genes (Figure 3.6E-F). These genes are thus significantly depleted (93) or 
enriched (61) in IP compared to Input samples only in Cre-positive mice (see Supplementary 
File 10 for complete summary). Similar to striatal synaptosomes (Figure 3.3), glial mRNAs such 
as Apoe, Cst3, Cpe, Glul, Mbp, and Plp1 were abundant in midbrain synaptosomes; however, 
these glial mRNAs were uniformly depleted from Cre-positive IP samples (Figure 3.6H). 
Strikingly, GO analysis of the Cre-positive IP-enriched genes revealed significant over-
representation of terms such as ‘regulation of exocytosis’, ‘process in the presynapse’, and 
‘synaptic vesicle exocytosis’ (Figure 3.6G). Thus, in addition to canonical dopaminergic 
mRNAs, we found Cre-dependent enrichment of mRNAs encoding a wide range of proteins with 
presynaptic function (Figure 3.6H). These included mRNAs encoding proteins involved in 
synaptic vesicle fusion and recycling (Erc2/CAST, Cplx1, Cplx2, Syt1, Sv2c, and Snca) as well as 
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release from dense core vesicles (Cadps2/CAPS2 and Scg2) (Figure 3.6H). We also observed 
near-significant enrichment of Rims1 mRNA, which encodes the active zone protein RIM1 that 
was recently shown to be critically involved in both axonal and somatodendritic DA release 
[88,109]. Many of these mRNAs have also been identified in the dendrites of both glutamatergic 
and GABAergic hippocampal neurons [425] (Figure C.7A). 
Because most mRNAs identified in the midbrain synaptosome IP are not specific to mDA 
neurons, we validated the dendritic localization of several mRNAs encoding release proteins in 
postnatally-derived mDA neuron cultures [79], which allowed unambiguous localization of these 
mRNAs in dopaminergic dendrites using FISH. We first confirmed that cultured mDA neurons 
recapitulate the dendritic localization of Th, Ddc, Slc6a3/DAT, and Slc18a2/VMAT2 mRNAs 
observed in the ventral midbrain (Figure C.7B-E). Although α-synuclein is abundant in 
presynaptic terminals, we found dense localization of Snca mRNA in dendrites (Figure 3.6I). 
Similarly, we found a striking density of Cplx1 (Complexin 1) mRNA in dendrites, along with 
scattered Rims1 mRNA (Figure 3.6J). Although Ca2+-dependent activator protein of secretion 2 
(CAPS2) is involved in catecholamine loading into dense core vesicles in neuroendocrine cells 
[439,440], CAPS2 has to our knowledge not been characterized in mDA neurons. We found 
Cadps2/CAPS2 mRNA within dopaminergic dendrites, along with Sv2c mRNA (Figure 3.6J). 
Synaptic vesicle glycoprotein 2C (SV2C) is involved in axonal DA release [441] and thus may 
also play a role in somatodendritic DA release. In accordance with the abundance of these 
mRNAs in the midbrain synaptosome IP (Figure 3.6H), quantification of mRNA puncta in 
dendrites revealed that Cplx1 and Snca were the most abundant, followed by Sv2c and Cadps2, 
and finally Rims1 (Figure 3.6K). Collectively, these data suggest that local translation of 





Distribution of translation machinery in mDA neurons 
We have used multiple immunofluorescence and biochemical approaches to characterize 
the subcellular distribution of tagged ribosomes in DATIRES-Cre:RiboTag mice, each of which 
identified the soma as the major site of protein synthesis in mDA neurons. Even with extensive 
signal amplification, eL22-HA immunoreactivity outside of the mDA neuronal soma was 
observed only in dendrites, and not in axons (Figure 3.1). Using western blotting, we found that 
a minor fraction of eL22-HA was present in striatal dissections (Figure 3.2D), but no evidence 
that this eL22-HA was associated with functional axonal ribosomes. eL22-HA has been found in 
non-ribosomal fractions of embryonic stem cells [442] and eL22 is known to have extra-
ribosomal functions [443–445]. We note, however, that visualization of eL22-HA tagged 
ribosomes in retinal axons required immunoelectron microscopy [248], and so we cannot 
definitively exclude the possibility that extremely low levels of translating ribosomes are present 
below the limit of detection in our studies. 
Many mDA axonal varicosities lack active zone scaffolding proteins and do not release 
DA upon stimulation [88,446], and we initially hypothesized that local translation could be 
responsible for the determination of active and silent presynaptic sites. However, we found no 
evidence of axonal mRNA localization, including for presynaptic scaffolding proteins such as 
Rims1 or Bsn. The paucity of eL22-HA in mDA axons is surprising given their massive axonal 
arborization. Strikingly, while the striatal axons of SNc mDA neurons likely comprise >90-95% 
of their cellular volume (e.g., [155]) and ~90% of their cellular protein [230], we found only 
~1% of eL22-HA in the striatum (Figure 3.2D). Even if all of this eL22-HA were presumed to 
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be present in functional ribosomes, the ribosome/protein ratio would be 3-4 orders of magnitude 
lower in striatal axons compared to mDA neuronal perikarya. Our results are consistent with 
evidence that a combination of slow and fast axonal transport [243,244] of somatically 
synthesized proteins provides the major source of axonal protein in mDA neurons. Indeed, the 
massive bioenergetic burden placed on axonal transport systems in mDA neurons may contribute 
to their demise in Parkinson’s disease [150,162]. 
 
Lack of dopaminergic mRNA translation in axons 
Using a variety of highly sensitive sequencing and imaging approaches, our data indicate 
that dopaminergic mRNAs (Th, Slc6a3/DAT, Ddc, and Slc18a2/VMAT2) are not locally 
translated in mDA neuronal axons in the mouse brain. One question raised by these results is the 
apparent discrepancy in axonal localization of Th mRNA in mDA neurons compared to cultured 
sympathetic neurons, where a motif in the 3’ untranslated region (UTR) of Th mRNA confers 
axonal localization and enhances catecholamine release [326,327]. Why is Th mRNA 
localization not observed in mDA axons in vivo? Recent evidence suggests that Th and Dbh 
(dopamine beta-hydroxylase) mRNAs may be transported into sympathetic axons via a shared 
ribonucleoprotein complex, and that their axonal trafficking is functionally regulated by 
angiotensin II signaling [447]. mDA neurons express angiotensin II receptors [448], but not Dbh 
mRNA, and may lack RNA-binding or trafficking proteins expressed by sympathetic neurons. 
As the axon of most SNc mDA neurons arises from a dendrite rather than the soma [93,417], we 
were surprised to find that Th mRNA was absent from MFB axons despite extensive localization 
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throughout SNr dendrites (Figure 3.4). Further research is needed to characterize the molecular 
mechanisms that control Th mRNA trafficking in central and peripheral catecholamine neurons. 
 
Regional heterogeneity in mDA neuronal molecular profile 
Integration of single-cell expression studies enables identification of major mDA 
neuronal subpopulations [198], but most studies have focused on embryonic or early postnatal 
timepoints [194,195,197,207,208]. It has been unclear if the mRNA levels that distinguish mDA 
neuronal subsets are conserved at the level of translation and at mature ages. Our translational 
profiling data from middle-aged adult (10-14 mo.) mice recapitulate the regional enrichment of 
mDA neuronal subset markers (Figure C.5B-C). Further, we demonstrate that similar to ventral-
tier SNc mDA neurons, SNr mDA neurons exhibit an Aldh1a1+/Sox6+ molecular signature 
(Figure 3.5). These data are in accordance with early studies that regarded SNr mDA neurons as 
displaced SNc mDA neurons [449,450] and later studies demonstrating similar 
electrophysiological properties of SNc and SNr mDA neurons [451,452]. However, we observed 
significant differences in expression of genes related to calcium homeostasis in this population. 
In addition to an established depletion of the Ca2+-binding protein calbindin D28k (Calb1) [187], 
we demonstrate the enrichment of Atp2a3/SERCA3 in SNr mDA neurons (Figure 3.5D-G). 
However, Atp2a3/SERCA3 expression was also observed in mDA neurons within the SNL, SNc, 
and VTA. Intriguingly, the only other neurons reported to express SERCA3 are cerebellar 
Purkinje neurons [433], which also exhibit pacemaker firing [453]. SERCA3 has a nearly 5-fold 
reduced affinity for Ca2+ compared to the ubiquitous SERCA2 isoform [454], and may be 
important for the regulation of cytosolic Ca2+ dynamics in these neurons. 
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mRNA localization and translation in dopaminergic dendrites 
In addition to their massive, complex axonal arborizations in the striatum, SNc mDA 
neurons must supply SNr projection dendrites with machinery for DA synthesis, release, and 
reuptake. Immunoelectron microscopy studies of SNc neurons revealed that plasma membrane-
associated DAT is sparse in proximal dendrites, with increasing density in distal dendrites, 
perhaps reflecting specific transport to functional dendritic sites [120,455]. Here, we show that 
Th, Ddc, Slc6a3/DAT, and Slc18a2/VMAT2 mRNAs are localized throughout mDA neuronal 
dendrites in the SNr (Figure 3.4) and are bound to dopaminergic ribosomes in midbrain 
synaptosomes (Figure 3.6). In conjunction with vesicular sorting mechanisms [456], dendritic 
translation could serve as a means to rapidly modify the local abundance of dopamine 
transmission machinery. In addition to plasma membranes and postsynaptic densities, DAT is 
also localized on vesicular and tubular membrane elements within dendrites [120,455]. VMAT2 
is also present on these structures, termed ‘tubulovesicles’, which are suspected to consist of 
smooth endoplasmic reticulum (ER) and may represent the site of dendritic DA storage and 
release [45,407]. The local synthesis of DAT and VMAT2 would require the presence of a form 
of dendritic ER, and suggests that translation of these DA transport and reuptake proteins may 
occur directly on ER-related storage and release structures within mDA dendrites. Although the 
‘tubulovesicle’ structures in dendrites have been classically described as smooth ER, a large 
fraction of mRNAs in neurites may be occupied by a single ribosome [282], which can elude 
detection in ultrastructural studies. 
Beyond the core dopaminergic machinery, how do mDA neurons manage simultaneous 
axonal and dendritic localization of vesicular release proteins? For proteins involved in both 
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axonal and somatodendritic DA release, such as RIM1 [88,109], our data show that post-
translational protein trafficking supplies the vast majority of protein to striatal mDA axons. On 
the other hand, local translation of RIM1 and other release proteins such as complexins may be 
important for establishing exocytic release sites in dopaminergic dendrites (Figure 3.6). 
Postsynaptic complexins are known to regulate AMPA receptor exocytic events during long-
term potentiation [457], although these receptors are recycled on dendritic endosomes [458] 
which are not known to be involved in DA release. 
Importantly, while evoked release of DA from dendrites was reported nearly a half 
century ago, the molecular characteristics of the organelles and fusion mechanisms that mediate 
somatodendritic DA release remain unclear [46]. When expressed in hippocampal neurons, 
VMAT2 colocalizes with brain-derived neurotrophic factor (BDNF) on vesicles that undergo 
regulated exocytosis in dendrites [456]. Given that CAPS2 binds to and regulates the 
depolarization-induced release of neurotrophin-containing vesicles in cerebellar granule cells 
[459], the dendritic translation of Cadps2/CAPS2 mRNA (Figure 3.6) raises the intriguing 
possibility of CAPS2 involvement in dendritic DA release. More broadly, it is possible that 
trafficking of synaptic vesicle release proteins in mDA neurons has been optimized to shuttled 
them into striatal axons, and that such a polarization is incompatible with simultaneous 
trafficking into dendrites. Local translation in dopaminergic dendrites may provide an alternative 
mechanism of localization for these proteins, enabling dynamic regulation of proteins at the 








All animals were housed in a 12h/12h light/dark cycle with ad libitum access to food and 
water. DATIRES-Cre mice (JAX #006660, RRID: IMSR_JAX:006660) [289], Ai9 mice (JAX 
#007909, RRID: IMSR_JAX:007909) [414] and RiboTag mice (JAX #029977, RRID: 
IMSR_JAX:029977) [278] were obtained from Jackson Laboratories (Bar Harbor, ME). DAT-
Cre mice (MGI:3770172, RRID: MGI:3770172) [410] used in FASS studies were a kind gift 
from Dr François Tronche. VGLUT1VENUS mice (Slc17a7tm1.1Ehzg, RRID: 5297706) used in 
FASS studies have been previously described [290,460]. 
Middle aged adult mice (10-14 months) of both sexes were used in most experiments 
unless otherwise noted, except for DA FASS studies which used mature adult mice (3-6 months) 
of both sexes. For RiboTag experiments involving early postnatal ages (P0-P31), mice of both 
sexes were used and the exact ages are indicated in the text and figure captions. DATIRES-
Cre:RiboTag experimental litters were bred by crossing homozygous RiboTag mice (RiboTag+/+) 
with heterozygous DATIRES-Cre (DATIRES-Cre/wt) mice, yielding litters of DATIRES-Cre/wt;RiboTag+/- 
(‘Cre positive’) and DATwt/wt;RiboTag+/- (‘Cre negative’) mice. Experimenters were blind to the 
genotype of mice in these litters throughout animal sacrifice and tissue dissection. Genotyping 
for the DATIRES-Cre allele was conducted prior to biochemical experiments using established 
protocols [289]. All experimental procedures were conducted according to NIH guidelines and 
were approved by the Institutional Animal Care and Use Committees of Columbia University 
and the New York State Psychiatric Institute, or according to the European guide for the care and 
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use of laboratory animals and approved by the ethics committee of Bordeaux Universities 
(CE50) under the APAFIS #21132-2019061314534378v4 (CNRS, France). 
 
Viral Injections 
As previously described [83], Stereotaxic injections were performed in heterozygous 
DAT-Cre+ mice of either sex at 8 to 9 weeks of age. An Adeno-Associated Virus (AAV1) 
pCAG-FLEX-EGFP-WPRE from the University of Pennsylvania core facility [461] was injected 
into DAT-Cre+ mice. Saline injected littermates were used as auto-fluorescence controls. The 
stereotaxic injections were performed in Isoflurane-anesthetized mice using a 30μl glass 
micropipette. Injection coordinates for the Substantia Nigra pars compacta (SNc) were 
anterior/posterior (A/P) - 3.6 mm, lateral (L) +/- 1.3mm, dorsal/ventral (D/V) - 4.2mm.  Injection 
coordinates for the Ventral Tegmental (VTA) were A/P - 3.16mm , L +/- 0.6mm; D/V - 4.2mm. 
A/P and L coordinates are with respect to the bregma, whereas D/V coordinates are given with 
respect to the brain surface. The animals were euthanized after 28 days at the maximal viral 
EGFP expression. For fluorescence activated synaptosome sorting (FASS) experiments, four to 
six DAT-Cre+ mice and one WT mouse were used. 
 
Neuronal Cultures 
Ventral mesencephalic cultures containing dopaminergic neurons were prepared 
according to established procedures [79]. The ventral midbrain (SN and VTA) from postnatal 
day 0–2 mice of either sex was dissected, dissociated, and plated on a monolayer of rat cortical 





Antibodies and Reagents 
Name Manufacturer Catalog RRID Usage 





















IgY (H+L), Alexa 
Fluor Plus 488 




Goat anti-Rabbit IgG 













Mm-Slc6a3-C1 ACD Biotechne 315441 NA FISH (NA) 
Mm-Th-C2 ACD Biotechne 317621-C2 NA FISH (NA) 
Mm-Ddc-C3 ACD Biotechne 318681-C3 NA FISH (NA) 
Mm-Slc18a2-C1 ACD Biotechne 425331 NA FISH (NA) 
Mm-Dgkz-C1 ACD Biotechne 534861 NA FISH (NA) 
Mm-Prkca-C2 ACD Biotechne 432261-C2 NA FISH (NA) 
Mm-Homer2-O1 ACD Biotechne 581231 NA FISH (NA) 
Mm-Atp2a3-C2 ACD Biotechne 1049861-C2 NA FISH (NA) 
Mm-Cplx1-C3 ACD Biotechne 482531-C3 NA FISH (NA) 
Mm-Snca-C1 ACD Biotechne 313281 NA FISH (NA) 
Mm-Cadps2-C3 ACD Biotechne 529361-C3 NA FISH (NA) 
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Mm-Sv2c-C1 ACD Biotechne 545001 NA FISH (NA) 
Mm-Rims1-C2 ACD Biotechne 539601-C2 NA FISH (NA) 
TSA Cy3 Perkin Elmer NEL744001KT NA FISH, 1:1500 
TSA Cy5 Perkin Elmer NEL745001KT NA FISH, 1:1500 
IHC, 1:7500 










Table 3.2: Antibodies and reagents 
IHC: Staining of acute brain slices or sections, ICC: Staining of cultured neurons, WB: western 
blotting, FISH: Fluorescence in situ hybridization. 
 
Immunohistochemistry (IHC) 
Mice were anesthetized with euthasol and transcardially perfused with ~15 mL of 0.9% 
saline followed by 40-50 mL of ice-cold 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer 
(PB), pH 7.4. Brains were post-fixed in 4% PFA in 0.1M PB for 6-12 hours at 4°C, washed three 
times in phosphate buffered saline (PBS), and sectioned at 50 µm on a Leica VT1000S 
vibratome. Sections were placed in cryoprotectant solution (30% ethylene glycol, 30% glycerol, 
0.1M PB, pH 7.4) and stored at −20°C until further use. 
Sections were removed from cryoprotectant solution and washed three times in tris-
buffered saline (TBS) at room temperature. Sections were then permeabilized in TBS + 0.2% 
Triton-X 100 for one hour at room temperature, followed by blocking in TBS + 10% normal goat 
serum (NGS) and 0.3% Triton-X 100 for 1.5 hours at room temperature. Sections were then 
directly transferred to a pre-chilled solution containing primary antibodies in TBS + 2% NGS + 
0.1% Triton-X 100 and incubated for ~40 hours at 4°C. Sections were washed in TBS + 0.05% 
Tween 20 (TBS+T) five times over an hour at room temperature. Sections undergoing tyramide 
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signal amplification were treated with 3% hydrogen peroxide in TBS+T for 15 minutes at room 
temperature, followed by another two washes in TBS+T. Sections were incubated in a solution 
containing secondary antibodies in TBS + 2% NGS + 0.1% Triton-X 100 at room temperature 
for 1.5 hours, followed by four washes in TBS+T over 45 minutes at room temperature. Sections 
undergoing tyramide signal amplification were then incubated in TSA-Cy5 (Perkin Elmer, 
1:7500) in the manufacturer’s diluent buffer for 1 hour at room temperature. Following four 
additional washes in TBS, sections were slide mounted and coverslipped with Fluoromount G 
(Southern Biotech). See Table 3.2 for a complete list of antibodies and concentrations used in 
this study. 
 
Tissue Dissection for RiboTag IP 
Mice were sacrificed by cervical dislocation and brains were rapidly extracted and 
submerged in ice-cold 0.32 M sucrose buffer with 5 mM HEPES pH 7.4, 10 mM MgCl2, and 100 
µg/mL cycloheximide (CHX). Brains were placed on an ice-cold brain matrix (Zivic 
Instruments) and separated into 0.5-1.0 mm sections using ice cold razor blades. Striatum was 
dissected from slices between approximately -0.5 mm to 1.5 mm AP to Bregma. To avoid 
potential DATIRES-Cre recombined cells in the lateral septum, a single vertical cut was made 
descending from the lateral ventricle on each side, and all medial tissue (including lateral septum 
and nucleus accumbens shell) was discarded. The corpus callosum, cortex, and ventral olfactory 
tubercle were removed. The remaining dorsal and ventral striatum tissue was flash frozen on 
liquid nitrogen and stored at -80°C. 
Ventral midbrain tissue was dissected from slices between approximately -2.5 mm to -
3.75 mm AP to Bregma. First, the cortex, hippocampi, and any hypothalamus or white matter 
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ventral to the midbrain were removed. For whole ventral midbrain tissue dissections, a single 
horizontal cut was made just dorsal to the rostral linear nucleus and all dorsal tissue was 
discarded. The remaining tissue containing the SN/VTA was flash frozen on liquid nitrogen and 
stored at -80°C. For regional dissections, the SNr was first dissected away from the midbrain 
using a conservative semilunar cut halfway from the edge of the cerebral peduncle to the SNc 
(see Figure 3.2A). The remaining SNc tissue on either side was separated from the VTA by a 
vertical cut at the lateral edge of the VTA. All tissues were flash frozen and stored at -80°C. 
 
Synaptosome Preparation for RiboTag IP 
Ventral midbrain or striatal dissections were homogenized in 1 mL of ice-cold 0.32 M 
sucrose with 5 mM HEPES pH 7.4, 10 mM MgCl2, 100 µg/mL cycloheximide (CHX), 1x 
EDTA-free protease inhibitors (Roche), and 100 U/ml SUPERaseIN. Nuclei and large debris 
were cleared at 2,000 xg for 10 minutes at 4°C. The supernatant (S1) was further centrifuged at 
7,000 xg for 15 minutes at 4°C to yield the P2 pellet. The supernatant (S2) (cytoplasm and light 
membranes) was removed from the P2 pellet, which was washed by resuspension in 1 mL of ice-
cold 0.32 M sucrose buffer (HEPES, MgCl2, CHX, and inhibitors as above) and re-centrifuged at 
10,000xg at 4°C prior to lysis. P2 pellets were lysed in 1 ml of lysis buffer (5 mM HEPES pH 
7.4, 150 mM KCl, 10 mM MgCl2, 1% Igepal CA-620, 100 µg/ml cycloheximide, 1x EDTA-free 
protease inhibitors (Roche), and 100 U/ml SUPERaseIN). After resuspension, samples were 
incubated at 4°C on a rotor for 15 minutes. The resulting synaptosome lysate was subjected to 





Fluorescence-Activated Synaptosome Sorting (FASS) 
Synaptosomes were prepared from the striatum or cortex of VGLUT1venus or DAT-Cre 
eGFP-expressing mice by homogenization in 1ml of ice-cold isosmolar buffer (0.32M sucrose, 4 
mM HEPES pH7.4, protease inhibitor cocktail Set 3 EDTA-free (EMD Millipore Corp.)), using 
a 2 ml-glass-Teflon homogenizer with 12 strokes at 900 rpm. The homogenizer was rinsed with 
250 μL of isosmolar buffer and 3 manual strokes and then, the pestle was rinsed with additional 
250  μL of isosmolar buffer. The final 1.5ml of homogenate (H) was centrifuged at 1000xg for 
5min at 4°C in a benchtop microcentrifuge. The supernatant (S1) was separated from the pellet 
(P1) and centrifuged at 12,600xg for 8 min at 4°C. The supernatant (S2) was discarded and the 
synaptosomes-enriched pellet (P2) was resuspended in 0.5 ml of isosmolar buffer and layered on 
a two-step Ficoll density gradient (900 µL of 7.5% and 900 µL of 13% Ficoll, 4 mM HEPES). 
The gradient was centrifuged at 50,000xg for 21min at 4°C (Beckman Coulter Optima MAX XP 
ultracentrifuge with a TL-55 rotor). Sucrose synaptosomes were recovered at the 7.5/13% Ficoll 
interface using a 0.5 mL syringe. 
Ficoll gradient-purified synaptosomes were diluted in PBS containing 1 µg /ml FM4-64 
and stored on ice throughout FASS procedures. The FACSAria-II (BD Biosciences) was 
operated with the following settings: 70 μm Nozzle, sample shaking 300 rpm at 4°C, FSC neutral 
density (ND) filter 1.0, 488 nm laser on, area scaling 1.18, window extension 0.5, sort precision 
0-16-0, FSC (340 V), SSC (488/10 nm, 365V), FITC (EGFP) (530/30 nm, 700 V), PerCP (FM4-
64) (675/20 nm, 700 V). Thresholding on FM4-64 was set with a detection threshold at 800. 
Samples were analyzed and sorted at rates of 15,000-20,000 events/s and flow rate of 3. Data 
was acquired using BD FACS DIVA 6. Cytometry plots were generated using FCS Express 7 
(De Novo Software). 
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Fluorescence in situ hybridization (FISH) 
For mouse brain tissue and neuronal cultures, FISH was performed using the highly 
sensitive RNAScope® Multiplex Fluorescent v2 assay (ACD Bio). See Antibodies and Reagents 
for complete list of probes and reagents used in this study. Although most single FISH puncta 
using this assay are likely single mRNA molecules [263], this cannot be definitively determined 
due to the enzymatic signal amplification and non-diffraction-limited size of the mRNA puncta. 
Mouse brain sections were prepared as above, removed from cryoprotectant solution, and 
washed three times in tris-buffered saline (TBS) at room temperature. Sections were incubated 
with hydrogen peroxide (ACD) for 15 minutes at room temperature, washed several times in 
TBS, and then mounted to Superfrost slides (Fisher). Sections were allowed to dry for 10 
minutes and a hydrophobic barrier (PAP pen, Vector Labs) was created around the tissue. Tissue 
was incubated in 50% EtOH, then 70% EtOH, then 100% EtOH for 5 minutes each. Sections 
were rehydrated in TBS for several minutes, digested with Protease IV (ACD) for 25 minutes at 
room temperature, and rinsed twice with TBS before proceeding to the RNA Scope Multiplex 
Fluorescent v2 assay (ACD). 
Neuronal cultures were fixed in 4% paraformaldehyde in 0.1M phosphate buffer + 4% 
sucrose for 10 minutes at room temperature. After several washes in TBS, the dish was filled 
with methanol pre-chilled to -20°C. Cultures were stored at -20°C for up to 4 weeks prior to 
FISH. After allowing cultures to room temperature, methanol was replaced with 70% EtOH at 
room temperature for 2 minutes, then with 50% EtOH for 2 minutes, and then cultures were 
washed for 10 minutes in TBS. Cultures were treated with hydrogen peroxide (ACD) for 10 
minutes at room temperature, followed by Protease III (ACD) diluted 1:15 in TBS for 10 minutes 
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at room temperature, followed by two rinses in TBS before proceeding to the RNA Scope 
Multiplex Fluorescent v2 assay. 
The RNA Scope Multiplex Fluorescent v2 assay was conducted according to the 
manufacturer’s instructions, with all incubations taking place in a humidified chamber at 40°C. 
Two 5-minute washes in excess RNA Scope Wash Buffer (ACD) took place between each 
incubation in sequential order: probes (2-hours), AMP1 (30 minutes), AMP2 (30 minutes), 
AMP3 (15 minutes), HRP-C1/2/3 (15 minutes), TSA Cy3 (30 minutes), HRP blocker (30 
minutes), HRP-C1/2/3 (15 minutes), and TSA Cy5 (30 minutes). Samples were washed twice 
more in RNA Scope Wash Buffer, then twice more in TBS. Samples were then blocked and 
immunostained for Tyrosine Hydroxylase as described above. After immunostaining, samples 
were mounted in Fluoromount G and stored at 4°C for up to 1 week before imaging. 
 
RiboTag Ribosome Immunoprecipitation 
Frozen tissues were thawed on ice in a glass-glass dounce homogenizer with 1-1.5 mL of 
ice-cold lysis buffer (20 mM HEPES pH 7.4, 150 mM KCl, 10 mM MgCl2, 0.5 mM DTT, 100 
µg/mL cycloheximide (CHX), 1x EDTA-free protease inhibitors (Roche), and 100 U/ml 
SUPERaseIN). Tissues were lysed on ice using 30 strokes each with A and B pestles. Lysates 
were transferred to pre-chilled Eppendorf tubes and centrifuged at 1,000 xg 4°C for 10 minutes, 
after which the supernatant was transferred to a new tube. 1/9th the volume of 10% Igepal CA-
630 was added to the lysates (final concentration 1%) and they were rotated at 4°C for 15 
minutes. Lysates were clarified by centrifuging at 20,000 xg 4°C for 10 minutes and transferred 
to a new tube. 5% of the lysate was reserved as Input and frozen at -80°C. 
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1.5 µg (for striatal samples) or 6 µg (for midbrain samples) of biotinylated rabbit anti-HA 
was then added and the lysates were rotated overnight at 4°C. Streptavidin T1 Dynabeads 
(ThermoFisher, catalog #65601) were then added to the lysates (5 µL per µg of biotinylated 
antibody) and rotated for 30 minutes at 4°C. Beads were captured on a magnetic rack and the 
lysate was discarded. Beads were resuspended in 500 µL of ice-cold high salt buffer (20 mM 
HEPES pH 7.4, 350 mM KCl, 10 mM MgCl2, 1% Igepal CA-630, 0.5 mM DTT, 100 µg/mL 
cycloheximide (CHX), 1x EDTA-free protease inhibitors (Roche), and 100 U/mL SUPERaseIN) 
and transferred to a new tube. Beads were rotated for 30 minutes at 4°C, then captured on a 
magnetic rack and washed again 3 more times with ice-cold high salt buffer (four washes total 
over two hours). After the last wash, beads were resuspended in 100 µL of ribosome release 
buffer (20 mM HEPES pH 7.4, 50 mM EDTA, 100 U/mL SUPERaseIN) and incubated for 10 
minutes at room temperature. Beads were captured on a magnetic rack and the eluate containing 
released mRNA was transferred to a new tube. Beads (with eL22-HA still bound) were flash 
frozen on liquid nitrogen and stored at -80°C. The aqueous mRNA eluate was purified using the 
RNEasy MinElute kit (Qiagen, catalog #74204) according to the manufacturer’s instructions. 
RNA was eluted in 14 µL of nuclease free water supplemented with 20 U/mL SUPERaseIN and 
stored at -80°C. 
 
Quantitative Reverse Transcription PCR (qRT-PCR) 
For RiboTag IP samples, an equal fraction of captured RNA was reverse transcribed (1.5 
µL of the 14 µL elution from RNEasy MinElute purification). For Input or other tissue samples, 
20-50 ng of total RNA was reverse transcribed. RNA was reverse transcribed in a 20 µL reaction 
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with 0.5 U of Maxima H Reverse Transcriptase (ThermoFisher, catalog # EP0753) and random 
hexamers (5 µM, ThermoFisher catalog #SO142). 
Quantitative PCR was run with TaqMan Universal Master Mix (ThermoFisher catalog 
#4440042) and TaqMan FAM-MGB primer/probe sets spanning exon junctions on a BioRad 
CFX96. The following primer/probe sets were used (ThermoFisher): Mouse ActB: 
Mm01205647_g1, Mouse Th: Mm00447557_m1, Mouse Slc6a3/DAT: Mm00438388_m1, 
Mouse Slc18a2/VMAT2: Mm00553058_m1, Mouse Gfap: Mm01253033_m1, Mouse Mbp: 
Mm01266402_m1, and ERCC-0096: Ac03460023_a1. For RiboTag IP samples, an equal 
fraction of cDNA was used in each reaction. For Input or other tissue samples, 3-5 ng cDNA was 
used in each reaction. 
 
Western Blotting 
Frozen Streptavidin T1 Dynabeads were thawed and resuspended in 1x LDS sample 
buffer supplemented with 20 mM DTT. To elute eL22-HA, beads were boiled at 95°C for 5 
minutes and then placed onto a magnetic rack. Samples were loaded into 10% Bis-Tris 
polyacrylamide gels (Invitrogen, ThermoFisher catalog #NP0303BOX) and transferred to PVDF 
membranes (Immobilon-P, MilliporeSigma, catalog #IPVH00010). Membranes were initially 
washed for 15 minutes in TBST (1X TBS + 0.1% Tween 20), blocked for an hour in 5% 
BSA/TBST, and incubated overnight at 4°C with primary antibody in 5% bovine serum 
albumin/TBST overnight. After primary incubation, membranes were washed three times in 
TBST prior to incubation with HRP-conjugated secondary antibody in 5% BSA/TBST for one 
hour at room temperature. After secondary incubation, membranes were washed three times in 
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TBST. Signal was developed using Immobilon enhanced chemiluminescent substrate (Millipore, 
catalog #WBKLS0500) and imaged on an Azure Biosystems C600 system. 
 
eL22-HA Image Analysis 
10 µm Z stacks of 60x fields of view from the SNr, MFB, and striatum were acquired and 
collapsed via maximum projection. A binary mask was used to identify pixels in TH+ dendrites 
and axons. The mean eL22-HA intensity for TH positive pixels was subtracted from the mean 
eL22-HA intensity for all pixels within each field and is reported in Figure 3.1F as normalized 
eL22-HA mean fluorescence intensity (MFI). 
 
FISH Image Analysis 
RNA puncta were analyzed using TrackMate [358]. The Laplacian of Gaussian spot 
detector with estimated blob diameter of 0.5-1.0 μm. Additional filtering was implemented using 
a combination of quality, contrast, and total intensity as necessary to suppress background spot 
detection. For each image, the centroid (X,Y,Z) coordinates, diameter, and other quantitative 
parameters of each punctum were exported for further analysis. 
For % co-localization shown in Figure 3.4D, a binary threshold was set for the TH 
immunofluorescence signal based on two standard deviations above the image background to 
generate a binary mask of pixels for TH+ neurites. The 23 pixels surrounding the TrackMate 
centroid coordinate of each punctum were analyzed (3 x 3 x 3 cube of pixels excluding the four 
corner pixels) for overlap with the TH+ neurite pixels. Puncta with >60% overlapping pixels 
were retained as co-localized within TH+ neurites. The number of puncta co-localized within 
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TH+ neurites was divided by the total volume of TH+ pixels in each field, yielding puncta per 
volume of TH+ neurite shown in Figure 3.4D. 
For quantification of puncta per µm of dendrite shown in Figure 3.4F, individual 
dendrites were segmented using the SimpleNeuriteTracer plugin in ImageJ. Dendrites were filled 
in three-dimensions and exported as a binary mask, from which the (X,Y,Z) coordinates of all 
pixels in each dendrite were extracted. TrackMate was run once on each original image file, and 
the number of puncta within each dendrite was determined using the same co-localization 
analysis as above. The number of puncta in each dendrite was divided by the path length of each 
dendrite from SimpleNeuriteTracer. 
For quantification of Atp2a3 puncta per neuron shown in Figure 3.5G, individual mDA 
neuronal soma were segmented in maximum projections of 10 μm Z-stack images using the 
ImageJ magic wand tool on thresholded TH pixel intensities. Each soma was saved as an ROI, 
and the (X,Y) coordinates of each ROI were exported. TrackMate was run once on each original 
image file, and the puncta within each soma were determined using the same co-localization 
analysis as above.  
For quantification of puncta per 10 µm of dendrite shown in Figure 3.6K, dendrites of 
cultured neurons were manually segmented using Selection – Straighten in ImageJ. TrackMate 
was run on each individual image file, and the number of puncta in each dendrite was divided its 
length. 
 
Full-length total RNA Sequencing 
Full-length total RNA-Seq was conducted using the SMARTer Stranded Total RNA-Seq 
Kit v3, Pico Input Mammalian (Takara Bio, catalog no. 634485). 1000 pg of total RNA was used 
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for Input samples. For RiboTag IP samples, an estimated 500-1000 pg (via ActB qPCR, see 
Figure C.1I) was used. Libraries were constructed according to the manufacturer’s instructions 
with the following parameters: 1) 4-minute fragmentation prior to reverse transcription, and 2) 
14-15 cycles of PCR following ZapR depletion. Unique dual indexes were assigned to each 
sample, and libraries were pooled at 1 nM following quantification using Qubit dsDNA HS and 
Agilent 2100 Bioanalyzer High Sensitivity DNA assays. Pooled libraries were sequenced on a 
NextSeq 500 with 2x75bp paired end reads (HO 150 kit, Illumina). 
The first 15 bp of Read 2 (UMI and TSO sequences) were removed using fastx-trimmer 
(http://hannonlab.cshl.edu/fastx_toolkit/index.html), and paired-end reads then were depleted of 
rRNA by alignment to mouse 5S, 5.8S, 18S, and 28S rRNA using bowtie2 [462]. rRNA-depleted 
paired-end reads were then aligned to the mouse genome (GENCODE M25, GRCm38.p6) using 
STAR 2.6.7a [463]. Uniquely mapped reads were then quantified at the exon level using 
featureCounts version 1.6 [464]. 
 
Low input RNA Sequencing with 96-well plate, pooled library construction 
The protocol for plate based, 3’ end unique molecular indicator (UMI)-based RNA 
sequencing of single cells has been described previously [418] and was further modified to 
accommodate ultra-low input RiboTag IP samples. See Supplementary File 1 for sequences of 
all custom primers and oligonucleotides used in this protocol. Briefly, an estimated 20 – 500 pg 
of total RNA (based on qPCR, see above) for each sample was loaded into the wells of a 96 well 
plate in a volume of 6 µL of nuclease-free water containing 1 U/µL SUPERaseIN 
(ThermoFisher). After adding 1.5 µL of 10 µM barcoded RT primer (Integrated DNA 
Technologies), primer annealing was performed at 72°C for 3 minutes. Reverse transcription was 
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performed by adding 7.5 µL RT mix to each well (2.81 µL of 40% polyethylene glycol 8000, 
0.15 µL of 100 mM dNTPs, 3 µL of 5X Maxima H RT Buffer, 0.2 µL of 200 U/µL Maxima H 
Reverse Transcriptase (ThermoFisher), 0.2 µL of 20 U/µL SUPERaseIN, and 0.15 µL of 100 
µM Template Switching Oligo (Integrated DNA Technologies), and 1 µL of nuclease free 
water). Reverse transcription was performed at 42°C for 90 minutes, followed by 10 cycles of 
50°C for 2 minutes, 42°C for 2 minutes, 75°C for 10 minutes, followed by a 4°C hold. Excess 
primers were removed by adding 2 µL of Exonuclease I mix (1.875U ExoI in water) to each well 
and incubating at 37°C for 30 minutes, 85°C for 15 minutes, 75°C for 30 seconds, 4°C hold. 
All wells were pooled into a single 15-ml falcon tubes and cDNA was purified and 
concentrated using Dynabeads™ MyOne™ Silane beads (ThermoFisher) according to the 
manufacturer’s instructions. The cDNA was split into duplicate reactions containing 25µl cDNA, 
25µl 2x HIFI HotStart Ready Mix (Kapa Biosystems), and 0.2M SMART PCR Primer. PCR was 
run as follows: 37°C for 30 minutes, 85°C for 15 minutes, 75°C for 30 seconds, 4°C hold. 
Duplicate reactions were combined and purified using 0.7 volumes AMPure XP beads (Beckman 
Coulter). The amplified cDNA was visualized on an Agilent 2100 Bioanalyzer and quantified 
using a Qubit II fluorometer (ThermoFisher). 
Sequencing libraries were constructed using Nextera XT (Illumina) with modifications. A 
custom i5 primer was used (NexteraPCR) with 0.6ng input cDNA and 10 cycles of amplification 
was performed. Unique i7 indexes were used for each plate. After amplification, the library was 
purified with two rounds of AMPure XP beads, visualized on the Agilent 2100 Bioanalyzer and 
quantified using the Qubit II fluorometer. Libraries were sequenced on an Illumina NextSeq 500 
using the 75 cycle High Output kit (read lengths 26(R1) x 8(i) x 58(R2)). Custom sequencing 
primers were used for Read 1 (SMRT_R1seq and ILMN_R1seq, see Antibodies and Reagents). 
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With each plate we targeted ~400M reads. Library pools were loaded at 1.8 pM with 20% PhiX 
(Illumina). 
Reads were aligned to the mouse reference genome GRCm38 and transcriptome 
annotation (Gencode vM10) using the STAR aligner with parameters –sjdbOverhang 65 –
twopassMode Basic after trimming poly(A)-tails from the 3’-ends. The aligned reads were 
demultiplexed using the well-identifying barcodes, correcting all single-nucleotide errors. All 
reads with the same well-identifying barcode, UMI, and gene mapping were collapsed to 
represent an individual transcript. To correct for sequencing errors in UMIs, we further collapsed 
UMIs that were within Hamming distance one of another UMI with the same well-identifying 
barcode and gene. For each 96-well plate, after generating a final list of individual transcripts 
with unique combinations of well-identifying barcodes, UMIs, and gene mapping, we produced a 
molecular count matrix for downstream analysis. 
 
Synaptosome mRNA Content Estimation 
For UMI-based estimation of mRNAs per particle shown in Figure 3.3J, the extent to 
which the Total UMIs per sorted particle underestimates the number of mRNAs per sorted 
particle was modeled as a function of the efficiency of RNA extraction and reverse transcription: 
 
	 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Where Efficiency is in decimal form (i.e., 1% efficiency = 0.01, such that the Estimated 




For the estimation of mRNAs per particle based on total RNA measurement of forebrain 
VGLUT1venus FASS samples [250] shown in Figure 3.3J, the total RNA yield (1-5 ng) from 100 
million sorted particles was converted to mRNA estimates as follows: 
 








Where % mRNA specifies the estimated mass % of mRNA amongst total RNA in decimal 
form (typically 1-5% or 0.01-0.05), and mRNA MW is the average molecular weight of a 
eukaryotic mRNA in g/mol = (2000 nt x 320.5 g/mol) + 159. In Figure 3.3J, the upper bound 
corresponds to Total RNA Yield = 5 ng and % mRNA = 0.05, while the lower bound corresponds 
to Total RNA Yield = 1 ng and % mRNA = 0.01. 
 
RNA-Seq Differential Expression Analysis 
Analysis of RiboTag IP and Input sample UMI count matrices shown in Figure 3.3, 
Figure C.2, and Figure 3.6 (from Low input RNA Sequencing with 96-well plate, pooled library 
construction) was conducted using a generalized linear model (GLM) in DESeq2 [419]. The 
likelihood ratio test (LRT) was used to identify genes for which a given term contributed 
significantly to the likelihood of the full GLM compared to a GLM lacking the given term. In 
other words, the LRT identifies genes for which a given term adds significant explanatory power 
to the GLM. The DESeq2 dds object was constructed with two- or three-factor models and their 
interaction terms as specified in the Results text. For example, in comparing the full model: 
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~genotype + fraction + genotype:fraction vs. the reduced model: ~genotype + fraction, the p-
values report on whether the increased likelihood of the full model is greater than by chance if 
the genotype:fraction term truly has no explanatory power. For most LRTs, the log2 Fold 
Changes specify the contrast between the two levels of the factor (e.g., IP vs. Input for fraction, 
Cre-negative vs. Cre-positive for genotype, etc.). For interaction terms, the contrast specifies the 
difference in log2 Fold Change for the effect of one factor between the levels of the other factor 
(i.e., for genotype:fraction, the difference in IP vs. Input between Cre-negative and Cre-positive 
samples). Note that the age factor in Figure 3.3A-B has multiple levels, and so the p-values do 
not relate specifically to any single contrast. The log2 Fold Changes specified for the age LRT in 
Supplementary File 5 are for the contrast P90 vs. P0. 
 
Complete DESeq2 summary for analyses related to the following figures is found in the 
corresponding supplementary files: 
 Supplementary File 5 contains DESeq2 results for bulk striatal RiboTag IP analysis 
related to Figure 3.3 
 Supplementary File 8 contains DESeq2 results for striatal synaptosome RiboTag IP 
analysis related to Figure C.2 
 Supplementary File 6 contains DESeq2 results for FASS analysis related to Figure 3.3 
 Supplementary File 10 contains DESeq2 results for Midbrain synaptosome RiboTag IP 
analysis related to Figure 3.6 
 
Analysis of midbrain RiboTag IP and Input samples in Figure 3.5 and Figure C.5 (from 
Full-length total RNA Sequencing) was conducted in a generalized linear model (GLM) in 
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DESeq2. The Wald test was used to make direct comparisons between specific IP samples (e.g., 
SNr IP vs. VTA IP) or between the IP and Input samples within each region (e.g., SNr IP vs. SNr 
Input). Downstream filtering of differentially expressed genes (DEGs, FDR < 0.05) to remove 
non-specific mRNAs is summarized in Figure C.5F. After identification of DEGs in 
comparisons of SNr IP vs. VTA or SNc RiboTag IPs, the intersection of SNr-enriched or SNr-
depleted genes (relative to SNc/VTA) from these two DEG lists is retained. Next, only genes 
enriched in SNr IP vs. Input or SNc/VTA IP vs. Input comparisons were retained. Fourth, genes 
that are significantly higher in Cre-negative IP samples compared to Cre-positive IP samples are 
removed (non-specific binders). Complete DESeq2 summary for Figure 3.5 and Figure C.5 are 
found in Supplementary File 9. 
 
Gene Set Enrichment Analysis (GSEA) and Gene Ontology (GO) Analysis 
For all GO analyses, a single list of unique genes was used (i.e., differentially expressed 
genes from DESeq2 analysis). The GO analyses shown in Figure 3.3H and Figure 3.6G were 
conducted using web-based Enrichr [465] with 2018 GO Terms for Cellular Component, 
Biological Process, and Molecular Function [466,467]. The synaptic gene ontology analysis 
shown in Figure 3.6G was conducted using SynGO [468]. The results shown in Figure 3.5E 
employed GSEA [429] in pre-ranked mode, with the SNr vs. SNc IP or SNr vs. VTA IP DESeq2 
log2 fold change as the rank list and the top 50 markers of each cluster as the gene sets. 
 
Statistical Analysis 
Unless otherwise noted, all statistical analysis and data visualization was conducted in 
Python using SciPy, Matplotlib, and Seaborn packages. Statistical comparisons were conducted 
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using Welch’s unequal variance t-tests or Mann-Whitney U tests, with number of replicates and 
other statistical testing information indicated in the figure captions.  
 
Data and Code Availability 
The RNA-Seq data generated in this study are publicly available on the NIH Gene 
Expression Omnibus (GEO) database as GSE180913. Raw count matrices and differential 
expression analysis output are provided as supplementary material. Python and Shell code used 
for processing of RNA-seq data is accessible at: https://github.com/simslab/DropSeqPipeline8, 
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 The absence of evidence for axonal translation in dopamine neurons was a surprise to us. 
In theory, local translation provides a more energy-efficient to protein localization and allows 
more dynamic local regulation of the proteome [310]. Álvarez, Giuditta, and Koenig even went 
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so far as to fully reject the theory of slow axonal transport, arguing that the ‘local synthesis 
model’ has better explanatory power in many situations [469]. Indeed, we envisioned a plethora 
of ways in which such a model could contribute to the maintenance, plasticity, and homeostasis 
of dopaminergic striatal axons. At least for dopamine neurons, the major problem with the local 
synthesis model is the complete lack of supporting evidence. The consistent detection of dim 
ribosomal signals and single mRNA puncta within dopaminergic dendrites further strengthens 
our negative results in striatal axons. Given the recent fervor surrounding axonal translation, I 
was not surprised to learn (via personal communication) that at least two other labs have 
attempted the axonal RiboTag IP without success. It seems likely that a selective publication bias 
has precluded the emergence of negative results in other contexts. Barring the discovery of 
mRNA localization within dopaminergic dendrites, this might well have become the fate of my 
studies. 
While protein synthesis within neuronal dendrites is well-established, translation in 
mature CNS axons remains somewhat controversial. However, several recent studies have made 
broader claims. In fact, one recent study claimed that axonal translation in the CNS is “more the 
rule than the exception” [251]. Another study claimed a “notably high level of ongoing protein 
synthesis” in both glutamatergic and GABAergic presynaptic terminals [250]. The extremely low 
RNA yield from our FASS experiments argues that this is not the case for dopaminergic 
varicosities. Our data are entirely consistent with a Poisson distribution of RNA loading in 
synaptosomes, wherein most nerve terminals contain no ribosomes and mRNA at all. If local 
translation is a broadly conserved feature of the presynapse [250], dopaminergic axons appear to 
be an exception. While local translation might be energetically favorable compared to protein 
trafficking, mRNA localization faces other problems, such as the need to encode structural 
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information to facilitate targeted localization (i.e., via interaction with RNA-binding proteins). 
The complex interactions required for subcellular targeting are presumably easier to achieve with 
protein than mRNA, due to the information content of their sequences. Indeed, our knowledge of 
RNA-protein interactions suggests that RNA-binding proteins exhibit relatively weak binding of 
low specificity sequence motifs (reviewed in [470]). 
Another issue for axonal translation in dopamine neurons is the sheer distance from the 
soma. Trafficking or diffusion time of an mRNA into distal axons may compete against its 
degradation kinetics. If dopamine neurons have a uniform distribution of cytoplasmic nucleases, 
then the relative mRNA concentration in various compartments would be predicted as: soma > 
dendrites > striatal axons, since mRNA molecules would degrade as they translocate along the 
axon. This simple model generally fits with our observations, although no mRNA or ribosomes 
were observed even in the posterior MFB. If ribosomes and mRNA and not freely diffusing into 
axons, how do most neurons exclude these molecules from their axonal compartments? 
Ribosomes are extremely sparse in the axonal initial segment (AIS) [471], which may act as a 
barrier to restrict free diffusion between the axonal and somatodendritic compartments [472]. 
What are the active transport mechanisms that enable certain neurons to achieve axonal ribosome 
localization? Of equal importance, which specific neuronal subpopulations are actually capable 
of transporting ribosomes past the AIS in the adult brain? Despite the difficulty in studying 
axonal translation within the mammalian brain, many of these mechanisms are unlikely to be 
fully resolved using primary neuronal cultures, which typically reflect an embryonic or early 
postnatal state of maturity. My experience suggests that subcellular fractionation and 
biochemical purification techniques are not currently suitable to study the low-levels of 
ribosomes and mRNA within axons. The next generation of studies should instead rely on 
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imaging techniques that can identify single molecules with sub-diffraction-limited resolution 
[473–475]. For those brave enough to carry the torch forward, there is no shortage of unsolved 
mysteries. 
 In addition to fundamental questions regarding axonal translation, the data presented 
here raise many questions about the role of local translation in dendritic dopamine release. The 
nature of the dendritic release vesicles certainly needs further characterization, particularly their 
origin and relationship to the ER. Freyberg and colleagues recently described a dynamic, mobile 
form of ER that was associated with translating ribosomes and found primarily near the plasma 
membrane [476]. It is tempting to speculate that a population of vesicles similar to these 
‘ribosome-associated vesicles’ [476] could be the site of VMAT2 synthesis and dopamine 
release within dopamine neurons. I discuss potential strategies to characterize these vesicles later 
in the Conclusion and Future Directions section. 
The molecular mechanisms of vesicle fusion within dopaminergic soma and dendrites are 
only beginning to be unraveled. Thus, the dendritic localization of mRNAs encoding exocytosis-
related proteins highlights these as candidates for future study. As mentioned above in section 
1.2, electrochemical studies of dendritic dopamine release in the SNr are difficult due to the low 
amount of release dopamine and high density of serotonergic fibers. Once the new dopamine 
imaging technologies have established robust conditions for optical measurement of dendritic 
dopamine release, protein-targeted studies are warranted. In addition to functional studies, I 
believe proximity labeling proteomics (the focus of Chapter 4) will also afford significant 
insight into the nature of somatic and dendritic dopamine release sites. I present several 
strategies to conduct such experiments in the Conclusion and Future Directions section. 
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Chapter 4: Subcellular Proteomic Profiling of Dopamine Neurons 
 
“Cellular pathology is not an end if one cannot see any alteration in the cell. Chemistry brings 
the clarification of living processes nearer than does anatomy. Each anatomical change must 
have been preceded by a chemical one.” – Rudolf Virchow, father of cellular pathology 
 
Whether by process of elimination or a dramatic paradigm shift, closing the door on a 
long-held hypothesis inevitably leads to new avenues of investigation. The premise of studying 
local translation is that the locally encoded proteins are functionally important for the neuron. 
But if my intent was to uncover new properties of dopamine axons, my results showed that 
studying axonal translation was not the road to enlightenment. At a certain point, I realized that 
the approach I had developed could be modified to directly isolate proteins from dopamine 
neurons. Although methods for cell type-specific ribosome IP were well-established, there were 
only several reports of cell type-specific proteomics technology in the mammalian brain. 
Although we had no experience in mass spectrometry, the time seemed ripe to get into the 
burgeoning field of proteomics. This chapter presents a proximity labeling approach to study the 
subcellular proteome of dopamine neurons in the mouse brain. Section 4.1 contains our 
manuscript [230], in which we exploit the anatomical segregation of dopamine neuronal 
compartments to isolate the somatodendritic and axonal proteome. Section 4.2 presents 
emerging work related to Synaptotagmin 17 (Syt-17), a protein identified within dopaminergic 





4.1 Section 4.1 is an adaptation of a bioRxiv preprint [230] that is currently under 
review at eLife. I conceived the overall project and APEX2 slice labeling procedures. I executed 
all mouse APEX2 experiments, with assistance from Se Joon Choi in transcardial perfusion and 
brain slice preparation. Se Joon Choi performed electrophysiological recordings. I executed 
protein purification, immunoprecipitation, western blotting, and immunofluorescence 
experiments. Rajesh Soni executed all on-bead digestion and mass spectrometry experiments. 
Peter Sims conducted scRNA-seq analysis and visualization. I conducted proteomics data 
analysis with input from Peter Sims. Peter Sims and David Sulzer supervised the research. I 
wrote the manuscript with input from Peter Sims and David Sulzer. All authors edited, read, and 
approved the final manuscript. 
4.2 Section 4.2 summarizes ongoing studies of Synaptotagmin 17 in dopamine 
neurons. I conducted all RNA experiments, including qRT-PCR, RiboTag RNA-seq, FISH, and 
single nucleus RNA-seq (in collaboration with the Columbia Center for Translational 
Immunology Flow Cytometry Core and the Single Cell Analysis Core at the Columbia Genome 
Center). Bruce Culbertson assisted with scRNA-seq data analysis. Avery McGuirt conducted the 
cyclic voltammetry recordings of striatal dopamine release. 
 
4.1   Subcellular proteomics of dopamine neurons in the mouse brain 
 
In this section, I describe a method for cell type-specific proximity biotinylation in mouse 
brain tissue using the engineered ascorbate peroxidase 2 (APEX2) [477]. As detailed below, this 
required a Cre-dependent viral expression system and delivery of labeling reagents to acute brain 
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slice preparations. However, my original goal was not to use this APEX2 system for proteomics: 
I was interested in using APEX2 proximity labeling for subcellular transcriptomic profiling. At 
the time, several groups had recently demonstrated that APEX2 was capable of directly labeling 
RNA [478,479]. I had hoped that direct biotinylation of dopamine neuronal mRNAs would 
provide a lower background compared to ribosomal IPs and would enable interrogation of the 
axonal and somatodendritic transcriptome. 
 After establishing dopamine neuron-specific APEX2 expression and biotinylation in 
acute slices, I attempted to capture biotinylated mRNAs from the labeled striatal and midbrain 
tissue. Unfortunately, I did not detect any dopaminergic (e.g., Th, Slc6a3/DAT) or housekeeping 
mRNAs (e.g., Actb, Gapdh) in streptavidin pulldowns, even from midbrain tissue using qRT-
PCR (data not shown). The histology clearly showed robust biotin deposition in dopaminergic 
somata — why was there no evidence of RNA biotinylation? I suspected that the biotin-phenol 
radicals were reacting much more efficiently with proteins. I repeated the experiment and 
submitted several test samples for proteomics. The mass spectrometry core was able to identify 
thousands of proteins using label-free quantification, including APEX2-specific enrichment of 
dopaminergic proteins (e.g., TH, DAT, VMAT2). We were off and running. 
Over the next several months, I optimized the labeling procedures and collected a large 
set of striatal and midbrain tissue samples. By dissecting the acute brain slices after labeling, it 
was possible to extract proteins solely derived from dopaminergic axons in the striatum and 
medial forebrain bundle. In this section, I present our manuscript describing subcellular 
proteomics of dopamine neurons in the mouse brain, which is available as a bioRxiv preprint 




The following is adapted from: 
Hobson BD, Choi SJ, Soni RK, Sulzer D, Sims PA (2021) Subcellular proteomics of 
dopamine neurons in the mouse brain reveals axonal enrichment of proteins encoded by 
Parkinson’s disease-linked genes. bioRxiv. doi: 10.1101/2021.06.01.446584 
 
Supplementary figures are in Appendix D. 
Supplementary files are online: https://www.biorxiv.org/content/10.1101/2021.06.01.446584v2 
 
4.1.1 Abstract 
Dopaminergic neurons modulate neural circuits and behaviors via dopamine release from 
expansive, long range axonal projections. The elaborate cytoarchitecture of these neurons is 
embedded within complex brain tissue, making it difficult to access the neuronal proteome using 
conventional methods. Here, we demonstrate APEX2 proximity labeling within genetically 
targeted neurons in the mouse brain, enabling subcellular proteomics with cell type-specificity. 
By combining APEX2 biotinylation with mass spectrometry, we mapped the somatodendritic 
and axonal proteomes of midbrain dopaminergic neurons. Our dataset reveals the proteomic 
architecture underlying proteostasis, axonal metabolism, and neurotransmission in these neurons. 
We find a significant enrichment of proteins encoded by Parkinson’s disease-linked genes in 
striatal dopaminergic axons, including proteins with previously undescribed axonal localization. 
These proteomic datasets provide a resource for neuronal cell biology, and this approach can be 




Dopamine (DA) release from the axons of midbrain dopaminergic (DA) neurons provides 
important signals that regulate learning, motivation, and behavior. Given that dopaminergic 
dysfunction is linked to neuropsychiatric diseases including Parkinson’s disease (PD), 
schizophrenia, and drug addiction, there is considerable interest in deep molecular profiling of 
DA neurons in health and disease. Molecular profiling of striatal DA axons is of particular 
interest, since they may be the initial site of DA neuronal degeneration in PD [480], a point 
strongly supported by neuropathological comparison of dopaminergic axonal and cell body loss 
in PD patients [199]. Thus, the study of proteins in striatal DA axons and how they are altered in 
disease or disease models is a topic of intense investigation. 
Despite their importance in behavior and disease, DA neurons are very few in number, 
with an estimated ~21,000 in the midbrain of C57BL/6 mice [156]. Thus, although proteomic 
profiling of midbrain tissue samples offers insight into PD pathophysiology [481,482], such 
studies do not analyze striatal DA axons, nor can they identify the cellular source of changes in 
protein levels. Most DA neuron-specific molecular profiling studies have focused on mRNA 
using translating ribosome affinity purification (TRAP) or single cell RNA-sequencing (scRNA-
seq) [194,196,206–208,411,483]. Although these methods have advanced our understanding of 
gene expression in DA neurons, there are important issues that are not addressed by the study of 
mRNA. First, mRNA levels do not always correlate with protein abundance, particularly for 
axonal proteins [484]. Second, transcriptomics cannot establish the localization or abundance of 
the encoded proteins within specific subcellular compartments, which is particularly important 
for DA neurons. 
217 
 
After exiting the midbrain, the axons of DA neurons travel within the medial forebrain 
bundle (MFB) to innervate forebrain structures. DA axonal arbors within the striatum are 
immense and highly complex: single DA neuron tracing has shown that DA axons can reach 
over 500,000 µm in total length [155]. Although their axons constitute the major volume and 
energy demand for DA neurons [155,158,160], dopaminergic axons represent only a small 
fraction of tissue protein in the striatum. The ability to directly interrogate subcellular proteomes 
of DA neurons in native brain tissue would significantly enhance our understanding of DA 
neuronal biology. 
To study the subcellular proteome of DA neuron in the mouse brain, we have adapted 
enzyme-catalyzed proximity labeling combined with mass spectrometry (MS)-based proteomics, 
a powerful approach for identifying protein interactions and/or localization in subcellular 
compartments [485–488]. For in-cell proximity labeling, a particularly efficient enzymatic 
approach uses the engineered ascorbate peroxidase APEX2 [477]. APEX2 rapidly biotinylates 
proximal proteins in the presence of hydrogen peroxide (H2O2) and biotin-phenol (BP), generally 
requiring <1 minute of labeling in cell culture [489,490]. While most proximity labeling studies 
have been conducted on cultured cells, APEX2 proximity labeling has also been demonstrated in 
live Drosophila tissues [491], and recently in mouse heart [492]. Selective expression of APEX2 
enabled electron microscopy reconstructions of genetically targeted neurons in mice [493,494], 
suggesting that APEX2 may be suitable for cell-type-specific proximity labeling and proteomics 
in live brain tissue. 
Here, we employ APEX2-mediated biotin labeling in acute brain slices to study the 
subcellular proteome of DA neurons. Using a combination of cell type-specific APEX2 
expression and proximity biotinylation in acutely prepared slices, we have characterized the 
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somatodendritic and axonal proteomes of midbrain DA neurons. We show that the striatal axonal 
arbors contain nearly 90% of DA neuronal proteins accessible to cytoplasmic APEX2 labeling, 
providing robust coverage of proteins involved in axonal transport, dopamine transmission, and 
axonal metabolism. Of particular interest, we find that proteins encoded by DA neuron-enriched 
genes and PD-linked genes are preferentially localized in striatal axons, including novel axonal 
proteins. Together, our data establishes a proteomic architecture for DA neurons and identifies 
candidates for mechanistic follow-up studies of PD-relevant DA neuronal cell biology. 
 
4.1.3 Results 
APEX2 enables rapid, DA neuron-specific biotin labeling in acute brain slices  
 
To express cytoplasmic APEX2 specifically in DA neurons, we employed an AAV5 viral 
vector containing the Cre-dependent construct developed by Joesch et al. [493], which expresses 
a V5-tagged APEX2 fused to a nuclear export sequence (NES) [495]. We injected AAV5-CAG-
DIO-APEX2NES into the ventral midbrain (VM) of DATIRES-Cre mice [289] (Figure 4.1.1a). To 
confirm the cellular specificity and Cre-dependence of APEX2 expression, we injected the virus 
into DATIRES-Cre mice crossed with Ai9 tdTomato reporter mice [414]. Immunostaining against 
V5 (APEX2), RFP (tdTomato), and tyrosine hydroxylase (TH), a canonical DA neuron marker, 
demonstrated specific expression of APEX2 in DA neurons (Figure 4.1.1b). We found that 
~97% of V5-APEX2+ neurons were also double-positive for tdTomato and TH, while V5-
APEX2 expression was never detected in non-dopaminergic (TH-/tdTomato-) neurons (Figure 
D.1a-b). All three markers displayed intense staining throughout the DA neuronal cytoplasm, 
including dendrites in the VM and axonal projections in the striatum (Figure 4.1.1b). Thus, 
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injection of Cre-dependent AAV-APEX2NES (hereafter referred to as APEX2) into the VM of 
DATIRES-Cre mice leads to robust expression of APEX2 throughout the DA neuronal cytoplasm. 




presence of H2O2 and BP. We chose to conduct labeling in acute brain slice preparations under 
conditions that preserve the integrity of neurons and severed axons, as shown by 
electrophysiological recordings and stable levels of evoked DA release for at least six hours 
[496]. Typical sets of coronal or sagittal slices are shown in Figure D.2a and our workflow is 
summarized in Figure 4.1.1c. Key steps in the protocol include: 1) transcardial perfusion with 
 
 
Figure 4.1.1: Cre-dependent viral expression of cytoplasmic APEX2 and mDA neuron-
specific biotinylation in acute brain slices 
(a) Schematic depicting viral expression strategy: Cre-dependent, cytoplasmic APEX2 
expressing AAV (AAV5-CAG-DIO-APEX2-NES) is injected into the midbrain of DATIRES-Cre 
mice for mDA neuron-specific APEX2 labeling. 
(b) Immunostaining of mDA neurons in DATIRES-Cre/Ai9tdTomato mice injected with AAV5-
CAG-DIO-APEX2-NES. Anti-TH, anti-RFP (tdTomato), and anti-V5 (APEX2) all display 
diffuse localization throughout somatic, dendritic, and axonal cytoplasm. Left, substantia 
nigra, scale bar: 200 µm, upper right: substantia nigra at high power, scale bar: 50 µm, middle 
right: dorsal and ventral striatum, scale bar: 500 µm, lower right: dorsal striatum at high 
power, scale bar: 10 µm. 
(c) Schematic depicting APEX2 labeling procedure in acute brain slices. Slice are incubated 
for one hour with 0.5 mM biotin phenol prior to labeling with 1 mM hydrogen peroxide for 
3 minutes. 
(d) Upper: Western blotting of ventral midbrain and striatal slice lysates with streptavidin-
horseradish peroxidase in the presence of biotin phenol with or without hydrogen peroxide 
(H2O2). Endogenously biotinylated proteins (ebp) are noted in all lanes at ~75 and ~150 kDa. 
Lower: Same as above but with anti-V5 (APEX2). 
(e) Streptavidin-AlexaFluor647 staining of sagittal slices after APEX2 labeling in mDA 
neurons. Left, sagittal slice at low power, scale bar: 1 mm. Insets indicated in white dashed 
lines, right: insets of the ventral midbrain, medial forebrain bundle, and striatum, scale bar: 
250 µm. 
(f) Streptavidin-AlexaFluor647 staining of coronal midbrain slices after APEX2 labeling in 
mDA neurons, scale bar: 50 µm. Labeling requires both biotin phenol and hydrogen 
peroxide.  
(g) Same as (f) but with fields of striatal slices. First three columns, scale bar: 50 µm. Far 
right panels at high magnification, scale bar: 5 µm. 
Abbreviations: (aCSF) artificial cerebrospinal fluid, (BP) biotin phenol, (H2O2) hydrogen 
peroxide, (HRP) horseradish peroxidase, (MFB) medial forebrain bundle, (NES) nuclear 




low-sodium cutting solution, which acts to preserve neuronal integrity in slices from adult mice 
[497] and removes catalase-rich blood, 2) incubation of slices with BP in oxygenated artificial 
cerebrospinal fluid (aCSF) during the slice recovery period, 3) rapid labeling with H2O2 in aCSF, 
and 4) rapid quenching by transferring slices to antioxidant aCSF. Because the slices are far 
thicker (300 µm) than monolayer cell cultures, we fixed, cleared, and stained them with 
fluorescent anti-V5 (APEX2) and streptavidin after biotin labeling in 1 mM H2O2 for 1-5 
minutes (Figure D.2b). We found that biotinylation was detectable at all time points, although 
streptavidin labeling appeared weaker within the center of slices, suggesting incomplete 
penetration of BP and/or H2O2.  Rather than targeting a specific organelle or protein complex, 
our goal in this work was to broadly label the entire cytoplasm of DA neurons. Therefore, we 
chose 3 minutes of H2O2 exposure for downstream applications, which provided sufficient 
labeling for proteomics while limiting H2O2 exposure. 
Western blotting of slices treated with BP and H2O2 showed broad biotinylation patterns 
in the midbrain and striatum (Figure 4.1.1d), consistent with labeling of somatodendritic and 
axonal proteins, respectively. Fluorescent streptavidin staining of sagittal slices after labeling and 
fixation revealed DA neuron-specific labeling throughout the VM, MFB, and striatum (Figure 
4.1.1e). We confirmed that both BP and H2O2 are required for APEX2-mediated biotinylation in 
DA neuronal soma/dendrites and axons (Figure 4.1.1f-g). Confocal imaging of striatal slices 
revealed a dense, intricate staining pattern consistent with the cytoarchitecture of DA axons 
(Figure 4.1.1g). Biotin labeling co-localized with V5-APEX2+ DA axons but not with 
surrounding soma or myelin tracts, since APEX-generated BP radicals do not cross membranes 
[487]. These results show that APEX2 can rapidly and specifically label the somatodendritic and 
axonal compartments of DA neurons in acute brain slices. 
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Proteomic profiling of subcellular compartments in DA neurons 
 
We next used DA neuron-specific biotin labeling in slices to perform proteomic profiling 
of these neurons with subcellular resolution. After biotin labeling and quenching, we rapidly 
dissected and froze the VM, MFB, and striatum of sagittal slices for downstream biotinylated 
protein enrichment and liquid chromatography tandem mass spectrometry (LC-MS/MS) (Figure 
4.1.2a). After lysis and protein precipitation to remove free biotin, we immunoprecipitated (IP) 
proteins from each region with streptavidin beads. To control for non-specific binding and 
potential labeling by endogenous tissue peroxidases, we prepared slices from DATIRES-Cre mice 
without APEX2 (APEX2-, no virus control) and treated them identically to APEX2+ slices at all 
stages of the protocol. Streptavidin horseradish peroxidase (HRP) blotting of captured proteins 
showed endogenously biotinylated carboxylase proteins at ~75 and ~150 kDa in all samples, 
while biotinylated proteins across a wide range of molecular weights were found only in 
APEX2+ samples (Figure 4.1.2b). Quantification of streptavidin HRP signal revealed that 
approximately 87% of DA neuronal APEX2 biotinylation is found within the striatum, 9% in the 
VM, and 4% in the MFB (Figure 4.1.2d). These results demonstrate that the majority of DA 
neuronal proteins are found within striatal axons. 
After on-bead tryptic digestion, we conducted label-free quantitative proteomics for 
single-mouse biological replicates of VM, MFB, and striatum IP samples. Using data-
independent acquisition (DIA), we quantified between 15,000-30,000 peptides representing 
2,100-2,600 proteins per APEX2+ sample, while only ~5,000 peptides representing ~1,000 
proteins were detected in APEX2- samples (Figure 4.1.2c). Using the same LC-MS/MS 
workflow to analyze the bulk tissue proteome of VM and striatum slices, we found that 
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approximately 45% of proteins quantified in these samples were also detected in APEX2+ 






Figure 4.1.2: APEX2 proximity labeling proteomics in mDA neurons 
(a) Schematic depicting APEX2 proximity labeling proteomics in mDA neurons. Slices are 
labeled, rapidly quenched, dissected, and flash frozen. Frozen tissues are lysed and 
precipitated to remove free biotin, after which re-solubilized tissue proteins are subjected to 
streptavidin bead immunoprecipitation to enrich biotinylated proteins. On-bead digestion 
produces peptides which are quantified by liquid chromatography with tandem mass 
spectrometry (LC-MS/MS). 
(b) Streptavidin-HRP western blotting of streptavidin IPs from tissue dissections of the 
indicated regions (duplicate lanes are biological replicates). Each lane contains proteins 
eluted from 5% of the streptavidin beads for each biological replicate (single mouse/region). 
Arrows on the right indicate prominent bands in APEX2+ and APEX2- samples of all regions, 
which represent endogenous biotinylated carboxylase proteins at ~75 and ~150 kDa. The 
majority of APEX2-specific biotinylation is found in the striatum, but specific labeling is 
present in both VM and MFB at high contrast (lower). 
(c) Mean ± SEM of peptides and proteins detected per biological replicate of APEX2- or 
APEX2+ streptavidin IPs of indicated regions (n = 4 each). See Figure 2 – source data 2 for 
raw label-free quantification intensity values of peptides and proteins for all samples used 
in this study. 
(d) Quantification of streptavidin-HRP reactivity in APEX2+ streptavidin IPs, related to 
panel (b). After subtraction of endogenously biotinylated protein signal within each lane, 
the APEX2-specific streptavidin-HRP intensity for each APEX2+ sample was determined by 
subtracting the average APEX2- lane intensity for the same region. Mean ± SEM normalized 
streptavidin-HRP intensity is plotted for each region (n=2 for VM, n=2 for MFB, n=4 for 
Striatum). The percentage of APEX2-specific biotinylation found in each region are denoted 
above the bars. 
(e) Log-log abundance plots of APEX2- vs. APEX2+ streptavidin IP samples for the indicated 
regions. Axes represents the average log2(normalized intensity + 1) of n=4 biological 
replicates for each sample type. Proteins significantly enriched or depleted from APEX2+ 
streptavidin IP samples are colored in red or blue, respectively. False discovery rate (FDR) 
represents q values from Benjamini-Hochberg procedure on Welch’s (unequal variance) t-
test. See Figure 2 – source data 4 for complete results of APEX2+ vs. APEX2- comparisons. 
(f) Heatmap of Z-scores for protein abundances for the union of the top 10 most abundant 
proteins enriched in APEX2+ vs. APEX2- differential expression analysis from panel (e). Each 
column represents a biological replicate (n=4) of APEX2- and APEX2+ streptavidin IP 
samples in the indicated regions. The green color bar on the right indicates whether a given 
protein was in the top 10 of each region. 
(g) Heatmap of Z-scores for protein abundances for markers of midbrain DA neurons, glia, 
striatal spiny projection neurons (SPN), and cholinergic interneurons (ChI). Each column 
represents a biological replicate (n=4) of bulk striatal tissue or APEX2+ streptavidin IP 




were identified based on quantification of multiple peptides (Figure D.3b), and protein 
abundances of biological replicate APEX2+ IP samples were highly correlated (Figure D.3c; 
Pearson’s r=0.93-0.94 for striatum, r=0.89-0.92 for VM, and r= 0.82-0.84 for MFB). Thus, even 
for specific subcellular compartments of small populations (~21,000 DA neurons), the high 
efficiency of APEX2 labeling enables highly reproducible cell type-specific proteomics from 
individual mice. We also conducted bulk tissue proteomics on VM and striatum slices that were 
immediately frozen or subjected to APEX2 labeling procedures (Figure D.4a). We found 
thousands of differentially expressed proteins when comparing VM vs. striatum slices, but no 
statistically significant differences when comparing acute vs. rested slices (Figure D.4b-c). We 
also found that incubation of slices with 0.5 mM BP for one hour had no effect on spontaneous 
action potential frequency in DA neurons (Figure D.4d-e). These data demonstrate that acute 
slice preparation and labeling procedures do not compromise DA neuronal function or 
significantly distort brain tissue proteomes. 
To identify APEX2-dependent proteins captured by streptavidin IP, we directly compared 
APEX2+ to APEX2- control samples (Figure 4.1.2e). The number of proteins enriched in 
APEX2+ samples scaled with the fraction of biotinylation derived from each region (see Figure 
4.1.2b-d), with 1449 proteins for VM, 702 proteins for MFB, and 1840 proteins for striatal 
samples (FDR < 0.05, Welch’s unequal variance t-test with Benjamini-Hochberg correction). 
Although proteins such as endogenously biotinylated carboxylases (e.g., pyruvate carboxylase, 
propionyl-CoA carboxylase) and other non-specific binders (e.g., myelin basic protein, 
proteolipid protein 1) were abundant in all samples, they were not enriched in APEX2+ samples. 
The most abundant APEX2-specific proteins within each region displayed considerable overlap 
across regions (Figure 4.1.2f), with 17 common proteins derived from the top 10 proteins in 
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each region (VM, MFB, and striatum). Although cytoskeletal proteins such as actin and tubulin 
subunits were highly abundant in APEX2+ samples from all three regions, the most abundant 
APEX2-specific proteins within each region also included proteins enriched in specific 
subcellular compartments. For example, the somatodendritic protein MAP-2 (microtubule-
associated protein 2) was in the top 10 only for VM samples (Figure 4.1.2f), while proteins 
involved in synaptic vesicle fusion and endocytosis were in the top 10 only for MFB or striatum 
samples (e.g., synaptophysin, synaptogyrin-3, alpha-synuclein). Compared to bulk striatal tissue, 
APEX2+ striatal samples show significant enrichment of dopaminergic proteins such as TH, 
dopamine transporter (DAT), aromatic-l-acid (dopa) decarboxylase (AADC), and vesicular 
monoamine transporter 2 (VMAT2) (Figure 4.1.2g). Meanwhile, proteins specific to astrocytes, 
microglia, oligodendrocytes, striatal spiny projection neurons (SPNs), and cholinergic 
interneurons (ChI) were either not detected or were significantly depleted from striatal APEX2+ 
samples (Figure 4.1.2g). Thus, mass spectrometry-based quantification of APEX2-enriched 
proteins enables proteomic profiling of the dopaminergic neuronal compartments contained 
within each region.  
 
Somatodendritic vs. axonal enrichment of proteins involved in diverse cellular functions 
 
To further establish the compartment-specificity of APEX2-specific proteins across 
regions, we first examined the abundance of the microtubule binding proteins MAP-2 and tau, 
which are known to be enriched in somatodendritic and axonal compartments, respectively. 
Consistent with previous work [498,499], we found that MAP-2 was highly abundant in the VM 
and steadily decreased in the MFB and striatum, while tau was most abundant in striatal samples 
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(Figure 4.1.3a). It should be noted that although we refer to VM samples as somatodendritic, 
these samples will necessarily include axons exiting the midbrain as well as somatically 
synthesized axonal proteins. Accordingly, the difference in abundance between striatal and VM 
samples was dramatically greater for MAP-2 compared to tau (Figure 4.1.3a). Thus, for our 
downstream analysis of somatodendritic and axonal compartments, we used the MFB samples 
only for filtering and focused primarily on VM and striatum samples. 
To filter the APEX2+ VM and striatum proteomics data, we took advantage of publicly 
available scRNA-seq data from the mouse ventral midbrain and striatum [196]. After 
identification of high-confidence DA neuron profiles, we used the mRNA expression distribution 
from scRNA-seq to establish a conservative lower bound for considering a gene as expressed in 
DA neurons (Figure D.5a, see Methods). The vast majority of proteins in the APEX2 data were 
encoded by genes expressed in DA neurons, with >93.0% of all detected proteins and >97.4% of 
APEX2-enriched proteins encoded by genes above our scRNA-seq threshold (Figure D.5b-c). 
We removed proteins that were not significantly enriched in APEX2+ > APEX2- samples, 
proteins encoded by genes below our DA neuron scRNA-seq threshold, and proteins that did not 
show evidence of APEX2-specificity in at least two regions (Figure D.5d, see Methods for 
complete description). For comparison between VM and striatal samples, we retained the union 
of proteins passing filters in VM and striatal samples. Out of 1,733 total proteins, 200 proteins 
passed filtering only in VM samples, 334 only in striatal samples, and 1,199 both (Figure 
4.1.3b). Hierarchical clustering of these 1,199 overlapping proteins clearly segregated VM 
APEX2+ and Str APEX2+ samples from each other and from all APEX2- samples (Figure D.6), 
and direct comparison between APEX2+ samples revealed 173 and 374 proteins with greater 
relative abundance in VM or striatal samples, respectively (Figure 4.1.3c). Manual examination 
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of VM- and Str- enriched protein clusters revealed striatal enrichment of synaptic vesicle 
proteins (e.g., Synaptotagmin-1 (Syt-1), Synaptophysin, SNAP25, VMAT2) and VM enrichment 





We first sought to confirm that cytoplasmic APEX2 labeling does not enrich proteins 
within membrane-enclosed structures. Amongst the 1733 total proteins passing filter in either 
VM or striatum, we found significant enrichment of gene ontology (GO) terms related only to  
nuclear and mitochondrial outer membranes (Figure D.7a-b), but not nuclear inner membrane, 
nuclear lamina, nuclear matrix, mitochondrial inner membrane, or mitochondrial matrix. These 
results confirm the membrane impermeability of BP radicals and the integrity of organellar 
membranes in the acute brain slices. 
 
 
Figure 4.1.3: Axonal and somatodendritic proteomics reveals gene ontologies enriched 
in subcellular compartments 
(a) APEX2 proteomics data for microtubule-associated proteins MAP-2, Tau, and MAP-1B. 
Mean ± SEM of the protein abundances, as log2(normalized intensity + 1), are shown for 
n=4 biological replicates of APEX2+ streptavidin IP samples in the indicated regions. 
(b) Schematic depicting proteins remaining after filtering. For complete filtering workflow, 
see 4.1.5 Methods and Figure D.5. Proteins present in both VM and Str after filtering 
were further compared by differential expression—see panel (c). Proteins present only in 
VM or Str, plus those enriched in VM vs. Str differential expression analysis, were used for 
subsequent GO Analysis. 
(c) Differential expression comparison of VM vs. Str APEX2+ streptavidin IP samples. 
Proteins colored red or blue had a false discovery rate (FDR) < 0.05 after Benjamini-
Hochberg corrected p-values from Welch’s (unequal variance) t-test. See Figure 3 – source 
data 2 for complete results and summary of proteins before and after filtering. 
(d) Gene ontology analysis (Enrichr) of VM- and Str-enriched proteins (373 and 708, 
respectively, see panel b). Selected GO Terms are listed along with adjusted p-values and 
adjusted p-value rank for each GO Term category (Cellular Component, Molecular 
Function, Biological Process). Canonical and representative proteins from the ontologies 
are shown. Every protein depicted is present in the filtered proteomics data of VM, Str, or 
both. Colors indicate significant (dark red/blue) enrichment, near-significant enrichment 
(light red/blue), or similar levels between VM and Str (gray). Slashes indicate separate 
proteins (e.g., DLC1/2 represents both DLC1 and DLC2). See Figure 3 – source data 3 for 
complete GO summary. 
Abbreviations: (MAP-2) Microtubule-associated protein 2, (Tau) Microtubule-associated 
protein tau, (MAP-1B) Microtubule-associated protein 1B, (MFB) medial forebrain bundle, 
(Str) striatum, (VM) ventral midbrain. See Figure 3 – source data 1 for list of protein 
abbreviations in (d). 
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To assess the relative enrichment of functionally related proteins within the 
somatodendritic and axonal compartments of DA neurons, we conducted GO analysis of proteins 
that either passed filtering in only one region or were significantly enriched in that region in the 
APEX2+ striatum vs. VM comparison (Figure 4.1.3b-c, 373 proteins for VM, 708 for striatum). 
First, we analyzed subcellular localization GO terms curated by the COMPARTMENTS 
resource [500]. We found that the top GO terms over-represented amongst VM-enriched proteins 
included ‘Postsynapse’, ‘Somatodendritic compartment’, ‘Dendrite’, and ‘Postsynaptic density’ 
(Figure D.7c), while those over-represented amongst striatum-enriched proteins included 
‘presynapse’, ‘axon’, ‘synaptic vesicle’, and ‘axon terminus’ (Figure D.7d). Given the clear 
segregation of axonal/pre-synaptic and dendritic/post-synaptic terms from the 
COMPARTMENTS resource in striatum- and VM-enriched proteins, respectively, we analyzed 
the VM- and Str-enriched proteins using the GO Consortium resource [467]. Similar to the 
COMPARTMENTS analysis, we found that GO terms related to postsynaptic function were 
over-represented in VM-enriched proteins, with terms such as ‘dendrite’, ‘glutamate receptor 
binding’, and ‘GABA-A receptor complex’. Canonical proteins associated with these terms 
included subunits and scaffolding proteins for AMPA, NMDA, GABA-A, and GABA-B 
receptors (Figure 4.1.3d). GO terms such as ‘RNA binding’ and ‘regulation of mRNA stability’ 
were also over-represented in VM-enriched proteins (Figure 4.1.3d), consistent with the 
somatodendritic compartment being the major site of protein synthesis in neurons. Despite a 
clear role for the ubiquitin proteasome system in axons [501], we found over-representation of 
GO terms such as ‘cytosolic proteasome complex’ in VM-enriched proteins, with nearly all 20S 




The enrichment of protein synthesis and degradation machinery within the 
somatodendritic compartment of DA neurons underscores the importance of cytoskeletal 
transport systems in axonal protein homeostasis [243,244]. Accordingly, GO terms such as 
‘vesicle-mediated transport’ and ‘protein transport’ were over-represented in striatum-enriched 
proteins. Striatum-enriched proteins in these ontologies included kinesin and dynein subunits, 
cargo adaptor proteins, and upstream kinases involved in transport regulation (Figure 4.1.3d). In 
addition to microtubule-based transport proteins, proteins related to the axonal actin cytoskeleton 
were also over-represented in striatum APEX2+ samples. These included actin subunits 
themselves, GTPases and other regulators of actin nucleation, and proteins that link actin rings in 
the distal axon [502,503] (Figure 4.1.3d). We also found that proteins involved in clathrin-
dependent endocytosis were uniformly enriched in striatum APEX2+ samples, consistent with 
high rates of synaptic vesicle recycling in DA neurons related to their tonic activity. Given the 
intense energetic demands placed on DA axons [159], we were intrigued to find an over-
representation of glycolytic enzymes in Str-enriched proteins: 7 out of 9 glycolytic enzymes 
show higher relative abundance in striatum compared to VM (Figure 4.1.3d). These results 
suggest that glycolysis may be especially important in dopaminergic axonal metabolism, 
consistent with glycolysis supporting axonal transport and presynaptic function in other neurons 
[504–507]. We note that striatum APEX2+ samples also showed extensive enrichment of GO 
terms related to presynaptic function and synaptic vesicle proteins, as detailed below (see Figure 
3 – source data 3 for a complete GO analysis summary). 
While anterograde transport is critical for delivery of new proteins to distal axons, it is 
likely that both local autophagy and retrograde transport contribute to protein clearance in DA 
axons. Many autophagosomes formed in distal axons are transported back to the soma prior to 
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fusion with lysosomes [508], although other findings implicate local autophagic degradation of 
damaged mitochondria in axons [509]. Indeed, we previously showed that macroautophagy 
regulates presynaptic structure and function in DA axons [496]. Consistent with these results, we 
found that GO terms related to autophagy were over-represented in Str-enriched proteins (Figure 
4.1.3d). Autophagy-related proteins enriched in striatum APEX2+ samples included kinases 
involved in upstream regulation of autophagy, membrane proteins involved in autophagosome 
maturation, and membrane proteins involved in lysosomal membrane fusion. Among the 
autophagy-related proteins present in striatal axons, vacuole membrane protein 1 (VMP1) was 
recently shown to be critical for survival and axonal integrity in DA neurons [510]. Our results 
suggest that VMP1 may regulate autophagy in the axons as well as soma of DA neurons, 
highlighting the ability of APEX2 proteomics to elucidate the distribution of proteins with 
unknown localization. Collectively, these results establish a foundation of protein localization 
that underlies diverse cellular functions within the somatodendritic and axonal compartments of 
DA neurons. 
 
The dopaminergic presynaptic proteome via APEX2 labeling in striatal slices and 
synaptosomes  
 
DA neuron-specific APEX2 labeling in striatal slices provides a convenient means to 
isolate proteins from dopaminergic axons, but acute slice preparation may not be practical for all 
laboratories. To further study the presynaptic proteome of dopaminergic axons and provide an 
alternative to the slice labeling procedure, we conducted APEX2 labeling in synaptosomes 
prepared from the striatum of DATIRES-Cre mice expressing APEX2NES (Figure 4.1.4a). 
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Synaptosomes are resealed nerve terminals formed by liquid shearing forces during 
homogenization of brain tissue in isotonic sucrose buffer [279,364]. After a brief, low-speed 
centrifugation to remove heavy cellular debris and nuclei, the majority of synaptosomes can be 
rapidly recovered in the pellet from moderate-speed centrifugation known as the P2 fraction. 
Although the P2 fraction also contains myelin and free mitochondria, we reasoned that these 
contaminants would not interfere with APEX2 labeling within resealed dopaminergic nerve 
terminals. After isolation and washing of the P2 fraction, reagents were added directly to 
synaptosomes under typical in vitro APEX2 labeling conditions (30 minutes incubation with 0.5 
mM BP followed by 60 seconds of 1 mM H2O2). Similar to the slice procedure, streptavidin-
HRP western blotting of striatal P2 lysates showed APEX2-dependent protein biotinylation 
across a wide range of molecular weights (Figure 4.1.4b). Staining of labeled P2 samples with 
fluorescent streptavidin revealed deposition of biotin within TH+/V5-APEX2+ particles 
approximately ~1 µm in diameter, consistent with APEX2 labeling within dopaminergic 
synaptosomes (Figure 4.1.4b). We analyzed APEX2-enriched proteins from striatal 
synaptosomes by mass spectrometry. As before, we controlled for non-specific binding by 
conducting all labeling and protein purification procedures on striatal synaptosomes from mice 
with and without APEX2 expression in DA neurons. 
Coverage of both peptides and proteins in APEX2+ synaptosome samples was 
remarkably similar to the APEX2+ striatal slice samples (Figure 4.1.4c), although non-specific 
binding was slightly higher in APEX2- synaptosome samples. Principal component analysis 
revealed tight co-segregation of APEX2+ striatal slice and synaptosome samples apart from all 
other samples, suggesting these APEX2+ proteomes are highly similar (Figure 4.1.4d). Indeed, 
the correlation between APEX2+ striatal slice and synaptosome samples was comparable to that 
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of biological replicates within each sample type (Pearson’s r = 0.93, p < 1e-15) (Figure 4.1.4e). 
Out of 1,533 proteins that passed filtering in striatal slices, 1,348 of these showed enrichment in 










Figure 4.1.4: APEX2 labeling in synaptosomes and dopaminergic presynaptic proteome 
(a) Schematic depicting APEX2 labeling in dopaminergic striatal synaptosomes. A crude 
synaptosome fraction (P2) is rapidly prepared from the striatum, washed, incubated with 
biotin phenol (0.5 mM for 30 minutes), labeled with 1 mM H2O2 for 60 seconds, quenched 
with antioxidants and sodium azide, centrifuged, and flash frozen as a pellet for 
downstream streptavidin IP and proteomics (see 4.1.5 Methods). 
(b) Left: Streptavidin HRP western blot of proteins captured by streptavidin IP from striatal 
synaptosomes of DAT-Cre mice with or without expression of APEX2-NES.  
Right: Immunostaining of synaptosomes from DAT-Cre:APEX2+ striatum. Synaptosomes 
were bound to poly-lysine coated coverslips during biotin phenol incubation, washed, and 
fixed after H2O2 treatment. Scale bar: 2 µm. 
(c) Mean ± SEM of peptides and proteins detected per biological replicate of APEX2- or 
APEX2+ streptavidin IPs of indicated regions. Str-slice data are the same as in same as in 
Figure 2c (n=4 each for APEX2-/APEX2+). n=4 for APEX2- Str-Syn, n=2 for APEX2+ Str-Syn. 
(d) Principal components analysis of all APEX2- and APEX2+ biological replicates for the 
1733 proteins present either in VM or Str after filtering (see Figure 3b). PC1 captures 73.6% 
of the variance and is dominated by APEX2+ vs. APEX2- samples, while PC2 captures 5.% of 
the variance and stratifies regional APEX2+ samples. APEX2+ Str-Syn samples are highly 
similar to APEX2+ Str-Slice samples. 
(e) Log-log abundance plots of APEX2+ streptavidin IP samples for the indicated regions. 
Axes represents the average log2(normalized intensity + 1) for each sample type (n=2 and 
n=4 biological replicates for Str-Synaptosomes and Str-Slice, respectively). Out of 1533 Str-
Slice APEX2+ filtered proteins (see Figure D.5d), 1348 show concordant enrichment in Str-
Syn APEX2+ vs. APEX2- comparisons (log2 FC > 0 and FDR < 0.15). These 1348 proteins were 
retained for Gene Ontology analysis (panel f). Accordingly, Str-Syn and Str-Slice APEX2+ 
samples show robust Pearson correlation (r = 0.93, p value < 1e-15). 
(f) Gene ontology analysis (SynGO) of Str-Slice- and Str-Syn-enriched proteins (1348 
proteins, see panel (e). Selected GO Terms are listed along with adjusted p-values and 
adjusted p-value rank for each GO Term category (Cellular Component, Biological Process). 
Canonical and representative proteins from the ontologies are shown. Proteins depicted are 
either present in the filtered Str-Slice proteomics data (FDR < 0.05, APEX2 vs. Control, dark 
green), nearly missed the Str-Slice significance thresholds (FDR < 0.1, APEX2 vs. Control, 
light green), or were not detected in any APEX2 or bulk striatal tissue samples (grey). See 
Figure 4 – source data 2 for complete GO summary. 
Abbreviations: (SPN PSD) Spiny projection neuron post-synaptic density, (TH) Tyrosine 
hydroxylase, (MFB) medial forebrain bundle, (Str) striatum, (VM) ventral midbrain. See 
Figure 4 – source data 1 for complete list of protein and metabolite abbreviations in (f). 
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Proteins involved in DA metabolism were significantly enriched in both slice and 
synaptosome APEX2+ samples, including canonical DA synthesis, release, and reuptake proteins 
(TH, AADC, VMAT2, and DAT) as well as enzymes involved in tetrahydrobiopterin synthesis 
(GTP cyclohydrolase I, 6-pyruvoyltetrahydropterin synthase, and sepiapterin reductase) and DA  
degradation (monoamine oxidase A/B, retinaldehyde dehydrogenase 1, aldose reductase, and 
aldehyde reductase) (Figure 4.1.4f). Thus, all of the protein machinery required for DA 
neurotransmission and metabolism is present within dopaminergic axonal boutons, including 
monoamine oxidases that metabolize DA and contribute to oxidative phosphorylation via 
presynaptic mitochondria [511]. We also found significant enrichment of proteins that contribute 
to DA vesicular uptake, including most subunits of the vesicular ATPase and SLC10A4, an 
orphan transporter found on monoaminergic synaptic vesicles that contributes to axonal DA 
homeostasis [512] (Figure 4.1.4f). 
Striatal DA release is powerfully modulated by nicotinic receptors and DA D2 receptors 
on dopaminergic axons [48]. Consistent with pharmacological studies [513], we found that β2 
and α4 nicotinic receptor subunits were enriched by APEX2 in striatal slices and synaptosomes 
(Figure 4.1.4f). Despite a wealth of functional evidence supporting their presence on DA axons, 
the DA D2 receptor as well as β3, α5, and α6 nicotinic receptor subunits were notably absent 
from our dataset. Since the vast majority of APEX2 labeling occurs on tyrosine residues 
[514,515], some membrane proteins may not be labeled if they lack cytoplasm-facing tyrosine 
residues accessible to BP radicals. However, the absence of these nicotinic receptor subunits and 
the DA D2 receptor is likely related to mass spectrometry, since none of these proteins were 
detected in any bulk striatal tissue sample (Figure 4.1.4f, grey boxes). Thus, the absence of a 
protein in our dataset does not necessarily indicate absence in DA axons, especially when other 
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functionally related proteins are enriched. For example, we found significant APEX2 enrichment 
of β-anchoring and -regulatory protein (BARP), a protein recently shown to interact with and 
modulate α6/β2/β3 nicotinic receptors on dopaminergic axons [516] (Figure 4.1.4f). Similarly, 
we find significant APEX2 enrichment of D2 receptor-interacting proteins (e.g., G protein 
subunits and neuronal calcium sensor NCS-1) and downstream effectors (e.g., adenylyl cyclase, 
PKA subunits, and GIRK2) known to function within DA neurons [517]. We also found 
significant enrichment of voltage gated potassium channels Kv1.2 and Kv1.6, consistent with 
previous work on Kv1 channels as downstream effectors of presynaptic D2 receptor function 
[66] (Figure 4.1.4f). 
We next focused on the dopaminergic presynapse, using the SynGO resource [468] to 
analyze the 1,348 proteins enriched in APEX2+ striatal slice and synaptosome samples. Ontology 
terms such as ‘presynapse’, ‘synaptic vesicle’, and ‘presynaptic active zone’ were all highly 
over-represented amongst APEX2-enriched proteins (Figure 4.1.4f and Figure D.8a). 
Consistent with recent work on the molecular architecture of striatal DA release sites, APEX2 
labeling of striatal and synaptosome samples significantly enriched active zone proteins RIM1, 
Bassoon, Liprin-α2 and -α3, Munc13-1, ELKS1/2, and RIM-BP2 (Figure 4.1.4f), although 
ELKS1/2 and RIM-BP2 are not essential for DA release [88,89]. Coverage of synaptic vesicle 
trafficking and fusion proteins was extensive, with significant enrichment of all major integral 
synaptic vesicle proteins (SV2A-C, CSPα, Synaptogyrin1-3, Synaptophysin, Synapsin-1, 
RAB3A-C, VAMP-2), target SNAREs (Syntaxin 1A/B, SNAP25), and functionally related 
proteins (NSF, SNAP-α/β, Munc18-1, Complexin1/2, and α/β/γ-synuclein). We also observed a 
significant enrichment of CAPS1 and CAPS2, proteins that prime synaptic vesicles in 
hippocampal neurons [518] and regulate catecholamine loading into large dense-core vesicles in 
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adrenal chromaffin cells [519] but whose function is to our knowledge unexplored in DA 
neurons. Notably, we find significant enrichment of Synaptotagmins-1 and -7 (Syt-1/Syt-7) 
(Figure 4.1.4f). These data support the recent finding that Syt-1 is the major fast Ca2+ sensor for 
synchronous DA release [116]. In addition to the established role of Syt-7 in somatodendritic DA 
release and the observation of its presence in DA axon terminals [117,520], our findings support 
Syt-7 as a candidate protein for asynchronous axonal DA release [116]. These data highlight 
candidate proteins for further investigation and provide a proteomic architecture of the 
dopaminergic presynapse that is highly consistent with recent functional studies [88,89,116]. 
Somewhat unexpectedly, we also found significant APEX2 enrichment of proteins with 
SynGO annotations for ontology terms related to postsynaptic function (Figure D.8a). Many of 
these proteins were annotated for both pre- and post-synaptic function, including proteins such as 
DAT and VMAT2 (Figure D.8b). Although these proteins are present within dopaminergic 
dendrites [45,120], they are clearly derived from dopaminergic axons in our striatal APEX2+ 
samples. Similarly, many proteins with postsynaptic annotations were functionally related to 
actin dynamics, PKA or MTOR signaling, or other functions not exclusively related to 
postsynaptic function. Other proteins bearing only postsynaptic SynGO annotations, such as the 
Netrin receptor DCC and metabotropic glutamate receptor mGluR1, have functional evidence 
supporting their localization on DA axons [320,521]. Nonetheless, 63 proteins with clear roles in 
dendritic spines or mRNA translation were enriched by APEX2 in both slice and synaptosome 
samples (Figure D.8b). These proteins were significantly lower in abundance than proteins with 
presynaptic annotations (Figure D.8c). Although we cannot rule out the possibility of low levels 
of post-synaptic contamination, the significant depletion of proteins highly expressed by glia and 
striatal neurons (Figure 4.1.2e) demonstrates the absence of extensive cross-membrane labeling. 
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Furthermore, we observed no enrichment of DARPP-32 and Spinophilin (Figure D.9a), proteins 
highly abundant within striatal dendritic spines [23,522–524]. 
APEX2 enrichment in all regions can provide additional evidence of axonal localization 
for proteins often found in the post-synapse. For example, GABA receptors are typically present 
on dendrites, but recent electrochemical and electrophysiological studies have demonstrated the 
presence of both GABA-A and GABA-B receptors on DA axons [70–72]. We found that 
GABA-A receptor subunits and scaffolding protein gephyrin were most abundant in VM 
APEX2+ samples, but still higher in APEX2+ than APEX2- samples from both MFB and striatum 
(Figure D.9b). Similar results were obtained for GABA-B receptor subunits, the PDZ scaffold 
Mupp1 [525], and the effector protein GIRK2 (Figure D.9c). Although many comparisons did 
not pass the FDR correction in MFB comparisons, likely due to substantially lower proteomic 
depth in these samples, APEX2 enrichment in both MFB and striatal samples supports axonal 
transport and localization of these proteins. 
Axonal APEX2 proteomics allowed us to identify proteins and protein complexes that are 
previously undescribed in striatal DA axons. The cytosolic chaperonin T-complex protein 1-ring 
complex (TRiC), or chaperonin containing T-complex (CCT) is an oligomeric complex that 
promotes folding of newly synthesized polypeptides, suppresses aggregation of huntingtin in 
Huntington’s disease, and can inhibit assembly of α-synuclein amyloid fibrils [526–528]. Recent 
work has implicated specific TRiC/CCT subunits in the regulation of axonal transport in cortical 
neurons [529,530], but axonal localization of TRiC subunits is largely undescribed. We detected 
seven out of eight TRiC subunits in our APEX2 proteomics data, six of which showed strong 
evidence of axonal localization (Figure D.9d). These results suggest that the recently described 
interaction between CCT5/CCTε, CDK5, and tau [529] may regulate retrograde transport in DA 
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neurons. Given that TRiC/CCT can regulate α-synuclein aggregation [527], future research on 
TRiC/CCT function in dopaminergic axons is warranted. 
 
Subcellular localization of proteins encoded by DA neuron-enriched and PD-linked genes 
 
Genetic analysis can identify mutations that cause familial PD or variants linked to 
sporadic PD risk, but not whether the relevant genes are expressed in DA neurons. Although 
TRAP and scRNA-seq provide significant insight into DA neuronal gene expression, these 
techniques do not address the subcellular localization of the encoded proteins. We leveraged our 
APEX2 proteomics data to interrogate proteins encoded by genes with high DA neuron-
specificity or by genes linked to PD via Mendelian inheritance or genome-wide association 
studies (GWAS) (Figure 4.1.5a). We re-analyzed published scRNA-seq data [196] (Figure 
D.10), and identified 64 genes with >8-fold higher expression in DA neurons compared to all 
other midbrain cells (see Methods). 55 proteins encoded by these genes were present in the 
filtered APEX2 proteomics data (Figure 5 – source data 1). For human genes linked to familial 
PD, Atypical Parkinsonism, and Dystonia-Parkinsonism [531], we identified 15 proteins encoded 
by orthologous mouse genes in the filtered APEX2 proteomics data (out of 26 genes, Figure 5 – 
source data 2). For human genes nearest to PD-linked single nucleotide polymorphisms (SNPs) 
in the most recent GWAS meta-analysis [532], we identified 86 orthologous mouse genes and 17 
proteins encoded by these genes in the filtered APEX2 proteomics data (Figure 5 – source data 
2). 
Only a minority of proteins encoded by DA neuron-enriched and PD-linked genes were 
preferentially localized to the somatodendritic compartment of DA neurons (Figure 4.1.5b-c). In 
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contrast, a significant majority of proteins encoded by DA neuron-enriched genes (35 out of 55, 






hypergeometric test, Figure 4.1.5c) were preferentially localized to dopaminergic axons (FDR < 
0.05 for APEX2+ striatal vs. VM samples). DA neuron-enriched genes encoding striatal APEX2-
enriched proteins included many canonical synaptic vesicle and active zone proteins mentioned 
above (e.g., Bassoon, Syt-1, Complexin-1/2, SV2B/C, RAB3C, CAPS2), highlighting the 
strikingly high proportion of DA neuronal gene expression dedicated to presynaptic function 
(Figure 4.1.5b). Accordingly, many striatum-enriched proteins involved in vesicular release or  
endocytosis are encoded by genes linked to hereditary Atypical Parkinsonism (Synaptojanin-1, 
 
 
Figure 4.1.5: Subcellular proteomic analysis of proteins encoded by DA neuron marker 
genes and PD-linked genes 
(a) Schematic depicting analysis workflow for integrating APEX2 proteomics data with 
scRNA-seq and genetic data. Proteins encoded by top DA neuron marker genes from 
mouse scRNA-seq data (Saunders et al., 2018) and human PD-linked gene orthologs 
(Marras et al., 2016; Nalls et al., 2019) are analyzed for subcellular protein localization in the 
APEX2 proteomics data. 
(b) Clustered heatmap of Z-scores for abundances of proteins encoded by the top 55 DA 
neuron marker genes present in the filtered APEX2 proteomics data. Each column 
represents a biological replicate (n=4) of APEX2+ streptavidin IP samples from the VM or 
striatum. The color bar on the left indicates whether a given protein was enriched in the VM 
(orange) or striatum (green) in differential expression analysis between APEX2+ IP samples 
(FDR < 0.05 after Benjamini-Hochberg corrected p-values from Welch’s t-test). **** indicates 
p = 4.8e-13, hypergeometric test for Str-enriched proteins (x=35) amongst the top 55 DA 
neuron markers present in the filtered proteomics data (1733 proteins). See Figure 5 – 
source data 1 for summary of DA neuron marker genes and protein abbreviations. 
(c) Clustered heatmap of Z-scores for abundances of proteins present in the filtered APEX2 
proteomics data and encoded by genes linked to hereditary PD/Parkinsonism or to PD via 
GWAS studies as indicated. Each column represents a biological replicate (n=4) of APEX2+ 
streptavidin IP samples from the VM or striatum. The color bar on the left indicates 
whether a given protein was enriched in the VM (orange) or striatum (green) in differential 
expression analysis between APEX2+ IP samples (FDR < 0.05 after Benjamini-Hochberg 
corrected p-values from Welch’s t-test). **** indicates p = 2.8e-06, hypergeometric test for 
Str-enriched proteins (x=17) amongst the 29 PD/Parkinsonism-linked genes present in the 
filtered proteomics data (1733 proteins). See Figure 5 – source data 2 for list of human 
genes, orthologous mouse genes, and protein abbreviations. 
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Auxilin) or to PD via GWAS (RIM-1, NSF, Endophilin-A1, and Sac2/INPP5F). Cao et al. [533] 
recently demonstrated a role of Sac2/INPP5F in synaptic vesicle recycling, and our data confirm 
the presynaptic localization of endogenous Sac2/INPP5F in DA neurons (Figure 4.1.5c). These 
proteomic data provide strong support for genetic data implicating endocytic membrane 
trafficking pathways in PD risk [534]. Another major group of APEX2+ striatum-enriched 
proteins were those involved in DA synthesis and transmission, many of which were DA neuron-
specific (AADC), linked to hereditary Dystonia-Parkinsonism (6-pyruvoyltetrahydropterin 
synthase and sepiapterin reductase), or both (TH, DAT, and GTP cyclohydrolase I) (Figure 
4.1.5b-c). These data suggest that dysfunction of tetrahydrobiopterin and/or DA synthesis 
pathways within dopaminergic axons may be central to the pathophysiology of these hereditary 
forms of Dystonia-Parkinsonism. Finally, we observed significant striatal enrichment of α-
synuclein, VPS13C, and DJ-1 (Figure 4.1.5c), proteins encoded by familial PD genes. 
Collectively, these data are consistent with axonal dysfunction as a major contributor to DA 
neuronal degeneration in genetic PD [480]. 
In addition to the well-studied PD-related proteins noted above, many striatum-enriched 
proteins encoded by PD GWAS-linked genes have been largely undescribed in axonal function. 
We particularly highlight two candidates, SPAK/STK39 and Synaptotagmin-17 (Syt-17), both of 
which are encoded by the probable causal gene within their respective PD GWAS loci [532]. 
SPAK (sterile-20 (Ste20)-related proline-alanine-rich kinase) is a serine/threonine kinase that 
phosphorylates and modulates the activity of cation-chloride transporters, such as the Na+–K+–
2Cl− cotransporter (NKCC1) and the K+–Cl− cotransporter KCC2 [535,536]. We find APEX2 
enrichment of NKCC1, KCC2, SPAK, and upstream regulatory kinases in in VM, MFB, and 
striatal samples (Figure D.11). Given the role of NKCC1 and KCC2 in setting the chloride 
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reversal potential [537], recent demonstration of GABA-A receptor currents in DA axons [72], 
and locomotor phenotype of SPAK knockout mice [538], these data warrant further study of 
SPAK function in dopaminergic axons. The axonal enrichment of Syt-17 is also of particular 
interest, given the linkage of human SYT17 to a PD risk locus and the enrichment of Syt17 
mRNA in DA neurons (Figure 4.1.5b-c). Syt-17 is an atypical synaptotagmin that does not bind 
calcium or participate in synaptic vesicle fusion [539] and has no established role in axons. 
Although hippocampal neurons from Syt-17 knockout mice display axonal growth defects, 
tagged Syt-17 is found in the Golgi complex of these cells and this phenotype appears to be 
mediated by deficits in vesicular trafficking [539]. We are currently investigating the unknown 
function of SYT-17 in dopaminergic axons. Thus, our APEX2 proteomic dataset elucidates the 
subcellular localization of proteins encoded by PD-linked genes and highlights novel areas for 
further study of PD-relevant DA neuronal cell biology. 
 
4.1.4 Discussion 
Our study demonstrates APEX2 labeling and mass spectrometry-based proteomics of 
axonal and somatodendritic compartments of DA neurons in the mouse brain. Thus, APEX2 
labeling in acute brain slices provides a general approach for cell type-specific proteomics and/or 
proximity labeling proteomics in the mouse brain (see also [540]), alongside promiscuous biotin 
ligase (BioID or TurboID)-catalyzed proximity labeling [541,542] and incorporation of non-
canonical amino acids via mutant tRNA synthetases [258,543]. Each of these methods has 
advantages and disadvantages. 
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The major advantages of APEX2 are speed and efficiency: we were able to capture 
thousands of proteins from multiple subcellular compartments of a relatively rare neuronal 
population in individual mice (Figure 4.1.2). In comparison, BioID and TurboID labeling in the 
mouse brain typically requires over seven days and pooling tissue from many mice, precluding 
the use of individual mice as biological replicates [541,542]. The mutant tRNA synthetase 
methods label all synthesized proteins during 7 – 21 days of non-canonical amino acid 
administration, which complicates dynamic studies of specific protein complexes [258,543]. In 
addition to its high efficiency, the speed of APEX2 labeling enables dynamic studies of protein 
complexes on a time scale of minutes [544], including during physiological responses in the 
mouse heart [492]. Future studies might combine APEX2 labeling with optical and 
electrophysiological slice manipulations to interrogate rapid changes in neuronal physiology at 
the proteomic level. Beyond neurons, selective expression of APEX2-fusion proteins will 
broadly facilitate proteomic profiling of organelles and protein-protein interactions within a 
variety of genetically targeted brain cells. 
APEX2 labeling in the mouse brain has several limitations compared to other 
aforementioned methods. First, the introduction of labeling reagents required preparation of 
acute brain slices or synaptosomes, which would preclude labeling during long-term behavioral 
or environmental manipulations (e.g., [258]). Second, the high efficiency of APEX2 may lead to 
low levels of off-target protein labeling. Although we observed biotin labeling within 
morphologically intact DA axons (Figure 4.1.1) and significant depletion of proteins specific to 
striatal SPNs and glia (Figure 4.1.2e), we cannot completely exclude post-synaptic 
contamination. We propose at least four possible explanations for the detection of proteins with 
‘postsynapse’ annotations in striatal APEX2 samples (Figure D.8d). First, it is possible that 
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many canonical ‘post-synaptic’ proteins are also localized within DA axons. For example, we 
and others have shown that NMDA receptors are present on DA axons [545,546], and most 
members of the membrane-associated guanylate kinase (PSD-93, PSD-95, SAP-102, SAP-97) 
and Shank families have been observed in axons and/or nerve terminals [547–550]. Similarly, 
the RNA binding- and translation-related proteins we observe may be derived from DA axons, 
given recent reports of translational machinery in mature axons [248–250]. Second, it is possible 
that a small amount of APEX2 is transferred between DA axons and post-synaptic compartments 
during slice preparation and synaptosome homogenization. Third, it is possible that BP radicals 
directly cross damaged axonal and synaptosomal membranes during APEX2 labeling. Finally, it 
is possible that biotinylated proteins present only in APEX2+ samples provide surfaces for non-
specific binding of non-biotinylated proteins. These mechanisms are not mutually exclusive, but 
appear to produce similar results in both slice and synaptosome labeling environments. 
Although the slice procedure may not be accessible to all laboratories, APEX2 labeling in 
synaptosomes provides a simple and rapid alternative to access the presynaptic proteome of 
genetically targeted projection neurons. Somewhat surprisingly, we found that the APEX2 
proteome of dopaminergic synaptosomes is largely comparable to that of the entire axonal arbor 
within the striatum (Figure 4.1.4e). We suspect this is due to the high density of boutons en 
passant along dopaminergic axons, which would provide a strong representation of the entire 
axonal proteome upon resealing as synaptosomes. Our data thus highlight the utility of the 
synaptosome sorting technique developed by Herzog and colleagues as a complementary 
approach for study of the presynaptic proteome [83,290]. Future work will determine whether 




Mass spectrometry-based quantification of proteins provides significant advantages over 
immunohistochemical methods, especially for fine structures like dopaminergic axons. Suitable 
antibodies that provide high quality immunofluorescence in brain tissue are not available for a 
majority of the proteome, and off-target binding affects the reproducibility and interpretation of 
research findings [551]. Many studies rely on overexpression of tagged proteins to establish 
localization, which can result in mis-localization and altered function. Our study demonstrates 
proximity labeling of endogenous proteins within subcellular compartments of genetically 
targeted neurons, and can thus be used for unbiased discovery as well as protein-targeted 
biochemical experiments. 
While they represent the vast majority of neuronal volume and are critically important to 
DA biology, dopaminergic axons have remained largely inaccessible to proteomic study. Due to 
the relative immaturity, limited axonal complexity, and incomplete synaptic and hormonal inputs 
of cultured DA neurons, we chose to examine the DA neuronal proteome in native brain tissue of 
adult mice. Cytoplasmic labeling in dopaminergic axons captured a diverse range of cytosolic 
and membrane proteins involved in metabolism, protein transport, endolysosomal trafficking, 
synaptic transmission, and autophagy (Figure 4.1.3 and Figure 4.1.4). Thus, our axonal 
proteomic dataset should be broadly useful to axonal and neuronal cell biologists. 
The axonal enrichment of autophagy-related proteins is of particular importance to DA 
neurons, given that autophagy dysfunction is heavily implicated in PD pathophysiology [552] 
and associated with methamphetamine toxicity [553]. Due to the limitations of bulk striatal 
tissue-based protein measurements, our previous studies of autophagy in DA axons were limited 
to electrochemical measurement of DA release and morphological changes via electron 
microscopy [496]. APEX2 labeling will enable future studies of protein biochemistry in DA 
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axons, including proteins that are ubiquitously expressed and difficult to resolve using 
immunohistochemistry.  
A majority of DA neuron-enriched genes encode proteins localized to axons (Figure 
4.1.5b), suggesting that this compartment is central to the identity of DA neurons. These findings 
may be particularly important for understanding pathogenic mechanisms in PD. Importantly, we 
show that mutations linked to hereditary PD or parkinsonism are far more likely to be found in 
genes that encode axonal proteins (Figure 4.1.5c). Thus, the massive axons of DA neurons can 
be considered a double-edged sword: while they are required for DA release to support healthy 
brain function, they are susceptible to myriad environmental and genetic insults. 
We note that the biggest risk factor for idiopathic PD is aging [150]. It is tempting to 
speculate that the proteomic framework and cytoarchitecture of DA neurons in the mammalian 
brain evolved under positive selective pressure related to motor control, reward, and motivation, 
with little selective pressure related to the organism’s lifespan. Comparing the axonal proteome 
of DA neurons to that of other neurons spared from degeneration in PD [149] may identify 
distinguishing features that contribute to increased risk of axonal degeneration in PD. Thus, our 
study lays a proteomic foundation upon which future studies of neuronal cell biology and PD 




Adult male and female mice (6-12 months old) were used in all experiments. DATIRES-Cre 
mice (JAX #006660, RRID: IMSR_JAX:006660) and Ai9 mice (JAX #007909, RRID: 
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IMSR_JAX:007909) were obtained from Jackson Laboratories (Bar Harbor, ME). Mice were 
housed on a 12-hour light/dark cycle with food and water available ad libitum. All experiments 
were conducted according to NIH guidelines and approved by the Institutional Animal Care and 
Use Committees of Columbia University and the New York State Psychiatric Institute.  
 
Plasmid and Virus 
AAV-CAG-DIO-APEX2NES was a gift from Joshua Sanes (Addgene plasmid #79907; 
http://n2t.net/addgene:79907; RRID:Addgene 79907). AAV-CAG-DIO-APEX2NES was 
packaged into an AAV5 vector by Vector BioLabs (Malvern, PA). The final titer of the AAV5-
CAG-DIO-APEX2NES preparation was 1 x 1012 GC/mL in PBS + 5% glycerol. To avoid freeze-
thaw, single-use 10 µL aliquots were stored at -80°C. 
 
Viral Injection 
All surgical procedures were approved by the Institutional Animal Care and Use 
Committee and the Department of Comparative Medicine at New York State Psychiatric 
Institute. Mice were anesthetized with 4% isoflurane. Animals were transferred onto a Kopf 
Stereotaxic apparatus and maintained under isoflurane anesthesia (1–2%). After hair removal and 
sterilization of the scalp using chlorhexidine and ethanol, a midline incision was made. Bregma 
and Lambda coordinates were determined, and minor adjustments in head position were made to 
match the DV coordinates. Virus was injected at AP –3.2, ML −0.9, and DV −4.4. A small hole 
was drilled into the skull and 230 nL of virus (see titer above) was injected through a pulled glass 
pipet using a Nanoject 2000 (Drummond Scientific; 10 pulses of 23 nL). At 5 minutes after 
injection, the glass pipet was slowly withdrawn over 5 min. After closing the skin with vicryl 
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sutures, mice received 0.5 mL of 0.9% saline i.p. and were allowed to recover for >1 hour before 
being returned to their home cages. Animals were housed for at least 3 weeks after injection to 
allow AAV expression before being experiments. 
 
Acute Brain Slice Preparation 
Mice were anesthetized with euthasol and transcardially perfused with 10-15 ml of ice-
cold cutting solution (92 mM NMDG, 2.5 mM KCl, 30 mM NaHCO3, 20 mM HEPES, 1.25 mM 
NaH2PO4, 2 mM thiourea, 5 mM sodium ascorbate, 3 mM sodium pyruvate, 10 mM MgSO4, 0.5 
mM CaCl2, and 25 mM D-glucose) at pH 7.3-7.4 and saturated with 95% O2/5% CO2. Brains 
were rapidly extracted and placed into ice-cold cutting solution saturated with 95% O2/5% CO2. 
For coronal slices, the brain was split roughly in half with a coronal cut at the level of the mid-
hypothalamus (approximately 1.5 mm posterior to Bregma), and the cut surfaces were glued 
directly to the vibratome stage (Leica VT1000S). For sagittal slices, brains were laterally split in 
half at the midline and the cut (medial) surfaces were glued to 2% agarose blocks angled at 11 
degrees. 300 µm-thick slices were prepared in ice-cold cutting solution continuously saturated 
with 95% O2/5% CO2. The brainstem and cerebellum were removed from sagittal slices. A 
typical set of coronal or sagittal slices from a mouse are shown in Figure D.2a. 
 
Electrophysiological recordings 
After preparation in cold cutting solution, slices were transferred to oxygenated normal 
ACSF containing 125.2 NaCl, 2.5 KCl, 26 NaHCO3, 1.3 MgCl2·6H2O, 2.4 CaCl2, 0.3 NaH2PO4, 
0.3 KH2PO4, and 10 D-glucose (pH 7.4, 290 ± 5 mOsm) at 34 °C and allowed to recover for at 
least 40 min before the recordings. After recovery, slices were transferred to ACSF +/- 0.5 mM 
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BP and incubated for 1 hr at room temperature. Electrophysiological recordings were performed 
on an upright Olympus BX50WI (Olympus, Tokyo, Japan) microscope equipped with a 40x 
water immersion objective, differential interference contrast (DIC) optics and an infrared video 
camera. Slices were transferred to a recording chamber and maintained under perfusion with 
normal ACSF (1.5-2 mL/min) at 34°C. All recorded dopaminergic neurons were located in the 
substantia nigra pars compacta and identified by larger somatic size than neighboring neurons. 
Patch pipettes (3-5 MΩ) were pulled using P-97 puller (Sutter instruments, Novato, CA) and 
filled with internal solutions contained (in mM): 115 K-gluconate, 10 HEPES, 2 MgCl2, 20 KCl, 
2 MgATP, 1 Na2-ATP, and 0.3 GTP (pH = 7.3; 280 ± 5 mOsm).  
Cell-attached patch clamp recordings were performed with a MultiClamp 700B amplifier 
(Molecular Devices, Forster City, CA) and digitized at 10 kHz with InstruTECH ITC-18 
(HEKA, Holliston, MA). Once obtaining stable patch configuration, spontaneous firing was 
recorded for 3 min. Data was acquired using WINWCP software (developed by John Dempster, 
University of Strathclyde, UK) and analyzed using Clampfit (Molecular Devices), and Igor Pro 
(Wavemetrics, Lake Oswego, OR). 
 
Table 4.1.1: Antibodies and reagents 



















IgY (H+L), Alexa 
Fluor Plus 488 















































MilliporeSigma H1009 NA APEX2, 1 mM 
IHC: Staining of acute brain slices or sections, ICC: Staining of synaptosomes, WB: western 
blotting, APEX2: slice and synaptosome labeling concentrations 
 
APEX2 biotinylation in brain slices 
After preparation in cold cutting solution, slices were transferred to jars containing 70 mL 
of aCSF (125.2 mM NaCl, 2.5 mM KCl, 26 mM NaHCO3, 1.3 mM MgCl2·6H2O, 2.4 mM 
CaCl2, 0.3 mM NaH2PO4, 0.3 mM KH2PO4, 10 mM D-Glucose) supplemented with 0.5 mM 
biotin-phenol and 1 µM tetrodotoxin. aCSF was continuously saturated with 95% O2/5% CO2. 
Slices were allowed to recover for 60 minutes at room temperature. After recovery, APEX2 
labeling was initiated by the addition of 1 mM H2O2 to aCSF at room temperature. We tested 
labeling periods of 1-5 minutes (Figure D.2b-d) and found 3 minutes to be sufficient for 
downstream applications. To quench labeling, slices were rapidly transferred to a separate jar 
containing 50 mL of quenching aCSF (aCSF supplemented with 10 mM Trolox, 20 mM sodium 
ascorbate, and 10 mM NaN3). After 5 minutes rest at room temperature, slices were either 
transferred to fixative solution for downstream immunostaining, or transferred to ice-cold 




Synaptosome Preparation and APEX2 biotinylation 
Synaptosomes were prepared using standard procedures [364]. Mice were sacrificed by 
cervical dislocation, after which forebrains were rapidly dissected and placed in 10 volumes of 
ice-cold buffer consisting of 0.32 M sucrose, 4 mM HEPES pH 7.4, and protease inhibitors 
(cOmpleteTM EDTA-free protease inhibitor, Roche). Tissue was homogenized on ice in a glass-
glass dounce homogenizer with 10 gentle strokes of loose and tight clearance pestles. All 
subsequent purification steps were performed on ice or at 4oC unless otherwise specified. The 
homogenate was centrifuged at 1,000 xg (Eppendorf 5424R) for 10 min to remove nuclei and 
cellular debris, yielding a P1 pellet and an S1 supernatant. The S1 supernatant was further 
centrifuged at 10,000 x g for 15 min to obtain the crude synaptosome pellet (P2). The P2 pellet 
was resuspended in sucrose buffer, incubated for 5 minutes on ice, and re-centrifuged at 10,000 x 
g for 15 min. The washed P2 pellet was resuspended in phosphate-buffered saline (PBS) with 0.5 
mM BP and incubated for 30 minutes at room temperature.  
For immunostaining experiments, the 30-minute incubation in PBS + BP occurred on 
poly-lysine coated coverslips to allow synaptosome sedimentation and adherence. Unbound 
synaptosomes were removed by several brief washes in PBS + BP prior to APEX2 labeling. 
APEX2 labeling was initiated by the addition of 0.5x volumes of 2 mM H2O2 (1 mM final). 
After 60 seconds, labeling was quenched by addition 4x volumes of ice-cold PBS + 12.5 mM 
Trolox, 25 mM sodium ascorbate, and 12.5 mM NaN3 (10, 20, and 10 mM final, respectively). 
For immunostaining, synaptosomes were washed several more times in quenching PBS over 5 
minutes, followed by addition of fixative solution. For western blotting and proteomics, 
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synaptosomes were collected by re-centrifugation at 10,000 x g for 15 min, flash frozen on liquid 
nitrogen, and stored at -80°C until further use. 
 
Histology and Immunofluorescence 
For initial characterization of AAV5-CAG-DIO-APEX2NES specificity, mice were 
anesthetized with euthasol and transcardially perfused with ~15 mL of 0.9% saline followed by 
40-50 mL of ice-cold 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB), pH 7.4. 
Brains were post-fixed in 4% PFA in 0.1 M PB for 6-12 hours at 4°C, washed three times in 
phosphate buffered saline (PBS), and sectioned at 50 µm on a Leica VT1000S vibratome. 
Sections were placed in cryoprotectant solution (30% ethylene glycol, 30% glycerol, 0.1 M PB, 
pH7.4) and stored at −20°C until further use. 
Sections were removed from cryoprotectant solution and washed three times in tris-
buffered saline (TBS) at room temperature. Sections were then permeabilized in TBS + 0.3% 
Triton-X 100 for one hour at room temperature, followed by blocking in TBS + 10% normal goat 
serum (NGS) and 0.3% Triton-X 100 for 1.5 hours at room temperature. Sections were then 
directly transferred to a pre-chilled solution containing primary antibodies in TBS + 2% NGS + 
0.1% Triton-X 100 and incubated overnight at 4°C. Sections were washed in TBS five times 
over an hour at room temperature. Sections were incubated in a solution containing secondary 
antibodies in TBS + 2% NGS + 0.1% Triton-X 100 at room temperature for 1.5 hours, followed 
by four washes in TBS+T over 45 minutes at room temperature. Following four additional 
washes in TBS, sections were slide mounted and coverslipped with Fluoromount G (Southern 
Biotech). See Table 4.1.1 for a complete list of antibodies and concentrations used in this study. 
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For immunostaining of acute brain slices after APEX2 labeling, slices were transferred to 
ice-cold 4% paraformaldehyde in 0.1M phosphate-buffer + 4% sucrose and fixed overnight at 
4°C. To remove lipids and enhance antibody penetration, fixed slices were transferred to CUBIC 
solution 1A, consisting of 10% wt Triton X-100, 5% wt NNNN-tetrakis (2-HP) ethylenediamine, 
10% wt Urea, and 25 mM NaCl [554]. Slices were blocked in TBS + 10% normal goat serum 
(NGS) and 0.3% Triton-X 100 for 6 hours at room temperature and then transferred to TBS + 2% 
NGS and 0.3% Triton-X 100 supplemented with primary antibodies. After 72 hours incubation at 
4°C with primary antibodies, slices were washed five times over 10 hours in TBS. Slices were 
incubated for 24 hours at room temperature in TBS + 2% NGS + 0.3% Triton-X 100 
supplemented with secondary antibodies and fluorophore-conjugated streptavidin. After five 
washes in TBS over 10 hours, sections were slide mounted and coverslipped with Fluoromount 
G. See Antibodies and Reagents for a complete list of antibodies and concentrations used in this 
study. 
For immunostaining of synaptosomes after APEX2 labeling, synaptosomes adhered to 
poly-lysine coverslips were fixed with 4% paraformaldehyde in 0.1 M phosphate-buffer + 4% 
sucrose for 10 minutes at room temperature. After several washes in PBS, synaptosomes were 
incubated with PBS + 0.1M glycine + 0.05% Tween-20 for 15 minutes at room temperature. 
After blocking/permeabilization with PBS + 10% NGS + 0.2% Tween-20 for one hour at room 
temperature, synaptosomes were incubated with primary antibodies in PBS + 2% NGS + 0.1% 
Tween-20 at 4°C overnight. After three washes in PBS, synaptosomes were incubated in 
secondary antibodies in PBS + 2% NGS + 0.1% Tween-20 for 1 hour at room temperature. After 
three more washes in PBS, coverslips were stored and imaged in Fluoromount G. See Antibodies 




Tissue lysis and protein processing 
Capture and processing of biotinylated proteins was conducted as previously described 
[492,555] with only minor modifications. Immediately after dissection in ice-cold quenching 
aCSF, tissues were flash frozen in liquid nitrogen and stored at -80°C until further use. Frozen 
tissues or synaptosome pellets were homogenized on ice in a glass dounce homogenizer (Sigma 
D9063) with 30 strokes of both A and B pestles. Lysis was in 0.75 mL of ice-cold tissue lysis 
buffer, consisting of 50 mM Tris pH 8.0, 150 mM NaCl, 10 mM EDTA, 1% Triton X-100, 5 mM 
Trolox, 10 mM sodium ascorbate, 10 mM sodium azide, and 1x EDTA-free protease inhibitors 
(Roche). After addition of 39 µL of 10% SDS (final concentration 0.5%), lysates were rotated 
for 15 minutes at 4°C. Lysates were clarified by centrifugation at 21,130 x g for 10 minutes at 
4°C. Supernatants were transferred to a new pre-chilled Eppendorf tube for trichloroacetic acid 
(TCA) precipitation (for mass spectrometry) or stored at -80°C (for western blotting). 
Proteins were precipitated from lysates by the addition of an equal volume of ice-cold 
55% TCA. Samples were incubated on ice for 15 minutes, followed by centrifugation at 21,130 x 
g for 10 minutes at 4°C. Protein pellets were resuspended in 1 mL of acetone pre-chilled to -
20°C and re-centrifuged as before. Pellets were resuspended and re-centrifuged another three 
times in 1 mL of acetone pre-chilled to -20°C, for a total of four washes. Residual acetone was 
removed, and protein pellets were resuspended in Urea Dissolve Buffer (8M Urea, 1% SDS, 100 
mM sodium phosphate pH 8, 100 mM NH4HCO3). Dissolution of pellets was facilitated by water 
both sonication for 10 minutes followed by gentle agitation on an orbital shaker for 1 hour at 
room temperature. Removal of residual TCA was confirmed by checking that the pH ~8.0. In 
some cases, a small aliquot (5%) of the resuspended protein was flash-frozen and stored at -
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80°C. 1/49 the volume of 500 mM TCEP (Sigma, cat. #646547) and 1/19 the volume of freshly 
prepared 400 mM iodoacetamide (ThermoFisher, cat. #90034) in 50 mM NH4HCO3 was added 
to the protein resuspension for disulfide reduction and cysteine alkylation at final concentrations 
of 10 mM TCEP and 20 mM iodoacetamide. The suspension was vortexed and incubated in the 
dark for 25 minutes at room temperature. Alkylation was quenched by addition of 1/19 the 
volume of 1 M DTT to reach 50 mM DTT. Samples were diluted with 0.87x volumes of H2O to 
reach a final concentration of 4 M urea and 0.5% SDS. 
Capture of biotinylated proteins for mass spectrometry 
Streptavidin magnetic beads (ThermoFisher #88817) were resuspended and washed three 
times in Urea Detergent Wash Buffer (4 M Urea, 0.5% SDS, 100 mM sodium phosphate pH 8) 
for at least 10 minutes at 4°C. After washing, streptavidin beads were resuspended in ice-cold 
Urea Detergent Wash Buffer and 50 µL containing 0.5 mg of beads was added to each sample. 
Proteins were incubated with streptavidin beads overnight on a rotor at 4°C. After 14-18 hours, 
the unbound supernatant was discarded, and beads were resuspended in 1 mL of Urea Detergent 
Wash Buffer and transferred to a new tube. Beads were washed three times for 5-10 minutes in 1 
mL of Urea Detergent Wash Buffer at room temperature. After the third wash, beads were 
resuspended in 1 mL of Urea Wash Buffer (4 M Urea, 100 mM sodium phosphate pH 8) and 
transferred to a new tube. After three 5-10-minute washes in 1 mL of Urea Wash Buffer at room 
temperature, beads were resuspended in 200 µL of Urea Wash Buffer and transferred to a new 
tube. A 10 µL aliquot (5%) was transferred to a separate tube for western blotting, and the 
remaining 190 µL of buffer were removed on a magnetic stand. Beads were flash frozen and 





The protein concentration of frozen tissue lysates was determined using the BCA assay 
(Pierce, ThermoFisher catalog #23225) and diluted with 4x LDS sample buffer (ThermoFisher, 
catalog #NP0007) supplemented with 20 mM DTT and boiled for 5 min at 95°C.  Frozen 
streptavidin beads were resuspended in ~ 20 µL of 1x LDS sample buffer supplemented with 20 
mM DTT and 2 mM biotin. Samples were boiled for 5 min at 95°C to elute biotinylated proteins. 
Beads were immediately placed immediately onto a magnetic rack and the entire sample was 
immediately loaded into 10% Bis-Tris polyacrylamide gels (Invitrogen, ThermoFisher catalog 
#NP0303BOX) and transferred to PVDF membranes (Immobilon-P, MilliporeSigma, catalog 
#IPVH00010). Membranes were initially washed for 15 minutes in TBST (1X TBS + 0.1% 
Tween 20), blocked for an hour in 5% BSA/TBST, and incubated overnight at 4°C with primary 
antibody in 5% bovine serum albumin/TBST overnight. After primary incubation, membranes 
were washed three times in TBST prior to incubation with streptavidin-HRP or HRP-conjugated 
secondary antibody in 2.5% BSA/TBST for one hour at room temperature. After secondary 
incubation, membranes were washed three times in TBST. Signal was developed using 
Immobilon enhanced chemiluminescent substrate (Millipore, catalog #WBKLS0500) and 
imaged on an Azure Biosystems C600 system. 
 
On bead digestion and liquid chromatography/tandem mass spectrometry (LC-MS/MS) 
Proteins bounded streptavidin beads were resuspended in 200 µl of digestion buffer (1M 
urea, 100mM EPPS pH 8.5 , 4% acetonitrile) and digested with 2 µg of trypsin/LysC mix 
overnight at 37°C. The next day, digested peptides were collected in a new microfuge tube and 
digestion was stopped by the addition of 1% TFA (final v/v), followed by centrifugation at 
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14,000 x g for 10 min at room temperature. Cleared digested peptides were desalted on a SDB-
RP Stage-Tip and dried in a speed-vac. Dried peptides were dissolved in 3% acetonitrile/0.1% 
formic acid. Desalted peptides (300-500 ng) were injected onto an EASY-Spray PepMap RSLC 
C18 50 cm x 75 μm column (Thermo Scientific), which was coupled to the Orbitrap Fusion 
Tribrid mass spectrometer (Thermo Scientific). Peptides were eluted with a non-linear 120 min 
gradient of 5-30% buffer B (0.1% (v/v) formic acid, 100% acetonitrile) at a flow rate of 250 
nL/min. The column temperature was maintained at a constant 50 ˚C during all experiments.  
Samples were run on the Orbitrap Fusion Tribrid mass spectrometer with a data 
independent acquisition (DIA) method for peptide MS/MS analysis [556]. Survey scans of 
peptide precursors were performed from 350-1200 m/z at 120K FWHM resolution (at 200 m/z) 
with a 1 x 106 ion count target and a maximum injection time of 60 ms. After a survey scan, 26 
m/z DIA segments acquired at from 200-2000 m/z at 60K FWHM resolution (at 200 m/z) with a 
1 x 106 ion count target and a maximum injection time of 118 ms. HCD fragmentation was 
applied with 27% collision energy and resulting fragments were detected using the rapid scan 
rate in the Orbitrap. The spectra were recorded in profile mode. 
 
Raw mass spectrometry data processing 
DIA data were analyzed with directDIA 2.0, a spectral library-free analysis pipeline 
featured in Spectronaut Pulsar X software (Biognosys AG). The default settings were used for 
targeted analysis of DIA data in Spectronaut except the decoy generation was set to “mutated”. 
False discovery rate (FDR) was estimated using the mProphet approach [557] and set to 1% at 
peptide precursor level and at 1% at protein level. For peptides and proteins that were not 
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detected in a given sample (directDIA output as ‘Filtered’), the intensity was set to 0 for 
downstream analysis. 
 
Proteomic Differential Expression Analysis and Filtering 
Total intensity normalized protein abundances were used for all differential expression 
analyses, which consisted of a Welch’s (unequal variance) t-test with Benjamini-Hochberg 
procedure to control the False discovery rate (FDR). For visualization and clustering, total 
intensity normalized protein abundances were log2 transformed after adding 1. 
A graphical summary of the initial filtering for VM and striatum APEX2 proteomics data 
is shown in Figure D.5d. Most filters were based on the APEX2 proteomics data alone, with 
some additional filters based on DA neuron scRNA-seq data derived from Saunders et al. [196] 
(see below). VM proteins were filtered as follows: 
1) Proteins meeting statistically significant (FDR < 0.05) enrichment in APEX2+ vs. 
APEX2- (Control) differential expression were retained 
2) Proteins were retained if they met either one of the two following conditions (a OR 
b): 
a. Mean DA neuron scRNA-seq expression above the lower bound (mean – 
standard deviation) 
b. Statistically significant (FDR < 0.05) enrichment in APEX2+ vs. APEX2- 
(Control) differential expression in all three regions (VM, MFB, and Str) 
3) Proteins were removed if they were encoded by genes with very low DA neuron-
specificity in scRNA-seq data (Mann-Whitney U-test comparing DA neurons vs. all 




Striatum proteins were filtered as follows: 
1) Proteins meeting statistically significant (FDR < 0.05) enrichment in APEX2+ vs. 
APEX2- (Control) differential expression were retained 
2) Proteins were retained if they met any of the following conditions (a OR b OR c): 
a. Statistically significant enrichment (FDR < 0.05) in APEX2+ vs. APEX2- 
(Control) differential expression for either VM or MFB 
b. log2 Fold Change > 1 in APEX2+ vs. APEX2- (Control) comparisons for both 
VM and MFB samples 
c. High mean DA neuron scRNA-seq expression (above the mean plus standard 
deviation) and DA neuron specificity (Mann-Whitney U-test comparing DA 
neurons vs. all other midbrain cells or vs. all striatal cells) 
3) Proteins were retained if they met either one of the two following conditions (a OR 
b): 
a. Mean DA neuron scRNA-seq expression above the lower bound (mean minus 
standard deviation) 
b. Statistically significant (FDR < 0.05) enrichment in APEX2+ vs. APEX2- 
(Control) differential expression in all three regions (VM, MFB, and Str) 
4) Proteins were removed if they were encoded by genes with very low DA neuron-
specificity in scRNA-seq data (Mann-Whitney U-test comparing DA neurons vs. all 
other midbrain cells or vs. all striatal cells). 
 
Gene Ontology (GO) Analysis 
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For all gene ontology analyses, a single list of unique genes encoding the corresponding 
proteins was used (i.e., a single gene entry was used when multiple protein isoforms in the list 
were encoded by a single gene). For peptides/protein groups mapped to multiple, homologous 
proteins, the first gene entry as determined by Spectronaut default settings was used. The VM vs. 
striatum GO analysis shown in Figure 4.1.3d was conducted using web-based Enrichr [465] 
with 2018 GO Terms for Cellular Component, Biological Process, and Molecular Function 
[466,467]. Enrichr was also used for subcellular compartments analysis shown in Figure D.7a-b. 
Additional targeted gene ontology analysis shown in Figure D.7c-d was conducted manually 
using the SciPy implementation of the hypergeometric test. Nuclear-related ontologies were 
obtained from COMPARTMENTS [500] and mitochondrial localization ontologies were 
obtained from MitoCarta 3.0 [558]. The synaptic gene ontology analysis shown in Figure 4.1.4 
and Figure D.8 was conducted using SynGO [468]. 
 
Image acquisition and analysis 
Imaging of 50 µm sections from perfusion-fixed brain was conducted on a Nikon Ti2 
Eclipse epifluorescence microscope or on a Leica SP8 scanning confocal microscope. To 
confirm the specificity of V5 expression in DA neurons, tile scan epifluorescence images of the 
entire ventral midbrain were collected at 2-3 z-planes per section. V5-positive neurons were first 
identified using only the V5 channel and their somas were segmented as ROIs. Each V5-positive 
neuronal ROI was subsequently scored for tdTomato and TH expression. Neurons within both 
the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) were quantified. 
High resolution (60x/1.4 NA) confocal images of striatal sections confirmed that V5 (APEX2), 
tdTomato, and TH were localized exclusively within dopaminergic axons. 300 µm thick brain 
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slices were imaged only by confocal microscopy. To assess biotin labeling throughout the slice, 




For comparison to scRNA-seq, we obtained Drop-seq count matrices for substantia nigra 
and striatum from GSE116470 (DropViz, Saunders et al. [196]).  To identify dopamine neurons, 
we first performed unsupervised clustering on the substantia nigra count matrices using the 
Phenograph [559] implementation of Louvain community detection after selection of highly 
variable genes and construction of a k-nearest neighbors graph as described previously [560]. We 
identified a single cluster with statistically significant co-enrichment of dopamine neuron 
markers such as Th and Slc6a3 based on the binomial test for expression specificity [561] as 
shown in the UMAP [562] embedding in Figure D.10a. After sub-clustering the putative 
dopamine neurons using the methods described above, we identified a small sub-cluster with 
statistical enrichment of astrocyte markers such as Agt, Gja1, Glul, and Slc1a3. We discarded 
this sub-cluster as likely astrocyte contamination and removed all remaining cells with fewer 
than 1,000 unique transcripts detected to produce a count matrix of high-confidence dopamine 
neuron profiles. We sub-clustered these profiles to identify five transcriptionally distinct 
dopamine neuron subsets with markers determined using the binomial test, as shown in Figure 
D.10b. 
We used these high-confidence profiles to identify genes with enrichment in dopamine 
neurons compared to all midbrain cells by differential expression analysis as described in Szabo, 
Levitin et al. [563] with minor modifications. Briefly, to perform differential expression analysis 
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between two groups of cells, we randomly sub-sampled the data so that both groups are 
represented by the same number of cells. Next, we randomly sub-sampled the detected 
transcripts so that both groups have the same average number of transcripts per cell. Finally, we 
normalized the two sub-sampled count matrices using scran [564] and analyzed differential 
expression for each gene using the SciPy implementation of the Mann-Whitney U-test. We 
corrected the resulting p-values for false discovery using the Benjamini-Hochberg procedure as 
implemented in the statsmodels package in Python. We used differential expression analyses 
between high-confidence dopamine neurons and the remaining cells in the midbrain to select 
genes with >8-fold specificity for expression in DA neurons (log2FC > 3 and FDR < 0.01). 
 
Analysis of Proteins Encoded by DA Neuron Marker Genes and PD-linked Genes 
DA neuron marker genes (genes specific to mouse dopamine neurons) were identified 
using scRNA-seq data as described above. Out of 64 genes with >8-fold specificity for 
expression in DA neurons, 55 corresponding proteins were present in the filtered APEX2 
proteomics data. See Figure 5 – source data 1 for complete summary of mouse DA neuronal 
marker genes, corresponding mouse proteins, and protein abbreviations shown in Figure 4.1.5b. 
Human genes linked to PD via monogenic inheritance were obtained and classified according to 
the guidelines put forth in Marras et al. [531]. Human genes linked to PD via GWAS were 
obtained from the most recent meta-analysis [532]. The closest gene to each SNP in Table S2 
was used for downstream analysis. For all human genes, mouse gene orthologs were obtained via 
the web-based ID conversion tool (BioMart, Ensembl). See Figure 5 – source data 2 for 
complete summary of human PD-linked genes, mouse gene orthologs, mouse proteins, and 
protein abbreviations shown in Figure 4.1.5c. 
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Visualization and Statistical Analysis 
Cartoon graphics (e.g., Figure 4.1.3d and Figure 4.1.4f) were created in Adobe 
Illustrator 24.3 (Adobe, Inc.) with additional illustrations from BioRender 
(https://biorender.com/). Proteins were selected for display on this basis of inclusion in 
significantly over-represented GO Terms, with additional proteins selected based on manual 
curation of the relevant literature. Unless otherwise noted, all proteins displayed were present in 
the filtered APEX2 proteomics data. Protein abbreviations and corresponding full protein names 
are provided as source data for each respective figure. 
Unless otherwise noted, all statistical analysis and data visualization was conducted in 
Python using SciPy, Matplotlib, and Seaborn packages. For visualization of proteomics data 
(log-log abundance plots, Z-scores, clustered heatmaps, etc.), total intensity normalized protein 
abundances were log2 transformed after adding 1. The total intensity normalized, log2 
transformed protein intensities are generally referred to as log2 protein abundance, as specified 
in figure captions. For clustered heatmaps, Z-scores of log2 protein abundances were first 
calculated using the zscore function within the SciPy Stats module, after which the row and 
column clustering was calculated using the linkage function (metric = ‘Euclidean’, method = 
‘average’) within fastcluster 1.2.3 [565] and passed to Seaborn clustermap. 
 
Materials Availability 
There are restrictions to the availability of AAV5-CAG-DIO-APEX2NES virus due to 
limited production size. The exact plasmid used for production of this virus (AAV-CAG-DIO-
APEX2NES, Addgene plasmid #79907) can be ordered from Addgene and/or sent directly to 
Vector BioLabs for further production. 
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Data and Code Availability 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium via the PRIDE [566] partner repository with the dataset identifier PXD026229. Raw 
label-free quantification intensity values for proteomics data can be found in Figure 2 — source 
data 2. The scRNA-seq data analyzed are publicly available as GSE116470 [196]. High 
confidence DA neuron profiles used in this study are reported in Figure 5 — source data 3. 
Python code used for clustering and visualization of scRNA-seq data can be found at 
www.github.com/simslab/cluster_diffex2018 and for differential protein expression analysis of 
mass spectrometry data at www.github.com/simslab/proteomics2021. 
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4.1.8 Conclusions 
 As mentioned above, there are now a number of technologies for proximity labeling 
proteomics in the mouse brain, including APEX2, BioID, TurboID, and non-canonical amino 
acid labeling. Based on its versatility, high efficiency, and rapid labeling kinetics, I expect that 
APEX2 will be widely employed in future studies. Indeed, another group recently employed 
APEX2 labeling in acute brain slices to conduct subcellular proteomic profiling of striatal SPNs 
[540]. Future efforts should focus on similar profiling of other neurons; for example, cortical and 
striatal projection neurons could be readily studied using the methods presented here. Axonal 
targeting of APEX2 fusion proteins will enable similar studies in neurons whose axonal 
projections are intermixed with their somatodendritic compartments. Comparison across 
neuronal populations will help identify which features of the dopaminergic axonal proteome are 
unique and may represent actionable targets. Further subcellular targeting of APEX2 within 
dopamine neurons will also accelerate our understanding of somatodendritic dopamine release 
sites, in the Conclusion and Future Directions section. In addition to further proteomic 
profiling studies, we were also interested in follow-up studies regarding novel proteins identified 
in dopaminergic axons. The following section presents ongoing work regarding one of these hits, 




4.2   Synaptotagmin 17 in dopamine neurons  
Among the unexpected proteins we identified as enriched in dopamine axons, 
Synaptotagmin-17 (Syt-17) stood out as an interesting candidate protein for follow-up studies. 
As detailed below, midbrain dopamine neurons express high levels of Syt-17 mRNA relative to 
most brain cells. The human SYT17 gene is linked to PD via GWAS [532], but Syt-17 is not 
well-studied and has never been described in axons before. We reached out to Edwin Chapman 
at the University of Wisconsin, who led the only study on Syt-17 function in neurons within the 
last five years [539]. He was eager to collaborate and generously offered to share Syt-17 
knockout mice and reagents with us. Our work on Syt-17 function in dopamine neurons is still 




Synaptotagmins (Syt-) are a family of seventeen proteins, many of which are involved in 
the regulation of exocytosis. A key structural feature of synaptotagmins is the presence of two 
C2 domains and an intervening flexible linker. As mentioned above, Syt-1 is the fast sensor for 
calcium-dependent SV fusion in striatal dopamine axons [116]. Calcium binding and regulation 
of vesicular exocytosis appear to be conserved functions of synaptotagmins, albeit with 
differences in calcium sensitivity and subcellular localization. For example, Syt-4 regulates 
BDNF release in dendrites and axons of hippocampal neurons [567] and Syt-4/Syt-7 are 
involved in somatodendritic dopamine release [117,520]. However, Syt-17 is an unusual isoform 
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in that it does not bind calcium, lacks a transmembrane domain, and does not trigger SNARE-
catalyzed membrane fusion [539]. 
Syt-17 is the most recently discovered synaptotagmin (1996), and was originally named 
“B/K” protein because of its expression in the brain and kidney of rats [568]. However, 
subsequent studies found that Syt-17 protein is expressed only within the brain [569]. Syt-17 
lacks the N-terminal transmembrane domain typically found in synaptotagmins, though it can 
bind to membranes via an N-terminal cluster of fatty-acylated cysteine residues [569]. In 
addition to dopamine neurons (see below), Syt-17 protein is highly expressed in hippocampal 
pyramidal cells [568–571], where it is upregulated following kainate-induced seizures [572]. 
Within hippocampal neurons, Syt-17 is localized predominantly to the Golgi apparatus and to 
Rab5+ early endosomes in dendrites [539]. Syt-17 knockout mice (Syt-17 KO) performed 
significantly worse than WT littermates on a novel object recognition task, which suggests a 
deficit in hippocampal dependent memory [539]. Indeed, Syt-17 KO neurons display alterations 
in synaptic physiology, including enhanced excitatory post-synaptic current (EPSC) amplitude 
and enhanced surface GluR2 expression [539]. These effects were attributed to a decrease in 
Rab5+ early endosomes within dendrites and decreased endosomal recycling of AMPA receptors 
[539]. Consistent with this hypothesis, hippocampal slices of Syt-17 KO mice show a significant 
deficit in hippocampal LTD [539], a form of plasticity requiring Rab5-mediated AMPA receptor 
internalization [573]. 
Hippocampal neurons from Syt-17 KO mice also exhibit deficits in neurite outgrowth, 
particularly axons, and Syt-17 overexpression actually increases axonal length [539]. This 
bidirectional effect on axonal growth was dependent on both the N-terminal cysteine residues 
and C2B domain [539]. Although earlier studies had demonstrated axonal localization of a Syt-
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17-pHluorin fusion protein [574], these results were considered to be  “spillover to non-
physiological compartments when strongly overexpressed” [539]. Instead, the effects of Syt-17 
loss on neurite outgrowth appear to be mediated by loss of trafficking between the ER and Golgi. 
Syt-17 KO neurons displayed accumulation of vesicles surrounding the Golgi complex, and Syt-
17 was shown to interact with two cis-Golgi proteins implicated in ER cargo import [539].  
These observations raise many interesting questions related to the unknown role of Syt-
17 in dopamine neurons. First, it seems possible that the axonal localization of Syt-17-pHluorin 
observed by Dean et al. [574] was not truly an artifact of overexpression. Our APEX2 
proteomics data identified a significant enrichment of endogenous Syt-17 in dopamine axons 
(Figure 4.1.5). Is the axonal localization of Syt-17 specific to dopamine neurons, and what is the 
function of axonal Syt-17? Second, given the presence of Syt-17 on Rab5+ endosomes in 
hippocampal dendrites, does Syt-17 regulate endosomal recycling in dopaminergic axons or 
dendrites? Endocytic membrane trafficking pathways are implicated in PD risk [534], and it 
would be of great interest if Syt-17 interacts with established PD-risk genes involved in 
endocytosis (e.g., Auxilin, Synaptojanin-1) or endosomal sorting (e.g., VPS35). Third, do 
alterations in Syt-17 expression lead to deficits in ER to Golgi trafficking within dopamine 
neurons? Simply by virtue of their massive axons, the demands placed on the secretory pathway 
of dopamine neurons are expected to be enormous. ER stress is heavily implicated in PD 
(reviewed in [575,576]), and deficits in Syt-17 function might exacerbate this problem by 
inhibiting flux through the secretory pathway. Although I cannot provide answers to these 





4.2.2 Genetic linkage of SYT17 to Parkinson’s disease 
As per the most recent PD GWAS meta-analysis, SYT17 is the probable causal gene 
within its respective PD GWAS locus [532]. There are several single nucleotide polymorphisms 
(SNPs) linked to PD risk near the SYT17 locus (Figure 4.2.1A) [577]. Three non-coding 
variants meet genome-wide significance, all of which are located within an intron between exon 
7 and exon 8, the final exon of SYT17 (Figure 4.2.1B). The lead risk variant is rs6497339 
(Chr16:19277493:A:T) with an odds ratio of 1.065 and p-value of 2.76e-11 [532,577]. However, 
there are two other variants that meet genome-wide significance as well as many other variants 
in intron 7 (between exons 7-8) that are near the threshold for genome-wide significance (Figure 
4.2.1A). To date, the functional significance of PD-linked SNPs within intron 7 of SYT17 is 
unknown. However, expression quantitative trait loci (eQTL) mapping using over 1400 samples 
of cerebral cortex revealed a significant association between the lead PD risk variant rs6497339 
and SYT17 expression [578] (Figure 4.2.2). A similar trend was observed for many of the intron 
7 variants, where a higher linkage disequilibrium relative to rs6497339 was associated with 
greater statistical significance in the cerebral cortex eQTL data (Figure 4.2.2). Another variant 
located between SYT17 and ITPRIPL2, rs8062326, has been linked to alcoholism in bipolar 
affective disorder [579]. The rs8062326-containing region upstream of SYT17 was shown to 
interact with the SYT17 promoter using promoter capture Hi-C [580]. Collectively, these results 
suggest that noncoding SNPs near or within the SYT17 locus may contribute to the genetic risk 


































































































































































































4.2.3 Syt-17 expression in midbrain dopamine neurons 
Since our previous APEX2 proteomics data identified a strong enrichment of Syt-17 
protein in striatal dopamine axons [230], we sought to confirm APEX2 mRNA localization and 
translation in dopamine neurons. We found that Syt17 mRNA was significantly enriched in 
DATIRES-Cre-RiboTag IPs from the VTA, SNc, and SNr (Figure 4.2.3A). Although enrichment of 
Figure 4.2.2: eQTL mapping of SYT17 risk variants 
(Left) Statistical significance of risk variants at the SYT17 locus for PD GWAS (Nalls et al., 
2019) and cerebral cortex eQTL mapping (Sieberts et al., 2020). (Right) Same as Left but 
with each axis plotted separately against chromosomal location. Figure adapted from the 




Syt17 mRNA in RiboTag IPs was comparable to Syt1, absolute levels of Syt17 mRNA are 
approximately ~10-fold lower than Syt1 (Figure 4.2.3A). Simultaneous immunostaining for TH 
and FISH for Syt17 mRNA provided further confirmation that Syt-17 is highly enriched in 
dopamine neurons. Syt17 mRNA puncta were primarily localized within dopaminergic somata, 





We also observed dynamic changes in Syt17 mRNA translation (DATIRES-Cre-RiboTag RNA-seq) 
across postnatal maturation of dopamine neurons. It is known that dopaminergic innervation of 
the striatum dramatically increases from birth (P0) to postnatal day 30 (P30), where evoked 
dopamine release reaches near-adult levels [69,427]. Ribosome-bound levels of Syt17 mRNA 
increased from P0 to P14 (~2-fold higher than P0) before stabilizing around P21 (Figure 
4.2.3C). Given the involvement of Syt-17 in axonal growth and arborization [539], these changes 
may correspond to an expression program related to axonal growth. Accordingly, Syt1 translation 
continued to steadily increase until P21 (~4-fold higher than P0). As mentioned above, Syt17 
levels remained ~10-fold lower than Syt1, but were comparable to Syt4 and Syt7 (Figure 
4.2.3D). While Syt-1 is the key calcium sensor for fast axonal dopamine release [116], Syt-4 and 
Syt-7 are known to be involved in somatodendritic dopamine release [117,520]. Thus, Syt17 
mRNA is dynamically regulated in developing dopamine neurons and is expressed at levels 
comparable to other non-canonical Synaptotagmins. 
To further establish which cell types express Syt17 mRNA, we conducted single nucleus 
RNA-seq (snRNA-seq) on ventral midbrain tissue. Similar to previous studies [196], we 
observed striking heterogeneity, particularly among neurons, with 38 subclusters identified by 
unsupervised clustering analysis (see Figure E.1). As shown in Figure 4.2.4A, we assigned   
 
 
Figure 4.2.3: Syt17 mRNA translation, localization, and developmental expression in 
dopamine neurons 
(A) (left) DAT-IRES-Cre:RiboTag immunoprecipitation (IP) enrichment of Syt1 and Syt17 
mRNA relative to input. **** DESeq2 adjusted p-values are < 1e-7 for both mRNAs in all 
three regions. (right) DESeq2 rlog normalized (log2) IP abundance for Syt1 and Syt17.  
(B) TH immunofluorescence (IF) and Syt17 FISH in midbrain dopamine neurons in the 
substantia nigra pars compacta. Scale bars, 15 µm (upper) and 50 µm (lower). 
(C-D) DESeq2 rlog normalized (log2) RiboTag IP abundance for Syt1, 4, 7, and 17 (D). Data 







nuclei to six major cell types based on expression of canonical marker genes (Figure E.2) and 
removed potential doublets (Figure E.3). In total, we retained 4,747 nuclei derived from three 
mice (biological replicates) for downstream analysis. In addition to canonical dopaminergic 
markers such as Th and Slc6a3/DAT, we found a striking density of Syt17 mRNA expression in 
dopamine neurons (Figure 4.2.4A). In contrast, Syt17 mRNA was virtually undetectable within 
oligodendrocytes, astrocytes, or microglia (Figure 4.2.4B). Syt17 expression was detectable 
within some glutamatergic (VGLUT2+) and GABAergic midbrain neurons, while levels were 
higher and detected in almost all dopamine neurons (Figure 4.2.4B). Accordingly, Syt17 was in 
the top 50 marker genes for dopamine neurons, with far greater specificity than Syt1 (Figure 
4.2.4C). Thus, Syt-17 is predominantly expressed by dopamine neurons within the ventral 
midbrain, with lower levels in other neurons are very low (or absent) expression in glia. 
Our dopamine neuronal APEX2 proteomics data correspond quite well with our 
transcriptome and translatome data. Syt-17 protein is enriched by dopamine neuronal APEX2 
labeling within the VM, MFB, and striatum. Syt-17 protein levels are lower than Syt-1 in all 
regions, although Syt-17 background binding is completely undetectably in all APEX2- control 
samples (Figure 4.2.5A). The subcellular distribution of Syt-1, Syt-7, and Syt-17 proteins are all 
similar, with the highest levels found in the striatum and striatal synaptosomes (Figure 4.2.5B). 
 
 
Figure 4.2.4: snRNA-seq reveals Syt17 enrichment in dopamine neurons 
(A) UMAP embedding of ventral midbrain snRNA-seq data (4,747 nuclei from 3 mice). 
(Upper left) Six major cell types are represented in the data, (Upper right and Lower) Cells 
colored by log2 (counts per million + 1) for the indicated genes. 
(B) Violin plots of Syt17 mRNA levels (expressed as log2 (counts per million + 1) within 
major cell types shown in A. 
(C) Dopamine neuron expression specificity for the indicated genes, as determined by the 
binomial test comparing the dopamine neuronal cluster to all other midbrain cells. FDR-
corrected p-values and rank as indicated. 
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Similar to translating mRNA levels measured by RiboTag RNA-Seq, Syt-7 and Syt-17 protein 
levels are comparable within dopamine axonal APEX2 samples, and both are ~10-fold lower 
than Syt-1 protein levels (Figure 4.2.5B). All three proteins were highly enriched in APEX2+ 
streptavidin pulldowns relative to bulk striatal tissue, with Z-scores of normalized abundances 






comparable to Syt-7 within dopamine axons, which may mediate asynchronous dopamine release 
in the absence of Syt-1 [116].  
 
4.2.4 Syt17 localization and trafficking in cultured dopamine neurons 
 Unfortunately, there are no commercially available antibodies suitable for 
immunoblotting or immunostaining of Syt-17. In fact, years of efforts to obtain such antibodies 
via custom antibody production services have been unsuccessful (personal communication, 
Edwin Chapman). To study the subcellular localization of Syt-17 in dopamine neurons, we used 
a lentivirus expressing a HaloTag:Syt-17 fusion protein (N-terminal HaloTag) and soluble EGFP 
from an internal ribosome entry site (HaloTag:Syt-17-IRES-EGFP) (Figure 4.2.6A). Cultured 
dopamine neurons expressing HaloTag:Syt-17 (under control of human Synapsin promoter) were 
labeled with JaneliaFluor 646 (JF646) to visualize subcellular localization and trafficking of Syt-
17. We found asymmetric, granular cytoplasmic HaloTag:Syt-17/JF646 staining within 
dopamine neuronal somata, consistent with the appearance of the Golgi apparatus and Syt-17 
localization to this compartment in hippocampal neurons (Figure 4.2.6B, left) [539]. 
 
 
Figure 4.2.5: Axonal enrichment of Syt-17 in DA neuronal APEX2 proteomics 
(A) Log-log abundance plots of APEX2- vs. APEX2+ streptavidin IP samples for the 
indicated regions. Axes represents the average log2(normalized intensity + 1) of n=4 
biological replicates for each sample type. SYT-1 (blue) and SYT-17 (green) are indicated. 
(B) APEX2 proteomics data for SYT-1, -7, and -17. Mean ± SEM of the protein abundances, 
as log2(normalized intensity + 1), are shown for n=4 biological replicates of APEX2+ 
streptavidin IP samples in the indicated regions. 
(C) Heatmap of Z-scores for protein abundances for the indicated proteins. Each column 








HaloTag:Syt-17/JF646 staining was also present as discrete puncta within neurites, which may 
represent endosomes [539]. We conducted time-lapse imaging of live neurons to track the 
motion of HaloTag:Syt-17/JF646 puncta within neurites of dopamine neurons. Many puncta 
within proximal neurites were relatively stable over a 5-minute period, whereas others exhibited 
semi-continuous directed movements (Figure 4.2.6B, right). In distal neurites, mobile puncta 
were more frequent and travelled in both directions (Figure 4.2.6C, right). Occasionally, some 
puncta traversed neurites rapidly, with mean velocities of up to ~1-1.5 µm/sec (Figure 4.2.6C, 
lower left), speeds that are seemingly consistent with fast axonal transport rates (typically ~0.8-5 
µm/sec in vivo) [581]. 
 
 
Figure 4.2.6: Live imaging of HaloTag:Syt-17 in cultured dopamine neurons 
(A) Schematic of the lentiviral FUGW-HaloTag:Syt17-IRES-EGFP construct. mRNA 
expression is driven by a human synapsin (hSyn) promoter and encodes an N-terminal 
HaloTag:Syt17 fusion protein followed by soluble EGFP from an IRES. 
(B) (Left) Cultured dopamine neuron expressing HaloTag:Syt17 labeled with JF646. Scale 
bar, 15 µm. (Right) Kymograph of JF646 fluorescence in the neurite traced in the JF646 inset 
(‘kym.’) in Left. The traced segment is ~16.5 µm in length, over 5 minutes of imaging at 1 Hz 
(301 frames) at room temperature. 
(C) (Upper left) Soluble EGFP and HaloTag:Syt17-JF646 fluorescence image of neurites. The 
neurite shown in the EGFP inset (‘kym.’) was traced to create the kymograph shown on 
Right. Scale bar, 10 µm. The field shown in the JF646 inset corresponds to the panels shown 
in Lower. (Lower left) Panel of JF646 fluorescence for the inset indicated in the Upper left JF646 
image at the indicated times over 5 minutes of imaging at 60 Hz. The particle shown 
corresponds to the track indicated with * in the kymograph shown on Right. Scale bar, 3 µm. 
(Right) Kymograph of JF646 fluorescence in the neurite traced in the EGFP inset (‘kym.’) in 
Upper left. The traced segment is ~16.5 µm in length, over 5 minutes of imaging at 1 Hz (301 
frames). * indicates the particle track shown in the lower left. 
(D) Histogram of mean velocity for all tracked HaloTag:Syt17 particles (4,555 tracks from 8 
fields, derived from 4 separate neuronal cultures). Imaging was conducted over 5 minutes 
at 1 Hz (301 frames). Inset shows box and whisker plots of the mean velocity for particles 
tracked within each replicate imaging trial. 
(E) Histogram of maximum velocity for all tracked HaloTag:Syt17 particles (4,555 tracks, 
grey) and the bottom 25% (1140 tracks, blue) or top 25% (1139 tracks, red) of all tracked 
particles based on total displacement (distance between start and finish of each track). 
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We analyzed the movement of HaloTag:Syt-17/JF646 particles within distal neurites 
using the particle tracking plugin TrackMate [358]. As shown in Figure 4.2.6D, the distribution 
of mean velocities for all tracked Syt-17 particles within distal neurites ranged between 0.01 – 
1.6 µm/sec and was positively skewed (median 0.17 µm/sec). Thus, while some Syt-17 particles 
exhibit rapid velocity in distal neurites, the majority travel at speeds of 0.01 – 0.2 µm/sec that are 
more consistent with slow axonal transport [582] (Figure 4.2.6D). However, many more 
particles exhibited maximal velocities greater than 0.5 µm/sec, and virtually all of the most 
mobile puncta (top 25th percentile for total displacement) exhibited maximal velocities greater 
than 0.8 µm/sec (Figure 4.2.6E). Meanwhile, the most stationary puncta (bottom 25th percentile 
for total displacement) dominated the lowest maximal velocities. Furthermore, the current 
experiments have been conducted at room temperature, which is likely to exponentially decrease 
the rate of microtubule-based axonal transport [583]. One study found a temperature coefficient 
(Q10) of 3.0 for axonal transport of nerve growth factor (NGF) [584], consistent with an 
Arrhenius dependence of transport velocity on temperature [583]. Based on that study, we would 
expect an increase in the rate of our Syt-17 transport velocities of ~4-6-fold (placing the median 
at ~0.68 – 1.0 µm/sec). While further studies are required, it seems likely that a significant 
fraction of Syt-17 particles on present on vesicular cargoes engaged in microtubule-dependent 
transport in the distal neurites of dopamine neurons. 
 
4.2.5 Evoked axonal dopamine release in Syt-17 knockout mice 
 Given the localization and trafficking of Syt-17 in dopamine axons, we sought to test 
whether Syt-17 loss alters axonal dopamine transmission. We conducted fast-scan cyclic 
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voltammetry (FSCV) recordings of electrically evoked dopamine release in striatal slices of WT 
and Syt-17 KO mice. As shown in Figure 4.2.7A, evoked dopamine release in Syt-17 KO mice 
was largely indistinguishable from WT littermates. Indeed, we found no significant differences 
between WT and Syt-17 KO mice in peak dopamine amplitude evoked by a single pulse (100 μs 
× 200 μA), train stimulation (100 Hz x 5 pulses; 5p/1p ratio), or paired-pulse ratio (interstimulus 
interval of 3 sec) (Figure E.5). There was a modest, but significant, increase in the half-life of 
dopamine released by a single pulse in Syt-17 KO mice (Figure 4.2.7B). We found no 





maximum and time decay constant (tau) were both modestly increased in Syt-17 KO mice 
(Figure 4.2.7D-E), both of which were near statistical significance. These data suggest that 
axonal dopamine release is largely intact in the absence of Syt-17, consistent with a lack of 
calcium binding activity or clear role in synaptic vesicle fusion [539]. Although preliminary, the  
modest effects on half-life, tau, and fall time suggest a possible deficit in extracellular dopamine 
uptake. The most straightforward explanation would be a decrease in axonal abundance of DAT, 
which would be consistent with the defects in ER to Golgi trafficking reported in hippocampal 
neurons [539]. We are currently analyzing striatal DAT levels as well as the morphology and 
density of striatal dopamine axons. 
 
4.2.6 Future directions 
As mentioned above, the HaloTag studies of Syt-17 trafficking need to be repeated at 
37°C. Furthermore, although we focused on distal neurites of small caliber, we could not 
definitively establish whether the neurites studied were axons or distal dendrites. Fixation and 
immunostaining with dendritic and axonal markers after imaging should enable a more detailed 
analysis. Furthermore, it would be of interest to compare the Syt-17 distribution with that of 
Figure 4.2.7: Electrically evoked striatal dopamine release in Syt-17 KO mice 
Data are derived from 16 slices from n = 3 mice of each genotype (5-6 slices per mouse). 
(A) Representative traces of FSCV recordings of dopamine release evoked by a single pulse 
in the dorsal striatum of Syt-17 WT and KO mice. 
(B) Half-life of dopamine release evoked by single pulses. ** indicates p < 0.01, unpaired t-
test. (t = 3.22, df = 32, p = 0.0029) 
(C-E) Dopamine rise slope (pA/ms) (panel C, p = 0.74); fall time from 75% maximum to 25% 
maximum (ms) (panel D, t = 1.90, df = 32, p = 0.066), or decay time constant (tau, ms) (panel 
E, t = 1.61, df = 32, p = 0.12). All measurements pertain to dopamine release evoked by single 
pulses. All comparisons made with an unpaired t-test; ns indicates p > 0.05. 
286 
 
active zone proteins such as RIM1 and bassoon. Given the deficits in endosomal recycling 
observed in hippocampal dendrites [539] and presence of Syt-17 in dopaminergic synaptosomes 
(Figure 4.2.5), it is possible that Syt-17 could be involved in sorting of vesicular cargoes at 
dopamine release sites. However, a direct role in synaptic vesicle recycling seems unlikely given 
the FSCV data. 
We have yet to conduct electrophysiological recordings in Syt-17 KO mice. At a 
minimum, we plan to assess tonic firing and other basic physiological properties of dopamine 
neurons (e.g., rheobase, input resistance, action potential threshold). We are also currently 
performing high performance liquid chromatography (HPLC) studies on midbrain and striatal 
tissue from WT and Syt-17 KO mice to assess whether Syt-17 loss affects steady-state levels of 
dopamine and its metabolites. In the absence of further physiological or biochemical data, it may 
be difficult to pinpoint functional deficits resulting from Syt-17 loss, especially in vivo where 
developmental compensation can mask phenotypes. Since Syt-17 is localized within the Golgi 
apparatus (Figure 4.2.6B and [539]) and may be involved in the axonal transport of vesicular 
cargoes, we plan to conduct somatodendritic and axonal APEX2 proteomics on dopamine 
neurons in Syt-17 KO mice. If a specific set of proteins require Syt-17 for proper trafficking into 
dopamine axons, we should be able to identify them using this approach. 
Finally, Syt-17 KO mice showed deficits in a hippocampal-dependent learning task, but 
not amygdala-dependent fear conditioning [539]. Although the functions of Syt-17 in dopamine 
axons remain unclear, we plan to conduct behavioral testing relevant to the dopaminergic system 
(e.g., open-field, psychostimulant sensitization, motor learning). It will also be of great interest to 
test whether dopamine neurons in Syt-17 KO mice are more susceptible to (or protected from) 
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degeneration in mouse models of PD. Thus, our investigations of Syt-17 in dopamine neurons 





Young adult male and female mice (2-4 months old) were used in all experiments. Syt-17 
KO mice (Syt17-tm1a-(KOMP)-Wtsi) crossed into a C57BL/6J (B6J) background were a 
generous gift from Edwin Chapman at the University of Wisconsin. The original Syt-17 KO 
mice described in Ruhl et al. [539] were generated in a C57BL/6NJ (B6N) background from ES 
cell clone EPD0659_3_A09, acquired from the KOMP repository (www.komp.org) by the 
Wellcome Trust Sanger Institute (WTSI). The B6N Syt-17 KO mice were backcrossed 5 times 
with B6J mice at Wisconsin Institute for Medical Research vivarium at UW-Madison. The 
resulting Syt-17 KO and WT B6J littermates were transferred to the New York State Psychiatric 
Institute and maintained there for these studies. Mice were housed on a 12-hour light/dark cycle 
with food and water available ad libitum. All experiments were conducted according to NIH 
guidelines and approved by the Institutional Animal Care and Use Committees of Columbia 
University and the New York State Psychiatric Institute.  
 
Neuronal cultures 
Ventral mesencephalic cultures containing dopaminergic neurons were prepared 
according to established procedures [79]. The ventral midbrain (SN and VTA) from postnatal 
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day 0–2 mice of either sex was dissected, dissociated, and plated on a monolayer of rat cortical 
astrocytes at the plating density of ∼100,000 cells/cm2. For Syt-17:HaloTag experiments, 
neurons were infected at 7 d after plating by removing 1.9 out of 2 mL media and adding 0.5 -1.0 
µL of Syt17-HaloTag lentivirus (titer > 4x108 TU/mL, VectorBuilder) to the remaining 100 µL 
of media overnight. The following morning, the reserved media was sterile filtered added back to 
the cultures. Imaging experiments were conducted 14–21 d after plating. 
 
HaloTag:Syt17 imaging 
 To label HaloTag:Syt17, neurons were incubated with 100-150 nM JaneliaFluor 646 
(JF646, added directly to the conditioned media) for 30 minutes at 37°C. The media was 
removed and cells were incubated in 3-4 mL of Tyrode’s solution (119 mM NaCl, 3 mM KCl, 10 
mM glucose, 2 mM CaCl2, 1.2 mM MgCl2-6 mM H2O, 3.3 mM HEPES, and 2.7 mM HEPES-
Na+ salt; pH 7.2–7.4, 270 mOsm) for 15-20 minutes at 37°C. After exchange for another 3-4 mL 
of fresh Tyrode’s solution, neurons were maintained at room temperature for live cell imaging on 
an epifluorescence microscope. Cultures were imaged with an Olympus IX81 inverted 
fluorescence microscope equipped with a digitized stage (ProScan; Prior Scientific), a 63×/1.3 
NA oil-immersion objective (Olympus), fluorescence filter sets for green (EGFP) and far-red 
(JF646) emission and a 2.0 neutral density filter using a CoolSNAP HQ camera (Roper 
Scientific/Photometrics) and MetaMorph software (Molecular Devices). Two to four fields were 






HaloTag:Syt17 Particle Tracking Analysis 
 Time lapse image stacks of EGFP+ neurites were quantified for the presence of 
HaloTag:Syt17-JF646 puncta using the freely available ImageJ plugin TrackMate v4.0.1 [358]. 
We used the Laplacian of Gaussian spot detector with estimated blob diameter of 0.4 µm and 
initial quality threshold of 50. We used the Simple LAP tracker to identify particle tracks 
(Linking max distance: 1.6 µm, Gap-closing max distance: 1.6 µm, and Gap-closing max frame 
gap: 2). Track statistics were exported for downstream statistical analysis. 
 
Antibodies and Reagents 
Name Manufacturer Catalog RRID Usage 














IgY (H+L), Alexa 
Fluor Plus 488 




Goat anti-Rat IgG 






Mm-Syt17-C3 ACD Biotechne 495741-C3 NA FISH (NA) 
TSA Cy3 Perkin Elmer NEL744001KT NA FISH, 1:1500 
TSA Cy5 Perkin Elmer NEL745001KT NA FISH, 1:1500 
 
Immunohistochemistry (IHC) 
Mice were anesthetized with euthasol and transcardially perfused with ~15 mL of 0.9% 
saline followed by 40-50 mL of ice-cold 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer 
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(PB), pH 7.4. Brains were post-fixed in 4% PFA in 0.1M PB for 6-12 hours at 4°C, washed three 
times in phosphate buffered saline (PBS), and sectioned at 50 µm on a Leica VT1000S 
vibratome. Sections were placed in cryoprotectant solution (30% ethylene glycol, 30% glycerol, 
0.1M PB, pH 7.4) and stored at −20°C until further use. 
Sections were removed from cryoprotectant solution and washed three times in tris-
buffered saline (TBS) at room temperature. Sections were then permeabilized in TBS + 0.2% 
Triton-X 100 for one hour at room temperature, followed by blocking in TBS + 10% normal goat 
serum (NGS) and 0.3% Triton-X 100 for 1.5 hours at room temperature. Sections were then 
directly transferred to a pre-chilled solution containing primary antibodies in TBS + 2% NGS + 
0.1% Triton-X 100 and incubated overnight at 4°C. Sections were washed in TBS + 0.05% 
Tween 20 (TBS+T) five times over an hour at room temperature. Sections were incubated with 
secondary antibodies in TBS + 2% NGS + 0.1% Triton-X 100 at room temperature for 1.5 hours, 
followed by four washes in TBS+T over 45 minutes at room temperature. Sections were slide 
mounted and coverslipped with Fluoromount G (Southern Biotech). 
 
Fluorescence in situ hybridization (FISH) 
For mouse brain tissue, FISH was performed using the highly sensitive RNAScope® 
Multiplex Fluorescent v2 assay (ACD Bio). Synaptotagmin-17 staining was conducted with 
ACD catalog no. 495741-C3 (see Antibodies and Reagents table). Mouse brain sections were 
prepared as above, removed from cryoprotectant solution, and washed three times in tris-
buffered saline (TBS) at room temperature. Sections were incubated with hydrogen peroxide 
(ACD) for 15 minutes at room temperature, washed several times in TBS, and then mounted to 
Superfrost slides (Fisher). Sections were allowed to dry for 10 minutes and a hydrophobic barrier 
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(PAP pen, Vector Labs) was created around the tissue. Tissue was incubated in 50% EtOH, then 
70% EtOH, then 100% EtOH for 5 minutes each. Sections were rehydrated in TBS for several 
minutes, digested with Protease IV (ACD) for 25 minutes at room temperature, and rinsed twice 
with TBS before proceeding to the RNA Scope Multiplex Fluorescent v2 assay (ACD). 
The RNA Scope Multiplex Fluorescent v2 assay was conducted according to the 
manufacturer’s instructions, with all incubations taking place in a humidified chamber at 40°C. 
Two 5-minute washes in excess RNA Scope Wash Buffer (ACD) took place between each 
incubation in sequential order: probes (2-hours), AMP1 (30 minutes), AMP2 (30 minutes), 
AMP3 (15 minutes), HRP-C1/2/3 (15 minutes), TSA Cy3 (30 minutes), HRP blocker (30 
minutes), HRP-C1/2/3 (15 minutes), and TSA Cy5 (30 minutes). Samples were washed twice 
more in RNA Scope Wash Buffer, then twice more in TBS. Samples were then blocked and 
immunostained for Tyrosine Hydroxylase as described above. After immunostaining, samples 
were mounted in Fluoromount G and stored at 4°C for up to 1 week before imaging. 
 
Single nucleus RNA-sequencing 
Mice were sacrificed by cervical dislocation and brains were rapidly extracted and 
submerged in ice-cold phosphate-buffered saline (PBS). Brains were placed on an ice-cold brain 
matrix (Zivic Instruments) and separated into 0.5-1.0 mm sections using ice cold razor blades. 
Ventral midbrain tissue was dissected from slices between approximately -2.5 mm to -3.75 mm 
AP to Bregma. First, the cortex, hippocampi, and any hypothalamus or white matter ventral to 
the midbrain were removed. A single horizontal cut was made just dorsal to the rostral linear 
nucleus and all dorsal tissue was discarded. The remaining tissue containing the SN/VTA was 
flash frozen on liquid nitrogen and stored at -80°C. 
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 Nuclei preparation and sorting were conducted as described by [405] with minor 
modifications. Frozen tissue was thawed in nuclear isolation medium 1 (NIM1: 250 mM sucrose, 
25 mM KCl, 5 mM MgCl2, 10 mM Tris, pH 8.0) supplemented with 1 mM DTT, 0.2 U/µL 
SUPERaseIN, 1x EDTA-free Protease Inhibitor Cocktail (Roche), and 0.1% Triton X-100. 
Tissue was homogenized on ice in a glass-glass dounce homogenizer with 30 gentle strokes of 
loose and tight clearance pestles. All subsequent purification steps were performed on ice or at 
4oC unless otherwise specified. Lysates were spun at 500xg for 5 minutes, resuspended in NIM1 
supplemented as above and also with 1% BSA, and passed through a 40µm cell strainer cap. 
Nuclei were centrifuged again at 500xg for 5 minutes and resuspended in staining buffer (PBS 
supplemented with 1% BSA, 5 mM MgCl2, 0.2 U/µL SUPERaseIN, 1 µg/mL propidium iodide, 
and 2 µg/mL mouse anti-NeuN AlexaFluor488). After 30 minutes incubation on ice, nuclei were 
centrifuged at 500xg for 5 minutes and resuspended in 0.5 mL of FACS buffer (PBS + 0.04% 
BSA, 0.2 U/µL SUPERaseIN, and 1 µg/mL propidium iodide) for sorting.  
Nuclei sorting was conducted on a BD Influx (BD Biosciences) using a 100 μm nozzle at 
11.1 psi. Single nuclei were gated first using FSC-H vs. FSC-A and then on propidium iodide 
fluorescence. NeuN/AlexaFluor488 fluorescence was used to establish NeuN- and NeuN+ gates 
on the single nuclei population. Approximately 70% NeuN+ and 30% NeuN- single nuclei were 
sorted per sample. Nuclei were sorted into 1.5 mL Eppendorf tubes that had been previously 
coated with 0.1% BSA in PBS overnight at 37oC. Sorted nuclei were placed on ice and 
immediately submitted to the Single Cell Analysis Core (Columbia Genome Center) for 10X 
Genomics Chromium Single Cell 3' v3 library preparation. The resulting libraries were 
sequenced on an Illumina NovaSeq 6000 with a targeted depth of >100,000 2x100 bp paired-end 





snRNA-seq data were processed as described previously [585] (code available at: 
https://github.com/simslab/DropSeqPipeline8). Reads were aligned to the mouse reference 
genome GRCm38 and transcriptome annotation (Gencode vM10) using the STAR aligner with 
parameters –sjdbOverhang 65 –twopassMode Basic after trimming poly(A)-tails from the 3’-
ends. All reads that uniquely aligned to a given gene body (including introns) were kept for 
downstream filtering analysis, because a large fraction of nuclear transcripts are unspliced. The 
aligned reads were demultiplexed using the well-identifying barcodes, correcting all single-
nucleotide errors. All reads with the same well-identifying barcode, UMI, and gene mapping 
were collapsed to represent an individual transcript. To correct for sequencing errors in UMIs, 
we further collapsed UMIs that were within Hamming distance one of another UMI with the 
same well-identifying barcode and gene. For each sample, after generating a final list of 
individual transcripts with unique combinations of well-identifying barcodes, UMIs, and gene 
mapping, we produced a molecular count matrix for downstream analysis. 
We first performed unsupervised clustering on the count matrices using the PhenoGraph 
[559] implementation of Louvain community detection after selection of highly variable genes 
and construction of a k-nearest neighbors graph as described previously [560]. We identified 
thirty-eight clusters (Figure E.1), two of which showed statistically significant co-enrichment of 
dopamine neuron markers such as Th and Slc6a3 based on the binomial test for expression 
specificity [561]. We identified six major cell types with sufficient coverage for downstream 
analysis as shown in the UMAP [562] embedding in Figure 4.2.4A. The assignment of 
PhenoGraph clusters into major cell type groupings was based on key marker genes significantly 
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enriched in each cluster, as shown in Figure E.2: Oligodendrocytes (Mal, Mag, Mog), 
Astrocytes (Gja1, Fgfr3, Atp1a2), Microglia (C1qb, Siglech, Csf1r), VGLUT2 neurons (Slc17a6, 
Cacna2d1, Ntng1), GABA neurons (Slc32a1, Gad1, Gad2), and DA neurons (Th, Slc6a3, En1, 
Slc10a4). Rare populations with insufficient cell numbers (e.g., mural cells, T cells) or 
ambiguous neuronal clusters possibly containing multiplets (e.g., Gad1+/Gad2+/Slc17a7+/Th+) 
were excluded from downstream analysis. 
While examining the neuronal profiles, we identified small subpopulations of nuclei with 
co-enrichment of neuronal and oligodendrocyte markers such as Mbp, Plp1, Mog, and Mag. To 
filter out oligodendrocyte doublets, we fit Gaussian mixture models to the sum of expression for 
oligodendrocyte marker genes within each major neuronal class (see Figure E.3A). The top 99 
oligodendrocyte marker genes were used, as determined by the binomial test (log2 specificity > 
3, FDR < 10e-50). For all non-oligodendrocyte clusters, we then removed nuclei with expression 
>8 standard deviations above the mean of the first gaussian component corresponding to single 
neurons (Figure E.3B). 
 
Slice preparation and cyclic voltammetry 
 Acute brain slices were generated as described previously [427]. Mice underwent rapid 
cervical dislocation. The brain was placed in ice-cold cutting buffer (in mM): 10 NaCl, 2.5 
KCl,25 NaHCO3, 0.5 CaCl2, 7 MgCl2, 1.25 NaH2PO4, 180 sucrose, 10 glucose bubbled with 
95% O2/5% CO2 to pH 7.4. Coronal slices (250 μm) were generated using a Leica vibratome 
and placed in artificial cerebrospinal fluid (ACSF) and allowed to rest at 34°C for 30 minutes. 
The recipe for ACSF was (in mM): 125 NaCl, 2.5 KCl, 25 NaHCO3, 2 CaCl2, 1 MgCl2, 1.25 
NaH2PO4 and 10 glucose bubbled with 95% O2/5% CO2 to pH 7.4. Slices were then maintained 
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at room temperature for a maximum of 5 hours for recordings. At the time of recording, slices 
were transferred to the recording chamber and superfused with ACSF maintained at 34°C. 
Electrochemical recordings of evoked DA release by fast-scan cyclic voltammetry 
(FSCV) were collected as detailed previously [427]. Carbon fiber working electrodes were made 
by aspirating a single carbon fiber (5 μm diameter) into a glass capillary (1.2mm borosilicate, A-
M Systems), and pulling to a long taper with a micropipette puller (Sutter; P-97). Fibers were cut 
to an exposed length of ~100 μm, and silver leads (0.015”; A-M Systems) were permanently 
affixed inside the pipette by coating with colloidal silver paint before insertion. Striatal slices 
were prepared as for electrophysiology experiments (see above). 
During recordings, slices were kept under constant superfusion of oxygenated ACSF (2 
mL/min, 34°C). A carbon fiber working electrode was placed in the dorsolateral striatum 
approximately 50 μm into the slice. A triangular voltage wave (−450 to+800 mV at 294 mV/ms 
versus Ag/AgCl) was applied across the working electrode every 100 ms and current was 
monitored with an Axopatch 200B amplifier (Axon Instruments) using a 5 kHz low-pass Bessel 
Filter setting and 25 kHz sampling rate. Signals were digitized using an ITC-18 board 
(Instrutech) and recorded with IGOR Pro 6.37 software (WaveMetrics), using in-house 
acquisition procedures. Slices were stimulated with a sharpened bipolar concentric electrode 
(400μm max outer diameter; Pt/Ir; WPI), placed ~150 μm from the recording electrode, using an 
Iso-Flex stimulus isolator (AMPI) triggered by a Master-9 pulse generator (AMPI). A single 
stimulus pulse (100 μs × 200 μA) was applied every 2 min until stable release was achieved, 
after which three consecutive peaks were averaged to define single pulse release magnitude. A 
train stimulus was then applied (100 Hz x 5 pulses). Slices were again stimulated with single 
pulses every two minutes until stable release (generally 10-15 minutes) was achieved. Finally, 
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slices were again stimulated with the 100 Hz train. Electrodes were calibrated by quantifying 
background-subtracted voltammograms in standard solutions of DA in ACSF, made fresh each 
recording day. Data were processed and peaks quantified using an in-house procedure in IGOR 




Conclusion and Future Directions 
 
This thesis describes both successes and failures in developing molecular profiling 
techniques to study dopamine neurons in the mouse brain. It is worth noting that most profiling 
studies, including those in Chapters 3-4, are limited to a static ‘snapshot’ of expression levels 
under physiological conditions. However, key differences underlying the selective vulnerability 
of dopamine neurons may only arise during dynamic responses to stressful stimuli. In another 
series of studies (omitted from this thesis for the sake of brevity), I am investigating dopamine 
neuronal responses to interferon gamma, a pro-inflammatory cytokine that induces anti-viral 
immune responses. Using RiboTag RNA-seq, FISH, and dopamine neuron-specific knockout of 
the interferon gamma receptor, I have shown that dopamine neurons directly respond to 
interferon gamma signaling. Interferon gamma induces expression of the core antigen 
presentation machinery within all midbrain cells, but snRNA-seq studies revealed substantial 
differences in the magnitude and scope of responses among neurons and glia. These data define 
conserved and cell type-specific interferon response programs in the ventral midbrain, with 
implications for immune involvement in Parkinson’s disease pathogenesis. I am currently 
conducting APEX2 experiments to map the subcellular proteome of dopamine neurons after 
interferon gamma signaling, and will shortly be preparing a manuscript describing these findings. 
Thus, the technologies developed in this thesis can also provide insight into dopamine neuronal 
responses to cellular perturbations. 
 Perhaps the most unexpected finding from our studies of local translation was the 
dendritic, but not axonal, localization of mRNAs encoding dopamine transmission machinery. 
Although the functional significance of these observations remains to be determined, translation 
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of VMAT2 on a local form of ER presents a unique opportunity to interrogate the nature of these 
organelles. Fusion of APEX2 to the N- or C-terminus of VMAT2, both of which face the 
cytoplasm, would facilitate proximity labeling proteomics of VMAT2 vesicular sites within the 
somatodendritic compartment of dopamine neurons. Furthermore, VMAT2:APEX2 proteomics 
could be combined with SNr dissection to elucidate the local proteome at dendritic release sites. 
Similar approaches could be modified to map the extracellular local proteome of axonal 
dopamine release sites. For example, fusion of horseradish peroxidase (HRP) to the luminal 
domain of synaptophysin [494] would facilitate proximity biotinylation at the external face of the 
axonal plasma membrane upon SV fusion. The slice labeling procedure could be modified to 
incorporate axonal depolarization (e.g., potassium chloride or optogenetic stimulation) and 
membrane-impermeable biotin-phenol to enhance the specificity of extracellular labeling. 
Proximity labeling in mammalian brain tissue is still in its infancy, and we can expect many 
exciting developments in the years to come. 
A clear takeaway from the translatome and proteome studies in Chapters 3-4 is that 
dopamine neurons critically rely on axonal transport of somatically synthesized proteins. Based 
on their axonal volume and protein mass, trafficking the majority of newly synthesized proteins 
into striatal axons appears to be a fundamental property of dopamine neurons. Disruption of this 
supply chain may occur due to aging, genetic risk factors, or environmental insults [17,162,586] 
and could lead to axonal dysfunction early in PD [199]. However, there are several outstanding 
questions regarding axonal proteostasis in dopamine neurons. For example, there are several 
distinct rate classes for slow axonal transport and the complete set of proteins transported in each 
class remain unknown [243]. What are the mechanisms underlying these distinct forms of axonal 
transport and what are the exact protein cargoes? Metabolic labeling combined with axonal 
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proteomics should enable a thorough characterization of transport rates for a wide variety of 
axonal proteins. In addition to synthesis and anterograde transport, the other key determinants of 
axonal protein abundance are degradation and retrograde transport. What is the role of local 
protein degradation in dopamine axons? Previous data suggest that both autophagy [496] and the 
ubiquitin proteasome system [501] regulate the axonal proteome. Future studies combining 
axonal proteomics with genetic or pharmacological inhibition of these systems will help to 
define the protein substrates targeted by these degradation systems. 
 Finally, how does the axonal proteome change over the course of a lifetime? In addition 
to measuring protein abundance, quantifying post-translational modifications of axonal proteins 
will be paramount. For example, post-translational modifications of tubulin critically regulate 
axonal transport and are linked to human disease [587,588]. Subcellular proteomic studies of 
human tissue have been limited to methods such as laser capture microdissection or multiplex 
ion beam imaging, techniques which lack the spatial resolution required to isolate dopamine 
axons. However, a recent study demonstrated proximity labeling proteomics in fixed samples 
without genetically encoded enzymes [589]. In this method, HRP-conjugated antibodies facilitate 
biotinylation of proximal proteins in lightly fixed and permeabilized tissue [589]. Proximity 
labeling of striatal tissue using anti-TH antibodies may provide a robust platform for dopamine 
axonal proteomics in human post-mortem tissues. The framework of dopamine neuronal cell 
biology established in this thesis will serve as a guide for future molecular profiling studies of 
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Appendix A: Supplement for “Elongation Inhibitors do not Prevent 





Figure A.1: U87 glioma cells do not express eL22-HA, and eL22-HA/Puro PLA does not 
distinguish between emetine-treated and untreated cells at high resolution 
(A) Representative images (20x) of eL22-HA and RiboP immunofluorescence in RiboTag and 
U87 glioma cells. Scale bar, 50 µm. (B) Quantification of eL22-HA/Puro PLA puncta per cell. 
Each dot represents a cell; n=20-24 cells per condition from 2-4 separate coverslips. Blue bars 
represent mean and standard deviation, with mean ± SEM indicated above. (C) Representative 
confocal images (60x) of eL22-HA/Puro PLA and RiboP immunofluorescence. DAPI in blue, 







Figure A.2: eL22-HA/Puro PLA signal does not report on proximity of ribosomes and 
puromycylated nascent chains 
(A) Schematic depicting state of cells after puromycin washout. Cells are briefly treated with 
puromycin, washed, and allowed to continue in fresh media for 15-45 minutes. The vast 
majority of puromycylated peptides should be released from ribosomes under these conditions. 
(B) Schematic depicting state of cells after harringtonine run-off. Harringtonine stalls newly 
initiating ribosomes without nascent chains, while elongating ribosomes complete. The vast 
majority of puromycylated nascent chains should be released, and no nascent chains should be 
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present under these conditions. (C) Violin plots of normalized fluorescence intensity for 
puromycin IF or eL22-HA/Puro PLA signal RiboTag glioma cells treated as indicated. Data are 
derived from 3 experiments and 96 cells per condition, and statistical comparisons indicated 
were conducted using Mann-Whitney U test. See Table A.1 for details. ** indicates p < 0.01, *** 
indicates p < 0.001. Representative images (10x) are shown below; DAPI in blue, puromycin IF 





Table A.1: Statistical information pertaining to Figure 2.2.1C and Figure A.2C 
Treatment Replicates Cells Median Mean StDev 
  
mRG.NoPuro_IF 4 288 0.068 0.074 0.062 
  
mRG.NoPuro_PLA 4 144 0.068 0.060 0.076 
  
mRG.Puro_IF 4 288 0.930 0.972 0.433 
  
mRG.Puro_PLA 4 144 0.886 0.924 0.441 
  
mRG.EmtPuro_IF 4 288 0.942 0.969 0.383 
  
mRG.EmtPuro_PLA 4 144 0.780 0.821 0.408 
  
mRG.EmtPuroNoHA_IF 3 144 0.862 0.883 0.357 
  
mRG.EmtPuroNoHA_PLA 3 112 0.052 0.055 0.048 
  
mRG.EmtPuroNoPuro_IF 3 144 0.073 0.074 0.024 
  
mRG.EmtPuroNoPuro_PLA 3 112 0.099 0.097 0.084 
  
mRG.AnisoPuro_IF 4 288 0.122 0.136 0.107 
  
mRG.AnisoPuro_PLA 3 112 0.057 0.055 0.059 
  
U87.EmtPuro_IF 3 264 0.844 0.875 0.388 
  
U87.EmtPuro_PLA 3 112 0.150 0.162 0.138 
  
mRG.PuroWash15_IF 3 128 0.906 0.970 0.510 
  
mRG.PuroWash15_PLA 3 128 0.942 0.980 0.460 
  
mRG.PuroWash45_IF 3 96 1.081 1.105 0.436 
  
mRG.PuroWash45_PLA 3 96 0.910 0.970 0.569 
  
mRG.HarrPuro_IF 3 96 0.095 0.096 0.035 
  
mRG.HarrPuro_PLA 3 96 0.114 0.118 0.052 
  
mRG.PuroWashHarr_IF 3 96 0.746 0.795 0.333 
  
mRG.PuroWashHarr_PLA 3 96 0.619 0.640 0.342 
  
        




U p n1 n2 
mRG.Puro_IF mRG.EmtPuro_IF 0.930 0.942 41096 0.4254 288 288 
mRG.Puro_PLA mRG.EmtPuro_PLA 0.886 0.780 8739 0.0106 144 144 
mRG.Puro_IF mRG.Puro_PLA 0.930 0.886 18997 0.0776 288 144 
mRG.EmtPuro_IF mRG.EmtPuro_PLA 0.942 0.780 15544 1.10E-05 288 144 
mRG.EmtPuroNoHA_IF mRG.EmtPuroNoHA_PLA 0.862 0.052 15 5.47E-43 144 112 
U87.EmtPuro_IF U87.EmtPuro_PLA 0.844 0.150 454 2.67E-50 264 112 
mRG.PuroWash15_IF mRG.PuroWash15_PLA 0.906 0.942 7736 0.220959 128 128 
mRG.PuroWash45_IF mRG.PuroWash45_PLA 1.081 0.910 3442 0.001233 96 96 




Figure A.3: Emetine increases yield of intact ribosomes in eL22-HA IP, but does not enable 
capture of ribosomal RNA in puromycin IP. 
(A) Regardless of puromycin treatment condition, emetine increases intact ribosome capture as 
shown by lower 28s/18s rRNA ratio (left; IP is against eL22-HA and therefore captures more free 
large subunits in the absence of emetine) and higher total RNA yield (right). * indicates p < 0.05, 
** indicates p < 0.01 for paired t-test. Left: t(2) = 8.000, p = 0.0153. Right: t(2) = 10.580, p = 0.0088. 
(B) RNA Pico Bioanalyzer of total RNA eluted from immunoprecipitation of eL22-HA or 




Figure A.4: SunTag puncta detection, minimal photobleaching, and consistency of replicate 
imaging trials 
(A) Representative images of SunTag puncta quantification using TrackMate spot detection; 
registered spots are circled in purple. Scale bars: 10 µm for large field, 5 µm for inset. (B) Live 
imaging time course of background cytoplasmic GFP intensity from cells treated as indicated. 
Cytoplasmic ROIs for each cell were normalized to the average GFP intensity in that cell during 
the initial 10 frames. Data correspond to the exact cells presented in Figure 2.2.3C. Puromycin 
was added at 60 seconds into the 8-minute imaging trial (dashed red line). Plotted are the mean 
± standard deviation of all cells, computed in five second time intervals. (C) Live imaging time 
course of normalized SunTag puncta for the exact cells presented in Figure 2.2.3C. Plotted is the 
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mean of all cells (n=7-12) in each replicate imaging trial for each treatment condition as 




Figure A.5: Representative images and traces of single cell SunTag imaging 
(A-D) Representative single cell raw puncta counts from each frame are plotted during live 
imaging with treatments as indicated. Puromycin was added at 60 seconds into the 8-minute 
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imaging trial (dashed red line). Images of cells are marked with labels 1-4, corresponding to the 
same labels on the time course of raw puncta counts plotted below. Scale bars: 10 µm. 
 
 





Structures of Comparable Resolution 
With Worse MolProbity Clashscores 
(%)b 
1 246.30 0 
2 196.19 0 
3 183.82 0 
4 177.55 0 
5 155.58 0 
6 143.09 0 
7 134.19 0 
8 126.94 0 
9 107.07 0 
10 105.83 0 
11 91.18 0 
12 85.79 0 
Best Fit in 
A Site 
22.89 25 
Structure PDB ID 
MolProbity 
Clashscorea 
Structures of Comparable Resolution 
With Worse MolProbity Clashscores 
(%) 
Ms IgG2a 1IGT 20.63 87c 
Rb 80S 6SGC 7 87b 
 
a The number of serious steric overlaps (> 0.4 Å) per 1000 atoms 
b Out of 1,784 structures solved using cryo-EM at any resolution 
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Figure B.1: Comparison of FSC from nuclei and PS beads 
We note that in these experiments, the FSC detector voltage had to be lowered in order to allow 
the 2.0 µm PS to fall within the detectable range; the FSC axis is therefore substantially different 
from all other plots in this study. (A) Mixture of fluorescent PS beads (Bangs Labs; B, or 
Spherotech; S) detected in FSC-trigger mode on the Influx (left) and SSC-trigger mode on the 
Fortessa (right). We note that the lowered FSC voltage on the Fortessa resulted in a significant 
amount of FSC noise (B) Crude nuclei detected in FSC-trigger mode on the Influx. Left: 
Hoechst33342 fluorescent staining of DNA identifies nuclei apart from all other particles. Right: 
Gated nuclei are then assessed for immunofluorescence of NeuN to identify neuronal nuclei. 




Table B.1: FSC and SSC measurements of PS and silica beads 
Median FSC and SSC measurements with coefficient of variation (CV) for gated bead 
populations in Figure 2.3.1. Data are listed in order of ascending median FSC, which does not 
correspond to true size due to the refractive index mismatch between silica and PS beads. 
Influx 
Gate FSC Median (CV) SSC Median (CV) FITC Median 
585nm Si (A) 38.3 (21.6) 21.0 (91.8) 1.0 
500 nm PS singlet (A) 77.0 (9.0) 53.2 (18.7) 2745.0 
500 nm PS (B) 104.4 (7.1) 84.3 (12.3) 266.6 
500 nm PS doublet (A) 175.4 (6.3) 124.7 (28.0) 4924.7 
880 nm Si (A) 254.6 (15.6) 37.9 (75.9) 1.0 
800 nm PS (B) 653.6 (8.7) 214.1 (12.5) 632.8 
1300 nm Si (A) 1286.8 (5.4) 112.9 (46.6) 1.0 
Fortessa 
Gate FSC Median (CV) SSC Median (CV) FITC Median 
500 nm PS doublet (A) 765.1 (53.3) 4803.3 (14.6) 86606.96 
880 nm Si (A) 943.8 (49.7) 1077.3 (13.6) -71.76 
500 nm PS singlet (A) 1022.5 (25.0) 2356.1 (24.9) 46027.60 





Figure B.2: Dilution series define a range of linear particle detection 
(A) Representative density plots of a P2 dilution series detected on the Fortessa in FSC-trigger 
mode. FM4-64 Low gate was set arbitrarily to quantify disappearance of events in this region 
with dilution. Although FSC-trigger threshold was set to reduce noise to below 10 
events/second, at the low end of the dilution curve these events begin to comprise a significant 
fraction of collected data. (B) Representative density plots of same P2 dilution series as in A, but 
detected on the Fortessa in FM-trigger mode. (C) Typical dilution series with FM4-64-triggering 
on the Influx, conducted with absolute counting beads. FM4-64 triggered event counts 
(excluding absolute counting beads) were used to determine particle concentration of each 











Figure B.3: Lack of Spectral Overlap Between Dyes and Lack of Calcein Dye Transfer to 
Unstained Samples 
(A) Matrix of representative density plots demonstrating lack of spectral overlap between any 
of the four dyes used in multicolor aggregation assays. Columns represent P2 samples single-
labeled with the indicated dye, while rows indicate the measured fluorescence in the detector 
for the indicated dye. All samples were detected by FM-triggering on the Influx. (B) A single P2 
sample was split into equal aliquots, one of which was left unstained, while the other was truly 
doubled-labeled with calcein-AM and calcein red. The double-labeled sample was then sonicated 
in the equivalent volume and concentration of PBS and subsequently mixed with the unstained 
sample as in the standard multicolor aggregation assay. A small aliquot of the double-labeled 
sample (right) and the sonicated double-labeled/unstained mixture (left) were detected using 
FM-triggering on the Influx. As shown, sonication fully disrupted all double-labeled particles, 









Figure B.4: Dilution Series Reduces False Double-Positive Bead Events but Not Double-
Calcein Positive P2 Events (Fortessa) 
(A) Representative density plots of a dilution series for a mixture of fluorescent 0.5 µm PS beads 
detected using FSC-triggering on the Fortessa. PS beads and double-positive events are 
distinguished by their green (FITC detector) or red (PE detector) fluorescence. In addition to 
clear overlaps between green and red fluorescent beads, we also observed what appeared to be 
doublet, triplet, and higher order multiplets of the Nile Red 0.5 µm PS beads. We confirmed this 
based on the doubling and tripling of the red fluorescence intensity of the ‘Double’ and ‘Triple’ 
gated populations relative to the ‘Single’ gate. At high concentrations (left), these multiplets 
could also be detected together with the green fluorescent beads. (B) Representative density 
plots of a dilution series for a mixture of single calcein-labeled P2 samples detected using FM-








Figure B.5: Scatter-based Singlet Gating Strategies Employed in Conventional Flow 
Cytometry are Not Effective for P2 Samples 
A mixture of single calcein-labeled P2 samples was analyzed by FM-triggering on the Influx or 
the Fortessa. Only events gated for either single calcein-positive events (top) or double calcein-
positive events (bottom) are displayed. Left: The Influx is an analog cytometer and does not 
measure Height and Width of pulses for the FSC detector; we instead compared the width of 
the trigger pulse (FM4-64) to the FSC intensity (equivalent to ‘Area’ on digital cytometers such 
as the Fortessa). Right: Comparison of Area and Height of FSC pulses on the Fortessa. On both 









Figure B.6: Effects of Different Sample Buffers on Calcein Labeling, FSC Intensity, and 
Fluorescence Measurements 
These experiments were conducted on the Influx using FSC-triggering (for beads in B) or FM-
triggering (for P2 samples in A and C). (A) Representative density plots for mixtures of single 
calcein-labeled P2 samples. Columns indicate the buffer designation for each sample, while the 
rows indicated the gated population displayed. (B) FSC and green fluorescence (FITC detector) 
of fluorescent 0.5 and 0.8 µm PS beads (Bangs Labs; B) run in PBS (left) or SET (right) buffer. 
The median and standard deviation of FSC and green fluorescence signal intensity are shown 
below for both gated bead populations. (C) Box and whiskers plots of fluorescent events (all 
events positive for either calcein), expressed as a percentage of all events. Central bar represents 
the median. Lower and upper edges correspond to 25th and 75th percentiles. Lower and upper 
whiskers extend to the smallest or largest value no greater than 1.5 times the interquartile range 
away from the corresponding edge. Data are derived from the same single calcein-labeled P2 
mixtures presented in Figure 2.3.6H (n=10 for ‘PBS’, n= 8 for ‘PBS-SET’, and n=10 for ‘SET’). A 









Figure B.7: Distribution of Immunostained P2 Events Across FSC Ranges and Comparison 
Between Single- and Double-Positive Event Frequencies 
All data are derived from the same samples as presented in Figure 2.3.7, i.e. P2 samples 
immunostained in PBS for VGAT, VGLUT1, and VMAT2 and run on the Influx with FM-
triggering in PBS or SET as sample buffer. (A) Representative histogram with overlay of FSC 
gates. Only events gated as positive for VGAT (left), VGLUT1 (middle), or VMAT2 (right) are 
displayed. (B) Box and whiskers plots of immunopositive events within each FSC gate, expressed 
as a percentage of all immunopositive events for the indicated antigen. Analogous to the 
histograms above, the sum across FSC gates is 100% for any one sample. Central bar represents 
the median. Lower and upper edges correspond to 25th and 75th percentiles. Lower and upper 
whiskers extend to the smallest or largest value no greater than 1.5 times the interquartile range 
away from the corresponding edge. (C) Relative abundance of all events immunopositive for a 
given antigen, expressed as a percentage of all events. Data for are plotted as mean +/- SEM for 
PBS or PBS-SET (n=6 for each). (D) Left: A simple model for collisions of single-positive events 
leading to double-positive events is given by sampling with replacement. The relative 
abundance of any given double-positive event is estimated by multiplying the relative 
abundances of the two single-positive events. Right: Comparison of the observed and expected 
frequency for each type of double-positive event, expressed as a percentage of all double-
positive events. Observed data represent the average for PBS or PBS-SET (n=6 for each). (E) 
AlexaFluor488 MESF calibration bead standards (left) used to construct a calibration curve 
based on measured median fluorescence intensity and the manufacturer’s stated MESF for each 
bead (right). (F) A P2 sample stained for VGAT (with anti-mouse AlexaFluor488 secondary) was 
gated for immunonegative and immunopositive events as shown in Figure 2.3.7A. Plotted are 












Table B.2: Single/double/triple-positive percentages for each type of immuno-positive event 
Data are from samples shown in Figure 2.3.7B-C (Mean ± SEM for n=6 replicates each buffer) 
VGAT+ 
FSC Gate Single-Positive Events, 
% of all VGAT+ 
Events 
Double-Positive Events, 
% of all VGAT+ Events 
Triple-Positive Events, 
% of all VGAT+ Events 
 PBS PBS-SET PBS PBS-SET PBS PBS-SET 
All Sizes 56 ± 4 60 ± 4 33 ± 3  31 ± 2  10 ± 2  9 ± 2 
FSC Noise  80 ± 5 83 ± 5 13 ± 2 11 ± 3 7 ± 3 5 ± 3 
<500nm PS 68 ± 4 71 ± 5  21 ± 3 20 ± 2  11 ± 3 9 ± 3 
<880nm Sil 57 ± 4 64 ± 5 31 ± 4 29 ± 4 11 ± 2 7 ± 2 
<1300nm Sil 35 ± 5 37 ± 4 57 ± 4 56 ± 4 8 ± 1 6 ± 3 
>1300nm Sil 12 ± 3 7 ± 2 73 ± 2 71 ± 4 15 ± 3 22 ± 2 
VGLUT1+ 
FSC Gate Single-Positive Events, 
% of all VGLUT1+ 
Events 
Double-Positive Events, 
% of all VGLUT1+ 
Events 
Triple-Positive Events, 
% of all VGLUT1+ 
Events 
 PBS PBS-SET PBS PBS-SET PBS PBS-SET 
All Sizes 71 ± 3 78 ± 2 23 ± 3 18 ± 2  5 ± 1 4 ± 0 
FSC Noise 75 ± 6  79 ± 5 17 ± 3 15 ± 3 8 ± 3 6 ± 2 
<500nm PS 73 ± 2 79 ± 2 20 ± 1 16 ± 1 7 ± 2 5 ± 1 
<880nm Sil 76 ± 3 83 ± 2 20 ± 3 15 ± 1 4 ± 0 3 ± 0 
<1300nm Sil  73 ± 5 82 ± 2 24 ± 4 16 ± 2 3 ± 1 2 ± 1 
>1300nm Sil 51 ± 8 61 ± 5 40 ± 6 31 ± 4 9 ± 2 9 ± 1 
VMAT2+ 
FSC Gate Single-Positive Events, 
% of all VMAT2+ 
Events 
Double-Positive Events, 
% of all VMAT2+ 
Events 
Triple-Positive Events, 
% of all VMAT2+ Events 
 PBS PBS-SET PBS PBS-SET PBS PBS-SET 
All Sizes 46 ± 8 48 ± 7 28 ± 6 27 ± 4 26 ± 3 26 ± 3 
FSC Noise 63 ± 9 64 ± 5 21 ± 4 23 ± 2 16 ± 6 14 ± 5 
<500nm PS 53 ± 10 58 ± 9 27 ± 6 22 ± 4 21 ± 5 20 ± 6 
<880nm Sil 44 ± 11 48 ± 11 34 ± 9 33 ± 7 22 ± 3 19 ± 4 
<1300nm Sil 32 ± 6 47 ± 13 39 ± 7 34 ± 9 29 ± 4 20 ± 7 







Table B.3: MESF calibration of AlexaFluor488 immunostaining 
Numerical data corresponding to those shown in Figure B.7E-F. 
Sample_FluorGate Size Gate Median Fluorescence 
Intensity (MESF) 
BD-rSD (MESF) 
MESF-Blank N/A  46 
MESF-Std1 N/A 3226 355 
MESF-Std2 N/A 22646 1693 
MESF-Std3 N/A 97603 4332 
MESF-Std4 N/A 336257 11637 
MsVGAT_Alexa488- FSC Noise 43 1 
MsVGAT_Alexa488- <500nm PS 54 14 
MsVGAT_Alexa488- <880nm Sil 64 28 
MsVGAT_Alexa488- <1300nm Sil 869 718 
MsVGAT_Alexa488- >1300nm Sil 4682 2944 
MsVGAT_Alexa488+ FSC Noise 513 312 
MsVGAT_Alexa488+ <500nm PS 1310 644 
MsVGAT_Alexa488+ <880nm Sil 2204 956 
MsVGAT_Alexa488+ <1300nm Sil 4827 2330 








Figure B.8: Particle Recovery in P2 Samples Following Repeated Centrifugations 
All data are derived from the samples presented in Figure 2.3.8, i.e. P2 samples subjected to two 
centrifugations for 5 min in PBS or SET buffer at varying relative centrifugal force (xg). Absolute 
counting beads were added to each sample to determine absolute particle counts. (A) Total 
particle counts in each fraction for P2-1, S2-1, P2-2, and S2-2 samples in PBS. (B) Same as A but 
for SET buffer. (C) Percent recovery in the pellet following each centrifugation at indicated rcf 
(xg). (D) Total particle counts for pellets and supernatants across varying centrifugation rcf (xg) 












Table B.4: Statistical Table 
Summary of statistical testing for all pertinent figures in this study. 




Power p value F/t 
value 







0.9950 0.0072 t(3.49) =  
-5.64 







0.8313 0.0046 t(5.23) =  
-4.74 







0.8251 0.0103 t(7.86) =  
-3.35 








0.6783 0.0260 t(11.29) =  
-2.56 







0.8487 0.0085 t(11.62) =  
3.16 







0.4452 0.0738 t(14.71) =  
-1.92 







0.7761 0.0124 t(14.83) =  
2.85 







0.6953 0.0242 t(10.95) =  
2.61 







0.8366 0.0092 t(11.73) =  
-3.11 







0.4428 0.0734 t(15.73) =  
1.92 







0.7423 0.0142 t(15.54) =  
-2.76 







0.0911 0.5286 t(2.00) =  
0.76 


















0.2397 0.2468 t(2.01) =  
1.62 







0.7653 0.0230 t(3.99) =  
-3.59 






0.0666 0.6775 t(14.11) =  
0.425 






0.2500 0.1779 t(12.49) =  
1.43 




0.5481 0.0417 t(17.44) =  
2.20 




















u 2.3.6H Interaction: 


















































































































































































































Appendix C: Supplement for “Subcellular and regional localization 







Figure C.1: DATIRES-Cre:RiboTag histology, eL22-HA signal amplification, eL22-HA staining in 
distal SNr dendrites, RiboTag IP optimization, and qRT-PCR estimation of RiboTag IP yield 
(A) Upper: Epifluorescence image of DATIRES-Cre:RiboTag midbrain immunostained for tyrosine 
hydroxylase (TH) and eL22-HA. Dashed lines indicate regions used for cell counting shown 
below. Lower left: SNc of DATIRES-Cre:RiboTag, representative of images for cell counting. Scale 
bar, 20 µm. Lower right: % of TH+ cells expressing eL22-HA at indicated ages. Data represent 
mean ± standard deviation, and are derived from n=2-3 mice and n=6 fields, (VTA) n= 717 cells; 
(SNc) n=451 cells. Mean is >95% in both regions. Scale bar, 100 µm. 
(B) Upper: DATIRES-Cre:RiboTag midbrain stained for TH and eL-22HA at the indicated 
coordinates. Lower: DATIRES-Cre:Ai9 section stained for TH and tdTomato at indicated 
coordinates. Both scale bars, 500 µm. 
(C) Comparison of AlexaFluor647-conjugated secondary antibody vs. TSA-Cy5 + HRP-
conjugated secondary antibody for eL22-HA immunostaining. Exposure was optimized to 
avoid saturation of soma. Scale bar, 50 µm. 
(D) Same as panel A, but using high exposure to detect dendritic labeling (somata are saturated 
for TSA-Cy5). Scale bar, 25 µm. 
(E) Quantification of somata eL22-HA intensity, related to panel A. Violin plot depicts n=100 
soma quantified from 2-3 fields each from 3 mice. 
(F) Upper: eL22-HA labeling in descending SNr dendrites can be distinguished from soma of 
SNr mDA neurons. Scale bar, 20 µm. Lower: Amplified eL22-HA labeling is observed in distal 
SNr mDA neuronal dendrites near the cerebral peduncle. Scale bar, 15 µm. Inset scale bar, 5 
µm. 
(G) DATIRES-Cre:RiboTag midbrain immunostained for TH and eL22-HA. Scale bar, 200 µm. 
Arrows: A few scattered Th+/eL22-HA+ mDA neurons are present in the SNr. Scale bar, 50 µm. 
(H) Optimization of eL22-HA IP conditions. Upper: Cre-negative or Cre-positive ventral 
midbrain (n=2 each genotype) lysate was split into three equal parts for capture with Rabbit 
anti-HA (Protein G beads) or biotinylated Rabbit anti-HA (Streptavidin C1/T1 beads). Mean and 
confidence intervals are plotted. Lower: Further optimization of capture time using four equal 
parts of DATIRES-Cre:RiboTag ventral midbrain lysate with biotinylated Rb anti-HA and 
Streptavidin T1 beads. Antibody was incubated with polysome lysates overnight, and beads 
were added for the capture time indicated. 
(I) Upper: qRT-PCR of beta-Actin (ActB) with total RNA input amounts (measured by Qubit) 
ranging from 1 pg – 5 ng. Lower: qRT-PCR (ActB) estimation of RNA concentration (measured 
by Qubit for Input samples, or RNA Pico bioanalyzer for IP samples, n=40-48 each). 
Abbreviations: SNc, Substantia nigra pars compacta; SNr, Substantia nigra parts reticulata; VTA, 
Ventral tegmental area, Aco, Anterior commissure; LS, Lateral septum; BNST, Bed nucleus of 
the stria terminalis, TSA; tyramide signal amplification, HRP; horseradish peroxidase, cpd; 
cerebral peduncle, Th; tyrosine hydroxylase, Mbp; myelin basic protein, DAT; dopamine 









Figure C.2: RNA-Seq analysis of bulk striatal and striatal synaptosome RiboTag IP samples, 
VGLUT1VENUS and DA:EGFP FASS Gating, and RNA-Seq analysis of FASS samples 
(A) Schematic depicting generalized linear model analysis of striatal RiboTag IP using the 
DESeq2 likelihood ratio test (LRT).  Analogous to a 2-way analysis of variance, the main effects 
of each factor and the interaction between them are each tested for statistical significance across 
all genes (with FDR correction). See Methods. 
(B) Number of genes meeting statistical significance (FDR < 0.05) in the DESeq2 LRT with the 
indicated terms omitted from the following reduced model: ~genotype + fraction + 
genotype:fraction. In addition to testing each age was independently (shown here), the effects of 
age, fraction, genotype, and fraction:genotype interaction were also on the entire dataset across all 
ages (see Figure 3.3A-B). In contrast to the genotype-independent effect of fraction (non-specific 
binding), the effects of genotype and genotype:fraction interaction were negligible at all ages. See 
Supplementary File 5 for complete summary of DESeq2 analysis. Mice per age and genotype: 
(P0, Cre-) n= 6, (P0, Cre+) n=6, (P7, Cre-) n=6, (P7, Cre+) n=6, (P14, Cre-) n=6, (P14, Cre+) n=6, 
(P21, Cre-) n=6, (P21, Cre+) n=7, (P31, Cre-) n=2, (P31, Cre+), n=2, (P90, Cre-) n=2, (P90, Cre+), 
n=3, (10-14 mo., Cre-) n=6, (10-14 mo., Cre+) n=4, where each n indicates an IP and 
corresponding Input sample. 
(C) qRT-PCR measurement of Th and ActB mRNA yield in striatal RiboTag IPs from Cre-
negative and Cre-positive mice. The difference between the average Cq values (Cre-positive Cq 
– Cre-negative Cq) is plotted at each age. Mice per age and genotype are the same as in panel B. 
nd: not detectable, ns: all comparisons are not significant (p > 0.05), Welch’s unequal variance t-
test. 
(D) Total UMIs per sample for striatal RiboTag IPs from Cre-negative and Cre-positive mice. 
Mice per age and genotype are the same as in panel B. ns: all comparisons are not significant (p 
> 0.05), Welch’s unequal variance t-test. 
(E) Density plots of Fluorescence-Activated Synaptosome Sorting (FASS) gating strategy. Upper: 
Particles are first selected from the ‘P1’ gate on forward and side scatter in order to avoid 
aggregates. Synaptosomes from wildtype controls are used to set a fluorescence threshold on 
which to sort VGLUT1VENUS and DA:EGFP particles. Lower: Representative density plots of 
Unsorted (left) and Sorted (right) synaptosomes from the indicated regions and genotypes. 
(F) Number of sorted particles vs. total UMIs for the indicated sorted samples (n=6 striatum 
DA:EGFP, n=3 striatum VGLUT1VENUS, n=3 cortex VGLUT1VENUS, where each n represents both a 
FASS sample and three corresponding small particle samples). Pearson’s r = 0.74, p = 2.3e-09. 
(G) Total UMIs per sorted particle for small particle and FASS samples as indicated. * indicates 
p < 0.05, ** indicates p < 0.01, Welch’s unequal variance t-test. Samples are the same as shown in 
panel F. 
(H) PCA of DESeq2 rlog normalized UMI counts for FASS and small particle samples. Samples 
are the same as shown in panel F, but small particle technical replicates (n=3 per FASS sample) 
were collapsed. 
(I) Same as panel H, but only FASS samples are included in the PCA. See Supplementary File 6 
for complete summary of DESeq2 testing. 
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(J) Upper and lower left: Volcano plots are derived from the DESeq2 LRT, with the indicated terms 
removed from the following two-factor GLM: ~ genotype + fraction + genotype:fraction. Lower right: 
Number of differentially expressed genes (DEGs, FDR < 0.05) from the DESeq2 LRT test for the 
indicated factors, related to panel A. See Supplementary File 8 for complete summary of 
DESeq2 testing. 
(K) Total UMIs for Input and IP samples from striatal synaptosome RiboTag IPs (n = 12 each 
genotype for Input, n = 4 each genotype for IP). ns indicates p > 0.05, Welch’s unequal variance 
t-test. 
(L-M) log2 fold change vs. abundance (MA) plot for FASS-enriched or FASS-depleted genes 
shown in Figure 3.3G. Log2(GenoCrePos.FractionIP) represents the difference in the fraction 












Figure C.3: Midbrain FISH for dopaminergic and control mRNAs, Ddc and Slc18a2/Vmat2 
mRNA in TH+ SNr dendrites 
(A) Multicolor fluorescence in situ hybridization (FISH, RNAScope assay) for Th and 
Slc6a3/DAT mRNA in the substantia nigra. Scale bar, 100 µm. 
(B) TH immunostaining combined with multicolor FISH for the negative control (bacterial) 
mRNA DapB and positive control mRNA Ppib. Scale bar, 100 µm. 
(C) TH immunostaining combined with multicolor FISH for Ddc and Slc18a2/Vmat2 mRNA in 
the SNr. Yellow large arrowheads indicate clusters of Ddc mRNA outside of TH+ dendrites. 
White arrows indicate Slc18a2/Vmat2 mRNA within TH+ dendrites. Red dashed lines indicate 
the inset in panel D. Scale bar, 25 µm. 
(D) Inset corresponding to red dashed lines in panel C. Yellow large arrowhead indicates a Ddc 
mRNA puncta outside of TH+ dendrites. White arrows indicate Ddc and Slc18a2/Vmat2 mRNA 
within TH+ dendrites. White dashed lines correspond to the intensity profiles shown below in 
panel E. Scale bar, 5 µm. 
(E) Intensity profiles for all three fluorescent channels, corresponding to the lines indicated 
above in panel D. 
(F) Left: TH immunostaining combined with multicolor FISH for Ddc and Slc18a2/Vmat2 mRNA 
in the distal SNr near the cerebral peduncle (cpd). Yellow dashed lines indicate the insets shown 
on the right. Scale bar, 25 µm. Right: Insets of Ddc and Slc18a2/Vmat2 mRNA in TH+ dendrites. 






Figure C.4: Th mRNA+ striatal neurons, not dopaminergic axons, are the source of Th mRNA 
in the striatum 
(A) TH immunostaining combined with FISH for Th mRNA in the striatum. Scale bar, 50 µm. 
(B) TH immunostaining combined with FISH for Th mRNA in the striatum. Occasionally, some 
Th mRNA+ neurons also display TH immunoreactivity (upper). Typically, they do not (lower). 
Scale bars, 15 µm. 
(C) qRT-PCR of the indicated dopaminergic mRNAs in the Ventral Midbrain (upper) or dorsal 
striatum (lower) of Wildtype (n=3) and Pitx3-/- mice (n=4). ** indicates p < 0.01, *** indicates p < 

















Figure C.5: RiboTag IP from midbrain dissections recapitulates mDA neuronal 
heterogeneity, qRT-PCR estimated yield of midbrain RiboTag IPs, SNr RiboTag IP Filtering, 
and Enrichment of Aldh1a1+/Sox6+ mDA neuronal markers 
(A) PCA of RiboTag IP and Input samples from VTA, SNc, and SNr dissections. 
(B) Schematic depicting anatomical dissections and the anatomical distribution of mDA 
neuronal clusters described by Poulin et al. (2020). 
(C) Clustered heatmap of DESeq2 rlog normalized counts, mean-normalized within each gene, 
for the indicated VTA, SNc, and SNr RiboTag IPs (n=3 each). The twenty genes shown are 
strong markers for specific mDA neuronal clusters as shown in panel B and in Poulin et al. 
(2020). 
(D) beta-Actin (ActB) Cq values for Cre-negative and Cre-positive RiboTag IPs in the indicated 
regions (n=4 each region/genotype). * indicates p < 0.05, *** indicates p < 0.001, Welch’s unequal 
variance t-test. 
(E) Estimated total RNA (picograms) based on ActB Cq values. Red line indicates 500 
picograms. 
(F) Schematic depicting filtering and comparison of SNr RiboTag IP to VTA and SNc RiboTag 
IPs (FDR < 0.05 at each step). First, DEGs in SNr vs. SNc and in SNr vs. VTA comparisons are 
identified. Second, the intersection of SNr-enriched or SNr-depleted genes (relative to 
SNc/VTA) from these two DEG lists is retained. Third, only genes enriched in SNr IP vs. Input 
or SNc/VTA IP vs. Input comparisons are retained. Fourth, genes that are significantly higher in 
Cre-negative IP samples compared to Cre-positive IP samples are removed (non-specific 
binders). The final list of DEGs includes genes enriched (red) or depleted (blue) in SNr RiboTag 
IPs relative to SNc and VTA RiboTag IPs. See Supplementary File 9 for complete summary of 
DEGs and filtering. 
(G-H) Log-log plots depicting the average DESeq2 rlog normalized counts for SNr RiboTag IPs 
(x-axis) and SNc (left) or VTA (right) RiboTag IPs (y-axis). DEGs corresponding to panel F are 






Figure C.6: SNr RiboTag IP-enriched mRNAs localized within SNr mDA somata and 
heterogeneous expression of Atp2a3 (SERCA3) in mDA neurons 
(A) Immunostaining for TH and Aldh1a1 reveals Aldh1a1+ mDA neurons within the SNr. Scale 
bar, 100 µm. Inset scale bar, 20 µm. 
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(B-D) TH immunostaining combined with multicolor FISH for Dgkz and Prkca mRNA in the 
proximal and distal SNr. Both of these SNr RiboTag IP-enriched mRNAs are localized within 
the soma of mDA neurons in the SNr, and are not distributed in dopaminergic dendrites. (B) 
Scale bar, 100 µm. Inset scale bar, 20 µm. (C) Scale bar, 50 µm. (D) Scale bar, 20 µm. 
(E-H) TH immunostaining combined with FISH for Atp2a3/SERCA3 mRNA in the indicated 
regions. Dashed white lines indicate the insets shown in the center (e-h). Yellow arrowheads in 
(E) indicate prominent labeling of blood vessels, likely within endothelial cells which are known 
to express SERCA3. Scale bar, 100 µm. Inset scale bar, 25 µm. See Figure 3.5G for quantification 

















Figure C.7: mRNAs encoding presynaptic proteins are also present in hippocampal dendrites, 
and dendritic localization of dopaminergic mRNAs in cultured mDA neurons 
(A) Volcano plots showing the Cre-dependent log2 fold change in IP vs. Input (Cre-positive – 
Cre-negative) for midbrain synaptosomal RiboTag IPs (same as Figure 3.6E) with genes colored 
by their expression level in the dendrites of four subsets of hippocampal neurons [425]. 
(B-C) Multicolor FISH for the indicated dopaminergic mRNAs in cultured mDA neurons. Scale 
bars, 20 µm.  
(D-E) TH immunostaining combined with multicolor FISH for the indicated dopaminergic 






Appendix D: Supplement for “Subcellular proteomics of dopamine 
neurons in the mouse brain reveals axonal enrichment of proteins 







Figure D.1: Specificity of APEX2-NES AAV expression 
(a) Immunostaining of mDA neurons in DATIRES-Cre/Ai9tdTomato mice injected with AAV5-CAG-
DIO-APEX2-NES. The vast majority of V5-APEX2+ neurons are TH+/tdTomato+. Left, ventral 
tegmental area, right: substantia nigra pars compacta, both scale bars: 250 µm. 
(b) Quantification and cell counts related to (a), data from 2 sections each from n = 3 mice. 















Figure D.2: Characterization of slice labeling 
(a) Typical sets of sagittal or coronal slices. Target regions for anatomical dissection of mDA 
neuronal compartments are indicated. 
(b) Anti-V5 (APEX2) and streptavidin-AlexaFluor647 staining of a cleared striatal slice after 5 
minutes labeling with 1 mM hydrogen peroxide. Upper left, images display XY view at Z1 plane 
as indicated in the ZX (lower left) and YZ (upper right) views, scale bar: 50 µm. Lower right, top, 
middle, and bottom third of XY view at Z1, Z2, and Z3 planes, respectively, as indicated in the 
ZX and YZ views, scale bar: 50 µm.  
(c-d) Anti-V5 (APEX2) and streptavidin-AlexaFluor647 mean fluorescence intensity as a 
function of Z depth and hydrogen peroxide (H2O2) labeling time. Mean ± standard deviation is 
plotted from 3 fields. Although V5-APEX2 fluorescence decreases throughout the slice depth 
(likely due to laser power attenuation), streptavidin fluorescence exhibits a bimodal distribution 








Figure D.3: Proteomic depth and reproducibility 
(a) Mean ± SEM  of peptides and proteins detected per biological replicate of each sample type 
(n = 4 each). Tissue regions and protein fractions (bulk tissue or streptavidin IP) are indicated.  
(b) Peptide coverage of detected proteins in each sample type (bulk tissue or streptavidin IP). 
Highlighted region shows proteins with >1 peptide. 
(c) Pearson correlation (r) of three biological replicates (APEX2+ streptavidin IP) samples from 







Figure D.4: APEX2 slice labeling conditions do not distort bulk tissue proteomes or disrupt 
spontaneous firing in dopamine neurons 
(a) Schematic depicting bulk tissue proteomics experimental design. Coronal slice prepared 
from the midbrain or striatum were split into lateral halves: one half was immediately frozen 
(acute), while the other half was subjected to APEX2 labeling conditions (1-hour aCSF + 0.5 mM 
biotin-phenol followed by 3 minutes of 1 mM H2O2) and then frozen. See Figure 2 – source data 
2 for raw label-free quantification intensity values of peptides and proteins for all samples used 
in this study. 
(b) Volcano plot comparing striatum and ventral midbrain bulk tissue proteomes. False 
discovery rate (FDR) represents q values from Benjamini-Hochberg procedure on Welch’s 
(unequal variance) t-test. See Figure 2 – source data 3 for complete results. 
(c) Volcano plot comparing acute vs. rested bulk tissue proteomes for both striatum and ventral 
midbrain. False discovery rate (FDR) represents q values from Benjamini-Hochberg procedure 
on Welch’s (unequal variance) t-test. See Figure 2 – source data 3 for complete results. 
(d) Cell attached recording of dopaminergic neurons in the substantial nigra. Representative 
traces of spontaneous firing of dopaminergic neurons from BP-treated and untreated slices.  
(e) 1 hour incubation with 0.5 mM BP does not affect the spontaneous action potential firing 
(Untreated group: n=7 cells, N=2 mice, BP-treated: n=4 cells, N=2 mice. No significant effects 
were observed in two-way ANOVA: (Time) F(17,100) = 0.218, p = 0.99, (Treatment) F(1,100) = 0.589, p = 





Figure D.5: Filtering of APEX2 proteomics data using single-cell RNA sequencing (scRNA-
seq) data and cross-regional comparisons 
(a) Histogram of average mRNA expression in DA neurons identified in our reanalysis of the 
DropViz scRNA-Seq data [196], see also Figure D.10. Data were fit with a gaussian mixture 
model (light blue trace), with the two gaussian distributions representing genes expressed 
(dashed red trace) or not expressed (green trace) in DA neurons. The mean (µ) and standard 
deviation (σ) for the DA neuronal component are indicated in red. A conservative threshold of 
µ - σ (dashed black line) was set as the lower bound to consider a gene expressed in DA 
neurons. 
(b) Histogram of average DA neuron mRNA expression for all proteins detected in VM APEX2+ 
IP samples (dark grey) and proteins enriched in VM APEX2+ vs. APEX2- IP samples (FDR < 0.05, 
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red). Only 6.6% of all VM IP proteins were below the lower bound of DA neuronal expression, 
which was decreased to 2.6% for proteins enriched in APEX2+ vs. APEX2- IPs. 
(c) Histogram of average DA neuron mRNA expression for all proteins detected in Str APEX2+ 
IP samples (dark grey) and proteins enriched in Str APEX2+ vs. APEX2- IP samples (FDR < 0.05, 
red). Only 7.0% of all Str IP proteins were below the lower bound of DA neuronal expression, 
which was decreased to 2.5% for proteins enriched in APEX2+ vs. APEX2- IPs. 
(d) Filtering strategy for VM (left) and striatum (right) APEX2 proteomics data. Filters using 
scRNA-Seq data are shown in red, while filters using the proteomics data are shown in grey. 
Numbers below the bottom right corner of each box indicate the number of proteins passing 
that individual filter, while the total number of proteins passing each filter set is indicated to the 
left of the arrows. See Methods for detailed description of the filters. In total, 1399 and 1533 
proteins were retained from the VM and striatum, respectively, with 1733 total. For most 
downstream analyses, the union of VM and striatum filtered proteins (1733) are referred to as 
the filtered APEX2 proteomics data. See Figure 3 – source data 2 for complete results and 







Figure D.6: Clustered heatmap of protein abundances for union of filtered VM and Str 
APEX2 proteins 
Clustered heatmap of Z-scores for abundances of proteins present in the filtered proteomics 
data from VM or striatum (1733 proteins). Each column represents a biological replicate (n=4) of 
APEX2+ or APEX2- streptavidin IP samples from the VM or striatum. The color bars on the left 
and right are identical; both indicate whether a given protein was enriched in the VM (orange) 
or striatum (green) in differential expression analysis between APEX2+ IP samples (FDR < 0.05 
after Benjamini-Hochberg corrected p-values from Welch’s t-test). Select proteins from within 








Figure D.7: Subcellular compartment gene ontology analysis of filtered VM and Str APEX2 
proteins 
(a) Targeted gene ontology analysis of proteins in filtered VM or striatum APEX2+ data (1733 
proteins encoded by 1713 genes). Proteins were analyzed for overlap with GO terms related to 
nucleus in the COMPARTMENTS resource [500]. The number of proteins present in the filtered 
APEX2 data out of all proteins in each ontology is shown below each term, with FDR-corrected 
p-values derived from the hypergeometric test. 
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(b) Same as (a) but using mitochondrial compartmental localizations present in the MitoCarta 
3.0 database [558]. Select proteins present in the mitochondrial outer membrane list are 
displayed. 
(c) Enrichr-based gene ontology analysis of proteins passing filter only in VM APEX2+ samples 
or enriched in APEX2+ VM vs. striatum differential expression (in total, 373 genes encoding 373 
proteins). The 373 genes were analyzed using the subcellular compartments ontology terms 
provided by the COMPARTMENTS resource [500]. All GO terms with p < 0.05 are colored in 
blue, with select terms indicated for those displaying the lowest p-values and highest odds 
ratio. See Figure 3 – source data 3 for complete results. 
(d) Same as (c) but for proteins passing filter only in striatum APEX2+ samples or enriched in 






Figure D.8: Synaptic gene ontology analysis proteins of striatal slice and synaptosomal 
APEX2 data 
(a) SynGO [468] analysis of striatum slice and synaptosome filtered proteins (1348 proteins 
encoded by 1329 genes, with 393 SynGO annotations). The top 10 Ontology Terms for Cellular 
Component and Biological Process are shown. See Figure 4 – source data 2 for complete results. 
(b) Downstream filtering of 179 genes from Cellular Component term “postsynapse”. 71 
proteins with dual annotation to presynapse and postsynapse were removed from the 
“postsynapse” set (proteins such as DAT, VMAT2, etc., shown in “Both”). The remaining 107 
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proteins were designated as having “Post-only” annotations, and were further filtered to 
remove generic cytoskeletal, signaling, and synaptic proteins with functions in both pre- and 
post-synapse. All 44 proteins removed are shown under “Post-only removed”. The remaining 
63 proteins were designated as “Post-only retained” for downstream analysis. See Figure 4 – 
source data 3 for complete list of protein abbreviations in (b). 
(c) APEX2 samples average log2(normalized intensity + 1) for indicated protein sets derived 
from SynGO analysis (panels a-b). * indicates p < 0.05 and **** indicates p < 0.0001 from Mann-
Whitney U test. Mann-Whitney test statistics are as follows, left to right: Str-Slice Pre vs. All (U = 
40948, p = 1.4e-14), Str-Slice Post vs. All (U = 30448, p = 0.071), Str-Slice Pre vs. Post (U = 1986, p 
= 6.2e-09), Str-Syn Post vs. All (U = 29166, p = 0.024), Str-Syn Pre vs. All (U = 39841, p = 1.3e-15), 
Str-Syn Pre vs. Post (U = 1793, p = 2.3e-10). 
(d) Schematic depicting possible mechanisms underlying striatal APEX2 enrichment of proteins 





Figure D.9: APEX2 enrichment of specific protein groups across DA neuronal regions 
For all panels, the difference in average log2(normalized intensity + 1) between APEX2+ and 
APEX2- (control) samples is plotted for the indicated proteins. The legend indicates the result of 
the Welch’s unequal variance t-test with Benjamini-Hochberg procedure to control the FDR (n = 
4 biological replicates each for APEX2+ and APEX2- samples in each region). * indicates FDR < 
0.05, ** indicates FDR < 0.001. 
(a) Dendritic spine proteins DARPP-32 and Spinophilin are not enriched in APEX2 striatal 
samples, while pre-synaptic proteins Synaptophysin and VMAT2 are massively enriched. 
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(b) GABA-A receptor subunits and scaffolding protein Gephyrin are strongly enriched by 
APEX2 in the ventral midbrain, but are also captured in the medial forebrain bundle and 
striatum. 
(c) GABA-B receptor subunits, PDZ-domain containing scaffolding protein Mupp1, and effector 
ion channel GIRK2 are captured by APEX2 in both VM and striatum. 
(d) CDK5 and most all members of the eukaryotic group II chaperonin TRiC (tailless complex 
polypeptide 1 ring complex) are captured by APEX2 in the VM and striatum. 
Protein Abbreviations: (DARPP-32) dopamine- and cyclic-AMP-regulated phosphoprotein of 
molecular weight 32 kDa, (SYP) synaptophysin, (VMAT2) vesicular monoamine transporter 2, 
(GABA-AR) GABA-A receptor subunit, (GABA-BR) GABA-B receptor subunit, (GIRK2) G 
protein-activated inward rectifier potassium channel 2, (CCT) chaperonin-containing tailless 





Figure D.10: Identification of DA neuron cluster and sub-clusters for downstream analysis 
(a) UMAP embedding of scRNA-Seq data from Saunders et al. [196]. A single cluster with 
statistically significant co-enrichment of dopamine neuron markers such as Th and Slc6a3, based 
on the binomial test for expression specificity, was identified. After sub-clustering the putative 
dopamine neurons, we identified a small sub-cluster with statistical enrichment of astrocyte 
markers such as Agt, Gja1, Glul, and Slc1a3. for pan-DA neuronal expression analysis. This sub-
cluster was discarded due to likely astrocyte contamination. After removal of low-quality cells, 
we retained the remaining subclusters as high-confidence DA neuron profiles (see Methods). 
DA neuron profiles used in this study are found in Figure 5 – source data 3. 
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(b) Sub-clustering of high-confidence DA neurons identified five transcriptionally distinct DA 
neuron subsets. Markers determined using the binomial test are shown in the heatmap, and 




Figure D.11: SPAK and associated proteins are present in DA axons 
The difference in average log2(normalized intensity + 1) between APEX2+ and APEX2- (control) 
samples is plotted for the indicated proteins. The legend indicates the result of the Welch’s 
unequal variance t-test with Benjamini-Hochberg procedure to control the FDR (n = 4 biological 
replicates each for APEX2+ and APEX2- samples in each region). * indicates FDR < 0.05, ** 
indicates FDR < 0.001. 
Protein Abbreviations: (NKCC1) Solute carrier family 12 member 2 / basolateral Na-K-Cl 
symporter, (KCC2) Solute carrier family 12 member 5 / K-Cl cotransporter 2 / mKCC2, (KCC3) 
Solute carrier family 12 member 6 / K-Cl cotransporter 3, (SPAK / STK39) STE20/SPS1-related 
proline-alanine-rich protein kinase / Ste-20-related kinase, (WNK) Serine/threonine-protein 











Figure E.1: PhenoGraph clusters and sample representation of snRNA-seq data 
UMAP embedding of single nucleus RNA-seq profiles (5,700) from the ventral midbrain of 





Figure E.2: Assignment of PhenoGraph clusters to six major cell types  
Clustered heatmap of the average expression (log2 [counts per million + 1]) of the indicated 
genes within each PhenoGraph cluster. PhenoGraph clusters were assigned to the six major 






Figure E.3: Filtering of oligodendrocyte doublets  
(A) Gaussian mixture models for unfiltered DA, GABA, or VGLUT2 neurons. The black 
trace indicates the fitted GMM; the red trace indicates component 1 (single neurons); the 
green trace indicates component 2 (multiplets), scaled up by a factor of 20 for visualization. 
The mean of the first component plus eight standard deviations is shown in blue. 
(B) Filtering of oligodendrocyte doublets from other major cell types. The blue trace 
indicates the average neuronal component 1 mean plus eight standard deviations, indicated 





Figure E.4: HaloTag:Syt17 JF646 Particle Tracking in Neurites 
(A) Neurites of cultured dopamine neurons expressing HaloTag:Syt17 labeled with JF646. 
Scale bar, 10 µm. (Right) Kymograph of JF646 fluorescence in the neurite traced in the JF646 
inset (‘kym.’) in Left.  
(B-C) Kymographs of JF646 fluorescence for the traced segments shown in A. The traced 
segments are ~40.0 (B) and ~18.0 (C) µm in length, and were imaged over 5 minutes of 






Figure E.5: Dopamine release amplitude and paired pulse ratio are not altered in Syt-17 
KO mice 
Data are derived from 16 slices from n = 3 mice of each genotype (5-6 slices per mouse). 
(A-C) Peak dopamine release amplitude evoked by a single pulse (panel A), paired pulse 
ratio (interstimulus interval: 3 sec) (panel B), or 5p/1p peak dopamine release amplitude (5 
pulses at 100 Hz relative to single pulse) (panel C). ns indicates p > 0.05, unpaired t-test. 
